emtricitabine has been researched along with HIV Infections in 1315 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.08) | 18.2507 |
| 2000's | 130 (9.89) | 29.6817 |
| 2010's | 743 (56.50) | 24.3611 |
| 2020's | 441 (33.54) | 2.80 |
| Authors | Studies |
|---|---|
| Bachmann, MH; Fessel, WJ; Kagan, RM; Mitsuya, Y; Shafer, RW; Shahriar, R; Varghese, V | 1 |
| Amblard, F; Bassit, L; Bondada, L; Coats, SJ; Detorio, M; Grier, J; Hernandez-Santiago, BI; Koontz, D; Mellors, JW; Rapp, KL; Schinazi, RF; Sluis-Cremer, N | 1 |
| Almond, MR; Buckheit, RW; Hartman, T; Keilholz, L; Lampert, BM; Lanier, ER; Mankowski, MK; Osterling, MC; Painter, GR; Ptak, RG | 1 |
| Bonnac, L; Clouser, CL; Daly, MB; Kim, B; Landman, SR; Mansky, LM; Patterson, SE; Rawson, JM; Reilly, CS; Roth, ME; Xie, J | 1 |
| Agarwal, HK; Chhikara, BS; Doncel, GF; Parang, K | 1 |
| Chan, DPC; Kwan, TH; Lam, TTN; Lee, KCK; Lee, SS; Lui, GCY; Wong, NS | 1 |
| Anderson, PL; Brooks, KM; Bushman, L; Castillo-Mancilla, JR; Ibrahim, M; Kiser, JJ; MaWhinney, S; Morrow, M; Nemkov, C; Peterson, S; Yager, JL | 1 |
| Ajana, F; Brainard, D; Chuck, SK; Collins, SE; Gandhi-Patel, B; Kityo, C; Koenig, E; Liu, Y; Makadzange, T; McNicholl, I; Natukunda, E; Orkin, C; Pikora, C; Wang, H; Wei, X; White, K | 1 |
| Barrail-Tran, A; Becker, PH; Castro Gordon, A; Catalan, P; Chéret, A; Furlan, V; Gasnault, J; Gelé, T; Gouget, H; Goujard, C; Nkam, L; Pallier, C; Taburet, AM | 1 |
| Aboud, M; Antinori, A; Arribas, JR; Brandon, DJ; Cahn, P; Clarke, AE; Curtis, L; Gartland, M; Girard, PM; Hung, CC; Man, CY; Ortiz, R; Pappa, KA; Rockstroh, JK; Sierra Madero, J; Sievers, J; Smith, KY; Underwood, M; Urbaityte, R; van Wyk, J; Wynne, B | 1 |
| Brand, RM; Chitwarakorn, A; Cranston, RD; Curlin, ME; Doncel, G; Hendrix, CW; Holtz, TH; Johnson, S; Kunjara Na Ayudhya, RP; Marzinke, MA; McGowan, IM; Piper, J; Raengsakulrach, B; Rooney, JF; Schwartz, JL | 1 |
| Bucovsky, M; Hoover, DR; Olali, AZ; Ross, RD; Shane, E; Shi, Q; Yin, MT | 1 |
| Adamson, J; Cele, S; Derache, A; Gosnell, BI; Govender, K; Gupta, RK; Harrichandparsad, R; Jeena, PM; Karim, F; Khan, K; Kløverpris, H; Lustig, G; Marais, S; Moosa, MS; Ngoepe, A; Ntshuba, N; Patel, VB; Sigal, A | 1 |
| Cruz, D; DeJesus, E; Hinestrosa, F; Nguyen, V; Patel, K; Rolle, CP | 1 |
| Balboa-Barreiro, V; Castro-Iglesias, Á; Cid-Silva, P; Fernández-Oliveira, C; Giménez-Arufe, V; López-Calvo, S; Margusino-Framiñán, L; Martín-Herranz, I; Martínez-Pradeda, A; Mena-De-Cea, Á; Míguez-Rey, E; Rotea-Salvo, S; Vázquez-Rodríguez, P | 1 |
| Allavena, C; Bani-Sadr, F; Cabie, A; Cuzin, L; Deschanvres, C; Duvivier, C; Hocqueloux, L; Joly, V; Lamaury, I; Palich, R; Raffi, F; Rey, D; Reynes, J; Robineau, O | 1 |
| Gao, LY; Hu, Y; Huang, XJ; Ma, P; Wu, H; Wu, Y; Xia, H; Yan, ZF | 1 |
| Antoni, G; Charreau, I; Chas, J; Chidiac, C; Cua, E; Delaugerre, C; Gras, J; Meyer, L; Molina, JM; Pillet, M; Raffi, F; Spire, B; Tremblay, C | 1 |
| Affram, Y; Benedetti, F; Bryant, J; Denaro, F; Heredia, A; Latinovic, OS; Munawwar, A; Ramadhani, HO; Reitz, M; Rikhtegaran-Tehrani, Z; Romerio, F; Sajadi, MM; Tagaya, Y; Weichseldorfer, M; Williams, SP; Zella, D | 1 |
| Bukkems, VE; Burger, DM; Colbers, AP; Garcia, C; Hidalgo-Tenorio, C; Richel, O; van Hulzen, AGW | 1 |
| Cogill, D; Decloedt, E; Gandhi, M; Jennings, L; Kellermann, T; Nkantsu, Z; Orrell, C; Spinelli, M; van Schalkwyk, M; van Zyl, G | 1 |
| Bazzi, R; Roa, PE | 1 |
| Brown, TT; Chege, W; Chen, YQ; Gulick, RM; Hendrix, CW; Klingman, KL; Landovitz, RJ; Marzinke, MA; Mayer, KH; Mccauley, MB; Wilkin, TJ; Yuhas, K | 1 |
| Cheng, CN; Chuang, YC; Hung, CC; Kuo, CH; Lin, KY; Lin, SW; Lin, YJ; Lin, YT; Liou, BH; Liu, WC; Sun, HY | 1 |
| Boucher, C; de Bree, G; Dijkstra, M; Prins, H; Prins, JM; Reiss, P; Rokx, C; Verbon, A | 1 |
| Akpomiemie, G; Jamieson, L; Johnson, LF; Makhubele, L; Mashabane, N; Meyer-Rath, G; Serenata, C; Sokhela, S; Venter, WDF | 1 |
| Hill, A; Pilkington, V; Shah, S | 1 |
| Blumenthal, J; Corado, K; Ellorin, E; He, F; Jain, S; Kofron, R; Landovitz, R; Moore, DJ; Morris, S; Ntim, GM; Rivet Amico, K; Stockman, JK | 1 |
| Antoniak, S; Begovac, J; Dragovic, G; Fleischhans, L; Gokengin, D; Harxhi, A; Hofman, S; Jilich, D; Kase, K; Kowalska, J; Lakatos, B; Matulionyte, R; Oprea, C; Papadopoulus, A; Rukhadze, N; Vassilenko, A; Vasyliev, M; Verhaz, A; Wasilewski, P; Yancheva, N | 1 |
| Barbini, B; Campbell, L; Fox, J; Gilleece, Y; Ibrahim, F; Orkin, C; Post, FA; Samarawickrama, A; Tariq, S; Waters, L | 1 |
| Bon, I; Borderi, M; Calza, L; Colangeli, V; Lazzarotto, T; Miani, T; Nuti, B; Viale, P | 1 |
| Blake, K; Cottrell, M; Doncel, GF; Fang, X; Jacot, TA; Ju, S; Ouattara, LA; Schwartz, J; Sykes, C; Thurman, AR; Vann, NC | 1 |
| Amin, J; Bavinton, BR; Carr, A; Chan, C; Dharan, NJ; Fraser, D; Grulich, AE; Holden, J; Jin, F; Ooi, C; Power, C; Vaccher, S; Vaughan, M; Yeung, B | 1 |
| Acosta, R; Andreatta, K; Chang, S; D'Antoni, ML; Martin, H; Martin, R; White, KL | 1 |
| Aidara, M; Alleyo, A; Diallo, K; Manga, NM; Wembulua, BS | 1 |
| Chang, HM; Chou, CH; Tsai, HC | 1 |
| Gelman, M; Holmes, J; Kraft, J; Mayer, KH; Melbourne, K; Mimiaga, MJ | 1 |
| Barrail-Tran, A; Benzemrane, MS; Bourgeois, C; Gelé, T; Gouget, H; Labarthe, L; Lambotte, O; Le Calvez, P; Le Grand, R; Legrand, N | 1 |
| Jamison, TF; Mear, SJ; Nguyen, LV; Rochford, AJ | 1 |
| Cressey, TR; Dossantos, S; Drain, PK; Niu, X; Sandlin, RD; Sevenler, D; Toner, M | 1 |
| Barbosa, AKP; Batista, JDL; Montarroyos, UR; Monteiro, P; Montenegro, D | 1 |
| Ambrosioni, J; Berrocal, L; Blanco, JL; Chivite, I; de la Mora, L; de Lazzari, E; González-Cordón, A; Inciarte, A; Laguno, M; Leal, L; Mallolas, J; Martinez, E; Martínez-Rebollar, M; Miró, JM; Rojas Liévano, J; Torres, B; Ugarte, A | 1 |
| Alcaraz, A; Alejos, B; Alonso Socas, MDM; Belza, MJ; Espacio, R; Garaialde, A; García-Yubero, C; Gómez-Ayerbe, C; Gutiérrez Cuéllar, I; Hernández, J; Jarrín, I; Martínez Madrid, OJ; Muñoz Sánchez, J; Olalla, J; Pierola Ruiz de Galarreta, B; Ruiz-Algueró, M; Suárez-García, I | 1 |
| Ciaranello, AL; Clement, ME; Cohen, MS; Freedberg, KA; Grinsztejn, B; Hyle, EP; Landovitz, RJ; Le, MH; McCauley, M; Neilan, AM; Paltiel, AD; Reddy, KP; Walensky, RP; Wattananimitgul, N | 1 |
| Han, J; Li, B; Liu, Y; Xiao, J; Zhang, L; Zhao, H | 1 |
| Bamford, L; Burkholder, GA; Cachay, ER; Christopoulos, K; Crane, HM; Delaney, JAC; Eron, JJ; Gravett, RM; Jacobson, JM; Keruly, J; Kitahata, MM; Ma, J; Martin, J; Mayer, KH; Moore, RD; Nance, RM; Napravnik, S; Saag, MS; Whitney, BM | 1 |
| Abdool Karim, Q; Abdool Karim, SS; Archary, D; Garcia-Lerma, JG; Heneine, W; Holder, A; Jewanraj, J; Liebenberg, LJP; Mansoor, LE; McKinnon, LR; Mtshali, A; Ngcapu, S; Osman, F; Passmore, JAS; Sivro, A | 1 |
| Anderson, M; Badal-Faesen, S; Bhattacharya, D; Chinula, L; Cloherty, G; Gaseitsiwe, S; Hawkins, C; Holzmayer, V; Kang, M; Kuhns, M; Lama, J; Matining, R; Mulinda, N; Murphy, R; Peters, M; Samaneka, W; Sugandhavesa, P; Thio, C | 1 |
| Chang, SF; Chang, SY; Chuang, YC; Hsiao, CY; Hsieh, TW; Hsu, JY; Huang, YS; Hung, CC; Liu, WC; Su, YC; Sun, HY | 1 |
| Bassetti, M; Beltramini, S; Briano, F; Bruno, SR; Di Biagio, A; Ferrara, S; Giacomini, M; Lo Caputo, S; Magnasco, L; Mora, S; Pincino, R; Poliseno, M; Sarteschi, G; Sasso, E; Taramasso, L | 1 |
| Egger, M; Goldstein, F; Hauser, A; Kouyos, RD; Reichmuth, ML; Riou, J; Wandeler, G | 1 |
| Ando, N; Aoki, T; Ishizuka, N; Mizushima, D; Oka, S; Takano, M; Uemura, H; Watanabe, K; Yanagawa, Y | 1 |
| Abdool Karim, Q; Akolo, C; Amparo da Costa Leite, PH; Azwa, I; Baggaley, R; Cáceres, CF; Dalal, S; Dourado, I; Green, K; Hettema, A; Hoornenborg, E; Jana, S; Kerschberger, B; Mahler, H; Matse, S; McManus, H; Molina, JM; Reza-Paul, S; Schaefer, R; Shahmanesh, M; Silva, R; Taylor, D; Vega-Ramirez, H; Veloso, VG | 1 |
| Aydin, OA; Bilge, B; Bolukcu, S; Dokmetas, I; Gumuser, F; Gunduz, A; Karaosmanoglu, HK; Mete, B; Tabak, F; Yildiz, DS | 1 |
| Bakshi, RP; Chaturvedula, A; Fuchs, EJ; Hendrix, CW; Marzinke, MA; Shieh, E; Tanaudommongkon, A | 1 |
| Hackett, C; Murray, G; Roche, D; Tobin, AM | 1 |
| Adeyeye, A; Agyei, Y; Anderson, PL; Bushman, LR; Chau, G; Cohen, MS; Cummings, V; Delany-Moretlwe, S; Eshleman, SH; Farrior, J; Fogel, JM; Ford, S; Haines, CD; Hanscom, B; Hendrix, CW; Hosseinipour, M; Hughes, JP; Hunidzarira, P; Kofron, R; Marzinke, MA; Mathew, CA; Mellors, J; Mpendo, J; Nair, G; Persaud, D; Petropoulos, C; Piwowar-Manning, E; Richardson, P; Rinehart, A; Rooney, JF; Spooner, E; St Clair, M; Sullivan, P | 1 |
| Alejos, B; Antonio Iribarren, J; Asensi, V; Galera, CE; García Yubero, C; Jarrín, I; Muñoz, A; Pascual-Carrasco, M; Pasquau, F; Riera Jaume, M; Ruiz-Algueró, M; Suárez-García, I | 1 |
| Adeyeye, A; Anderson, PL; Beigel-Orme, S; Bock, P; Cohen, MS; Delany-Moretlwe, S; Eshleman, SH; Farrior, J; Hanscom, B; Hendrix, CW; Hosek, S; Hosseinipour, MC; Hughes, JP; Hunidzarira, P; Kalonji, D; Kayange, N; Makhema, J; Mandima, P; Marzinke, MA; Mathew, C; Mgodi, N; Mpendo, J; Mukwekwerere, P; Nair, G; Nakabiito, C; Ntege, PN; Nuwagaba-Biribonwoha, H; Ouma, SG; Panchia, R; Rinehart, A; Rooney, JF; Rose, S; Singh, N; Sista, N; Siziba, B; Smith, K; Spooner, E; Spreen, WR; Tolley, E | 1 |
| Acosta, RK; Cihlar, T; D'Antoni, ML; Mulato, A; White, KL; Yant, SR | 1 |
| de la Court, F; de Vries, HJ; Hoornenborg, E; Jurriaans, S; Koole, JC; Op de Coul, EL; Prins, M; Stalenhoef, JE; Welkers, MR; Yap, K | 1 |
| Joob, B; Wiwanikit, V | 1 |
| Acosta, R; Andreatta, K; Blair, C; Chang, S; Collins, SE; D'Antoni, ML; Daar, ES; Gallant, J; Hagins, D; Liu, H; Martin, H; Martin, R; McNicholl, I; Molina, JM; Sax, PE; White, KL | 1 |
| Anderson, P; Baeten, JM; Celum, CL; Choopanya, K; Garcia-Cremades, M; Glidden, DV; Grant, R; Hendrix, CW; Jarlsberg, L; Jayachandran, P; Marrazzo, J; Martin, M; Savic, RM; Vanichseni, S; Vučićević, K | 1 |
| Buskin, S; Cannon, CA; Dombrowski, J; Golden, MR; Ramchandani, MS | 1 |
| Alessandri-Gradt, E; Martin, C; Plantier, JC; Unal, G | 1 |
| Ehteshami, M; Patel, D; Schinazi, RF | 1 |
| Carrozzo, G; Cattaneo, D; Gervasoni, C; Poloni, A; Riva, A | 1 |
| Abdool Karim, Q; Abdool Karim, SS; Baxter, C | 1 |
| Bookstaver, PB; Clary, JC; Derrick, C; Drummond, M; Rowe, SM; Sanasi, K | 1 |
| Blanco, JL; Callau, P; de la Mora, L; de Lazzari, E; Gonzalez-Cordón, A; Inciarte, A; Laguno, M; Mallolas, J; Martinez, E; Martinez-Rebollar, M; Rojas, J; Subirana, M; Torres, B | 1 |
| Berenguer, J; Blair, C; Chuck, SK; D'Antoni, ML; De Wit, S; Gallant, J; Haubrich, R; Maggiolo, F; Martin, H; McNicholl, IR; Molina, JM; Piontkowsky, D; Pulido, F; Rizzardini, G; Vandekerckhove, L | 1 |
| Harrington, P; Hayes, C; Marshall, L; Moran, P; O Murchu, E; Ryan, M; Teljeur, C | 1 |
| Chambon, P; Freel Meyers, C; Hern, FY; Liptrott, N; Liu, C; McDonald, TO; Neary, M; Owen, A; Rannard, SP; Shakil, A; Temburnikar, K | 1 |
| Drak, D; Gowers, A; Gracey, DM; Lin, J | 1 |
| Bernardino, JI; de Gea Grela, A; Martín Carbonero, L; Micán, R; Ramos, L; Valencia, ME | 1 |
| Cottrell, ML; Imaz, A; Kashuba, ADM; Morenilla, S; Niubo, J; Podzamczer, D; Saumoy, M; Scévola, S; Soriano, I; Tiraboschi, J; Van Horne, B | 1 |
| Bhattacharya, D; Butler, K; Chakhtoura, N; Currier, JS; Dula, D; Fowler, MG; George, K; Govender, V; Kiweewa, FM; Mohtashemi, N; Moodley, D; Musoke, P; Peters, MG; Ship, H; Tierney, C; Vhembo, T | 1 |
| Post, FA; Sinxadi, P | 1 |
| Fernandez, G; Imaz, A; Navarro, A; Piatti, C; Podzamczer, D; Prieto, P; Saumoy, M; Scevola, S; Silva, A; Tiraboschi, J | 1 |
| Aceiton, J; Bruguera, A; Casabona, J; Deig, E; Díaz, Y; Domingo, P; Imaz, A; Llibre, JM; Miro, JM; Moreno, S; Navarro, G; Navarro, J; Nomah, DK; Reyes-Urueña, J; Vivanco-Hidalgo, RM | 1 |
| Amico, KR; Andrew, P; Chege, W; Chen, YQ; Cottle, LM; Eshleman, SH; Farley, JE; Frank, I; Gulick, RM; Hendrix, CW; Ho, K; Landovitz, RJ; Liu, AY; Magnus, M; Marcus, C; Marzinke, MA; Mayer, KH; McCauley, M; Richardson, P; Rinehart, AR; Rooney, JF; Salata, RA; Santana, J; Stekler, JD; Wilkin, T; Yuhas, K | 1 |
| Aguilar, G; Ávila-Ríos, S; De Arias, AR; García-Morales, C; Giron, A; Lopez, G; López-Sánchez, DM; McFarland, W; Ovelar, P; Rios-Gonzalez, C; Samudio, T; Tapia-Trejo, D; Truong, HM | 1 |
| Czarnogorski, M; Evans, TM; Pilgrim, NA | 1 |
| Bonnichsen, MH; Bye, W; Post, JJ; Tschuchnigg, M | 1 |
| Audo, I; Joharjy, H; Le-Lez, ML; Pisella, PJ | 1 |
| García-Lerma, JG; Heneine, W; McNicholl, JM | 1 |
| Flexner, C | 1 |
| Liegeon, G | 1 |
| Mellors, JW; Parikh, UM | 2 |
| Abel, S; Ajana, F; Avettand-Fenoel, V; Bauer, R; Calin, R; Chéret, A; Goujard, C; Lacombe, K; Lascoux, C; Lopez, P; Meiffrédy, V; Meyer, L; Morlat, P; Reynes, J; Rouzioux, C | 1 |
| Algarte-Genin, M; Assoumou, L; Ben-Mechlia, M; Beniguel, L; Costagliola, D; Delaugerre, C; Ghosn, J; Goldwirt, L; Katlama, C; Le Mestre, S; Liegeon, G; Lourenco, J; Loze, B; Molina, JM; Mouhim, H; Ohayon, M; Pavie, J; Pialoux, G; Rojas-Castro, D; Slama, L; Spire, B; Surgers, L | 1 |
| Ferrara, P; Gianfredi, V | 1 |
| Chahine, EB; Durham, SH; Milam, A; Waer, D | 1 |
| Bossolasco, S; Bruzzesi, E; Carini, E; Castagna, A; Chiurlo, M; Galli, L; Gianotti, N; Lazzarin, A; Mancusi, D; Mastrangelo, A; Nozza, S; Poli, A; Ranzenigo, M; Spagnuolo, V; Termini, R | 1 |
| Chang, HY; Chang, SF; Chang, SY; Chen, GJ; Chen, LY; Chuang, YC; Hsieh, SM; Huang, YS; Hung, CC; Lin, KY; Liu, WC; Liu, WD; Luo, YZ; Sheng, WH; Su, YC; Sun, HY; Wu, PY | 1 |
| Andreoni, M; Antinori, A; Armenia, D; Berno, G; Bertoli, A; Borghi, V; Buonomini, A; Ceccherini-Silberstein, F; Cicalini, S; Forbici, F; Gagliardini, R; Gennari, W; Lanini, S; Latini, A; Malagnino, V; Mussini, C; Perno, CF; Santoro, MM; Sarmati, L; Teti, E | 1 |
| Babusis, D; Bilello, JP; Chan, J; Cihlar, T; Cohen, C; Du Pont, V; Duong, V; Feng, JY; Gordon, CJ; Götte, M; Juneja, K; Perry, JK; Tchesnokov, EP; Vijjapurapu, A; Zhao, X | 1 |
| Barry, S; Chopra, A; Ibrahim, A; Pokhrel, K; Smith, T | 1 |
| Anderson, P; Bushman, L; Cardoso, SW; Castro, CRV; Cattani, VB; Eksterman, L; Estrela, R; Grinsztejn, B; Jalil, EM; Monteiro, L; Torres, T; Veloso, VG; Wilson, E | 1 |
| Arribas, JR; Bernardino, JI; Busca, C; Cadiñanos, J; de Gea Grela, A; de Miguel, R; González-García, J; Martín-Carbonero, L; Micán, R; Montejano, R; Montes, ML; Moreno, V; Pérez Valero, I; Serrano, L; Valencia, E | 1 |
| Aoun-Barakat, L; Cartwright, EJ; Casas, JP; Dickerman, BA; Hernán, MA; Justice, AC; Li, G; Lodi, S; Logan, RW; Park, LS; Rentsch, CT | 1 |
| Naito, T; Schmerold, L; Wang, X | 1 |
| Alhassan, Y; Bokako, S; Burger, D; Byamugisha, J; Byrne, K; Chen, T; Chiong, J; Colbers, A; Hodel, EM; Hu, NC; Khoo, S; Kintu, K; Lamorde, M; Malaba, TR; Mrubata, M; Myer, L; Nakatudde, I; Orrell, C; Read, J; Read, L; Reynolds, H; Seden, K; Stemmet, LA; Taegtmeyer, M; Theunissen, H; Twimukye, A; Waitt, C; Wang, D | 1 |
| Arribas, JR; Borobia, AM; Carcas, AJ; Ciudad, M; de la Calle-Prieto, F; de Miguel, M; Del Álamo, M; Díaz-Brasero, A; Díez, C; Estrada, V; Goikoetxea, AJ; González-Ruano, P; Guijarro, C; Gutiérrez, Á; Ibarra, S; Ibarrola, M; Jiménez-González, M; Marcelo, C; Marcos, J; Martínez, P; Merino, E; Montejano, R; Moreno, S; Novella, M; Queiruga-Parada, J; Rivera, MA; Ruiz-Muñoz, M; Ryan, P; Soler, L; Torralba, M; Velasco, M | 1 |
| Dobard, C; García-Lerma, JG; Gary, J; Gatto, G; Heneine, W; Holder, A; Johnson, L; Khalil, G; Krovi, A; Li, L; Luecke, E; Massud, I; Mills, P; Mitchell, J; Nishiura, K; Pan, Y; Ruone, S; van der Straten, A | 1 |
| Berry, E; Covaci, A; Gys, C; Heytens, L; Jacobs, W; Lambert, W; Meskal, A; Mortelé, O; Neels, H; Schouwers, S; Van Hemeldonck, E; van Nuijs, ALN; van Rafelghem, B | 1 |
| Brunet, L; Fusco, GP; Fusco, JS; Hsu, RK; Lamori, JC; Mounzer, K | 1 |
| Alfaro, EM; Arazo, P; Arellano, JP; Arribas, JR; Bachiller, P; Buzón, L; Del Amo, J; Díaz de Santiago, A; Díaz-Brito, V; García Del Toro, M; García-Albéniz, X; Garcinuño, MA; Gómez-Sirvent, JL; Guerra, JM; Hernán, MA; Hernández-Torres, A; Hita, C; Martínez de Salazar, P; Masiá, M; Morales, M; Moreno, S; Muñoz, L; Polo, R; Rial-Crestelo, D; Santos, J; Sanz, J; Terán, C | 1 |
| Anderson, PL; Brooks, KM; Brothers, J; Glenny, C; Hosek, S; Landovitz, R; Malhotra, M; Mulligan, K; Reirden, D; Yager, J | 1 |
| Chiodi, F; Else, L; Fox, J; Gray, CM; Herrera, C; Kaleebu, P; Khoo, S; Lebina, L; Martinson, N; Mugaba, S; Namubiru, P; Odoch, G; Opoka, D; Petkov, S; Pillay, AAP; Seiphetlo, TB; Serwanga, J; Ssemata, AS; Webb, EL | 1 |
| Decloedt, EH; Esterhuizen, T; Joska, JA; Kamau, F; Kellermann, T; Khoo, S; Maartens, G; Solanke, T; Strijdom, H | 1 |
| Appolloni, L; Bon, I; Calza, L; Pensalfine, G; Viale, P; Vitale, S | 1 |
| Buskin, SE; Dombrowski, JC; Golden, MR; Herbeck, JT; Kerani, RP; Lechtenberg, RJ; Slaughter, FA | 1 |
| Hsiao, NY; Hu, NC; Joseph Davey, D; Mashele, N; Mvududu, R; Myer, L; Sonderup, M; Wendy Spearman, C | 1 |
| Adebisi, SA; Adedeji, NO; Adedeji, TA; Ajeigbe, AK; Ajose, AO; Akande, AA; Fawale, MB; Jeje, OA; Okesina, BA; Smith, OS | 1 |
| Anderson, PL; Blumenthal, J; Bolan, R; Burke, L; Chow, K; Corado, K; Dubé, MP; He, F; Henderson, P; Jain, S; Moore, DJ; Morris, SR; Sun, S | 1 |
| Cao, T; He, Y; Jia, X; Ju, B; Liu, J; Liu, X; Peng, Q; Rao, M; Song, Y; Sun, L; Wang, H; Wang, S; Xu, L; Zhang, H; Zhang, L; Zhang, Q; Zhao, F; Zhou, J; Zhou, Y | 1 |
| Brady, M; Chen, YQ; Cover, J; Cressey, TR; Drain, P; Duerr, A; Kariithi, E; Mori, K; Obanda, R; Obong'o, C; Okomo, G; Oluoch-Madiang, D; Tapsoba, JD | 1 |
| Bogoch, II; Nhean, S; Sheehan, NL; Tseng, A | 1 |
| Anderson, PL; Brothers, J; Hosek, S; Huhn, G; Keckler, K; Liu, H; Xiong, D | 1 |
| Granade, TC; Heneine, W; Pau, CP; Pohl, J; Reed, MS; Switzer, WM; Vanderford, TH; Youngpairoj, AS | 1 |
| Alcantarini, C; Bono, V; Bonora, S; Calcagno, A; Cannizzo, ES; Cusato, J; D'Avolio, A; De Nicolò, A; De Vivo, E; Di Perri, G; Ferrara, M; Ianniello, A; Marchetti, G; Nozza, S; Salvador, E; Trentalange, A; Trunfio, M | 1 |
| Hideta, K; Higasa, S; Hikasa, S; Kimura, T; Sawada, A; Shimabukuro, S; Tanaka, K; Tokugawa, T; Yanai, M | 1 |
| Hebel, SK; Hermans, LE; Lalla-Edward, ST; Nijhuis, M; Tempelman, HA; Umunnakwe, CN; Venter, WDF; Wensing, AMJ | 1 |
| De Clercq, E | 3 |
| Chen, T; Gui, F; Tan, J; Wei, G; Yang, J; Zhao, Y | 1 |
| Baxter, C; Beyer, A; Derkach, E; Lobodina, A; Pyadushkina, E; Rozenberg, V; Ugrekhelidze, D | 1 |
| Barham, L; Dzinamarira, T; Mhango, M; Moyo, E; Musuka, G | 1 |
| Abdool Karim, Q; Abdool Karim, SS; Archary, D; Elsherbini, JA; Kwon, DS; Lewis, L; Mansoor, LE; Mazibuko-Motau, N; Mtshali, A; Mzobe, G; Ngcapu, S; Ntuli, L; San, JE; Sobia, P; Xu, J | 1 |
| Assoumou, L; Beniguel, L; Costagliola, D; Duvivier, C; El Mouhebb, M; Genin, M; Ghosn, J; Goldwirt, L; Liegeon, G; Molina, JM; Palacios, C; Palich, R; Rojas Castro, D; Slama, L; Surgers, L | 1 |
| Aurpibul, L; Best, BM; Campbell, H; Cassim, H; Cooper, E; Flynn, P; Gray, KP; Krotje, C; McCarthy, K; McFarland, E; Melvin, AJ; Moye, J; Ounchanum, P; Rungmaitree, S; Scheckter, R; Teppler, H; Tobin, NH; Townley, E; Wan, H; Yedla, M; Yee, KL | 1 |
| Chang, J; Delgado, H; Do, D; Huynh, A; Kanimian, N | 1 |
| Ali, S; Bayserkin, B; Dzissyuk, N; Issanov, A; Mukhatayev, Z; Mukhatayeva, A; Mustafa, A; Vermund, SH | 1 |
| Blair, HA | 1 |
| Derkach, EV; Pyadushkina, EA | 1 |
| Abdul Massih, S; Andrade, A; Beselman, S; Breakey, J; Fuchs, EJ; Hendrix, CW; Marzinke, MA; McNicholl, I | 1 |
| Aung, W; Bakshi, RP; Bream, JH; Bumpus, NN; Coleman, JS; Diniz, CP; Farzadegan, H; Fuchs, EJ; Hendrix, CW; Hudson, S; Marzinke, MA; Nilles, TL; Rooney, JF; Rosenblum, MA; Schwartz, GJ | 1 |
| Buscemi, L; Mossholder, B | 1 |
| Alix, A; Bois, J; Brucato, S; Dargere, S; Fournel, F; Fournier, A; Got, L; Gregoire, N; Hocqueloux, L; Lefeuvre, S; McNicholl, I; Parienti, JJ; Peyro-Saint-Paul, L; Prazuck, T; Valentin, C | 1 |
| Agot, K; El-Sadr, WM; Franks, J; Lahuerta, M; Lamb, MR; Mantell, J; Naitore, D; Omollo, D; Reed, DM; Zerbe, A | 1 |
| Delany-Moretlwe, S; Hosseinipour, MC; Jamieson, L; Johnson, LF; Meyer-Rath, G; Nichols, BE; Russell, C | 1 |
| Boodhram, R; Dooley, KE; Dorse, G; Naidoo, A; Naidoo, K; Osuala, EC; Padayatchi, N; Perumal, R; Yende-Zuma, N | 1 |
| Achila, OO; Andegiorgish, AK; Ghebrat, HB; Ghebremeskel, GG; Ghebrenegus, AS; Leake, N; Mengistu, ST; Mesfin, AB; Wendmhuney, FG; Yeibyo, N; Yohannes, NA | 1 |
| Ondrush, NM; Sidman, EF | 1 |
| Johnson, TM; Rivera, CG | 1 |
| Arribas, JR; Cabello, A; Curran, A; de la Cámara, SP; Del Amo, J; Díaz, A; Dueñas, C; Hernán, MA; Iribarren, JA; Jarrín, I; Macías, J; Mariño, AI; Martínez, E; Montero, M; Moreno, S; Polo, R | 1 |
| Andreoni, M; Barchi, V; De Simone, G; Iannazzo, R; Iannetta, M; Massa, B; Rindi, LV; Sarmati, L | 1 |
| Chen, CP; Hung, CC; Hung, TC; Lee, CH; Lee, CY; Lee, YT; Li, CW; Liou, BH; Liu, CE; Sun, HY; Tang, HJ; Tsai, MS; Yang, CJ | 1 |
| Alcalá, JC; Castro, A; Grau, S; Miró, JM; Olalla, J; Rubio-Rodríguez, D; Rubio-Terrés, C | 1 |
| Kanie, N; Katoh, S; Takahashi, K; Yamauchi, M | 1 |
| Eckardt, PA; Montalvo, S; Partosh, D; Sherman, EM; Unger, N | 1 |
| Benson, CA; Blaschke, TF; Browne, SH; Tucker, AJ; Umlauf, A; Vaida, F | 1 |
| Conway-Washington, C; Dinh, C; Edwards, TE; Fountain, J; García-Lerma, JG; Haaland, RE; Hall, L; Heneine, WM; Holder, A; Kelley, CF; Lupo, LD; Martin, A; Massud, I | 1 |
| Akpomiemie, G; Bosch, B; Chandiwana, N; Hill, A; McCann, K; Mirchandani, M; Qavi, A; Sokhela, S; Venter, WDF | 1 |
| Burger, DM; Colbers, A; Grintjes, K; Jacobs, TG; Nieuwenstein, T; Zino, L | 1 |
| Baeten, JM; Benson, P; Berhe, M; Crofoot, G; Dvory-Sobol, H; Gupta, SK; Koenig, E; Liu, SY; McDonald, C; Ramgopal, M; Rhee, MS; Ruane, P; Sanchez, WE; Scribner, A; Sims, J; VanderVeen, LA | 1 |
| Liu, QZ; Qin, QQ; Tang, HL; Xu, P; Yang, X | 1 |
| Fan, L; Gao, L; Hu, Y; Huang, R; Li, L; Ma, P; Qiu, C; Wu, Y; Yu, A; Zhang, D | 1 |
| Bouldouyre, MA; Brun, A; Caraux-Paz, P; Chabrol, A; De Castro, N; Delaugerre, C; Froguel, E; Garrait, V; Hamet, G; Mechaï, F; Molina, JM; Rozenbaum, W; Sellier, P; Troisvallets, D | 1 |
| Bischof, JJ; Boyer, EW; Chai, P; Merchant, RC; Mohamed, Y; Padappayil, R; Reyes-Gibby, CC; Rosen, R; Viamonte, M; W Carrico, A | 1 |
| Griesel, R; Hill, A; Keene, C; Maartens, G; Meintjes, G; Omar, Z; Simmons, B; van Zyl, G; Zhao, Y | 1 |
| Anderson, PL; Glidden, DV; Marzinke, MA | 1 |
| Assoumou, L; Bachelard, A; Benalycherif, A; Charpentier, C; Descamps, D; Donadille, C; Duvivier, C; El Mouhebb, M; Ghosn, J; Isernia, V; Lacombe, K; Landman, R; Mora, M; Peytavin, G; Spire, B | 1 |
| Aristegui, I; Cahn, P; Cardozo, N; Cesar, C; Figueroa, MI; Fink, V; Frola, CE; Gun, A; Patterson, P; Radusky, PD; Sued, O; Zalazar, V | 1 |
| Mekraksakit, P; Nichols, J; Nugent, K; Parmar, K | 1 |
| Cassidy, T; Flowers, T; Goemaere, E; Griesel, R; Hill, A; Jackson, A; Keene, CM; Maartens, G; Meintjes, G; Ngwenya, O; Omar, Z; Sayed, K; Van Zyl, G; Zhao, Y | 1 |
| Chen, M; Huobu-Mo, M; Li, C; Li, J; Wu, M; Xiao, H; Zeng, L; Zhang, Y | 1 |
| Bu Dou Re Xi Ti, GA; Dai, L; Gao, Y; Hua, W; Li, A; Li, J; Li, Z; Liu, A; Shao, Y; Sun, L; Wang, X; Wang, Z; Wu, RE; Xin, R; Ye, J; Zhang, H | 1 |
| Akodu, J; Ambrose, A; Barber, TJ; Bowman, C; Flores, K; Hart, J; Hunter, A; Kanitkar, T; Simoes, P | 1 |
| Donald, JL; Gift, TL; Salas, SB; Schmidt, MA; Tao, G | 1 |
| Clark, R; Desmond, AC; Govender, V; Gray, G; Lombard, C; Mhlongo, O; Moodley, D; Naidoo, K; Naidoo, M; Newell, ML; Rooney, JF; Sebitloane, M | 1 |
| Brunet, L; Dunbar, M; Fusco, GP; Fusco, JS; McCurdy, LH; McNicholl, IR; Mounzer, K; Sension, M | 1 |
| Chang, HY; Chen, LY; Chuang, YC; Huang, YS; Hung, CC; Lin, KY; Liu, WC; Liu, WD; Luo, YZ; Su, YC; Sun, HY; Wu, PY | 1 |
| Castro, H; Collins, IJ; Jesson, J; Judd, A; Leroy, V; Milanzi, E; O'Rourke, J; Penazzato, M; Renaud, F; Townsend, CL; Vicari, M | 1 |
| Asselin, J; Carter, A; Chen, M; Donovan, B; Gracey, DM; Grulich, A; Guy, R; Heron, JE; Lewis, DA; McManus, H; O'Connor, CC; Ryan, K; Ryder, N; Stoove, M; Templeton, DJ; Varma, R; Vickers, T; Wright, E | 1 |
| Del Amo, J | 1 |
| Castano, J; DeJesus, E; Hinestrosa, F; Nguyen, V; Patel, K; Rolle, CP | 1 |
| Avihingsanon, A; Chetchotisakd, P; Kiertiburanakul, S; Martin, H; Ratanasuwan, W; Siripassorn, K; Supparatpinyo, K; Wang, H; Wang, HY; Wong, T | 1 |
| Anderson, D; Bushen, J; Cai, J; Dunn, K; Luo, D; Simonson, RB | 1 |
| Burke, RL; Caro, L; Grant, EM; Kowalczyk, UM; Lalezari, JP; Main, DW; Manning, CM; Sterman, FL | 1 |
| Badowski, ME; Brizzi, M; Chastain, DB; Cluck, D; Drwiega, EN; Durham, SH; Green, SB; Michienzi, SM; Nicol, MR; Nowicki, DN; Sahloff, EG; Sherman, EM; Truong, WR | 1 |
| Baum, MM; Gallay, PA; Ramirez, CM | 1 |
| Galindo, MJ; González, CS; Lillo, IS; Rodríguez, AP | 1 |
| Burns, JA; Hull, SJ; Inuwa, A; Moriarty, P; Scott, RK | 1 |
| Adeyeye, A; Anderson, PL; Arduino, RC; Bhandari, P; Bushman, LR; Chariyalertsak, S; Cohen, MS; Eshleman, SH; Fogel, JM; Ford, SL; Gollings, R; Grinsztejn, B; Halvas, EK; Hanscom, B; Hendrix, CW; Kofron, R; Landovitz, RJ; Marzinke, MA; Mayer, K; McCauley, M; Mellors, J; Moser, A; Persaud, D; Piwowar-Manning, E; Rinehart, AR; Rooney, JF; St Clair, M; Wang, Z; Weng, L | 1 |
| Allavena, C; Arvieux, C; Becker, A; Cabié, A; Chéret, A; Delpierre, C; Duvivier, C; Hocqueloux, L; Joly, V; Menard, A | 1 |
| Allard, SD; Ausselet, N; Darcis, G; De Wit, S; Delforge, M; Demeester, R; Florence, E; Henrard, S; Messiaen, P; Nasreddine, R; Van Praet, J; Vandekerckhove, L; Yombi, JC | 1 |
| Arshad, I; Feinstein, A; Gandhi, M; Gossai, M | 1 |
| Guevara-Maldonado, MF; Kammar-García, A; Mancilla-Galindo, J; Mata-Marín, JA; Ortiz-Hernández, A; Pérez-Barragán, E; Pérez-Cavazos, S | 1 |
| Corona, D; Lluis, C; López-Cavanillas, M; Luque, I; Martínez, N; Pérez-Valero, I | 1 |
| Coltart, H; Dominguez, L; Fitzgerald, N; Flanagan, K; Gilleece, Y | 1 |
| Surial, B; Wandeler, G | 1 |
| Albendín Iglesias, H; Alejos, B; Díaz, A; Hernando, V; Jarrín, I; Moreno, S; Peraire, J; Pérez Elías, MJ; Rial-Crestelo, D; Suárez-García, I; Tiraboschi, J; Vera García, M; Viñuela, L | 1 |
| Avorn, J; Barenie, RE; Kesselheim, AS; Tessema, FA | 1 |
| Conway, B; Niyongabo, B; Zaccarelli, M | 1 |
| Amico, KR; Boyce, C; Brummel, S; Cassim, H; Chakhtoura, N; Chinula, L; Coletti, A; Currier, JS; Fairlie, L; Frenkel, LM; Hoffman, R; Jean-Philippe, P; Johnston, B; Knowles, K; Korutaro, V; Krotje, C; Lockman, S; Masheto, G; McCarthy, K; Mmbaga, BT; Moyo, S; Patel, F; Purdue, L; Rooney, JF; Sax, PE; Shapiro, R; Stranix-Chibanda, L; Stringer, J; van Wyk, J; Ziemba, L | 1 |
| Cao, B; Ding, P; Huang, F; Huang, Y; Jiang, J; Jiang, T; Liu, M; Yu, Q; Yuan, T; Zhou, X | 1 |
| Chen, X; Kou, L; Li, J; Li, Y; Wei, D; Xie, X | 1 |
| Han, M; Liu, H; Liu, J; Shan, D; Xue, H; Yu, F; Zan, X; Zhang, D | 1 |
| Anderson, PL; Coyer, L; Davidovich, U; de Vries, HJ; Hoornenborg, E; Prins, M; Schim van der Loeff, MF; van den Elshout, MA | 1 |
| Daharwal, SJ; Singh, VD; Singh, VK | 1 |
| Alinde, B; Besethi, A; Chiodi, F; Else, L; Fox, J; Gray, CM; Herrera, C; Kaleebu, P; Khoo, S; Leach, L; Lebina, L; Malhangu, B; Martinson, N; Mbangiwa, T; Motaung, B; Mugaba, S; Namubiru, P; Odoch, G; Opoka, D; Petkov, S; Pillay, AAP; Rametse, CL; Sebaa, S; Seiphetlo, TB; Serwanga, J; Ssemata, AS; Webb, EL | 1 |
| Eleje, GU; Ikechebelu, JI; Nwagha, UI; Okafor, HU; Ugwu, AO; Ugwu, EO; Umeh, UA | 1 |
| Deshpande, V; Freedberg, KA; Grinsztejn, B; Kazemian, P; Luz, PM; Pereira, G; Pimenta, C; Scott, JA; Shebl, FM; Spaeth, H; Stern, M; Struchiner, CJ; Veloso, VG | 1 |
| Hachey, D; Shiluama, R; Singu, BS; van Woerden, I | 1 |
| Bamford, A; Burger, DM; Bwakura-Dangarembizi, M; Chabala, C; Colbers, A; Denti, P; Doerholt, K; Gibb, DM; Griffiths, AL; Makumbi, S; McIlleron, HM; Monkiewicz, LN; Mulenga, V; Mumbiro, V; Musiime, V; Nangiya, J; Szubert, AJ; Waalewijn, H; Wasmann, RE; Wiesner, L | 1 |
| Brumme, CJ; DeKoven, S; Naccarato, M; Tan, DHS | 1 |
| Alieu, A; Alinde, B; Callebaut, C; Chiodi, F; Else, L; Fox, J; Gray, CM; Herrera, C; Kaleebu, P; Khoo, S; Limakatso, L; Martinson, N; Mugaba, S; Muhumuza, R; Namubiru, P; O'Hagan, K; Odoch, G; Opoka, D; Penchala, SD; Petkov, S; Pillay, AD; Seatlholo, P; Seeley, J; Seiphetlo, TB; Serwanga, J; Ssemata, AS; Webb, EL; Weiss, H | 1 |
| Álvarez-Díaz, AM; Esteban-Cartelle, B; Gramage-Caro, T; Montero-Llorente, B; Parro-Martín, MLÁ; Rodríguez-Sagrado, MÁ; Vélez-Díaz-Pallarés, M | 1 |
| Ariyawansa, J; Palmer, M; Van Hemelryck, S; Van Landuyt, E; Vanveggel, S | 1 |
| Bhagani, S; Mburu, M; Nkuranga, J; Ombajo, LA; Otieno, D; Penner, J; Pozniak, A; Wahome, S | 1 |
| Baeten, JM; Bekker, LG; Cohen, MS; Corey, L; Delany-Moretlwe, S; Donnell, D; Edupuganti, S; Gao, F; Gray, G; Hanscom, B; Hosseinipour, M; Hughes, JP; Mgodi, N; Rees, H | 1 |
| Avedissian, SN; Fletcher, CV; Mykris, TM; Podany, AT; Scarsi, KK; Weinhold, J; Winchester, LC | 1 |
| Barnabas, R; Boily, MC; Dimitrov, DT; Donnell, DJ; Doyle, CM; Hanscom, B; Heitner, J; Maheu-Giroux, M; Milwid, RM; Mitchell, KM; Moore, M; Stansfield, SE; Vijver, DV; Wang, H; Xia, Y | 1 |
| Godinez, H; Li, J; Mackey, TK; McMann, TJ; Xu, Q | 1 |
| Abalat-Torrres, A; Arrieta-Aldea, I; Cañas-Ruano, E; Canepa, C; González-Mena, A; Guelar, A; Güerri-Fernández, R; Knobel, H; Knobel, P; Marcos, A; Villar-García, J | 1 |
| Ishikawa, K; Kawai, F; Mori, N | 1 |
| Curran, A; Diaz-Brito, V; Domingo, P; Garcia, B; Imaz, A; Morenilla, S; Niubó, J; Peñafiel, J; Podzamczer, D; Scévola, S; Soriano, I; Tiraboschi, J; Verdejo, G | 1 |
| Abbasian, L; Alavian, G; Alinaghi, SAS; Ashtiani, MF; Hasannezhad, M; Khalili, H; Manshadi, SAD | 1 |
| Dominguez-Macias, M; Espinosa, N; Gutierrez-Valencia, A; Herrero, M; Lopez-Cortes, LE; Lopez-Cortes, LF; Lozano, C; Muñoz-Muela, E; Praena-Fernandez, JM; Roca-Oporto, C; Saborido-Alconchel, A; Serna-Gallego, A; Sotomayor, C; Trujillo-Rodriguez, M | 1 |
| Benfield, T; de Magalhães, JP; Escos, A; Gelpi, M; Høgh, J; Knudsen, AD; Mikaeloff, F; Neogi, U; Nielsen, SD | 1 |
| Daniels, A; Kriegel, D; Seehusen, DA | 1 |
| Angioni, G; Attala, L; Bandera, A; Bargiacchi, O; Bonfanti, P; Cascio, A; Cenderello, G; De Socio, GV; Di Biagio, A; Falasca, K; Maggi, P; Maurizio Celesia, B; Menzaghi, B; Orofino, G; Pellicanò, GF; Piconi, S; Ricci, E; Sarchi, E; Simeone, F; Squillace, N; Taramasso, L; Valsecchi, L | 1 |
| Gatanaga, H; Mizushima, D; Oka, S | 1 |
| Berni, A; Castagna, A; Cazanave, C; Chounta, V; D'Amico, R; Di Perri, G; Diaz-Brito, V; Dretler, R; Garges, HP; Latham, CL; Oka, S; Osiyemi, O; Pascual Bernáldez, M; Patel, P; Ramgopal, MN; Sims, J; Smith, K; Spreen, WR; Sutherland-Phillips, D; Sutton, K; Van Eygen, V; Van Solingen-Ristea, R; van Wyk, J; Walmsley, S; Zhang, F | 1 |
| Almangour, TA; Chang, PP; Corbett, A; Farel, CE; Rodgers, JE; Skersick, PT | 1 |
| Ahmed, A; Blazina, I; Bougatsos, C; Chou, R; Selph, S; Spencer, H | 1 |
| Fu, Y; Gan, L; Kong, L; Long, H; Ma, S; Xie, X; Yang, X | 1 |
| Chiarabini, T; Devred, I; Kayembe, K; Lacombe, K; Lambert-Niclot, S; Meyohas, MC; Rougier, H; Shinga, BW; Valin, N | 1 |
| Armstrong, I; Bourns, A; Chan, LYL; Fung, R; Halpenny, R; Hranilovic, S; Iyer, H; Jeyarajah, N; Kennedy, VL; Kia, H; Kovchazov, G; Lacombe-Duncan, A; Loutfy, M; McCully, J; Nguyen, Q; Persad, Y; Scarsi, KK; Tseng, A; Underhill, A; Weisdorf, T | 1 |
| Ripamonti, D; Zazzi, M | 1 |
| Ardila, F; Bernal, E; Casadellà, M; Curran, A; Echeverria, P; Estrada, V; Fanciulli, C; Gutierrez, A; Hernández, C; Hidalgo-Tenorio, C; Imaz, A; Knobel, H; Lagarde, M; Lopez-Lirola, A; Macias, J; Masiá, M; Montero-Alonso, M; Morano, L; Navarro-Alcaraz, A; Parera, M; Podzamczer, D; Portilla, J; Prieto, P; Rigo, R; Rivero, A; Troya, J; Valencia, E; Vivancos, MJ | 1 |
| Hsu, SJ; Hung, CT; Liu, CJ | 1 |
| Andreoni, M | 1 |
| Espinosa, A; Horta, AM; Lázaro, A; Mendoza, I; Sánchez, L; Torralba, M | 1 |
| Adeyeye, A; Cardozo, N; Cohen, MS; Coutinho, C; Donnell, D; Eshleman, SH; Feliciano, KG; Ford, S; Franks, J; Grinsztejn, B; Hanscom, B; Jalil, E; Jennings, A; Khan, T; Landovitz, RJ; Lucas, J; Maia, B; Marzinke, MA; McCauley, M; Middelkoop, K; Psaros, C; Richardson, PA; Rinehart, AR; Rooney, JF; Safren, SA; Sanchez, N; Singh, Y; Sullivan, P; Valencia, J; Wang, Z | 1 |
| Bonvillain, A; Cottrell, M; Davies, M; Degrange, P; Di Mascio, M; Ho, RJY; Jang, H; Kaplan, J; Perazzolo, S; Srinivasula, S; Tobery, A; Turnier, R | 1 |
| Anderson, PL; Bekker, LG; Boily, MC; Celum, CL; Delany-Moretlwe, S; Dimitrov, D; Donnell, DJ; Mgodi, NM; Mitchell, KM; Moore, M; Stansfield, S | 1 |
| Ait-Khaled, M; Espinosa, N; Fernvik, E; Grove, R; Gulminetti, R; Hagins, D; Man, C; Sierra Madero, J; Sievers, J; Tsai, HC; van Wyk, J; Wynne, B; Zolopa, A | 1 |
| Ambrosioni, J; Berrocal, L; Blanch, J; Blanco, JL; Borjabad, B; Chivite, I; De La Mora, L; De Lazzari, E; Foncillas, A; Gonzalez-Cordon, A; Inciarte, A; Laguno, M; Llobet, R; Mallolas, J; Martinez, E; Martinez-Rebollar, M; Miro, JM; Rocabert, A; Rodriguez, A; Sempere, A; Solbes, E; Torres, B | 1 |
| Cao, X; Peng, Y; Wang, M; Wang, Y; Yu, W; Zeng, Z | 1 |
| Martin, VO; Sunguya, BF; Tesha, NA | 1 |
| Akello, CA; Anderson, P; Baeten, JM; Bekker, LG; Brown, ER; Bunge, K; Celum, C; Garcia, M; Hendrix, C; Hillier, SL; Hosek, S; Jacobson, C; Johnson, S; Levy, L; Livant, E; Macdonald, P; McClure, T; Milan, G; Muhlanga, F; Nair, G; Nakabiito, C; Nakalega, R; Ngure, K; Palanee-Phillips, T; Parikh, U; Reddy, K; Rooney, JF; Siziba, B; Soto-Torres, L; Steytler, J; Szydlo, D; Tahuringana, E; van der Straten, A | 1 |
| Deng, Y; He, L; Li, J; Wang, Y; Wei, Y; Wen, L; Xu, R; Zhong, H | 1 |
| Fuller, B; Killelea, A; McManus, KA; Powers, SD; Rogawski McQuade, ET; Strumpf, A | 1 |
| Allan-Blitz, LT; Mayer, KH | 2 |
| Adeyeye, A; Anderson, PL; Berman, R; Clement, ME; Cohen, MS; Del Rio, C; Donnell, D; Eron, JJ; Eshleman, SH; Fields, SD; Grinsztejn, B; Hanscom, BS; Hendrix, CW; Kallas, EG; Kofron, RM; Landovitz, RJ; Lucas, JP; Magnus, M; Marzinke, MA; McCauley, M; Piwowar-Manning, EM; Richardson, PA; Rinehart, AR; Rooney, JF; Sanchez, J; Scott, H; Spinelli, MA; Sued, O; Sullivan, PA; Tran, HV | 1 |
| Bruxvoort, K; Dourado, I; Grangeiro, A; Greco, D; Magno, L; Pinto, JA; Soares, F | 1 |
| Cao, Y; Chu, M; Huang, H; Li, M; Qin, G; Zhuang, X; Zou, M | 1 |
| Chaturvedula, A; Haberer, JE; Hendrix, CW; Iannuzzi, S; Irungu, E; von Kleist, M; Zhang, L | 1 |
| Ackerman, ME; Anderson, PL; Andrew, P; Angier, H; Azzam, Y; Cohen, MS; Corey, L; Donnell, D; Edupuganti, S; Gama, L; Gilbert, PB; Huang, Y; Hural, J; Juraska, M; Karuna, S; Koup, RA; Lemos, MP; McElrath, MJ; Mgodi, NM; Morgan, E; Swann, E; Weiner, JA; Zhang, L | 1 |
| Baral, S; Hausler, H; Lesko, C; Mcingana, M; Mcloughlin, J; Mhlophe, H; Pretorius, A; Rao, A; Schwartz, S; Shipp, L | 1 |
| Balkus, JE; Bunge, K; Chakhtoura, N; Chappell, CA; Fairlie, L; Gadama, L; Hillier, SL; Matrimbira, M; Mayo, AJ; Mgodi, N; Nakabiito, C; Piper, J; Richardson, B; Szydlo, DW | 1 |
| Chung, L; Dixon, SW; Ellis, JJ; Hu, A; Rastegar, J; Schwab, P; Stevens, L | 1 |
| Chu, Z; Ding, H; Geng, W; Jia, Y; Jiang, Y; Leuba, SI; Mei, Z; Shang, H; Wang, H; Xu, J; Zhang, J; Zhang, Y | 1 |
| Allavena, C; Chauveau, M; Raffi, F | 1 |
| Andreatta, K; Chang, S; Graham, H; Liu, H; Liu, YP; Martin, H; Martin, R; Quirk, E; Wei, L; White, KL; Willkom, M | 1 |
| Dretler, RH; Moye-Dickerson, PM; Nwaesei, AS | 1 |
| Brown, K; DeJesus, E; Eron, JJ; Girard, PM; Huhn, GD; Lathouwers, E; Luo, D; Molina, JM; Nettles, RE; Orkin, C; Petrovic, R; Van Landuyt, E; Wong, EY | 1 |
| Brown, TT; Landay, A; Masters, MC; Miyahara, S; Robertson, K; Taiwo, BO; Vecchio, A | 1 |
| Bale, MJ; Boltz, VF; Coffin, JM; Currier, JS; Halvas, EK; Hogg, E; Hughes, MD; Kearney, MF; Lockman, S; Luke, B; McIntyre, JA; Mellors, JW; Sawe, F; Schooley, RT; Shao, W | 1 |
| Amico, KR; Chitwarakorn, A; Curlin, ME; Grant, RM; Holtz, TH; Hughes, JP; Li, M; Mock, PA; Varangrat, A | 1 |
| Alejos, B; Arribas, JR; Bernardino, JI; De Miguel, R; Esser, S; Esteban-Cantos, A; Goujard, C; Montejano, R; Raffi, F; Rodes, B; Rodriguez-Centeno, J; Sarmento-Castro, R; Schwimmer, C; Stella-Ascariz, N; Wallet, C | 1 |
| Coelho, LE; Grinsztejn, B; Landovitz, RJ; Torres, TS; Veloso, VG | 1 |
| Burgi, A; Letendre, SL; Little, SJ; Ma, Q; Morse, GD; Ocque, AJ; Sanders, C | 1 |
| Bai, F; Bandera, A; Bernasconi, DP; Bonora, S; Castelli, F; Di Biagio, A; Focà, E; Gori, A; Lapadula, G; Migliorino, GM; Monforte, AD; Squillace, N | 1 |
| Dunn, DT; Geng, EH; Glidden, DV; Mehrotra, ML | 1 |
| Castagna, A; Gianotti, N | 1 |
| Das, M; Haubrich, R; Maggiolo, F; Mateo-Garcia, MG; McNicholl, I; Molina, JM; Ong, E; Piontkowsky, D; Pulido, F; Raffi, F; Rizzardini, G; Shao, Y | 1 |
| Briano, F; Comi, L; Di Biagio, A; Di Filippo, E; Giacomini, M; Gori, A; Maggiolo, F; Mora, S; Riccardi, N; Taramasso, L | 1 |
| Acosta, RK; Avihingsanon, A; Cao, H; Chetchotisakd, P; DeJesus, E; Gankina, N; Hagins, D; Kityo, C; Koenig, E; Makadzange, T; Martin, H; Pokrovsky, V; Quirk, E; Stephens, JL; Supparatpinyo, K; Voronin, E; Wang, H | 1 |
| Adamson, L; Akkina, R; Blake, K; Burgunder, EM; Devanathan, AS; Garcia, JV; Kashuba, ADM; Kovarova, M; Luciw, P; Pirone, JR; Remling-Mulder, L; Rosen, EP; Schauer, AP; Srinivas, N; Sykes, C; White, NR | 1 |
| Hollenbeck, BL; Kishore, S; Lee, MSL; Padival, S | 1 |
| Batey, DS; Beyrer, C; Cummings, V; Del Rio, C; Eshleman, SH; Farley, JE; Fernandez, RE; Fogel, JM; Gamble, T; Hart, S; Hughes, JP; Laeyendecker, O; Mayer, KH; McKinstry, L; Remien, RH; Sivay, MV; Wilson, EA | 1 |
| Saag, MS | 3 |
| Goldstein, RH; Walensky, RP | 1 |
| Bailey, AC; Barbini, B; Burling, K; Campbell, L; Hamzah, L; Ibrahim, F; Jones, R; Musso, CG; Post, FA; Williams, D | 1 |
| Aung, W; Bakshi, R; Breakey, J; Brown, T; Bumpus, NN; Fuchs, EJ; Hamlin, A; Hendrix, CW; Marzinke, MA; Poteat, T; Shieh, E | 1 |
| Beste, LA; Garner, W; Maier, MM; Ohl, ME; Van Epps, P; Wilson, BM | 1 |
| Cottrell, M; Dellon, ES; Gonzalez, D; Kashuba, ADM; Madanick, RD; Maffuid, K; Nelson, JAE; Prince, HA; Shaheen, NJ; Srinivas, N; Sykes, C; White, N | 1 |
| Kerkemeyer, KLS; Lai, FYX; Mar, A | 1 |
| Boffito, M; Bonora, S; Cursley, A; D'Avolio, A; Di Perri, G; Dickinson, L; Fäetkenheuer, G; Gurjar, R; Molina, JM; Owen, A; Pozniak, A; Raffi, F; Richert, L; Stöhr, W; Vandekerckhove, L | 1 |
| Chi, BH; Fairlie, L; Farhad, M; Fenton, T; Fowler, MG; Moodley, D; Naik, S; Nakabiito, C; Stringer, JSA; Venkatesh, KK | 1 |
| Harrigan, PR; Lapointe, HR | 1 |
| Fulco, PP; Gomes, D; Leibrand Kaczmar, CR; Smith, T | 1 |
| Datir, R; Derache, A; Gregson, J; Gupta, RK; Perno, CF; Pillay, D; Rhee, SY; Shafer, RS | 1 |
| Parienti, JJ | 2 |
| Ascher, SB; Defechereux, P; Estrella, MM; Gandhi, M; Glidden, DV; Grant, RM; Jotwani, V; Mehrotra, ML; Scherzer, R; Shigenaga, J; Shlipak, MG; Spaulding, KA | 1 |
| Jewsbury, S; Ward, C | 1 |
| Ajana, F; Bani-Sadr, F; Bouvet, E; Cotte, L; Galempoix, JM; Gantner, P; Hessamfar, M; Hustache-Mathieu, L; Lebrette, MG; Muret, P; Pellissier, G; Piroth, L; Rey, D; Rouveix, E; Simon, A; Souala, MF; Truchetet, F; Valin, N | 1 |
| Eron, JJ; Esser, S; Hufkens, V; Jezorwski, J; Lathouwers, E; Opsomer, M; Orkin, C; Podzamczer, D; Rockstroh, J; Van Landuyt, E; Vandekerckhove, L | 1 |
| Bhatia, R; Rizza, S; Temesgen, Z; Zeuli, J | 1 |
| Di Perri, G | 1 |
| Bansi-Matharu, L; Barnabas, RV; Cambiano, V; Castor, D; Homan, R; Jamieson, L; Johnson, L; Mellors, JW; Meyer-Rath, G; Moyo, S; Nakagawa, F; Parikh, UM; Phillips, AN; Rehle, T; Revill, P; Russell, E; Shahmanesh, M; Shroufi, A; Tanser, F | 1 |
| Benson, C; Bolan, R; Crofoot, G; Dunn, K; Gathe, J; Huhn, GD; Luo, D; Nettles, RE; Ramgopal, M; Simonson, RB | 1 |
| Baker, D; Bloch, M; Carr, M; Hoy, JF; Richardson, R; Tong, W | 1 |
| Asboe, D; Dunn, DT; Gilson, R; Hill, T; Mackie, NE; Pozniak, A; Sabin, CA; Stirrup, OT; Tostevin, A | 1 |
| Aizire, J; Brooks, KM; Butler, K; Cababasay, M; Fenton, T; Flynn, PM; Fowler, MG; Kiser, JJ; Mirochnick, M; Siberry, GK | 1 |
| Dalodom, T; Himmad, L; Hiransuthikul, A; Janamnuaysook, R; Kerr, SJ; Kongkapan, J; Mills, S; Pankam, T; Phanjaroen, K; Phanuphak, N; Phanuphak, P; Vannakit, R | 1 |
| Saberi, P; Scott, HM | 1 |
| Aschenbrenner, DS | 1 |
| Aboud, M; Baril, JG; Bogner, J; Eron, J; Falcó, V; Gartland, M; Hung, CC; Koteff, J; Maggiolo, F; Man, CY; Mills, A; Pappa, KA; Sievers, J; Slim, J; Smith, KY; Tenorio, AR; Underwood, M; Urbaityte, R; Wynne, B | 1 |
| Álvarez, M; Chueca, N; Collado, A; de Salazar, A; Fernández, JM; Fernández-Fuertes, E; García, F; Lozano, AB | 1 |
| Applin, S; Asmuth, DM; Cox, S; Das, M; Goldstein, D; Guyer, B; Haubrich, RH; Hinestrosa, F; Huhn, GD; Jain, MK; Jiang, S; Nguyen-Cleary, T; Piontkowsky, D; Ramgopal, M; Rossaro, L; Ryu, JH; Slim, J | 1 |
| Bailey, AC; Mackie, N; Muir, D; Ring, K | 1 |
| Lazzarin, A; Llibre, JM; Stellbrink, HJ; Woolley, I | 1 |
| Howe, Z; Huesgen, E; Moore, SE | 1 |
| Badowski, ME; Biagi, MJ; Chiampas, TD; Michienzi, SM; Patel, MC; Schriever, CA; Young, JD | 1 |
| Amoura, NJ; Bares, SH; Cirrincione, LR; Dyavar, SR; Fletcher, CV; Gwon, Y; Havens, JP; Johnson, TM; Podany, AT; Scarsi, KK | 1 |
| Atukunda, M; Ayieko, J; Balzer, LB; Black, D; Brown, LB; Bukusi, EA; Camlin, CS; Chamie, G; Charlebois, ED; Clark, TD; Cohen, CR; Gandhi, M; Havlir, DV; Jain, V; Kabami, J; Kamya, MR; Koss, CA; Kwarisiima, D; Marquez, C; Mwangwa, F; Mwinike, Y; Olilo, W; Owaraganise, A; Peng, J; Petersen, ML; Rooney, JF; Ruel, TD; Sang, N; Zhang, K | 1 |
| Abuna, F; Anderson, PL; Baeten, JM; Dettinger, JC; John-Stewart, G; Kinuthia, J; Lagat, H; Mugwanya, K; Odinga, D; Pintye, J; Sila, J | 1 |
| Castagna, A; Comi, L; Di Filippo, E; Fumagalli, L; Galli, L; Gianotti, N; Maggiolo, F; Nozza, S; Rizzi, M; Valenti, D | 1 |
| Freedberg, KA; Horn, T; McCann, NC; Paltiel, AD; Walensky, RP | 2 |
| Arvieux, C; Brunet-Cartier, C; Canestri, A; Cotte, L; Frange, P; Le Chenadec, J; Mandelbrot, L; Reynes, J; Sibiude, J; Tubiana, R; Warszawski, J | 1 |
| Abdelhameed, AS; Al-Kahtani, HM; Al-Majed, AA; Al-Qahtani, BM; Bakheit, AHH | 1 |
| Baeten, JM; Defechereux, P; Deutsch, M; Gandhi, M; Glidden, DV; Grant, RM; Mugo, NR; Ngure, K; Okochi, H; Rodrigues, WC; Spinelli, MA; Stalter, R; Vincent, M; Wang, G | 1 |
| Anderson, J; Bagkeris, E; Boffito, M; Dickinson, L; Khoo, S; Mallon, P; McClure, M; Ndoutoumou, A; Post, FA; Sabin, C; Vera, J; Wang, X; Williams, I; Winston, A | 1 |
| Anderson, PL; Chan, DPC; Kwan, TH; Lam, TTN; Lee, KCK; Lee, SS; Lui, GCY; Wong, NS | 1 |
| Ajibola, G; Batlang, O; Bennett, K; Davey, S; Diseko, M; Hughes, MD; Isaacson, A; Kuritzkes, DR; Lichterfeld, M; Lockman, S; Makhema, J; Maswabi, K; Moyo, S; Sakoi, M; Shapiro, R; Zash, R | 1 |
| Fulco, PP | 1 |
| Antinori, A; Cavellec, M; de Wit, S; Gaultier, A; Jessen, H; Le Thuaut, A; Molina, JM; Ningre, M; Pozniak, A; Raffi, F; Soria, A | 1 |
| Adam, A; Buhk, T; Fenske, S; Hansen, S; Hoffmann, C; Sabranski, M; Schewe, K; Stellbrink, HJ | 1 |
| Berruti, M; Briano, F; Di Biagio, A; Taramasso, L | 1 |
| Baeten, J; Celum, C | 2 |
| Chan, PA; Crowley, C; Galárraga, O; Marak, T; Napoleon, S; Nocka, K; Raifman, J; Tao, J; Wilson, IB | 1 |
| Bouazza, N; Bregigeon, S; Descamps, D; Dhiver, C; Gattacceca, F; Lacarelle, B; Lê, MP; Mokhtari, S; Néant, N; Peytavin, G; Solas, C; Tamalet, C; Yazdanpanah, Y | 1 |
| Baker, J; Rolls, J | 1 |
| Anderson, PL; Castillo-Mancilla, J; Chai, PR; Gandhi, M; Haberer, JE; Spinelli, MA | 1 |
| Bermejo-Vicedo, T; Gramage-Caro, T; Montero-Llorente, B; Rodríguez-Sagrado, MÁ; Vélez-Díaz-Pallarés, M | 1 |
| André-Garnier, E; Charpentier, C; Ferré, V; Hingrat, QL; Leducq, V; Malet, I; Marcelin, AG; Peytavin, G; Raffi, F; Reliquet, V; Rodallec, A | 1 |
| Killelea, A; McManus, KA; Powers, S; Rogawski McQuade, E; Tello-Trillo, S | 1 |
| Alagaratnam, J; Boffito, M; Bozzali, M; Cercignani, M; Mora-Peris, B; Nelson, M; Toniolo, S; Underwood, J; Vera, JH; Winston, A | 1 |
| Coleman, H; Douthwaite, ST; Lee, MJ; Simons, R; Snell, LB | 1 |
| Hill, A; Venter, WDF | 1 |
| Acosta, R; Arribas, JR; Brainard, DM; Brinson, C; Clarke, A; Collins, SE; DeJesus, E; Flamm, JA; Gupta, SK; Hagins, D; Huang, H; Maggiolo, F; Martin, H; Martorell, C; Orkin, C; Podzamczer, D; Sax, PE; Stellbrink, HJ; Stephens, JL; Thompson, MA; Wohl, D | 1 |
| Anderson, PL; Brooks, KM; Bushman, LR; Castillo-Mancilla, J; Ibrahim, ME; Kiser, JJ; MaWhinney, S; McCallister, S; McHugh, C; Morrow, M; Yager, J | 1 |
| Baeten, JM; Cressey, R; Cressey, TR; Drain, PK; Gandhi, M; Klinbuayaem, V; Kubiak, RW; Okochi, H; Quame-Amaglo, J; Siriprakaisil, O; Sukrakanchana, PO; Tawon, Y | 1 |
| Allavena, C; Bregigeon, S; Cabie, A; Cotte, L; Duvivier, C; Gantner, P; Makinson, A; Ravaux, I; Rey, D; Reynes, J | 1 |
| Achilles, SL; Chen, BA; Hendrix, CW; Marzinke, MA; Meyn, LA; Tarleton, J | 1 |
| Arribas, JR; Del Amo, J; Díaz, A; Hernán, MA; Jarrín, I; Martínez, E; Moreno, S; Polo, R | 1 |
| Adachi, E; Hoshina, T; Ikeuchi, K; Saito, M; Yotsuyanagi, H | 1 |
| Goffard, JC; Henrard, S; Noure, L; Simeni Njonnou, SR | 1 |
| Adimora, AA; Anastos, K; Bay, CP; Davalos, A; De Paris, K; Dumond, JB; Edmonds, A; Fischl, MA; French, AL; Gange, S; Kassaye, S; Nelson, JAE; Ofotokun, I; Sharma, R; Sykes, C; Tamraz, B; Vance, DE | 1 |
| Anderson, SA; Busch, MP; Custer, B; Glick, S; Glynn, SA; Haaland, R; Kessler, D; Martin, A; McFarland, W; Melton, CD; Quiner, C; Raymond, HF; Reik, R; Robinson, WT; Sey, K; Steele, WR; Stone, M; Stramer, SL; Williams, AE; Williamson, PC | 1 |
| Acosta, R; Brainard, DM; Collins, SE; Liu, H; Luetkemeyer, AF; Martin, H; Rieger, A; Rockstroh, JK; Sax, PE; Trottier, B; Ward, D; Yazdanpanah, Y | 1 |
| Chang, SY; Chen, YT; Chen, YW; Huang, CK; Huang, SH; Huang, WC; Hung, CC; Lin, SW; Liu, WC; Ou, ST; Sun, HY | 1 |
| Anderson, PL; Defechereux, P; Gandhi, M; Grant, RM; Jee, K; Johannessen, D; Kearney, MF; Kuncze, K; Lowery, B; McDonald, C; McFarlane, JR; Okochi, H; Phung, N; Shuford, JA; Smith, DK; Spindler, J; Spinelli, MA | 1 |
| Bremner, S; Bruce, C; Churchill, D; Geretti, AM; Iwuji, CC; Lambert, D; Orkin, C; Perry, N; To, Y; Waters, L | 1 |
| Amador, C; de Zárraga, MA; Díez Martínez, M; Górgolas, M; Jarrín, I; Moreno, C; Navarro, M; Pérez-Elías, MJ; Pérez-Martínez, L; Ruiz-Algueró, M; Suárez-García, I; Viciana, P | 1 |
| Cattaneo, D; Filice, C; Gervasoni, C; Riva, A | 1 |
| Foreman, RM; Zappas, MP | 1 |
| Acosta, RK; Andreatta, K; Collins, S; Liu, H; Martin, H; Martin, R; Parvangada, A; White, KL; Willkom, M | 1 |
| Cong, ME; Dinh, C; García-Lerma, JG; Haaland, R; Heneine, W; Holder, A; Johnson, R; Kelley, CF; Kelley, K; Khalil, G; Massud, I; Mills, P; Pan, Y; Ruone, S; Sanchez, T; Zlotorzynska, M | 1 |
| Bao, R; Chen, Y; Chu, Z; Ding, H; Geng, W; He, X; Hu, Q; Hu, Z; Huang, X; Jiang, Y; Jin, X; Li, H; Li, S; Lv, W; Shang, H; Wang, H; Xu, J; Zhang, J; Zhang, L | 1 |
| Spiegel, HML | 1 |
| Anderson, PL; Brainard, DM; Brinson, C; Callebaut, C; Clarke, A; Coll, P; Collins, SE; Das, M; De Wet, JJ; DeJesus, E; Ebrahimi, R; Grant, RM; Hare, CB; Jessen, H; Mathias, A; Mayer, KH; McCallister, S; Molina, JM; Mounzer, KC; Post, FA; Ruane, PJ; Thompson, MA; Wong, P; Zhong, L | 1 |
| D'Angelo, AB; Daskalakis, DC; Grov, C; Johnson, J; Nash, D; Westmoreland, DA | 1 |
| Chang, SF; Chang, SY; Chen, GJ; Cheng, CY; Chuang, YC; Hsieh, MH; Huang, SH; Hung, CC; Lee, CH; Lee, YC; Lee, YL; Su, LS; Sun, HY; Tang, HJ; Tsai, HC | 1 |
| Baum, MM; Bobardt, M; Gallay, PA; Gunawardana, M; Moss, JA; Ramirez, CM | 1 |
| Anderson, PL; Bhasin, S; Defechereux, PA; Deutsch, MB; Glidden, DV; Grant, RM; O'Neal, J; Pellegrini, M; Sevelius, J; Yager, J; Yu, M | 1 |
| Adams-Huet, B; Bedimo, RJ; Maalouf, NM; Moore-Matthews, D; Nguyen, V; Poindexter, J | 1 |
| Ahouada, C; Alary, M; Batona, G; Béhanzin, L; Diabaté, S; Gning, NN; Guédou, FA; Hessou, S; Mondor, M; Zannou, DM | 1 |
| Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y | 1 |
| Alonso-Vega, GG; Ferrández, JS; García, AL; García, TM; González, AO | 1 |
| Kandala, B; Vaddady, P; Yee, KL | 1 |
| Bush, S; Das, M; Shreay, S; Ting, J | 1 |
| Chivite, I; Cottrell, ML; Domingo, P; Garcia, B; Imaz, A; Kashuba, ADM; Martinez-Picado, J; Morenilla, S; Negredo, E; Niubó, J; Podzamczer, D; Scévola, S; Schauer, A; Silva-Klug, A; Tiraboschi, JM; Urrea, V; Van Horne, B | 1 |
| Castel, AD; Hoffman, HJ; Jones, JS; Kramer, MR; Kuo, I; McGuinness, P; Mera Giler, R; Mouhanna, F; Siegler, AJ; Sullivan, PS | 1 |
| Barbini, B; Campbell, L; Gilleece, Y; Hamzah, L; Ibrahim, F; Kegg, S; Post, FA; Samarawickrama, A; Vincent, R; Waters, L | 1 |
| Burger, DM; Mollema, FP; Roelofsen, EE; Wildenbeest, S | 1 |
| Abrams, E; Akpomiemie, G; Arulappan, N; Chandiwana, N; Chersich, M; Clayden, P; Fairlie, L; Hill, A; Lalla-Edward, S; Maartens, G; Masenya, M; Mashabane, N; McCann, K; Moorhouse, M; Norris, S; Qavi, A; Serenata, C; Simmons, B; Sokhela, S; Venter, WDF; Vos, A | 1 |
| Baeten, JM; Berard, AR; Birse, K; Burgener, A; Calienes, FL; Cameron, MJ; Cartwright, M; Collier, AC; Cranston, RD; Curlin, ME; Golden, JB; Hladik, F; Holtz, TH; Hughes, SM; Irungu, E; Katabira, E; Lama, JR; Levy, CN; Lingappa, JR; Mackelprang, R; McElrath, MJ; McGowan, I; Mugo, N; Muwonge, T; Noël-Romas, L; Pandey, U; Richardson, B; Stekler, JD; Stevens, CE; Vojtech, L | 1 |
| Bazan, J; Bowman, ER; Cameron, C; Cameron, M; Doblecki-Lewis, S; Funderburg, NT; Gabriel, J; Hornsby, L; Kettelhut, A; Klatt, NR; Koletar, SL; Kulkarni, M; Kwiek, JJ; Lake, JE; Lederman, MM; Malvestutto, C; Richardson, B; Turner, AN | 1 |
| Aho, I; Alexiev, I; Balayan, T; Begovac, J; Bukovinova, P; Gokengin, D; Harxhi, A; Holban, T; Horban, A; Jevtovic, D; Kase, K; Kowalska, JD; Lakatos, B; Latysheva, I; Matulionyte, R; Oprea, C; Papadopoulos, A; Rukhadze, N; Salemovic, D; Sedlacek, D; Skrzat-Klapaczyńska, A; Tomazic, J; Vassilenko, A; Vasylyev, M; Verhaz, A; Yancheva, N; Yurin, O | 1 |
| Anugulruengkitt, S; Kawichai, S; Pornpaisalsakul, K; Puthanakit, T; Songtaweesin, WN; Suponsilchai, V; Tepmongkol, S; Wongharn, P | 1 |
| Devitt, E; Hegarty, D; Loy, A; Lyons, F; Mulcahy, F; Quinn, L; Quirke, S | 1 |
| Mc Mullan, K; McIntyre, M; Quah, SP; Rafferty, P; Wood, A | 1 |
| Akpomiemie, G; Chandiwana, NC; Chersich, M; Fairlie, L; Hill, A; Lockman, S; Moorhouse, MA; Serenata, CM; Simmons, B; Venter, WDF | 1 |
| Anderson, KS; Bertoletti, N; Chan, AH; Schinazi, RF | 1 |
| Baeten, JM; Bagaya, M; Bambia, F; Brown, C; Celum, C; Haberer, JE; Heffron, R; Katabira, E; Kyambadde, P; Mujugira, A; Muwonge, TR; Nakyanzi, A; Nsubuga, R | 1 |
| Patel, RR; Rowan, SE; Schneider, JA; Smith, DK | 1 |
| Dunn, DT; Glidden, DV; Stirrup, OT | 1 |
| Bernasconi, E; Braun, DL; Buzzi, M; Calmy, A; Cavassini, M; Decosterd, LA; Egger, M; Günthard, HF; Limacher, A; Marinosci, A; Metzner, KJ; Schmid, P; Sculier, D; Stoeckle, M; Vernazza, P; Wandeler, G; Yerly, S | 1 |
| DeMarais, P; Max, B | 1 |
| Anderson, PL; Brooks, KM; Bushman, L; Castillo-Mancilla, JR; Ibrahim, ME; Kiser, JJ; MaWhinney, S; Saba, L; Yager, J | 1 |
| Babusis, D; Barouch, DH; Bekerman, E; Callebaut, C; Campigotto, F; Cihlar, T; Cox, S; Das, M | 1 |
| Gandhi, M; Robles, G; Sauermilch, D; Starks, TJ | 1 |
| Archary, M; Mngqibisa, R | 1 |
| Bekker, LG; Dietrich, J; Fynn, L; Gill, K; Gray, G; Hosek, S; Johnson, L; Jones, K; Marcus, R; Mendel, E; Myer, L; Pidwell, T; Rooney, J; Slack, C; Spiegel, H; Strode, A; Wallace, M; Wiesner, L | 1 |
| Barr, E; Best, BM; Brooks, KM; Capparelli, EV; Chakhtoura, N; Cielo, M; Denson, K; Deville, JG; Espina, R; Febo, IL; George, K; Haubrich, R; Mirochnick, M; Momper, JD; Pinilla, M; Rooney, JF; Rungruengthanakit, K; Shapiro, DE; Smith, E; Stek, AM; Weinberg, A | 1 |
| Cheng, CY; Cheng, SH; Ho, MW; Huang, SH; Huang, YS; Hung, CC; Lee, CH; Lee, YT; Lin, SP; Liou, BH; Liu, CE; Lu, PL; Sun, HY; Tang, HJ; Tsai, HC; Yang, CJ | 1 |
| Ma, R; Tong, ZW; Xu, B; Zhang, Q; Zhang, YS; Zhao, CS; Zhao, RG | 1 |
| Baugh, B; De Meyer, S; Ghys, A; Jezorwski, J; Lathouwers, E; Mohsine, EG; Van Landuyt, E; Weinsteiger, S | 1 |
| Dunn, D; Gilks, C; Gilson, R; Hakim, J; Kaleebu, P; Kityo, C; Musoro, G; Pillay, D; Price, H; Vudriko, T | 1 |
| Castagna, A; Esser, S; Haubrich, R; Llibre, JM; Margot, N; McNicholl, IR; Molina, JM; Perez-Valero, I; Piontkowsky, D; Pulido, F; Shao, Y; Temme, L | 1 |
| Ambrosioni, J; Laguno, M; Liegeon, G; Miró, JM; Petit, E | 1 |
| Hanna, GJ; Hwang, C; Kumar, S; Lin, G; Martin, E; Molina, JM; Orkin, C; Sax, PE; Squires, KE; Sussmann, O; Teppler, H | 1 |
| Amin, J; Bavinton, B; Cabrera Quichua, G; Grulich, AE; Guy, R; Holden, J; Jin, F; McManus, H; McNulty, A; Ogilvie, E; Price, K; Selvey, C; Smith, D; Vaccher, S; Vickers, T; Yeung, B; Zablotska, I | 1 |
| Galvani, AP; Goedel, WC; Marshall, BDL | 1 |
| Belenky, P; Chan, PA; Maynard, M; Montgomery, M; Perler, BK; Reinhart, EM; Shapiro, JM | 1 |
| Conway-Washington, C; Dinh, C; Fountain, J; Haaland, RE; Hall, L; Kelley, CF; Lupo, LD; Martin, A; Mengesha, M | 1 |
| Alejos, B; Bautista, A; Bernardino, JI; Blanco, JR; Gutiérrez, F; Hernando, V; Jarrín, I; Peñaranda, M; Suárez-García, I | 1 |
| Ancona, G; Baldelli, S; Bossolasco, S; Cattaneo, D; Cernuschi, M; De Bona, A; Fusi, M; Gervasoni, C; Rossotti, R; Suardi, E; Vinti, P; Zagato, D | 1 |
| Bacon, O; Chen, MJ; Cohen, SE; Johnson, KA; Kohn, R; Lee, S; Sachdev, D | 1 |
| Baeten, JM; Donnell, D; Gandhi, M; Glidden, DV; Hendrix, C; Marzinke, M; Mugo, N; Mujugira, A; Rodrigues, WC; Spinelli, MA; Stalter, RM; Vincent, M; Wang, G | 1 |
| Baugh, B; Brown, K; El Ghazi, M; Huhn, GD; Jezorwski, J; Lathouwers, E; Mussini, C; Spinner, CD; Van Landuyt, E; Wilkin, A | 1 |
| Aizire, J; Browning, R; Dadabhai, S; Fan, B; Fowler, MG; George, K; Mofenson, LM; Moodley, D; Mukwasi-Kahari, C; Nelson, B; Sebikari, D; Shepherd, J; Siberry, GK; Sommer, MJ; Stranix-Chibanda, L; Theron, G; Tierney, C; Vhembo, T; Violari, A; Zanga, A | 1 |
| Bao, RT; Chen, YK; Chu, ZX; Ding, HB; Geng, WQ; He, XQ; Hu, QH; Hu, ZL; Huang, XJ; Jiang, YJ; Li, H; Li, SC; Li, Y; Shang, H; Sylvia, S; Wang, H; Wang, HY; Xu, JJ; Zhang, J; Zhang, LK | 1 |
| Bassa, A; Hill, A; Kumar, S; Mngqibisa, R; Nelson, M; Orkin, C; Rassool, M; Rodgers, A; Teal, V; Teppler, H; Winston, A | 1 |
| Becker, ML; Gangakhedkar, RR; Jana, S; Kadam, A; Moses, S; Ray, P; Rewari, BB; Roy, S | 1 |
| Chang, SF; Chang, SY; Hsiao, YY; Huang, YC; Hung, CC; Kuo, CH; Lee, YL; Lin, YT; Luo, YZ | 1 |
| Harris, P; Henderson, R | 1 |
| Mesplède, T | 1 |
| Baeten, JM; Barasch, J; Branch, AD; Celum, C; Donnell, D; Heffron, R; Mugo, NR; Mugwanya, KK; Nickolas, TL; Ronald, A; Wanga, V; Wyatt, CM | 1 |
| DeJong, C; Gandhi, M; Okochi, H; Spinelli, MA | 1 |
| Ajana, F; Avettand-Fènoël, V; Bernard, L; Darasteanu, I; de la Blanchardière, A; Etienne, M; Hocqueloux, L; Le Moal, G; Parienti, JJ; Pasdeloup, T; Pialoux, G; Ponscarme, D; Prazuck, T; Roncato-Saberan, M; Sunder, S; Verdon, R; Viard, JP | 1 |
| Aguilera-Alonso, D; Beltrán-Pavez, C; Bernardino, JI; Díez, C; Guillen, S; Gutiérrez-López, M; Holguín, Á; Jiménez de Ory, S; Mellado, MJ; Navarro, M; Prieto, L; Ramos, JT; Sainz, T; Santos, MDM | 1 |
| Benet, LZ; Gandhi, M; Koss, CA; Kuncze, K; Louie, A; Okochi, H; Phung, N; Spinelli, MA; Tallerico, RM; Zhang, K | 1 |
| Butcher, L; Davidson, AM; Johnson, M; Joshi, SR; Lataillade, M; Min, S; Pene Dumitrescu, T; Webster, L; Xu, J; Zhan, J; Zimmerman, E | 1 |
| Amico, KR; Brummel, SS; Cassim, H; Chakhtoura, N; Chinula, L; Coletti, A; Currier, J; Fairlie, L; Frenkel, LM; Hanley, S; Hoffman, RM; Holmes, LB; Jean-Philippe, P; João, E; Johnston, B; Korutaro, V; Krotje, C; Lockman, S; Masheto, G; McCarthy, K; Mmbaga, BT; Momper, JD; Moyo, S; Purdue, L; Rooney, JF; Sax, PE; Shapiro, RL; Stranix-Chibanda, L; Stringer, JS; Thoofer, NK; Ziemba, L | 1 |
| Carini, E; Castagna, A; Galli, A; Galli, L; Gianotti, N; Lazzarin, A; Muccini, C; Nozza, S; Poli, A; Spagnuolo, V; Torre, LD; Vinci, C | 1 |
| Amico, KR; Anderson, P; Anton, P; Brand, RM; Chege, W; Cranston, RD; Eron, J; Frank, I; Gulick, RM; Hendrix, CW; Kekitiinwa, AR; Landovitz, RJ; Manabe, YC; Marzinke, MA; Mayer, KH; McCauley, M; McGowan, I; Sekabira, R; Wilkin, TJ; Yuhas, K | 1 |
| Amico, KR; Anderson, PL; Blumenthal, J; Chow, K; Corado, K; Ellorin, E; Haubrich, R; He, F; Jain, S; Kofron, R; Landovitz, RJ; Moore, DJ; Morris, S; Ntim, GM; Psaros, C; Stockman, JK | 1 |
| Acosta, RK; Brainard, D; Chang, S; Chen, GQ; Collins, SE; Huang, H; Martin, H; Martin, R; Wang, X; White, KL | 1 |
| Hill, A; Hindley, L; McCann, K; Qavi, A; Serenata, C; Shah, S; Simmons, B; Sokhela, S; Venter, WDF | 1 |
| Bogas, S; das Neves, J; Faria, MJ; Gonçalves, H; Lúcio, M; Nunes, R; Sarmento, B; Viseu, T | 1 |
| Otto, A; Pecora Fulco, P | 1 |
| Anderson, PL; Boyd, A; Coyer, L; Davidovich, U; de Vries, HJ; Hoornenborg, E; Jongen, VW; Prins, M; Schim van der Loeff, MF; van den Elshout, MA; Zimmermann, HM | 1 |
| Brown, TT; Carter, CC; Cohen, C; Das, M; Erlandson, KM; Esser, S; Huang, H; Koethe, JR; Lake, JE; Martin, H; McComsey, GA; Melbourne, K; Orkin, C; Post, FA; Rockstroh, JK; Sax, PE; Stellbrink, HJ; Waters, L; Wei, X | 1 |
| Dunn, K; Hardy, H; Kassam, PT; Luo, D; Rogers, R; Seyedkazemi, S; Sheng, S; Simonson, RB | 1 |
| Conway-Washington, C; Dinh, C; Fountain, J; Garcia-Lerma, JG; Haaland, RE; Hall, L; Heneine, W; Kelley, CF; Lupo, LD; Martin, A | 1 |
| Anderson, PL; Baeten, JM; Das, M; Dunn, DT; Ebrahimi, R; Glidden, DV; Stirrup, OT; Zhao, Y | 1 |
| Gutiérrez-Lorenzo, M; Rubio-Calvo, D; Urda-Romacho, J | 1 |
| Agboyibor, MK; Anoma, C; Coulibaly, A; Dagnra, CA; Dah, TTE; De Baetselier, I; Dembélé Keita, B; Diallo, F; Diandé, S; Eubanks, A; Fayé-Ketté, H; Koné, A; Laurent, C; Le Guicher, G; Malan, JB; Mensah, E; Riegel, L; Rojas Castro, D; Sagaon-Teyssier, L; Serrano, L; Spire, B; Traoré, I; Vuylsteke, B; Yaya, I | 1 |
| Pozniak, AL; Wood, BR | 1 |
| Kriebs, JM; Ruppe, LB; Spencer, LA | 1 |
| Alrubayyi, A; Burns, F; Fisher-Pearson, N; Gilson, R; Griffith, SA; Gupta, RK; Kinloch, S; McCoy, LE; Muir, L; Pellegrino, P; Peppa, D; Rees-Spear, C; Rowland-Jones, S; Touizer, E; Waters, L | 1 |
| Fox, HS; George, JW; Lamberty, BG; Mattingly, JE; Roland, NJ; Small, CM; Stauch, KL | 1 |
| Barnabas, RV; Celum, C; Gunda, R; Koole, O; Krows, M; Moshabela, M; Schaafsma, T; Siedner, MJ; Sithole, N | 1 |
| Bachelard, A; Chalal, L; Damond, F; Descamps, D; Ghosn, J; Isernia, V; Landman, R; Le Gac, S; Peytavin, G; Vallois, D; Yazdanpanah, Y | 1 |
| Anderson, PL; Bushman, LR; Castillo-Mancilla, JR; Coleman, SS; Coyle, RP; Ellison, L; Kiser, JJ; MaWhinney, S; Morrow, M; Zheng, JH | 1 |
| Aydin, E; Celen, MK; Demir, Y; Yildirim, Y; Yilmaz Aydin, F | 1 |
| Bamoulid, J; Clairet, AL; Davani, S; Ducloux, D; Flammang, M; Lagoutte-Renosi, J; Lepiller, Q; Muret, P; Royer, PY | 1 |
| Arribas, JR; Asensi, V; Berenguer, J; Del Romero, J; Díez, C; Galera, C; García-Fraile, LJ; González-García, J; Gutiérrez, F; Iribarren, JA; Izquierdo, R; Jarrín, I; López, JC; Martín-Vicente, M; Micán, R; Moreno, S; Pérez-Elías, MJ; Podzamczer, D; Portilla, J; Poveda, E; Pulido, F; Resino, S; Suárez-García, I; Vidal, F | 1 |
| Asmuth, DM; Baeten, JM; Brainard, DM; Brunetta, JM; Carter, C; Cox, S; Das, M; Ebrahimi, R; Gilson, R; Henry, K; Kintu, A; Kronborg, G; Ogbuagu, O; Podzamczer, D; Ruane, PJ; Salazar, LC; Shao, Y; Spinner, CD; Whitlock, G; Wohl, D | 1 |
| An, M; Ding, H; Dong, X; Han, X; Li, X; Song, W; Tian, W; Wang, L; Wang, Z; Zhao, B | 1 |
| Asif, S; Baxevanidi, E; Chandiwana, N; Fairlie, L; Hill, A; Masenya, M; Serenata, C; Sokhela, S; Venter, WDF | 1 |
| Anderson, PL; Bauer, R; Buschman, L; Charreau, I; Cotte, L; Cua, E; Delaugerre, C; Goldwirt, L; Laghzal, A; Liegeon, G; Meyer, L; Molina, JM; Mourah, S; Pialou, G | 1 |
| Bavinton, B; Bloch, M; Drak, D; Gracey, DM; Grulich, AE; Guy, R; Heron, JE; Jin, F; Mcmanus, H; O'Connor, CC; Vaccher, S; Vickers, T; Zablotska, I | 1 |
| Coleman, M; Glick, N; Houlberg, M; McCallister, S; Mena, L; Rawlings, MK; Smith, DK; Wiener, J | 1 |
| Iannuzzi, S; von Kleist, M | 1 |
| Cao, Y; Kashuba, ADM; Scholz, EMB | 1 |
| Carneiro, PB; D'Angelo, AB; Grov, C; Johnson, J; Westmoreland, DA | 1 |
| Alnajebi, B; Huang, A; Ma, Q; Shang, J; Tan, R; Yan, B; Yang, J; Zhang, Y; Zhong, X | 1 |
| Andreatta, K; Berger, D; Blair, C; Brainard, DM; Brar, I; Collins, SE; Hagins, D; Hileman, CO; Kumar, P; Martin, H; McDonald, C; Osiyemi, O; Ramgopal, MN; Saag, M; Wurapa, AK | 1 |
| Abdi, B; Calvez, V; Cuzin, L; Katlama, C; Marcelin, AG; Palich, R; Pourcher, V; Sayon, S; Schneider, L; Seang, S; Soulie, C; Teyssou, E; Tubiana, R; Valantin, MA; Wirden, M | 1 |
| Avihingsanon, A; Avihingsanon, Y; Gatechompol, S; Iampenkhae, K; Surintrspanont, J; Udomkarnjananun, S; Ueaphongsukkit, T | 1 |
| Agrati, C; Antinori, A; Cicalini, S; D'Avolio, A; De Nicolò, A; Tempestilli, M | 1 |
| Khamadi, SA; Lihana, RW; Mabeya, SN; Ngugi, C; Nyamache, AK | 1 |
| Gupta, R; Kalabalik, J; Özdener, AE; Park, TE | 1 |
| Castagna, A; Chiappetta, S; Galli, L; Lazzarin, A; Nozza, S; Poli, A; Ripa, M; Rovelli, C; Spagnuolo, V; Tambussi, G | 2 |
| Agingu, W; Ahmed, K; Crucitti, T; de Baetselier, I; Deese, J; Fransen, K; Owino, F; Rammutla, E; Van Damme, L; Venter, G | 1 |
| Cohan, D; Seidman, DL; Weber, S | 1 |
| Prabhu, VR; Ripin, D | 1 |
| Adimora, AA; Cole, SR; Eron, JJ | 1 |
| Doherty, M; Ford, N; Gray, A; Vitoria, M | 1 |
| Badal-Faesen, S; Brown, TT; Campbell, TB; Cardoso, SW; Erlandson, KM; Fiorillo, SP; Hakim, J; Kumarasamy, N; Kumwenda, J; Lalloo, U; Riviere, C; Sanchez, J | 1 |
| Arcondo, F; Cordova, E; Morganti, L; Odzak, A; Rodriguez, C; Silva, M; Zylberman, M | 1 |
| Anderson, PL; Costa Leite, ID; De Boni, RB; Goulart, S; Grinsztejn, B; Hoagland, B; Kallas, EG; Liu, AY; Luz, PM; Madruga, JV; Marins, LMS; Moreira, RI; Torres, TS; Vasconcelos, R; Veloso, VG | 1 |
| Díez-Pérez, A; González-Mena, A; Guelar, A; Güerri-Fernández, R; Herrera, S; Knobel, H; Molina-Morant, D; Trenchs-Rodríguez, M; Villar-García, J | 1 |
| Conrad, F; Govender, M; Maartens, G; Manning, K; Papavarnavas, NS | 1 |
| Conyngham, SC; Daughtridge, GW; Koenig, HC; Lalley-Chareczko, L; Montaner, LJ; Moorthy, GS; Mounzer, K; Sloan, CE; Tebas, P; Zuppa, AF | 1 |
| Abram, ME; Callebaut, C; Kulkarni, R; Margot, NA; Miller, MD; Porter, D; White, K; Wong, P | 1 |
| Collins, S; Fox, J | 1 |
| Esser, S; Streeck, H | 1 |
| Kurmi, M; Singh, S | 1 |
| Anderson, M; Bailey, B; Balba, G; Brooks, KM; Garrett, KL; George, JM; Kuriakose, SS; Lane, HC; Maldarelli, F; Pau, AK | 1 |
| Li, J; Mesplède, T; Nekka, F; Sanche, S; Sheehan, N; Wainberg, MA | 1 |
| Angione, SA; Cherian, SM; Özdener, AE | 1 |
| Baeten, J; John-Stewart, G; Mugwanya, KK | 1 |
| Incardona, F; Meini, G; Mloka, D; Mugusi, F; Mugusi, S; Neogi, U; Sönnerborg, A; Svärd, J; Zazzi, M | 1 |
| Avettand-Fenoel, V; Bellecave, P; Bonnet, F; Caldato, S; Hessamfar, M; Morlat, P; Ngo Bell, EC; Saunier, A; Tumiotto, C; Vandenhende, MA | 1 |
| Bandera, A; Bonfanti, P; Calza, L; Carenzi, L; Celesia, BM; Cordier, L; De Socio, GV; Di Biagio, A; Falasca, K; Gori, A; Madeddu, G; Maggi, P; Martinelli, C; Orofino, G; Pellicanò, GF; Quirino, T; Ricci, E; Rusconi, S; Squillace, N; Vichi, F | 1 |
| Anderson, PL; Bekker, LG; Buchbinder, SP; Chariyalertsak, S; Glidden, DV; Grant, RM; Grinsztejn, B; Guanira, J; McMahan, V; Mulligan, K; Schechter, M | 2 |
| Boffito, M; Day-Weber, I; Hill, A; Korologou-Linden, R; McClure, MO; Nwokolo, N; Wang, X; Whitlock, G | 1 |
| Fountain, JJ; Haaland, RE; Hall, L; Heeke, S; Holder, A; Kelley, CF; Martin, A; Pescatore, NA | 1 |
| Battegay, M; Bernasconi, E; Calmy, A; Cavassini, M; Fehr, J; Gayet-Ageron, A; Hirzel, C; Schmid, P; Sculier, D | 1 |
| Andreatta, K; Antinori, A; Berenguer, J; Bloch, M; Cote, P; Flamm, J; Garner, W; McColl, DJ; Nguyen-Cleary, T; Piontkowsky, D; Pozniak, A; Szwarcberg, J; Ward, D | 1 |
| Arrabal-Durán, P; Chamorro-de-Vega, E; Gijón-Vidaurreta, P; Herranz-Alonso, A; Rodríguez-González, CG; Sanjurjo-Sáez, M | 1 |
| Aboud, M; Aylott, A; Belonosova, E; Buchanan, AM; Falcó, V; Hagins, DP; Man, CY; Orrell, C; Porteiro, N; Smith, KY; Vavro, C; Walmsley, S; Wynne, B | 1 |
| Baeten, JM; Balkus, JE; Bukusi, E; Celum, C; Cohen, CR; Donnell, D; Fiedler, T; Fredricks, DN; Heffron, R; Kiarie, J; Lingappa, J; McClelland, RS; Mugo, N; Munch, M | 1 |
| Bernaud, C; Capitant, C; Charreau, I; Chas, J; Chidiac, C; Cotte, L; Cua, E; Delaugerre, C; Doré, V; Fonsart, J; Mestre, SL; Meyer, L; Molina, JM; Pasquet, A; Pialoux, G; Pintado, C; Ponscarme, D; Rojas-Castro, D; Sagaon-Teyssier, L; Spire, B; Thompson, D; Tremblay, C; Wainberg, MA | 1 |
| Balán, IC; Bekker, LG; Brown, W; Carballo-Diéguez, A; Chariyalertsak, S; Chitwarakorn, A; Cranston, RD; Dolezal, C; Giguere, R; Gomez, K; Gonzales, P; Grossman, C; Hendrix, CW; Holtz, TH; Horn, S; Jacobson, C; Johnson, S; Kunjara Na Ayudhya, RP; Lama, J; Leu, CS; Liu, A; Marzinke, MA; Mayer, KH; McGowan, I; Patterson, K; Piper, JM; Richardson, BA; Zorrilla, C | 1 |
| Bulut, N; Yılmaz, B | 1 |
| Ahoua, L; Baggaley, R; DiMattei, P; El-Sadr, WM; Falcao, J; Lahuerta, M; Morales, F; Ramiro, I; Zerbe, A | 1 |
| Arduino, RC; Luque, A; Ma, Q; Mapstone, M; Miller, E; Qiu, X; Schifitto, G; Tivarus, M; Wang, L; Weber, M; Zhong, J; Zhuang, Y | 1 |
| Brar, I; Cheng, A; Custodio, J; Daar, ES; Gallant, J; Girard, PM; Lazzarin, A; Martin, H; Mills, A; Orkin, C; Podzamczer, D; Quirk, E; Rockstroh, J; Tebas, P; Wei, X; White, K; Wohl, D | 1 |
| Antinori, A; Cheng, A; Custodio, J; DeJesus, E; Garner, W; Koenig, E; Montes, ML; Pozniak, A; Quirk, E; Reynes, J; Sax, PE; SenGupta, D; Slim, J; Stellbrink, HJ; White, K; Workowski, K | 1 |
| Baum, MM; Chatterji, U; Gallay, PA; Gandarilla, A; Gunawardana, M; Kirchhoff, A; Marzinke, MA; Moss, JA; Pyles, RB | 1 |
| Cao, H; Chang, S; Hodder, SL; Kulkarni, R; Miller, MD; White, KL | 1 |
| Agarwal, A; Alexander, PE; Chang, Y; Foroutan, F; Guyatt, GH; Hepworth, E; Lee, Y; Lesi, O; Mah Ming, J; Merglen, A; Mir, H; Mirza, R; Siemieniuk, RA; Zeraatkar, D; Zhang, Y | 1 |
| Cotarelo, M; Macías, J; Mancebo, M; Merchante, N; Merino, D; Montes-Ramírez, ML; Pérez-Pérez, M; Pineda, JA; Pulido, F; Raffo, M; Rivero-Juárez, A; Téllez, F | 1 |
| Avihingsanon, A; Bloch, M; Cahn, P; East, L; Homony, B; Kaplan, R; Katlama, C; Leavitt, R; Molina, JM; Nguyen, BY; Rassool, M; Ratanasuwan, W; Rawlins, S; Rodgers, A; Rojas, E; Ruane, P; Sax, PE; Sklar, P; Squires, K; Teppler, H; Vandekerckhove, L; Wenning, L; Xu, X; Yazdanpanah, Y | 1 |
| Achterbergh, RCA; Anderson, PL; Cornelissen, M; de Bree, GJ; de Vries, HJC; Hoornenborg, E; Jurriaans, S; Kootstra, NA; Prins, JM; Prins, M; Reiss, P; Woittiez, LR | 1 |
| Bonito, A; Bonora, S; Calcagno, A; Casari, S; Castelli, F; D'Avolio, A; Di Perri, G; Domenighini, E; Focà, E; Quiros Roldan, E; Simiele, M; Trentini, L | 1 |
| Brenner, BG; Ibanescu, RI; Mesplède, T; Oliveira, M; Wainberg, MA; Xu, H | 1 |
| Amico, KR; Anderson, PL; Bekker, LG; Dye, BJ; Elharrar, V; Eshleman, SH; Grant, RM; Hendrix, CW; Hughes, JP; Li, M; Marzinke, MA; McKinstry, L; Piwowar-Manning, E; Rooney, JF; Roux, S; Sebastien, E; Stirratt, M; Yola, N | 1 |
| Anderson, PL; Bacon, O; Buchbinder, SP; Chege, W; Cohen, SE; Coleman, ME; Doblecki-Lewis, S; Elion, R; Kolber, MA; Liu, AY; Shlipak, M; Tang, EC; Vittinghoff, E | 1 |
| Arribas, JR; Eron, JJ; Gathe, J; Hufkens, V; Lathouwers, E; Molina, JM; Negredo, E; Opsomer, M; Orkin, C; Petrovic, R; Van Landuyt, E; Vanveggel, S | 1 |
| Anderson, PL; Bacchetti, P; Benet, LZ; Gandhi, M; Horng, H; Hosek, SG; Koss, CA; Kuncze, K; Liu, AY; Louie, A; Saberi, P; Wilson, CM | 1 |
| Alejos, B; Arribas, JR; Barrufet, P; Cervero, M; Curran, A; Domingo, P; Iribarren, JA; Knobel, H; Lagarde, M; Palacios, R; Payeras, A; Pérez-Valero, I; Pulido, F; Ribera, E; Rivero, A; Rodríguez-Gómez, FJ; Ryan, P; Sanz, J; Téllez, MJ; Yllescas, M | 1 |
| Donahue Carlson, R; Frisch, MB; Haaland, RE; Kraft, CS; Martin, A; Mehta, CC; Ofotokun, I; Patel, AS; Pau, CP; Read, TD; Sheth, AN | 1 |
| Anderson, PL; Buchbinder, S; Bushman, LR; Campbell, K; Castillo-Mancilla, JR; Gardner, EM; Ibrahim, M; Kiser, JJ; Liu, AY; MaWhinney, S; McHugh, C; Morrow, M; Seifert, SM; Wagner, T | 1 |
| Cairns, G; Cambiano, V; Delpech, V; Desai, M; Dunn, D; Field, N; Gill, ON; Hart, G; McCormack, S; Miners, A; Nardone, A; Ong, KJ; Phillips, AN; Rodger, A | 1 |
| Deeks, ED | 3 |
| Ayudhya, RPKN; Balán, IC; Brown, W; Carballo-Diéguez, A; Cranston, RD; Giguere, R; Hendrix, CW; Horn, S; Lama, JR; Marzinke, MA; McGowan, I; Patterson, K; Piper, JM | 1 |
| Abaasa, A; Anderson, P; Bumpus, NN; Gandhi, M; Haberer, JE; Hendrix, C; Kamali, A; Kibengo, F; Mutua, G; Priddy, F; Sanders, EJ | 1 |
| Arnaiz, JA; Cruceta, A; García, F; Gatell, JM; González, E; González-Cordón, A; Inciarte, A; Laguno, M; Leal, L; León, A; Lucero, C; Mallolas, J; Martínez-Rebollar, M; Rojas, J; Torres, B | 1 |
| Ganase, B; Harrigan, PR; Harris, M; Hull, MW; Montaner, JSG; Watson, B | 1 |
| Cottrell, ML; Kashuba, ADM; Prince, H; Schauer, AP; Sykes, C | 1 |
| Badiou, S; Bado, G; Ciaffi, L; Cournil, A; Delaporte, E; Diouf, A; Eymard-Duvernay, S; Héma, A; Kabore, FN; Koulla-Shiro, S; Zoungrana, J | 1 |
| Balán, IC; Bekker, LG; Brown, W; Carballo-Diéguez, A; Chariyalertsak, S; Chitwarakorn, A; Cranston, RD; Dolezal, C; Giguere, R; Gonzales, P; Holtz, TH; Lama, JR; Leu, CS; Liu, A; Mayer, KH; McGowan, I; Piper, JM; Rael, C; Richardson, BA; Zorrilla, CD | 1 |
| Carbone, A; Castagna, A; Galizzi, N; Galli, L; Gianotti, N; Lazzarin, A; Merli, M; Nozza, S; Poli, A; Ripa, M; Spagnuolo, V | 1 |
| Bruzzone, B; D'Ambrosio, B; Del Puente, F; Di Biagio, A; Riccardi, N; Ripamonti, D; Taramasso, L; Viscoli, C | 1 |
| Balestre, E; Bärnighausen, T; Bazin, B; Boyer, S; Dabis, F; De Oliveira, T; Dreyer, J; Herbst, K; Iwuji, CC; Larmarange, J; Makowa, T; McGrath, N; Newell, ML; Okesola, N; Orne-Gliemann, J; Pillay, D; Rekacewicz, C; Tanser, F; Thiebaut, R | 1 |
| Beck, B; Beste, L; Howren, MB; Lund, B; Maier, M; Ohl, ME; Skolnik, A; van Epps, P; Vaughan-Sarrazin, M | 1 |
| Aboud, M; Angelis, K; Blair, EA; Brinson, C; Castelli, F; Gartland, M; Girard, PM; Hung, CC; Kahl, LP; Llibre, JM; Smith, K; Underwood, M; Vandermeulen, K; Wynne, B | 1 |
| DeJesus, E; Haas, B; Liu, YP; Makadzange, T; Margot, N; McCallister, S; Mills, A; Ramgopal, MN; Segal-Maurer, S | 1 |
| Cadinha, S; Malheiro, D; Moreira da Silva, JP; Mota, M; Sousa, MJ; Teixeira, T | 1 |
| Dalzero, S; Degli Antoni, A; Floridia, M; Guaraldi, G; Liuzzi, G; Masuelli, G; Personeni, C; Pinnetti, C; Ravizza, M; Sansone, M; Spinillo, A; Tamburrini, E; Tassis, B | 1 |
| Carlson, K; Seidman, D; Weber, S; Witt, J | 1 |
| Cautela, MP; das Neves, J; Moshe, H; Sarmento, B; Sosnik, A | 1 |
| Amico, KR; Anderson, PL; Chitwarakorn, A; Curlin, ME; Dye, BJ; Elharrar, V; Eshleman, SH; Grant, RM; Hendrix, CW; Hirsch-Moverman, Y; Holtz, TH; Hughes, JP; Li, M; Loquere, A; Mannheimer, S; Marzinke, MA; McKinstry, L; McNicholl, JM; Piwowar-Manning, E; Rooney, JF; Stirratt, M; van Griensven, F | 1 |
| Anderson, PL; De Boni, RB; Freitas, L; Goulart, S; Grinsztejn, B; Hoagland, B; Kallas, EG; Leite, IC; Liu, A; Luz, PM; Madruga, JV; Martins, LMS; Moreira, RI; Torres, TS; Vasconcelos, R; Veloso, VG | 1 |
| Chetty, T; Coutsoudis, A; Thorne, C | 1 |
| Castelli, F; Cheng, A; Cox, S; Crofoot, G; Das, M; DeJesus, E; Di Perri, G; Estrada, V; Mallon, PWG; Peyrani, P; Podzamczer, D; Post, FA; Raffi, F; Rhee, MS; Ruane, P; Winston, A; Yan, M | 1 |
| Avihingsanon, A; Cao, H; Cheng, A; Hagins, D; Hodder, S; Jiang, S; Kido, A; Kityo, C; Kulkarni, R; Squires, K | 1 |
| Cevik, M; Orkin, C | 1 |
| Chang, HH; Choi, JY; Jung, H; Kim, S; Kim, SW; Lee, JM; Lee, SA; Park, HK | 1 |
| Amico, KR; Mayer, KH; Riddell, J | 1 |
| Besseghir, A; Blum, L; Brun-Vezinet, F; Charpentier, C; Chene, G; Collin, F; Damond, F; Descamps, D; Gallien, S; Matheron, S; Mortier, E; Peytavin, G; Ponscarme, D; Sellier, P; Tubiana, R | 1 |
| Freedberg, KA; Grinsztejn, B; Losina, E; Luz, PM; Maclean, RL; Mesquita, F; Osher, B; Paltiel, AD; Parker, RA; Stern, ME; Struchiner, CJ; Veloso, VG; Walensky, RP | 1 |
| Achterbergh, RC; Davidovich, U; de Vries, HJ; Hogewoning, A; Hoornenborg, E; Prins, M; Sonder, GJ; van der Helm, JJ; van der Loeff, MFS; van Duijnhoven, YT | 1 |
| Eron, JJ; Hoffman, E; Hudgens, M; Marcus, C; Menezes, P; Mollan, K; Rublein, J; Wills, J; Xie, Z | 1 |
| Choonara, YE; du Toit, LC; Kondiah, PPPD; Kumar, P; Pillay, V; Siyawamwaya, M | 1 |
| Gandhi, M; Hurt, CB; McKellar, MS; Okochi, H; Thaden, JT | 1 |
| Diseko, M; Essex, M; Jacobson, DL; Lockman, S; Makhema, J; Mayondi, G; Mmalane, M; Petlo, C; Rough, K; Shapiro, RL; Zash, R | 1 |
| Buchbinder, SP | 1 |
| Barr, E; Chadwick, EG; Currier, JS; Hernandez-Diaz, S; Hoffman, RM; Huo, Y; Patel, K; Rough, K; Seage, GR; Shapiro, DE; Williams, PL | 1 |
| Garofalo, R; Kuhns, L; Mimiaga, MJ; Ogunbajo, A; Reisner, SL; Restar, AJ | 1 |
| Andrews, E; Bay, C; De Paris, K; Dellon, ES; Gay, CL; Kashuba, AD; Madanick, RD; Nelson, JA; Prince, HA; Rosen, EP; Shaheen, NJ; Sykes, C; Weber, MD | 1 |
| Amiel, C; Chaix, ML; Charpentier, C; Delaugerre, C; Descamps, D; Dufayard, J; Flandre, P; Grude, M; Guinard, J; Lambert-Niclot, S; Le Guillou-Guillemette, H; Maillard, A; Marcelin, AG; Mirand, A; Montes, B; Morand-Joubert, L; Mourez, T; Reigadas, S; Rodallec, A; Vallet, S | 1 |
| Jones, J; Taylor, BS; Tieu, HV; Wilkin, TJ | 1 |
| Franconi, I; Guaraldi, G | 1 |
| Castagna, A; Lazzarin, A; Spagnuolo, V | 2 |
| Fulco, PP; Higginson, RT | 1 |
| Clotet, B; Negredo, E | 1 |
| Bennett, M; Coca, SG; Defechereux, P; Gandhi, M; Glidden, DV; Grant, RM; Jotwani, V; Liu, A; Mehrotra, M; Parikh, CR; Scherzer, R; Shlipak, MG | 1 |
| Bloch, M; Cahn, P; Greaves, W; Hanna, GJ; Hepler, D; Homony, B; Molina, JM; Nguyen, BY; Rassool, M; Ratanasuwan, W; Sax, PE; Squires, K; Teppler, H; Xu, X; Zhou, Y | 1 |
| Bacon, O; Cardenas, G; Cohen, SE; Coleman, M; Doblecki-Lewis, S; Elion, R; Feaster, DJ; Kolber, MA; Liu, AY | 1 |
| Degen, O; Ebert, J; Schröder, AS; Sperhake, JP | 1 |
| Bachiller, P; Bahamonde, A; Barberá, JR; Casado, A; Diz, J; Domingo, P; Fernández, P; Lorenzo, JF; Martínez, E; Mayorga, MI; Muñoz, A; Ocampo, A; Podzamczer, D; Rodriguez, M; Rozas, N; Salgado, X; Santos, J; Sepúlveda, MA; Torres, C; Yzusqui, M | 1 |
| Antinori, A; Cossarizza, A; Cozzi-Lepri, A; d'Arminio Monforte, A; Gori, A; Lichtner, M; Lorenzini, P; Marchetti, G; Mussini, C; Nozza, S; Rusconi, S | 1 |
| Calinas, F; Costa, MN; Germano, I; Loureiro, RV | 1 |
| Dunn, DT; Glidden, DV; McCormack, S; Stirrup, OT | 1 |
| Corbino, JA; Cottrell, ML; Nicol, MR | 1 |
| Harris, M | 1 |
| Andreatta, K; Brar, I; Brinson, C; Cheng, A; Custodio, J; Liu, H; López-Cortés, L; Martin, H; Mills, A; Molina, JM; Podzamczer, D; Quirk, E; Ruane, P; Stellbrink, HJ; Ward, D | 1 |
| Andreatta, K; Cheng, A; Creticos, C; Crofoot, G; Custodio, J; Daar, ES; DeJesus, E; Graham, H; Koenig, E; Liu, YP; Martin, H; Molina, JM; Oguchi, G; Quirk, E; Rockstroh, JK; Ruane, P | 1 |
| Butini, L; Costantini, A; Martini, M; Rocchi, M; Tontini, C | 1 |
| Clarke, A; Garner, W; Laouri, M; Maggiolo, F; Martin, H; Quirk, E; Wohl, D | 1 |
| Ananworanich, J; Colby, DJ; Gandhi, M; Grant, RM; Kroon, E; Phanuphak, N; Phanuphak, P; Robb, ML; Sacdalan, C | 1 |
| Bradshaw, CS; Chen, MY; Chow, EPF; Cornelisse, VJ; Fairley, CK; Fortune, R; Needleman, R; Towns, JM; Yang, TZT | 1 |
| Alejos, B; Allavena, C; Arribas, JR; Bernardino, JI; de Miguel, R; Esteban-Cantos, A; Gisslén, M; Hoffmann, C; Montejano, R; Raffi, F; Rodes, B; Rodriguez-Centeno, J; Schwimmer, C; Stella-Ascariz, N; Wallet, C | 1 |
| Antonyak, S; Bukovinowa, P; Bursa, D; Gökengin, D; Horban, A; Jilich, D; Kowalska, JD; Mulabdic, V; Tomazic, J; Vasylyev, M | 1 |
| Li, J; Mesplède, T; Nekka, F; Sanche, S; Sheehan, NL | 1 |
| Baettig, V; Battegay, M; Courlet, P; Delko, T; Marzolini, C | 1 |
| Duggan, JM; Sahloff, EG | 1 |
| Anderson, PL; Arduino, RC; Ballerini, A; Bruno, G; Bushman, LR; Chua, CYX; Di Trani, N; Filgueira, CS; Folci, M; Gao, S; Grattoni, A; Gupte, M; Hood, RL; Hu, M; Jain, P; Marzinke, MA; Nehete, P; Sastry, JK; Shelton, K; Susnjar, A | 1 |
| Álvarez, H; Díaz-Cambre, H; García-González, J; Llibre, JM; Mariño, A; Valcarce, N | 1 |
| Chen, J; Cottrell, ML; Dumond, JB; Garrett, KL; Maas, BM; Prince, HA; Schauer, AP; Sykes, C; White, N | 1 |
| Azariah, S; Coughlan, E; Giola, M; Ludlam, A; Myers, J; O'Toole, C; Pohl, M; Rich, J; Saxton, P | 1 |
| Baillargeon, G; Diaz, M; Harzke, AJ; Koranek, A; Sandmann, R; Tong, E; Zepeda, S | 1 |
| Aslan, A; Balavoine, S; Bauer, R; Brun, A; Delaugerre, C; Leplatois, A; Loze, B; Molina, JM; Moudachirou, K; Noret, M; Pintado, C; Rozenbaum, W; Siguier, M | 1 |
| Anderson, PL; Bacchetti, P; Castillo-Mancilla, J; Gandhi, M; Koss, CA; Kuncze, K; Liu, AY; Louie, A; MaWhinney, S; McHugh, C; Morrow, M; Okochi, H; Seifert, S | 1 |
| Burgess, JF; Christiansen, CL; Drainoni, ML; Horný, M; Kuohung, W; Leech, AA; Linas, BP; Sullivan, M | 1 |
| Gordon, CM; Havens, PL; Kapogiannis, BG; Long, D; Mulligan, K; Price, G; Schuster, GU; Stephensen, CB; Wilson, CM | 1 |
| Domingo, P; Gutierrez, MDM; Mateo, MG; Vidal, F | 1 |
| Anton, PA; Baum, MM; Butkyavichene, I; Churchman, SA; Cortez, JM; Dawson, L; Fanter, R; Gunawardana, M; Guthrie, KM; Hendrix, CW; Marzinke, MA; Miller, CS; Moss, JA; Olive, TJ; Pyles, RB; Rosen, RK; Vargas, SE; Vincent, KL; Yang, F | 1 |
| Anderson, PL; Gordon, CM; Havens, PL; Hosek, SG; Kapogiannis, BG; Liu, N; Mulligan, K; Schuster, GU; Stephensen, CB; Tamhane, A; Wilson, CM | 1 |
| Edelstein, H; Maruff, P; Robertson, K; Ross, LL; Shaefer, MS; Small, CB; Wohl, D | 1 |
| Bogner, JR; DeGrosky, M; Dicker, IB; Gartland, M; Joshi, SR; Lataillade, M; Llamoso, C; Lombaard, J; Min, S; Molina, JM; Morales-Ramirez, J; Pene Dumitrescu, T; Stock, DA | 1 |
| Blake, KH; Chen, J; Cohen, MS; Dumond, JB; Gay, CL; Greene, SA; Kashuba, ADM; Maas, BM; Nelson, JAE; Prince, HMA; Schauer, AP; Sykes, C | 1 |
| Eichner, A; Shalit, P; Thomas, A; Tung, EL | 1 |
| Eberle, J; Kroidl, A | 1 |
| Aboud, M; Antinori, A; Arribas, JR; Cahn, P; Clarke, AE; Currie, A; Fettiplace, A; Gartland, M; Girard, PM; Hung, CC; Madero, JS; Man, C; Ortiz, R; Pappa, K; Rockstroh, JK; Sievers, J; Smith, K; Tenorio, AR; Underwood, M; Wynne, B | 1 |
| Bogner, JR | 1 |
| Naing, C; Poovorawan, Y; Tong, KS | 1 |
| Castro, L; Chow, DC; Duerler, T; Gangcuangco, LMA; Kallianpur, KJ; Kohorn, L; Nagamine, L; Nakamoto, BK; Paul, R; Pien, FD; Shikuma, CM; Soll, B; Souza, S; Walker, M | 1 |
| Baptiste, SL; Etya'ale, HM; Taro, TB | 1 |
| Bagella, P; Baldin, G; Capetti, A; Ciccullo, A; Cossu, MV; De Luca, A; Di Giambenedetto, S; Giacomelli, A; Lagi, F; Latini, A; Madeddu, G; Rusconi, S; Sterrantino, G | 1 |
| Bandera, A; Bozzi, G; Colella, E; Gori, A; Squillace, N | 1 |
| Siegler, AJ; Sullivan, PS | 1 |
| Andreoni, M; Cerva, C; Maffongelli, G; Malagnino, V; Sarmati, L; Teti, E | 1 |
| Baggaley, R; Dalal, S; Hodges-Mameletzis, I; Msimanga-Radebe, B; Rodolph, M | 1 |
| Bärnighausen, TW; Geldsetzer, P; Gómez-Olivé, FX; Harling, G; Kahn, K; Manne-Goehler, J; Montana, L; Rohr, J; Siedner, M; Tollman, S; Wagner, R; Wiesner, L | 1 |
| Cottrell, ML; Garcia, B; Imaz, A; Kashuba, ADM; Morenilla, S; Niubó, J; Perez, E; Podzamczer, D; Tiraboschi, JM | 1 |
| Destache, CJ; Fan, W; Kang, G; Li, Q; Mandal, S; Prathipati, PK; Zhou, Y | 1 |
| Capetti, AF; Cossu, MV; Giacomet, V; Rizzardini, G; Zuccotti, G | 1 |
| Amico, KR; Andrade, A; Chege, W; Chen, YQ; Gulick, RM; Kapadia, SN; Landovitz, RJ; Mayer, KH; McCauley, M; Schackman, BR; Wilkin, TJ; Wu, C | 1 |
| Arendt, G; Orhan, E; Schlonies, S; Stüve, O | 1 |
| Anderson, PL; Bushman, LR; Castillo-Mancilla, J; Coleman, SS; Coyle, RP; Ellison, L; Frasca, K; Kiser, JJ; Mawhinney, S; Morrow, M; Zheng, JH | 1 |
| Allavena, C; Billaud, E; Bonnet, B; Bouchez, S; Chauveau, M; Hall, N; Hitoto, H; Merrien, D; Michau, C; Perez, L; Raffi, F; Sécher, S | 1 |
| Boyer, EW; Carrico, AW; Chai, PR; Jambaulikar, GD; Mayer, KH; O'Cleirigh, C; Pereira, LM | 1 |
| Mesplède, T; Pham, HT | 1 |
| Touger, R; Wood, BR | 1 |
| Ammassari, A; Angeletti, C; Antinori, A; Bellagamba, R; Gallo, AL; Giancola, ML; Narciso, P; Nicastri, E; Pinnetti, C; Piselli, P; Tempestilli, M; Tommasi, C; Zaccarelli, M | 1 |
| Dickinson, L; Else, LJ; Gini, J; Khoo, S; Neary, M; Olagunju, A; Siccardi, M; Waitt, C | 1 |
| Beauchamp, G; Chen, YQ; Emel, LM; Fields, SD; Hendrix, CW; Hightow-Weidman, L; Hucks-Ortiz, C; Kuo, I; Lucas, J; Magnus, M; Mayer, KH; Nelson, LE; Piwowar-Manning, E; Shoptaw, S; Watkins, P; Watson, CC; Wheeler, DP; Wilton, L | 1 |
| Coy, KC; Delpino, A; Hazen, RJ; Kirkham, HS; Siegler, AJ | 1 |
| Acosta, RK; Chang, S; Garner, W; Lutz, J; Majeed, S; Martin, H; Martin, R; Quirk, E; SenGupta, D; Wei, X; White, KL; Willkom, M | 1 |
| Bugnon, S; Godinho, R; Gracin, T; Tataw, J | 1 |
| Amico, KR; Franks, J; Grant, RM; Hirsch-Moverman, Y; Hughes, JP; Li, M; Loquere, A; Mannheimer, S | 1 |
| Abrams, EJ; Brittain, K; Gomba, Y; Hu, NC; Maartens, G; Myer, L; Norman, J; Orrell, C; Phillips, TK; Sinxadi, P; Wiesner, L; Zerbe, A | 1 |
| Baidoobonso, S; Husbands, W; Kaul, R; Nelson, LE; Sa, T; Tharao, W; Thomas-Pavanel, J; Zhabokritsky, A; Zhang, N | 1 |
| Al-Khouja, A; Curley, P; Flexner, C; Hobson, JJ; Meyers, CF; Meyers, D; Owen, A; Rannard, SP; Siccardi, M | 1 |
| Cohen, K; Maartens, G; Njuguna, C; Viljoen, C | 1 |
| Gibas, KM; Krakower, DS; Powell, VE; van den Berg, P | 1 |
| Armishaw, J; Asselin, J; Batrouney, C; Chang, CC; Cornelisse, VJ; Cundill, P; El-Hayek, C; Fairley, CK; Forgan-Smith, G; Gall, J; Hellard, ME; Hoy, JF; Lal, L; Lockwood, JT; Mak, A; Murphy, DA; Nguyen, L; Penn, M; Pickett, C; Price, B; Roth, NJ; Ruth, S; Ryan, KE; Spelman, TD; Stoové, MA; Tee, BK; Traeger, MW; Vujovic, O; West, M; Willcox, J; Wright, EJ | 1 |
| Burack, JH; Erguera, X; Frazier, R; Grant, R; Horowitz, J; Kang Dufour, MS; Kennedy, K; Koester, KA; Myers, JJ; Packard, R; Udoh, I | 1 |
| Laroche, H; Lions, C; Poizot-Martin, I; Tamalet, C; Zaegel-Faucher, O | 1 |
| Borsa, A; Carnevale, C; Cohall, A; Gordon, P; Gottlieb, F; Hyden, C; Olender, S; Richards, P; Slowikowski, J; Sobieszczyk, ME; Vakkur, I; Zucker, J | 1 |
| Blake, K; Chen, J; Cohen, MS; Dumond, JB; Gay, CL; Greene, SA; Nelson, JAE; Prince, HMA; Schauer, AP; Sykes, C | 1 |
| Alves Saldanha, S; Brown, JA; Calmy, A; Cavassini, M; Courlet, P; Csajka, C; Decosterd, LA; Labhardt, ND; Marzolini, C; Stoeckle, M | 1 |
| Barber, TJ | 1 |
| Acosta, R; Albrecht, H; Arribas, JR; Brainard, D; Collins, SE; Creticos, C; Maggiolo, F; Martin, H; Martorell, CT; Sax, PE; Stellbrink, HJ; Stephens, JL; Wei, X | 1 |
| Boffito, M; Brady, M; Green, I; McClure, M; Nutland, W; Wang, X | 1 |
| Alexander, K; Anderson, PL; Brooks, KM; Bushman, LR; Castillo-Mancilla, JR; Ellison, L; Hosek, S; Huhn, GD; Ibrahim, ME; Kerr, BJ; Kiser, JJ; MaWhinney, S; McHugh, C; Tilden, S | 1 |
| Anderson, PL; Bacon, O; Buchbinder, SP; Cohen, S; Coleman, ME; Elion, R; Gandhi, M; Glidden, DV; Kolber, MA; Liu, AY; Scott, H; Spinelli, MA; Vittinghoff, E | 1 |
| Cahn, P; Hanna, G; Hwang, C; Kumar, S; Martin, E; Molina, JM; Orkin, C; Rodgers, A; Sax, P; Squires, K; Teppler, H; Thompson, M; Xu, X | 1 |
| DeJesus, E; Hanna, G; Hwang, C; Kumar, S; Lombaard, J; Martin, E; Molina, JM; Orkin, C; Rodgers, A | 1 |
| Townsend, L; Tuite, H | 1 |
| Beksinska, M; Brown, TT; Eneh, P; Fowler, MG; Isingel, E; Kabwigu, S; Kaiser, T; Kiweewa Matovu, F; Nakalega, R; Nicol, MR; Staley, C; Sykes, C | 1 |
| Chellappan, DK; Chellian, J; Collet, T; Dua, K; Gupta, G; Liew, YK; Loo Xin, GL; Tan, YY; Yap, PK | 1 |
| Amico, KR; Bekker, LG; Chitwarakorn, A; Dye, BJ; Grant, RM; Hendrix, CW; Holtz, TH; Hughes, JP; Li, M; Mannheimer, S; Marzinke, M; Ojeda, VD; Wilson, E | 1 |
| Elopre, L; Mena, L; Siegler, AJ; Sullivan, PS | 1 |
| Anderson, PL; Cofield, SS; Havens, PL; Hosek, SG; Kapogiannis, BG; Landovitz, RJ; Liu, N; Mulligan, K; Patki, A; Perumean-Chaney, SE; Wilson, CM | 1 |
| Bougatsos, C; Chou, R; Dana, T; Evans, C; Grusing, S; Hoverman, A; Korthuis, PT; Sun, C | 1 |
| Barry, MJ; Cabana, M; Caughey, AB; Curry, SJ; Davidson, KW; Doubeni, CA; Epling, JW; Krist, AH; Kubik, M; Landefeld, CS; Mangione, CM; Owens, DK; Pbert, L; Silverstein, M; Simon, MA; Tseng, CW; Wong, JB | 1 |
| Geng, E; Glidden, DV; Glymour, MM; Grant, RM; McMahan, VM; Mehrotra, ML; Westreich, D | 1 |
| Anderson, PL; Bushman, LR; Castillo-Mancilla, JR; Coleman, SS; Coyle, RP; Ellison, L; Gardner, EM; Kiser, JJ; MaWhinney, S; Morrow, M; Zheng, JH | 1 |
| Barriere, G; Chas, J; Cotte, L; Cua, E; Durand, F; Ghosn, J; Mera, R; Molina, JM; Ohayon, M; Pialoux, G; Pintado, C; Siguier, M; Valin, N | 1 |
| Beymer, MR; Holloway, IW; Landovitz, RJ; Pulsipher, C | 1 |
| Azariah, S; Forster, R; Franklin, R; Jenkins, R; Saxton, P; Werder, S | 1 |
| Boyer, L; Citerne, Q; Garon, J; Gillet, P; Moreau, E; Petitpain, N | 1 |
| Brown, K; Cunningham, D; De Wit, S; Eron, JJ; Hufkens, V; Jezorwski, J; Lathouwers, E; Opsomer, M; Orkin, C; Petrovic, R; Post, FA; Pulido, F; Van Landuyt, E | 1 |
| Gatanaga, H; Oka, S | 1 |
| Kaplun, O; Psevdos, G | 1 |
| Affolabi, D; Alary, M; Aza-Gnandji, M; Bachabi, M; Béhanzin, L; Boily, MC; Cianci, F; Diabaté, S; Diallo, M; Dramane, K; Gagnon, MP; Gangbo, F; Geidelberg, L; Geraldo, N; Giguère, K; Goma-Matsétsé, E; Guédou, FA; Kêkê, RK; Kessou, L; Lafrance, C; Mboup, A; Vickerman, P; Zannou, DM | 1 |
| Brieva, J; Kosche, C; Nardone, B; Palella, FJ; Para, A; West, DP | 1 |
| Baggaley, R; Dalal, S; Fonner, VA; Hodges-Mameletzis, I; Msimanga-Radebe, B; Mugo, N | 1 |
| Castillo-Mancilla, JR | 1 |
| Bacchetti, P; Baeten, JM; Cressey, R; Cressey, TR; Drain, PK; Gandhi, M; Klinbuayaem, V; Kubiak, RW; Okochi, H; Punyati, P; Quame-Amaglo, J; Siriprakaisil, O; Sirirungsi, W; Sukrakanchana, PO; Tanasri, S | 1 |
| Amico, KR; Bacchetti, P; Curlin, ME; Dye, BJ; Eshleman, SH; Gandhi, M; Grant, RM; Hendrix, CW; Holtz, TH; Hughes, JP; Li, M; Liu, A; Mannheimer, S; Marzinke, MA; Murnane, P; Piwowar-Manning, E; Velloza, J | 1 |
| Conway-Washington, C; Dinh, C; Fountain, J; Haaland, RE; Hall, L; Holder, A; Kelley, CF; Livermont, T; Lupo, LD; Martin, A | 1 |
| Avettand-Fènoël, V; De Dieuleveult, B; Gardiennet, E; Gubavu, C; Guinard, J; Hocqueloux, L; Lefeuvre, S; Lopez, P; Mille, C; Prazuck, T; Rouzioux, C; Sève, A | 1 |
| Asano, T; Fujiki, K; Furumoto, Y; Hayakawa, Y; Horiuchi, T; Kobayashi, K; Matsumoto, T; Matsuoka, M; Misumi, Y; Miura, N; Nozaka, T; Sakamoto, N | 1 |
| Babusis, D; Callebaut, C; Cong, ME; Deyounks, F; Dinh, C; García-Lerma, JG; Heneine, W; Holder, A; Johnson, R; Khalil, G; Lipscomb, J; Massud, I; McCallister, S; Nishiura, K; Pan, Y; Park, Y; Rooney, JF; Ruone, S | 1 |
| DeJesus, E; DiNubile, MJ; Leavitt, R; Lennox, JL; Miller, M; Nguyen, BY; Rockstroh, JK; Rodgers, AJ; Saag, MS; Sklar, P; Teppler, H; Walker, ML; Wan, H; Yazdanpanah, Y | 1 |
| Adams, JL; Corbett, AH; Dumond, JB; Forrest, A; Jennings, SH; Kashuba, AD; Kendrick, RL; Malone, S; Patterson, KB; Prince, HM; Sykes, C; Wang, R; White, N | 1 |
| Bayonne Kombo, ES; Gathse, A | 1 |
| Agarwal, K; Bruce, M; Byrne, R; Carey, I; Childs, K; Joshi, D; Taylor, C | 1 |
| Plosker, GL | 1 |
| Barrail-Tran, A; Descamps, D; Duval, X; Goujard, C; Mentré, F; Nembot, G; Panhard, X; Parienti, JJ; Taburet, AM; Vigan, M; Vrijens, B | 1 |
| Baltussen, R; Boucher, CA; Nichols, BE; Nouwen, JL; Sloot, PM; Thuma, PE; van de Vijver, DA; van de Wijgert, J; van Dijk, JH | 1 |
| Cahn, P; Sued, O | 1 |
| Andrade-Villanueva, J; Antunes, F; Arastéh, K; Callebaut, C; Cheng, AK; Chetchotisakd, P; DeJesus, E; Fehr, J; Gallant, JE; Koenig, E; Liu, Y; Moyle, G; Rhee, MS; Rizzardini, G; Szwarcberg, J; Zhong, L | 1 |
| Endo, T; Fujii, T; Gatanaga, H; Higasa, S; Horiba, M; Ishisaka, M; Kaneda, S; Kikuchi, Y; Koibuchi, T; Komatsu, H; Matsushita, S; Mitsuya, H; Naito, T; Nishijima, T; Oka, S; Tachikawa, N; Takada, K; Takano, M; Tanabe, Y; Tateyama, M; Uchiumi, H; Ueda, M; Yamamoto, M; Yokomaku, Y; Yoshida, M | 1 |
| Choo, HW; Davis, J; Fang, J; Hansson, AG; Langdon, G; Layton, G; Tawadrous, M; Vourvahis, M | 1 |
| Angeletti, C; Antonucci, G; Armignacco, O; Cassola, G; De Stefano, G; Girardi, E; Grossi, P; Mazzotta, F; Orani, A; Pagano, G; Petrosillo, N; Puoti, M; Sagnelli, C; Sagnelli, E | 1 |
| Andrasik, M; Broder, G; Fuchs, JD; Grove, D; Hammer, S; Karuna, ST; Koblin, B; Madenwald, T; Mayer, K; Sherwat, A; Sobieszczyk, ME | 1 |
| Anglaret, X; Bohoussou, F; Carrou, JL; Danel, C; Eholie, SP; Gabillard, D; Konan, R; Moh, R; Ouattara, E; Peytavin, G | 1 |
| Antinori, A; Bansi, L; Boumis, E; Callegaro, A; Ceccherini-Silberstein, F; Dunn, D; Fearnhill, E; Forbici, F; Francisci, D; Maggiolo, F; Mussini, C; Nicastri, E; Palamara, G; Perno, CF; Sabin, C; Santoro, MM; Zazzi, M; Zoncada, A | 1 |
| Mayer, KH; Morrow, KM; Operario, D; Underhill, K | 1 |
| Albert, J; Brun-Vezinet, F; Gatell, JM; Gupta, RK; Nachega, JB; Sönnerborg, A; Wainberg, MA | 1 |
| Abgrall, S; Antinori, A; Cavassini, M; Costagliola, D; Crane, HM; Gill, MJ; Gomez Sirvent, JL; Guest, JL; Ingle, SM; Manzardo, C; May, MT; Mercie, P; Mugavero, MJ; Phillips, A; Reekie, J; Reiss, P; Saag, MS; Samji, H; Stephan, C; Sterling, TR; Sterne, JA; Tate, J; Wasmuth, JC | 1 |
| Gatanaga, H; Kikuchi, Y; Komatsu, H; Nishijima, T; Oka, S; Tanuma, J; Teruya, K; Tsukada, K | 1 |
| Folayan, MO; Haire, B; Hankins, C; McCormack, S; Ramjee, G; Sugarman, J; Warren, M | 1 |
| Fowler, S; Senn, H; Sharma, M; Tan, DH; Wilton, J | 1 |
| Arends, JE; Feuth, T; Hoepelman, AI; van Baarle, D | 1 |
| Blanche, S; Chaix, ML; Frange, P | 1 |
| Baeten, JM; Haberer, JE; Liu, AY; Sista, N | 1 |
| Chen, YQ; Donnell, D; Fleming, TR; Hughes, JP; Wang, L | 1 |
| Mayer, KH; Sugarman, J | 1 |
| Blumenthal, J; Haubrich, R | 1 |
| Allavena, C; Bach-Ngohou, K; Billaud, E; Dejoie, T; Fakhouri, F; Raffi, F; Reliquet, V; Sécher, S | 1 |
| Boot, J; Boucher, CA; Burger, DM; Fanoy, EB; Op de Coul, EL; Rump, BO; van Agtmael, MA; van de Vijver, DA | 1 |
| Boeke, AJ; Heijnen, AM | 1 |
| Benko, E; Blazkova, J; Casazza, JP; Chun, TW; Costiniuk, CT; Fauci, AS; Hallahan, CW; Kandel, G; Kaul, R; Kim, CJ; Koup, RA; Kovacs, C; Moir, S; Murray, D; Ostrowski, M; Shawn Justement, J | 1 |
| Cauda, R; Digiambenedetto, S; Fabbiani, M; Fortuna, S; Lisi, L; Navarra, P; Ragazzoni, E | 1 |
| Arribas, JR; Compston, J; Domingo, P; Gartland, M; Granier, C; Moyle, GJ; Orkin, C; Pearce, H; Sedani, S; Stellbrink, HJ | 1 |
| Echenique, IA; Rich, JD | 1 |
| Abbas, UL; Boucher, CA; Cambiano, V; Eaton, JW; Glaubius, R; Hallett, TB; Lythgoe, K; Mellors, J; Nichols, BE; Phillips, A; Sigaloff, KC; van de Vijver, DA | 1 |
| Feucht, N; Hadeler, J; Lanzl, I; Loos, D; Schmid, RM; Schwerdtfeger, C; Spinner, CD | 1 |
| Endo, T; Fujii, T; Gatanaga, H; Horiba, M; Itoda, I; Koga, M; Komatsu, H; Mitsuya, H; Miyakawa, T; Naito, T; Nishijima, T; Oka, S; Shimbo, T; Takada, K; Tanabe, Y; Tei, M; Yamamoto, M | 1 |
| Ahmed-Jushuf, I; Arumainayagam, J; Carlin, EM; Chandramani, S; Das, S; Ghanem, M; Kumari, B; Pammi, M; Riddell, L | 1 |
| Gulholm, T; Jamani, S; Poynten, IM; Templeton, DJ | 1 |
| Rosenberg, K | 1 |
| Carr, A; Ingersoll, A; McAllister, J; McNulty, A; Read, P; Tong, WW | 1 |
| Aldir, I; Horta, A; Serrado, M | 1 |
| Bansi-Matharu, L; Bibby, D; Bulteel, N; Churchill, D; Dunn, D; Hill, T; Nelson, M; Sabin, C | 1 |
| Baeten, JM; Bangsberg, DR; Campbell, J; Celum, C; Donnell, D; Haberer, JE; Katabira, E; Kidoguchi, L; Krows, M; Psaros, C; Ronald, A; Safren, SA; Thomas, KK; Tumwesigye, E; Wangisi, J; Ware, NC | 1 |
| Bahemuka, U; Bangsberg, DR; Barin, B; Bwanika, AN; Chetty, P; Fast, P; Haberer, JE; Kamali, A; Katende, D; Kibengo, FM; Mark, D; Priddy, FH; Rooney, JF; Ruzagira, E | 1 |
| Amico, KR; Buchbinder, S; Gilmore, HJ; Goicochea, P; Grant, R; Koester, KA; Liu, A; Lubensky, D; McMahan, V; Vargas, L | 1 |
| Cheng, A; Custodio, JM; Hepner, M; Kearney, BP; Ling, KH; Ramanathan, S; Yin, X | 1 |
| Aoki, M; Desai, DV; Kodama, EN; Maeda, K; Mitsuya, H; Nakata, H | 1 |
| Doherty, M; Ford, N; Gray, A; Hill, A; Mills, EJ; Shubber, Z; Vitoria, M | 1 |
| Estrada, V; Portilla, J | 1 |
| Calvez, V; Charpentier, C; Descamps, D; Flandre, P; Fofana, D; Fourati, S; Lambert-Niclot, S; Marcelin, AG; Masquelier, B; Morand-Joubert, L; Soulie, C; Storto, A; Wirden, M | 1 |
| Brooks, JT; Chirwa, LI; Henderson, FL; Johnson, JA; Li, JF; Matlhaba, O; Niska, RW; Paxton, LA; Rose, CE; Segolodi, TM; Thigpen, MC | 1 |
| Amico, KR; Buchbinder, SP; Glidden, DV; Grant, RM; Kallas, EG; Liu, AY; Marcus, JL; Mayer, KH; McMahan, V; Montoya-Herrera, O; Pilotto, J | 1 |
| Andrade, A; Chan, ES; Clagett, B; Daar, E; Feinberg, J; Funderburg, NT; Jacobson, JM; Kuritzkes, D; Lederman, MM; Lu, D; Mellors, J; Pilch-Cooper, HA; Rodriguez, B; Rosenkranz, SL | 1 |
| Baeten, JM; Bukusi, E; Campbell, JD; Celum, C; Donnell, D; Kahle, EM; Mugo, N; Mujugira, A; Murnane, PM; Tappero, J; Thomas, KK | 1 |
| Currier, J; Hogg, E; Hosseinipour, M; Hughes, MD; Lockman, S; Mulenga, L; Mwafongo, A; Nkanaunena, K; Samaneka, W; Siika, A; Zheng, Y | 1 |
| Dufrene, SL; Li, J; Okulicz, JF | 1 |
| Benaboud, S; Bouazza, N; Fauchet, F; Foissac, F; Ghosn, J; Hirt, D; Tréluyer, JM; Urien, S; Valade, E; Viard, JP | 1 |
| Bekker, LG; Burns, DN; Chariyalertsak, S; Glidden, DV; Grant, RM; Guanira, JV; Kallás, EG; Lama, JR; Liu, AY; Mayer, KH; McMahan, V; Mulligan, K; Schechter, M; Solomon, MM; Veloso, VG | 1 |
| Anderson, S; Doncel, GF; Thurman, AR | 1 |
| DeGrosky, M; Farajallah, A; Hardy, H; McGrath, D; Moyle, GJ | 1 |
| Bao, Y; Currier, J; Hogg, E; Hughes, MD; Lockman, S; Moses, A; Sawe, F; Shaffer, D | 1 |
| Buchbinder, S; Cohan, D; Cohen, S; Follansbee, S; Liu, A; Sachdev, D; Weber, S | 1 |
| Buchbinder, SP; Glidden, DV; Goicochea, P; Grant, RM; Guanira, JV; Liu, AY; Mayer, KH; McMahan, V | 1 |
| Blum, JD; Kiser, JJ; MacBrayne, CE | 1 |
| Henderson, FL; Kasonde, M; Niska, RW; Paxton, LA; Rose, C; Segolodi, TM; Smith, DK; Thigpen, MC; Turner, K | 1 |
| Adesoye, A; Chen, CY; Danavall, D; Easley, K; Evans-Strickfaden, T; Gatcliffe, C; Haaland, R; Hart, C; Lupo, LD; Martin, A; Ofotokun, I; Omondi, MW; Pau, CP; Sheth, AN | 1 |
| Behrens, G; Bosse, M; Chuck, SK; Cohen, C; DeMorin, J; Elion, RA; Mills, A; Nelson, M; Orkin, C; Rijnders, B; Rimsky, L; Stevens, M; Thorpe, D; Vanveggel, S; White, K; Zhong, L | 1 |
| Hsiao, CB; Ma, Q; Sawyer, JR | 1 |
| Amin, J; Cooper, DA; Cordery, DV; Emery, S; Haskelberg, H; Kelleher, AD | 1 |
| Aberg, JA; Hollabaugh, K; Kang, M; Koletar, SL; Pham, V; Smurzynski, M; Wu, K | 1 |
| Fonjungo, PN; Hart, C; Henderson, FL; Niska, R; Paxton, LA; Rose, CE; Segolodi, TM; Turner, KT; Zeh, C | 1 |
| Allworth, A; Amin, J; Carr, A; Ebeling, PR; Emery, S; Haskelberg, H; Pocock, N | 1 |
| Rijnders, BJ; Rokx, C; Verbon, A | 1 |
| Abdel-Mohsen, M; Anderson, PL; Atchison, R; Bentley, LG; Buchbinder, S; Eden, C; Glidden, DV; Grant, RM; Guanira, JV; Javier, J; Li, P; Liegler, T; McMahan, V; Mehrotra, M; Schmidt, T; Wong, JK | 1 |
| Cardoso, SW; Demeter, LM; Godfrey, C; Infante, R; Johnson, VA; Moran, LE; Sanchez, J; Smeaton, LM; Vogler, MA; Wright, RL | 1 |
| Ayala-Sims, VA; Fulco, PP | 1 |
| Baeten, JM; Bangsberg, DR; Brantley, J; Bumpus, NN; Celum, C; Donnell, D; Haberer, JE; Hendrix, C; Mugo, N; Mujugira, A; Ndase, P | 1 |
| Domingo, JC; Domingo, P; Gallego-Escuredo, JM; Giralt, M; Gutierrez, Mdel M; Lamarca, K; Mateo, MG; Torres, F; Vidal, F; Villarroya, F; Villarroya, J | 1 |
| Baeten, JM; Brantley, J; Bukusi, E; Campbell, J; Celum, C; Donnell, D; Katabira, E; Kiarie, J; Mugo, N; Ndase, P; Tumwesigye, E; Wangisi, J; Were, E | 1 |
| Chima-Okereke, C; Sivaprakasam, V | 1 |
| Henderson, H; Kruse, L; Stover, K | 1 |
| Boucherie, C; Breton, G; Bugault, F; Chakrabarti, LA; Chêne, G; Cumont, MC; Lortholary, O; Patey, O; Richert, L; Roussillon, C | 1 |
| Barthe, Y; Bouix, C; Cacoub, P; Carrat, F; Lascoux-Combe, C; Lebossé, F; Maynard-Muet, M; Miailhes, P; Piroth, L; Pol, S; Rey, D; Sogni, P; Zoulim, F | 1 |
| Allavena, C; André-Garnier, E; Billaud, E; Bonnet, B; Bouchez, S; Bouquié, R; Boutoille, D; Dailly, E; Pineau, S; Raffi, F; Raveleau, A; Reliquet, V | 1 |
| Debyser, Z; Schrijvers, R | 2 |
| Arribas, JR; Di Perri, G; Ebrahimi, R; Gathe, J; Nguyen, T; Pialoux, G; Piontkowsky, D; Reynes, J; Tebas, P; White, K | 1 |
| Antela, A; Domingo, P; Garner, W; Girard, PM; Guyer, B; Henry, K; Markowitz, M; Mills, A; Nguyen, T; Piontkowsky, D; Pozniak, A; Stellbrink, HJ; White, K | 1 |
| Chariyalertsak, S; Fernandez, T; Glidden, DV; Grant, RM; Guanira, JV; Liu, AY; Mayer, KH; McMahan, VM; Solomon, MM | 1 |
| Baum, MM; Brooks, AA; Butkyavichene, I; Dinh, CT; Lopez, G; Martin, A; Moss, JA; Smith, JM; Smith, TJ; Srinivasan, P | 1 |
| Asmelash, A; Currier, J; Hughes, MD; Kaloustian, KW; Lockman, S; Ogwu, A; Salata, R; Sawe, F; Shaffer, D; Zheng, Y | 1 |
| Baeten, JM; Celum, C; Donnell, D; Fife, KH; Hendrix, CW; Hong, T; Morrow, RA; Mujugira, A; Nakku-Joloba, E; Thomas, KK | 1 |
| Chau, JJ; Giancola, MA; Keller, SB; King, HL; Little, SJ; Rodriguez, DA; Smith, DM; Young, JA | 1 |
| Clumeck, N; Delforge, M; Ilunga, J; Kabeya, K; Kadiebwe, D; Kapend, L; Kasamba, E; Matanda, S; Milolo, C; Mwamba, C; Necsoi, C; Vaira, D | 1 |
| Bruzzone, B; Di Biagio, A; Gustinetti, G; Prinapori, R; Sticchi, L; Taramasso, L; Viscoli, C | 1 |
| Gürtler, LG | 1 |
| Haire, B | 1 |
| De Castro, N; Delaugerre, C; Flandre, P; Gallien, S; Molina, JM; Nguyen, N | 1 |
| Bosco, O; Cruciani, M; Malena, M; Mengoli, C; Moyle, G; Parisi, SG; Serpelloni, G | 1 |
| Babu, GR; Detels, R; Han, N; Mahapatra, S; Mahapatra, T; Tang, W; Wang, L; Yu, W; Zhang, X; Zhao, J | 1 |
| Allavena, C; Antinori, A; Arribas, JR; Babiker, AG; Chêne, G; Delfraissy, JF; George, EC; Grarup, J; Hudson, F; Jansson, PO; Molina, JM; Pozniak, A; Raffi, F; Richert, L; Saillard, J; Schwimmer, C; Van Leeuwen, R; Vella, S; Wallet, C | 1 |
| Amiel, C; Chas, J; Guessant, S; Hamidi, M; Kherallah, K; Lebrette, MG; Lependeven, C; Pialoux, G; Schneider, V | 1 |
| Daar, ES; Gupta, SK; Ha, B; Kitch, D; McComsey, GA; Melbourne, K; Sax, PE; Tierney, C; Wyatt, CM | 1 |
| Baldeyrou, M; Batard, ML; Bernard-Henry, C; Cheneau, C; de Mautort, E; Fafi-Kremer, S; Gantner, P; Muret, P; Partisani, M; Priester, M; Reinhart, S; Rey, D | 1 |
| Agot, K; Ahmed, K; Corneli, AL; Deese, J; Kapiga, S; Kashuba, A; Lombaard, J; Manongi, R; Taylor, D; Van Damme, L; Wang, M | 1 |
| Bedimo, RJ; Castanon, R; Cutrell, J; Drechsler, H; Farukhi, I; Jain, M; Li, X; Maalouf, NM; Tebas, P; Zhang, S | 1 |
| Becker, A; Desprez, S; Froidure, M; Gagneux, M; Huguet, D; Leduc, D; Legout, L; Sifaoui, F; Vignoli, P | 1 |
| Antinori, A; Bonora, S; Castagna, A; d'Arminio Monforte, A; De Luca, A; Maserati, R; Perno, CF | 1 |
| Gray, SC; Henderson, FL; Kebaabetswe, PM; McLellan-Lemal, E; Paxton, LA; Rose, CE; Stirratt, MJ; Williams, T | 1 |
| Camejo, RR; Cuffe, R; Gilchrist, KA; Lim, JW; Nichols, G; Patel, DA; Pulgar, S; Snedecor, SJ; Stephens, J; Sudharshan, L; Tang, WY | 1 |
| Deyounks, F; Ellis, S; García-Lerma, JG; Hanley, K; Heneine, W; Jenkins, L; Mitchell, J; Radzio, J | 1 |
| Baeten, JM; Bukusi, EA; Celum, C; Heffron, R; Mugo, NR; Mujugira, A; Were, EO | 1 |
| Boucher, CA; Langebeek, N; Mudrikova, T; Nijhuis, M; Pingen, M; Richter, C; van Laarhoven, A; Wensing, AM | 1 |
| Brun-Vezinet, F; Costagliola, D; Mokhtari, S; Poizot-Martin, I; Potard, V; Pradier, C; Rey, D; Rozenbaum, W | 1 |
| Aweeka, F; Baugh, BP; Benson, CA; Brown, TT; Cohn, SE; Currier, JS; Fichtenbaum, CJ; Godfrey, C; Haas, DW; Koletar, SL; Kuritzkes, DR; Landovitz, RJ; Leavitt, RY; Lennox, JL; McComsey, GA; Na, LH; Ofotokun, I; Patterson, KB; Presti, RM; Ribaudo, HJ; Rooney, JF; Sagar, M; Seekins, D | 1 |
| Buchbinder, S | 1 |
| Baeten, JM; Bangsberg, D; Bukusi, EA; Campbell, JD; Celum, C; Cohen, CR; Coombs, RW; Donnell, D; Farquhar, C; Fife, KH; Frenkel, L; Haberer, JE; Hendrix, C; John-Stewart, G; Katabira, E; Kiarie, J; Kidoguchi, L; Marzinke, MA; Mugo, NR; Ndase, P; Ronald, A; Tappero, JW; Thomas, KK; Tumwesigye, E; Wangisi, J; Were, E | 1 |
| Boyd, A; Fonquernie, L; Girard, PM; Meynard, JL; Morand-Joubert, L; Surgers, L; Valin, N; Viala, C | 1 |
| Cheng, AK; Kulkarni, R; McColl, DJ; Miller, MD; Rhee, MS; Szwarcberg, J; White, KL | 1 |
| Almond, S; Arasteh, K; Brennan, C; Brinson, C; Cuffe, RL; Eron, J; Górgolas, M; Granier, C; Nichols, WG; Pappa, K; Rachlis, A; Raffi, F; Walmsley, S | 1 |
| Baker, J; OʼHara, KM | 1 |
| Agot, K; Ahmed, K; Corneli, A; Lombaard, J; Van Damme, L; Wang, M | 1 |
| Berendes, S; Campbell, TB; Cardoso, SW; Christian, P; Gupta, A; Gupte, N; Kanyama, C; Lama, JR; Mwelase, N; Pillay, S; Riviere, C; Samaneka, W; Semba, RD; Shivakoti, R; Sugandhavesa, P; Tang, AM; Yang, WT | 1 |
| Anderson, PL; Bushman, LR; Castillo-Mancilla, JR; Gardner, EM; Glidden, DV; Guida, LA; Kerr, BJ; Klein, B; Meditz, AL; Predhomme, JA; Rower, C; Seifert, SM; Zheng, JH | 1 |
| Ferrada, MA; Nuermberger, E; Xie, Y | 1 |
| Anzala, O; Bangsberg, DR; Barin, B; Haberer, JE; Mugo, PM; Mutua, G; Priddy, FH; Sanders, EJ; van der Elst, E | 1 |
| Deese, J; Hubacher, D; Otunga, S; Steiner, MJ; Todd, CS; Van Damme, L; Wang, M | 1 |
| Abram, ME; Andrade-Villanueva, JF; Beraud, C; Cheng, AK; Fisher, M; Graham, H; Liu, Y; Post, FA; Rhee, MS; Szwarcberg, J; Winston, J | 1 |
| Álvarez, ML; Arterburn, S; Berenguer, J; Clotet, B; Curran, A; Estrada, V; Ferrer, P; Larrousse, M; Martínez, E; Negredo, E; Pulido, F; Ribera, E; Rubio, R; Sanz, J | 2 |
| Bacon, O; Blue, RW; Buchbinder, S; Castro, JG; Chege, W; Cohen, SE; Coleman, ME; Doblecki-Lewis, S; Elion, R; Estrada, Y; Feaster, DJ; Kolber, MA; Liu, AY; Matheson, T; Philip, SS; Postle, BS; Trainor, N; Vittinghoff, E | 1 |
| Abdel-Mohsen, M; Agingu, W; Ahmed, K; Bentley, G; Crucitti, T; Damme, LV; De Baetselier, I; Deese, J; Defechereux, P; Fransen, K; Grant, RM; Kashuba, AD; Liegler, T; Taylor, D | 1 |
| Baeten, JM; Celum, C; Donnell, D; Kiarie, J; Mugo, NR; Mugwanya, KK; Ronald, A; Tappero, J; Wyatt, C | 1 |
| De Baetselier, I; Deese, J; Lombaard, J; Malahleha, M; Mandala, J; Manongi, R; Nanda, K; Owino, F; Taylor, D; Van Damme, L; Wang, M | 1 |
| Baeten, JM; Celum, C; Donnell, D; Frenkel, L; Hendrix, CW; Lehman, DA; Marzinke, MA; Matsen, FA; Mbara, G; McCoy, CO; Mugo, NR; Ndase, P; Overbaugh, J; Peterson, D; Thomas, KK; Weis, JF | 1 |
| Callahan, R; Kapiga, S; Malahleha, M; Mandala, J; Nanda, K; Ogada, T; Taylor, D; Van Damme, L | 1 |
| Calvez, V; Desire, N; Girard, PM; Katlama, C; Marcelin, AG; Mercier-Darty, M; Morand-Joubert, L; Rodriguez, C; Todesco, E; Wirden, M | 1 |
| Chirenje, ZM; Dai, JY; Ganesh, S; Gomez, K; Grossman, C; Hendrix, CW; Hillier, SL; Marrazzo, JM; Marzinke, MA; Mâsse, B; McGowan, IM; Mgodi, N; Mkhize, B; Nair, G; Nakabiito, C; Noguchi, L; Palanee, T; Parikh, UM; Piper, J; Ramjee, G; Richardson, BA; Rooney, J; Schwartz, JL; Taljaard, M; van der Straten, A; Watts, H | 1 |
| Back, DJ; Byakika-Kibwika, P; Else, L; Katwere, M; Khoo, SH; Lamorde, M; Merry, C; Mukisa, L; Sempa, JB; Walimbwa, S | 1 |
| Anderson, J; Dhar, J; Ebrahimi, R; Ewan, J; Fisher, M; Moyle, GJ; Orkin, C; Wang, H; Wilkins, E | 1 |
| Krakower, DS; Mayer, KH | 2 |
| Alonso-Villaverde, C; Ferrer, E; Martinez-Picado, J; Maso, M; Muñoz-Moreno, JA; Ouchi, D; Podzamczer, D; Prats, A; Puertas, MC; Rozas, N; Tiraboschi, JM | 1 |
| Rowniak, S | 1 |
| Agot, K; Ahmed, K; Corneli, AL; Malamatsho, F; McKenna, K; Odhiambo, J; Perry, B; Skhosana, J; Van Damme, L | 1 |
| Mayer, KH | 2 |
| Bae-Harboe, YS; Mahalingam, M; Marszalek, RM; Masterpol, K | 1 |
| Antinori, A; Brunetta, J; De-Oertel, S; Ebrahimi, R; Johnson, B; Johnson, M; Moreno Guillén, S; Shalit, P; Wade, B; Walker, I; Yeni, P | 1 |
| Amiel, C; Caseris, M; Charpentier, C; Descamps, D; Desnoyer, A; Farnoux, C; Lassel, L; Lê, MP; Pain, JB; Peytavin, G; Pialoux, G | 1 |
| Anglaret, X; Boyd, A; Danel, C; Delaugerre, C; Eholié, SP; Gabillard, D; Girard, PM; Lacombe, K; le Carrou, J; Maylin, S; Moh, R; Zoulim, F | 1 |
| Bravo, I; Clotet, B; Curran, A; Estany, C; Llibre, JM; Navarro, J; Negredo, E; Paredes, R; Podzamczer, D; Ribera, E; Santos, JR; Saumoy, M | 1 |
| Amin, J; Belloso, W; Carey, D; Cooper, DA; Crabtree-Ramirez, B; Emery, S; Foulkes, S; Jessen, H; Kumar, S; Lee, MP; Losso, M; Mohapi, L; Phanupak, P; Puls, R; Winston, A | 1 |
| Baeten, JM; Wyatt, C | 1 |
| Andrade-Villanueva, J; Callebaut, C; Cao, H; Cheng, AK; Crofoot, G; Custodio, JM; DeJesus, E; Fordyce, MW; Koenig, E; Martin, H; McCallister, S; Molina, JM; Oka, S; Plummer, A; Podzamczer, D; Post, F; Pozniak, A; Saag, M; Sax, PE; Thompson, M; Trottier, B; Wohl, D; Yin, MT; Zhong, L | 1 |
| Falutz, J | 1 |
| Anderson, PL; Bekker, LG; Buchbinder, S; Chariyalertsak, S; Chodacki, P; de Mendonca, LM; Glidden, DV; Gonzales, P; Grant, RM; Guanira, JV; Lama, JR; Liu, A; McMahan, V; Mulligan, K; Namwongprom, S; Ramirez-Cardich, ME; Schechter, M; Veloso, VG; Wang, F | 1 |
| Barré-Sinoussi, F; Bekker, LG; Beyrer, C; Pozniak, A | 1 |
| Gordon, M; Moodley, P; Naidoo, A; Parboosing, R; Paredes, R; Samuel, R; Singh, L | 1 |
| Balasubramanian, R; Bangsberg, DR; Ertel, K; Haberer, JE; Hankinson, SE; Kintu, A; Tumwesigye, E | 1 |
| Brown, TT; Currier, JS; Dubé, MP; Kelesidis, T; McComsey, GA; Moser, C; Murphy, RL; Ribaudo, HJ; Rothenberg, J; Stein, JH; Yang, O | 1 |
| Ajose, O; Beanland, RL; Calmy, A; Doherty, M; Ford, N; Irvine, C; Mayer, KH; Rapparini, C; Shubber, Z; Vitoria, M | 1 |
| Epelboin, S; Flores, J; Luton, D; Mabileau, G; Mandelbrot, L; Matheron, S; Patrat, C; Schwarzinger, M; Yazdanpanah, Y | 1 |
| Amico, KR; Eden, C; Goicochea, P; Grant, RM; Hosek, S; Koester, KA; Liu, A; Mayer, KH; McMahan, V | 1 |
| Bender, R; Berenguer, J; Garner, W; Mills, A; Nguyen, T; Pozniak, A; Speck, RM | 1 |
| Walter, M | 1 |
| Arribas, JR; Cabié, A; Crespo, M; Domingo, P; Dronda, F; Estrada, V; Gatell, JM; Girard, PM; Iribarren, JA; Knobel, H; Landman, R; Mallolas, J; Martínez-Rebollar, M; Montero, M; Pich, J; Podzamczer, D; Portilla, J; Pulido, F; Weiss, L; Zamora, FX | 1 |
| Antela, A; Esteban, H; Estébanez, M; Mariño, A; Moreno, S; Navarro, J; Pasquau, J; Perez-Molina, JA; Riera, M; Rivero, A; Rubio, R; Santos, J; Sanz-Moreno, J; Suárez-Lozano, I; Troya, J | 1 |
| Amico, KR; Avelino-Silva, VI; Burns, D; Chodacki, P; Defechereux, PA; Fernandez, T; Glidden, DV; Grant, RM; Liu, AY; Mayer, KH; McMahan, VM; Mehrotra, M; Vargas, L | 1 |
| Brown, ER; Chirenje, ZM; Dai, JY; Hendrix, CW; Kelly, C; Marrazzo, JM; Marzinke, M; Richardson, BA | 1 |
| Vermund, SH; Walker, AS | 1 |
| Abram, ME; Andrade-Villanueva, JF; Antunes, F; Arastéh, K; Cao, H; Chetchotisakd, P; DeJesus, E; Fehr, J; Gallant, JE; Koenig, E; Liu, HC; Rizzardini, G; Szwarcberg, J | 1 |
| Amara, A; Back, D; Boffito, M; Dickinson, L; Else, L; Higgs, C; Jackson, A; Karolia, Z; Khoo, S; Moyle, G; Yapa, HM | 1 |
| Cáceres, CF; Godfrey-Faussett, P; Goicochea, P; Koechlin, F; Mayer, KH; O'Reilly, KR; Sow, PS | 1 |
| Charpentier, C; Descamps, D; Joly, V; Landman, R; Lariven, S; Lê, MP; Peytavin, G; Phung, B; Visseaux, B; Yazdanpanah, Y; Yéni, P | 1 |
| Bossolasco, S; Castagna, A; Cernuschi, M; Cinque, P; Galli, L; Gianotti, N; Lazzarin, A; Maillard, M; Nozza, S; Poli, A; Spagnuolo, V; Tambussi, G | 1 |
| Hyslop, WB; Lee, YZ; Napravnik, S; Wilkin, A; Wohl, DA; Young, L | 1 |
| Assoumou, L; Bouazza, N; Chenevier-Gobeaux, C; De Sousa Mendes, M; Foissac, F; Ghosn, J; Hirt, D; Illamola, SM; Lui, G; Rouzioux, C; Suzan-Monti, M; Tréluyer, JM; Urien, S; Valade, E; Viard, JP | 1 |
| Arribas, JR; Bender, R; Garner, W; Gathe, J; Nguyen, T; Shreay, S; Speck, RM; Van Lunzen, J | 1 |
| Anglaret, X; Boyd, A; Danel, C; Delaugerre, C; Eholié, SP; Gabillard, D; Girard, PM; Lacombefor, K; Mahjoub, N; Maylin, S; Moh, R; Zoulim, F | 1 |
| Doll, M; Kleinberg, M; Kokh, D; Riedel, DJ | 1 |
| Mayor, S | 1 |
| Binda, K; Chen, JY; Dryden-Peterson, S; Essex, M; Lockman, S; Makhema, J; Mmalane, M; Shapiro, R; Souda, S; Zash, R | 1 |
| Biguenet, S; Bunupuradah, T; Krystal, M; Lataillade, M; Pavia-Ruz, N; Rossouw, M; Sáez-Llorens, X; Seekins, D; Sevinsky, H; Taylor, M; Yang, R | 1 |
| Anderson, PL; Andrade, A; Bakshi, RP; Bumpus, NN; Bushman, LR; Donnell, D; Elharrar, V; Fuchs, EJ; Hendrix, CW; Kashuba, AD; Li, X; Marzinke, MA; Mayer, KH; McKinstry, L; Moore, A; Patterson, KB; Prince, HA; Radebaugh, C; Richardson, P; Shieh, E; Wang, R; Wiggins, I | 1 |
| Grome, H; Jenkins, CA; Kalams, SA; Koethe, JR; Sterling, TR | 1 |
| Baeten, JM; Bii, DK; Bukusi, EA; Bulya, N; Campbell, JD; Celum, C; Egessa, JJ; John-Stewart, G; Kusemererwa, S; Morrison, S; Mubezi, S; Mugume, F; Wangisi, J | 1 |
| Arribas, JR; Babiker, A; Bernardino, JI; Buño, A; Castagna, A; Chene, G; De Wit, S; Gerstoft, J; Girard, PM; Katlama, C; Mallon, PW; Mocroft, A; Raffi, F; Reiss, P; Richert, L; Russell, C; Wallet, C | 1 |
| Bon, I; Borderi, M; Calza, L; Colangeli, V; Conti, M; Danese, I; Magistrelli, E; Mancini, R; Motta, R; Re, MC; Viale, P | 1 |
| Arends, J; Chene, G; Cosin, J; Dabis, F; Daikos, G; de Wit, S; Mallolas, J; Montforte, Ad; Mussini, C; Peters, L; Raben, D; Rockstroh, J; Smit, C; Zangerle, R; Zinkernagel, A | 1 |
| Boissonnault, M; Charest, L; Galanakis, C; Huchet, E; Longpré, D; Machouf, N; Murphy, D; Thomas, R; Trottier, B; Vézina, S | 1 |
| Grant, RM; Koester, KA | 1 |
| Cairns, G; McCormack, S; Molina, JM | 1 |
| Chariyalertsak, S; Deutsch, MB; Glidden, DV; Grant, RM; Guanira, J; Kallas, EG; Keatley, J; McMahan, V; Sevelius, J | 1 |
| Aboulker, JP; Capitant, C; Charbonneau, P; Charreau, I; Chas, J; Cheret, A; Chidiac, C; Cotte, L; Cua, E; Delaugerre, C; Delfraissy, JF; Doré, V; Etien, N; Fonsart, J; Girard, G; Le Gall, JM; Lorente, N; Loze, B; Marchand, L; Meyer, L; Molina, JM; Pasquet, A; Peytavin, G; Pialoux, G; Pintado, C; Préau, M; Raffi, F; Rooney, JF; Rozenbaum, W; Simon, MC; Spire, B; Suzan-Monti, M; Thompson, D; Timsit, J; Tremblay, C; Wainberg, MA | 1 |
| Abram, ME; Arribas, JR; Avihingsanon, A; Benson, P; Bloch, M; Cheng, A; Chetchotisakd, P; Crofoot, G; Custodio, JM; Fordyce, MW; Gathe, J; Gupta, SK; Lichtenstein, K; McCallister, S; Post, FA; Pozniak, A; Ramgopal, M; SenGupta, D; Wei, X | 1 |
| McCarthy, M | 1 |
| Baeten, J; McCormack, S | 1 |
| Haberer, JE | 1 |
| Anderson, PL; García-Lerma, JG; Heneine, W | 1 |
| Baeten, JM; Mugwanya, KK | 1 |
| Bonora, S; Calcagno, A; Di Perri, G; Trentalange, A | 1 |
| Baeten, JM; Bukusi, E; Celum, C; Donnell, D; Fluharty, TR; Lingappa, JR; Lund, JM; McElrath, MJ; Mugo, N; Murnane, PM; Pattacini, L; Ronald, A; Thomas, KK | 1 |
| Anderson, PH; Ebeling, PR; Emery, S; Fairley, CK; Kimlin, MG; Klassen, KM | 1 |
| Boucherie, C; Breton, G; Caumes, E; Chaix, ML; Chêne, G; Fagard, C; Lortholary, O; May, T; Molina, JM; Padoin, C; Patey, O; Rami, A; Robert, J; Roussillon, C; Tod, M; Veziris, N | 1 |
| Bugnon, O; Cavassini, M; Fayet Mello, A; Locatelli, I; Parienti, JJ; Rotzinger, A; Schneider, MP | 1 |
| Brooks, JT; García-Lerma, JG; Hanson, D; Heneine, W; McLaurin, T; Paxton, L; Ruone, S; Taylor, A | 1 |
| Barchiesi, F; Castelletti, S; Cirioni, O; Di Campli, FM; Falasca, K; Giacometti, A; Mazzocato, S; Orsetti, E; Ucciferri, C; Valeriani, C; Vecchiet, J | 1 |
| Cottrell, M; Dumond, JB; Forrest, A; Francis, O; Hudgens, MG; Malone, S; Mollan, K; Patterson, KB; Prince, HM; Sharpless, NE; Sykes, C; Torrice, C; Trezza, C; Van Dam, C; Wang, R; White, N | 1 |
| Baeten, JM; Celum, C; Donnell, D; Hendrix, CW; Lehman, DA; Marzinke, MA; Matsen, FA; McCoy, CO; Mugo, N; Thomas, KK; Warth, C; Weis, JF | 1 |
| Du, S; Guo, F; Han, Y; Li, T; Li, Y; Lv, W; Qiu, Z; Song, X; Thio, CL; Wang, H; Wang, N; Xie, J; Zhu, T | 1 |
| Baeten, JM; Bangsberg, DR; Haberer, JE; Musinguzi, N; Muwonge, T; Thomas, K | 1 |
| Duwal, S; von Kleist, M | 1 |
| Amico, KR; Anderson, PL; Buchbinder, SP; David, B; Glidden, DV; Grant, RM; Grinsztejn, B; Guanira, J; Hosek, SG; Liu, AY; Mayer, KH; McMahan, V; Schechter, M | 1 |
| Calvez, V; Marcelin, AG; Meynard, JL; Morand-Joubert, L; Surgers, L; Todesco, E | 1 |
| Anderson, PL; Bushman, LR; Castillo-Mancilla, J; Guida, LA; Kiser, JJ; Klein, B; McAllister, K; Meditz, A; Rower, C; Zheng, JH | 1 |
| Arribas, JR; Brinson, C; Brunetta, J; Callebaut, C; Cheng, A; Cheret, A; Clarke, A; Clumeck, N; Das, M; Fordyce, M; Mussini, C; Oka, S; Rashbaum, B; Sax, PE; Stephens, J; Tashima, K; Tebas, P; Wohl, D; Zhong, L | 1 |
| Gras, L; Rijnders, B; Rokx, C; van de Vijver, D; Verbon, A | 1 |
| Capitant, C; Chas, J; Chidiac, C; Demoulin, B; Lorente, N; Meyer, L; Molina, JM; Mora, M; Préau, M; Rojas Castro, D; Sagaon-Teyssier, L; Spire, B; Suzan-Monti, M | 1 |
| Callebaut, C; Fordyce, M; Kitrinos, KM; Margot, NA; McCallister, S; Miller, MD | 1 |
| Bacon, O; Cohen, SE; Hare, CB; Liu, AY; Marcus, JL; Pinder, J; Volk, JE | 1 |
| Cottrell, ML; Dellon, ES; Hudgens, MG; Kashuba, AD; Madanick, RD; Malone, S; Nelson, JA; Patterson, KB; Prince, HM; Shaheen, NJ; Sykes, C; White, N; Wulff, J; Yang, KH | 1 |
| Cárden-Santana, MA; Carrillo-Díaz, T; Castillo-Sainz, R; Suárez-Lorenzo, I | 1 |
| Agot, K; Callahan, R; Dorflinger, L; Jenkins, D; Nanda, K; Taylor, D; Van Damme, L; Wang, M | 1 |
| Bertucci, R; Bonora, S; Calcagno, A; D'Avolio, A; Di Perri, G; Mornese Pinna, S; Motta, I; Simiele, M | 1 |
| Maki, DG | 1 |
| Bowman, VQ; Daar, ES; Diamond, C; Dube, MP; Goicoechea, M; Haubrich, RH; Jain, S; Karris, MY; Kemper, C; Kerkar, S; Morris, S; Rieg, G; Sun, X | 1 |
| Ebell, MH | 1 |
| Amico, KR; Anderson, P; Avelino-Silva, VI; Grant, R; Guanira, J; McMahan, V; Mehrotra, M; Veloso, VG | 1 |
| Díez-García, LF; Gálvez-Contreras, MC; Romero-León, JM | 1 |
| Anoma, C; Aranda, JF; Bernier, A; Dah, E; Gapiya, J; Himmich, H; Somda, M; Sylla, A | 1 |
| Abram, ME; Brinson, C; Cheng, AK; Clumeck, N; Daar, ES; DeJesus, E; Gallant, JE; Johnson, M; Morales-Ramirez, J; Osiyemi, O; Plummer, A; Raffi, F; Rhee, MS; Ruane, P; Ward, D; Yan, M | 1 |
| Bolduc, P; Cheeseman, SH; Colgate, E; Roder, N | 1 |
| Allavena, C; Bani-Sadr, F; Cabié, A; Cheret, A; Chirouze, C; Cotte, L; Cuzin, L; Flandre, P; Katlama, C; Pugliese, P; Rey, D | 1 |
| Benson, P; Brinson, C; Brunetta, J; Cheng, A; Crofoot, G; Das, M; Fordyce, M; Gallant, J; Garner, W; McCallister, S; Mills, A; Oka, S | 1 |
| Deeks, ED; Greig, SL | 1 |
| Battegay, M; Bernasconi, E; Braun, DL; Darling, K; Günthard, HF; Hirzel, C; Hoffmann, M; Kouyos, RD; Kovari, H; Marzel, A; Rougemont, M; Scherrer, AU; Shilaih, M | 1 |
| Carrero, A; Collado, A; de Lagarde-Sebastián, M; Delgado-Fernández, M; Espinosa, N; Gómez-Berrocal, A; Hernández-Quero, J; Hontañón-Antoñana, V; Jiménez-Aguilar, P; Macías, J; Merino, D; Neukam, K; Pérez-Camacho, I; Pineda, JA; Ríos, MJ; Rivero-Juárez, A; Ruiz-Morales, J; Téllez, F; Vera-Méndez, F | 1 |
| Behrens, G; Borg, P; Bouee, S; M Llibre, J; Moyle, G; Piontkowsky, D; Raffi, F; Reilly, G; Rogatto, F | 1 |
| Barber, TJ; Girometti, N; Jones, R; Levy, J; McCormack, S; Sullivan, A | 1 |
| Allavena, C; Andre, E; Calvez, V; Flandre, P; Grude, M; Jovelin, T; Katlama, C; Lambert-Niclot, S; Marcelin, AG; Raffi, F; Rodallec, A; Sayon, S; Wirden, M | 1 |
| Carbone, A; Castagna, A; Galli, L; Gianotti, N; Lazzarin, A; Merli, M; Nozza, S; Poli, A; Ripa, M; Salpietro, S | 1 |
| Brown, TT; Chan, ES; Eron, JJ; Fichtenbaum, CJ; Klingman, KL; Landay, AL; Martinson, J; Mirmonsef, P; Ofotokun, I; Plants, J; Ribaudo, HJ; Taiwo, BO; Weitzmann, MN | 1 |
| Atta, MG; Decker, BS; Gupta, SK; Kashuba, ADM; Slaven, JE; Wyatt, CM | 1 |
| Briz, V; De Ory, SJ; Falcon-Neyra, L; Fortuny, C; Frick, MA; González-Tomé, MI; López-Cortés, LF; Moreno, EB; Navarro Gómez, ML; Neth, O; Noguera-Julian, A; Olbrich, P; Palladino, C; Santos, JL; Soler-Palacín, P | 1 |
| Bloch, M; Grulich, A; Holden, J; McAllister, J; McNulty, A; Poynten, IM; Prestage, G; Templeton, DJ; Vaccher, S; Zablotska, I | 1 |
| Gordon, M; Julian, MN; Moodley, P; Naidoo, A; Parboosing, R; Paredes, R; Samuel, R; Singh, L | 1 |
| Anderson, PL; Bushman, LR; Castillo-Mancilla, JR; Chen, X; MaWhinney, S; McAllister, KB; Seifert, SM; Zheng, JH | 1 |
| Baeten, JM; Bangsberg, D; Celum, CL; Chaturvedula, A; Fossler, MJ; Goti, V; Haberer, JE; Hendrix, CW; Lu, Y; Sale, ME | 1 |
| Anderson, PL; Castillo-Mancilla, J; Reirden, D | 1 |
| Brochier, C; Cottalorda-Dufayard, J; Cotte, L; Dellamonica, P; Durant, J; Gagnieu, MC; Gatey, C; Izopet, J; Jacomet, C; Lucht, F; Pradat, P; Raffi, F; Trabaud, MA; Vassallo, M | 1 |
| Burdo, TH; Feldpausch, MN; Grinspoon, SK; Hoffmann, U; Ishai, AE; Lee, H; Lu, MT; Martin, A; Melbourne, K; Robbins, GK; Suchindran, S; Tawakol, A; Toribio, M; Triant, VA; Williams, KC; Zanni, MV | 1 |
| Buscemi, L | 1 |
| Destache, CJ; Mandal, S; Prathipati, PK | 1 |
| Alcaro, S; Alteri, C; Andreoni, M; Antinori, A; Artese, A; Bellagamba, R; Bertoli, A; Carta, S; Ceccherini-Silberstein, F; Continenza, F; Costa, G; Di Maio, VC; Di Santo, F; Fedele, V; Girardi, E; Giuliani, M; Gori, C; Latini, A; Liuzzi, G; Monforte, AD; Orchi, N; Parrotta, L; Perno, CF; Petrosillo, N; Pinnetti, C; Romeo, I; Santoro, MM; Surdo, M; Svicher, V | 1 |
| Avihingsanon, A; Cao, H; Cheng, A; Hagins, D; Hodder, S; Jiang, S; Johnson, M; Kityo, C; Koenig, E; Squires, K; Szwarcberg, J; Voronin, E; White, K | 1 |
| Anderson, PL; Bushman, LR; Campbell, K; Castillo-Mancilla, J; Coleman, S; Gardner, EM; Glidden, DV; Grant, R; Hosek, S; Liu, A; MaWhinney, S; McAllister, K; Seifert, S; Wilson, CM; Zheng, JH | 1 |
| Borghi, V; Bruzzone, B; Callegaro, AP; Colao, G; Gismondo, MR; Micheli, V; Penco, G; Rossotti, R; Rusconi, S; Vicenti, I; Zazzi, M | 1 |
| Dahlby, JS; Guillemi, SA; Harris, M; Hogg, RS; Hull, MW; Lima, VD; Ling, SH; Montaner, JS; Werb, R; Yip, B; Zhang, W | 1 |
| De Swardt, G; Egan, JE; Hugo, JM; McIntyre, JA; Rebe, K; Stall, RD; Struthers, H | 1 |
| García-Arieta, A; Gordon, J; Gwaza, L; Leufkens, H; Potthast, H; Stahl, M; Welink, J | 1 |
| Hongzhou, LU; Yinzhong, S | 1 |
| Justesen, K; Prasad, S | 1 |
| Brown, TT; Currier, JS; Dube, MP; Kelesidis, T; McComsey, GA; Moser, C; Ribaudo, HJ; Stein, JH; Tran, TTT; Yang, OO | 1 |
| Cope, AB; Crooks, AM; Eron, JJ; Ferrari, G; Fiscus, SA; Gay, CL; Hicks, CB; Kuruc, JD; Margolis, DM; McGee, KS; McKellar, MS; Sebastian, J; Willis, SJ | 1 |
| Boucher, CAB; Nichols, BE; Rijnders, BJA; van de Vijver, DAMC; van der Valk, M | 1 |
| Baeten, JM; Celum, CL; Hendrix, CW; John-Stewart, G; Katabira, ET; Marzinke, M; Mugo, NR; Mugwanya, KK; Muthuri, G; Muwonge, TR; Ngure, K; Semiyaga, NB; Stergachis, A | 1 |
| Andrade, A; Funderburg, NT; Joshi, AA; Kuritzkes, DR; Lederman, MM; Mehta, NN; Playford, MP; Xu, D | 1 |
| Battle, S; Closson, EF; Denson, D; Herbst, JH; Holman, J; Landers, S; Mansergh, G; Mimiaga, MJ; Pitts, N | 1 |
| Batra, J; Chakraborty, R; Gaur, AH; Kizito, H; Kosalaraksa, P; Luesomboon, W; Myers, M; Porter, D; Prasitsueubsai, W; Quirk, E; Rakhmanina, N; Rassool, M; Rhee, MS; SenGupta, D; Shao, Y; Ting, L | 1 |
| Bedimo, R; Myers, J; Rosenblatt, L | 1 |
| Akula, SM; Artola, RT; Barone Gibbs, B; Bielke, LR; Bironaitė, D; Bogomolovas, J; Bukelskienė, V; Burke, LE; Chen, B; Chen, D; Chen, WJ; Cook, FJ; Cook, PP; Cotutiu, P; Cui, Y; Davis, KK; Dumitras, DE; El-Sayed, MA; Grabauskienė, V; Gretz, N; Gupta, R; Hargis, BM; Heck, C; Hernandez-Velasco, X; Huang, W; Huete-Ortega, M; Jakicic, JM; Jian, J; Jiang, K; Jiang, M; Jiang, Q; Jin, T; Kiuchi, M; Kovacs, SJ; Labeit, D; Labeit, S; Lang, W; Lang, XY; Latorre, JD; Li, HF; Li, J; Li, YQ; Lin, H; Lin, X; Liu, BT; Liu, M; Longworth, J; Lu, JB; Luo, C; Mahmoud, MA; Marx, A; Menconi, A; Mihos, CG; Muresan, D; Notter, RH; Pant, B; Petrisor, FM; Podkopajev, A; Popp, RA; Portzer, LA; Pradhan, S; Qian, G; Ranjit, M; Regmi, T; Rinkūnaitė, I; Rogers, RJ; Rotar, IC; Sakurai, H; Santana, O; Schwan, AL; Shi, XM; Shkoor, MG; Šimoliūnas, E; Smalinskaitė, L; Stamatian, F; Stang, AT; Tellez, G; Vaidyanathan, S; Vicente, JL; Walker, LR; Walther, FJ; Wan, Y; Wang, H; Wang, X; Wang, Z; Weis, CA; Wen, Z; Wolfenden, AD; Wolfenden, RE; Wright, PC; Wu, D; Xing, H; Xiong, X; Yang, H; Yang, Y; Yu, Q; Yue, D; Zang, Q; Zhang, L; Zhao, B; Zheng, Y; Zhou, L; Zhou, M; Zhuge, F | 1 |
| Amin, J; Azwa, I; Belloso, WH; Boyd, MA; Chetchotisakd, P; Cooper, DA; Emery, S; Hoy, J; Kumarasamy, N; Lombaard, J; Mallon, PW; Mohapi, L; Molina, JM; Moore, CL; Phanuphak, P; Wood, R | 1 |
| Belshan, M; Destache, CJ; Holec, A; Mandal, S; Zhou, Y | 1 |
| Anderson, PL; Bushman, LR; Castillo-Mancilla, JR; Chen, X; Kiser, JJ; MaWhinney, S; Seifert, SM; Zheng, JH | 1 |
| Asari, V; Baxter, C; Garrett, N; Grobler, A; Karim, QA; Karim, SSA; Majola, N; Naicker, N; Naidoo, A; Werner, L | 1 |
| Gilson, R; Nugent, D | 1 |
| Hoornenborg, E; Laga, M; Reyniers, T; Vuylsteke, B; Wouters, K | 1 |
| Baeten, JM; Bangsberg, D; Celum, C; Chaturvedula, A; Fossler, MJ; Haberer, JE; Hendrix, CW; Madrasi, K; Sale, M | 1 |
| Ammassari, A; Andreoni, M; Antinori, A; Armenia, D; Bellagamba, R; Berno, G; Bertoli, A; Bonora, S; Calcagno, A; Carta, S; Ceccherini-Silberstein, F; Cicalini, S; Continenza, F; Di Carlo, D; Di Perri, G; Fedele, V; Forbici, F; Ghisetti, V; Libertone, R; Perno, CF; Santoro, MM; Vendemiati, G; Zaccarelli, M | 1 |
| Anderson, PL; Flynn, PM; Gordon, CM; Havens, PL; Hazra, R; Hosek, SG; Kapogiannis, BG; Liu, N; Mulligan, K; Pan, CG; Rutledge, B; Schuster, GU; Seifert, SM; Stephensen, CB; Van Loan, MD; Wilson, CM; Woodhouse, LR | 1 |
| Cottrell, ML; Dumond, JB; Francis, O; Hudgens, MG; Lee, C; Maas, BM; Malone, S; Mollan, KR; Prince, HM; Sharpless, NE; Sykes, C; Torrice, C; Trezza, C; White, N | 1 |
| Callebaut, C; Cox, S; Das, M; Margot, N; McCallister, S; Miller, MD | 1 |
| Garner, W; Kulkarni, R; Miller, MD; Porter, DP; White, KL | 1 |
| Imaz, A; Podzamczer, D | 1 |
| Kransdorf, LN; Ntim, GJ | 1 |
| Ahmad, S; Brima, N; Chaponda, M; Davies, C; Hay, P; Johnson, M; Kingston, M; Lewis, JM; Marshall, N; Mulka, L; Muqbill, G; Nelson, M; Shaw, J; Smith, C; Tomkins, A; Torkington, A; Waters, L; Williams, D | 1 |
| Denton, PW; Garcia, JV; Garrett, KL; Ho, PT; Hudgens, MG; Kashuba, AD; O'Neill, C; Swartz, G; Veronese, F; Wahl, A | 1 |
| Corado, KC; Daar, ES | 1 |
| Chi, BH; Chilengi, R; Davies, MA; Egger, M; Hoffmann, CJ; Mulenga, LB; Saag, MS; Sinkala, E; Vinikoor, MJ; Wandeler, G; Zyambo, Z | 1 |
| Ambrosioni, J; Miró, JM; Mosquera, MM | 1 |
| Blondel, L; Charpentier, C; Descamps, D; Joly, V; Landman, R; Lê, M; Matheron, S; Perrier, M; Peytavin, G; Pinto, A; Visseaux, B; Yazdanpanah, Y | 1 |
| Benson, P; Brinson, C; Cheng, A; Crofoot, G; DeJesus, E; Dretler, R; Martin, H; Mills, A; Peloquin, J; Quirk, E; Sax, PE; Ward, D; Wei, X; White, K | 1 |
| Burger, D; Havenith, T; Oude Lashof, A; Schippers, J; Visschers, MJ | 1 |
| Cao, H; Cheng, A; Crofoot, G; de Wet, J; DeJesus, E; LaMarca, A; Liu, Y; Martorell, CT; Mills, A; Molina, JM; Porter, D; Post, FA; Quirk, E; Ramgopal, M; Ruane, P; SenGupta, D; Stellbrink, HJ; Valero, IP | 1 |
| Cao, H; Cheng, A; Crofoot, G; de Wet, J; DeJesus, E; LaMarca, A; Lazzarin, A; Liu, HC; Mills, A; Orkin, C; Podzamczer, D; Porter, D; Quirk, E; Ramgopal, M; Rijnders, B; Rockstroh, J; Ruane, P; SenGupta, D; Stoeckle, M; Thalme, A; Vandercam, B | 1 |
| Arribas, JR; Callebaut, C; Cheng, A; Clarke, AE; Das, M; DeJesus, E; Guo, S; Haas, B; McCallister, S; McDonald, C; Plummer, A; Sax, PE; Thompson, M; Wang, H; Wohl, DA | 1 |
| Carr, A; Foster, R; McAllister, JW; Mcnulty, A; Pierce, AB; Richardson, R; Towns, JM | 1 |
| Bhagani, S; Chaloner, C; Johnson, MA; Lampe, FC; Lodwick, RK; Phillips, AN; Sabin, CA; Smith, CJ; Tyrer, M; Youle, M | 1 |
| Cantrell, RA; Chi, BH; Chintu, N; Kankasa, C; Kruse, G; Mbewe, F; Sinkala, M; Smith, PJ; Stringer, EM; Stringer, JS | 1 |
| de Groot-Mijnes, JD; Rothova, A; Schneider, M | 1 |
| Bläckberg, J; Duberg, AS; Fischler, B; Friman, S; Karlström, O; Lindh, M; Norkrans, G; Reichard, O; Sangfeldt, P; Söderström, A; Sönnerborg, A; Uhnoo, I; Weiland, O; Wejstål, R; Wiström, J | 1 |
| Baietto, L; Bonora, S; D'Avolio, A; Di Perri, G; Gonzalez de Requena, D; Sciandra, M; Siccardi, M | 1 |
| Bentata, M; Chêne, G; Collin, F; Garré, M; Goujard, C; Lafaurie, M; Leport, C; Levy, Y; Molina, JM | 1 |
| Jaen, P; Vano-Galvan, S | 1 |
| Carrington, M; Davis, B; Duh, FM; Jean-Pierre, P; La Roche, M; Markowitz, M; Mehandru, S; Mohri, H; Poles, M; Prada, N | 1 |
| Morrow, JS; Redfield, RR | 1 |
| Barreiro, P; Collado, A; de Los Santos Gil, I; González-Serrano, M; Hernández-Burruezo, JJ; López-Cortés, LF; López-Ruz, MA; Macías, J; Martín-Rico, P; Merino, D; Mira, JA; Muñoz, L; Pineda, JA; Ríos-Villegas, MJ; Rivero, A; Soriano, V; Torres-Tortosa, M; Tural, C; Viciana, P | 1 |
| Bele, V; Dravid, A; Gupte, N; Joshi, K; Pujari, S | 1 |
| Calza, L; Manfredi, R | 2 |
| Barreiro, P; García-Samaniego, J; Martín-Carbonero, L | 1 |
| Arrivé, E; Avit, D; Blanche, S; Coffié, P; Dabis, F; Ekouévi, DK; Hirt, D; Lalsab, S; Leang, SK; McIntyre, J; Nerrienet, E; Rey, E; Tréluyer, JM; Urien, S | 1 |
| Freedberg, KA; Losina, E; Paltiel, AD; Sax, PE; Schackman, BR; Scott, CA; Seage, GR; Sloan, CE; Walensky, RP; Wang, B | 1 |
| Fiorante, S; Pulido, F | 1 |
| Alvarez-Uria, G; Ratcliffe, L; Vilar, J | 1 |
| Albrecht, H | 1 |
| Arrivé, E; Avit, D; Blanche, S; Chaix, ML; Coffie, PA; Dabis, F; Diallo, A; Ekouévi, DK; Gray, G; Kruy Leang, S; McIntyre, J; N'Dri-Yoman, T; Nerrienet, E; Rouzioux, C; Srey, VH | 1 |
| Dejesus, E; Ebrahimi, R; Ecker, J; Farajallah, A; Flaherty, JF; Maa, JF; McColl, D; Morales-Ramirez, JO; Reilly, K; Seekins, D; Sloan, L; Ward, DJ; Young, B | 1 |
| Arnaiz, JA; Arranz, JA; Arribas, JR; Barragán, P; Barrufet, P; Blanco, JL; Casas, E; Clotet, B; Cosín, J; Cruceta, A; Curran, A; Dalmau, D; Ferrer, E; Gatell, JM; González, A; Gutiérrez, F; Knobel, H; Llibre, JM; Loncá, M; Mallolas, J; Martínez, E; Miró, JM; Pich, J; Podzamczer, D; Ribera, E; Roca, V; Sanz, J; Segura, F | 1 |
| Perry, CM | 1 |
| Cope, D; Iskander, E; Mikhail, N | 1 |
| Arasteh, K; Ebrahimi, R; Fenske, S; Freiwald, M; Gallo, L; Kuhlmann, B; Mertenskoetter, T; Ranneberg, R; Weitner, L | 1 |
| Bellos, N; Fine, D; Kumar, PN; Lackey, P; Patel, P; Shaefer, MS; Sloan, L; Smith, KY; Sutherland-Phillips, DH; Vavro, C; Wannamaker, P; Yau, L | 1 |
| Ebrahimi, R; Ewan, J; Fisher, M; Kingston, M; Liu, H; Moyle, GJ; Orkin, C; Reilly, G; Shahmanesh, M; Wilkins, E | 1 |
| Andrade, A; Eshleman, SH; Flanigan, T; Flexner, C; Gross, R; Hogg, E; Lalama, C; Mildvan, D; Reisler, R; Rosenkranz, S; Salomon, N; Santana, J; Tierney, C; Wiggins, I | 1 |
| Cheng, AK; Enejosa, J; Margot, NA; McColl, DJ; Miller, MD | 1 |
| Barnard, RJ; Berger, DS; DeJesus, E; DiNubile, MJ; Lazzarin, A; Leavitt, R; Lennox, JL; Madruga, JV; Miller, MD; Nguyen, BY; Pollard, RB; Rodgers, AJ; Sklar, P; Williams-Diaz, A; Xu, X; Zhao, J | 1 |
| Barreiro, P; Fernández, JV; Labarga, P; Medrano, J; Soriano, V; Tuma, P; Vispo, E | 1 |
| Chetchotisakd, P | 1 |
| Bickel, M; Bodtländer, A; Gute, P; Klauke, S; Knecht, GK; Kurowski, M; Lutz, T; Stephan, C; von Hentig, N | 1 |
| Hill, A; Sawyer, W | 1 |
| Cavassini, M; Hayoz, D; Mazzolai, L; Periard, D; Widmeier, A; Yerly, P | 1 |
| Boccafoglio, F; Concia, E; Gottardi, M; Lanzafame, M; Lattuada, E; Soldani, F | 1 |
| Amin, J; Baker, D; Bloch, M; Carr, A; Cooper, DA; Emery, S; Martin, A | 2 |
| Reiss, P | 1 |
| Bangsberg, DR | 1 |
| Aldrovandi, GM; Cantrell, RA; Chi, BH; Chintu, N; Ellis, GM; Frenkel, LM; Mbewe, F; Nakamura, K; Sinkala, M; Stringer, EM; Stringer, JS; Warrier, R | 1 |
| Collier, AC; Daar, ES; Farajallah, A; Fischl, MA; Geiseler, PJ; Godfrey, C; Ha, B; Jahed, NC; Johnson, VA; Katzenstein, D; Koletar, SL; Mollan, K; Myers, L; Peeples, L; Rooney, JF; Sax, PE; Tierney, C; Woodward, WC | 1 |
| Barragán, P; Casamitjana, R; Deulofeu, R; Gatell, JM; Gutiérrez, F; Larrousse, M; Loncá, M; Mallolas, J; Martínez, E; Pérez, I; Pich, J; Podzamczer, D | 1 |
| Absalon, J; Andrade-Villanueva, J; Chetchotisakd, P; Corral, J; David, N; Echevarria, J; Lataillade, M; Mancini, M; McGrath, D; Molina, JM; Moyle, G; Percival, L; Wirtz, V; Yang, R | 1 |
| Aubron-Olivier, C; Bittar, R; Bollens, D; Bonnefont-Rousselot, D; Costagliola, D; de Truchis, P; Giral, P; Katlama, C; Pétour, P; Slama, L; Valantin, MA | 1 |
| Bigoloni, A; Castagna, A; Cossarini, F; Danise, A; Galli, L; Lazzarin, A; Marcotullio, S; Seminari, E; Soria, A; Tiberi, S | 1 |
| Battegay, M; Bernasconi, E; Cavassini, M; Elzi, L; Furrer, H; Hirschel, B; Ledergerber, B; Marzolini, C; Vernazza, P; Weber, R | 1 |
| Altice, FL; Springer, SA | 1 |
| Baraboutis, IG; Georgiou, O; Kotsianopoulou, M; Papastamopoulos, V; Samarkos, M; Skoutelis, AT; Vrionis, E | 1 |
| Denton, PW; Estes, JD; Garcia, JV; Krisko, JF; Kwak, YT; Martinez-Torres, F; Mathias, M; Payne, DA; Powell, DA; Zou, W | 1 |
| Bruzzone, B; Colao, G; De Silvestri, A; Di Biagio, A; Di Pietro, M; Maserati, R; Re, MC; Tinelli, C; Uglietti, A; Zazzi, M | 1 |
| Flux, K; Gholam, P; Hartmann, M; Hueter, E; Weberschock, T | 1 |
| Dejesus, E; Ebrahimi, R; Ecker, J; Esker, S; Farajallah, A; Flaherty, JF; Grimm, K; Hodder, SL; Mounzer, K | 1 |
| de Mendoza, C; Labarga, P; Medrano, J; Morello, J; Poveda, E; Rodriguez-Novoa, S; Seclen, E; Soriano, V; Vispo, E | 1 |
| Landman, GW; Soonawala, D | 1 |
| DeJesus, E; Fischl, MA; Horton, JH; Lancaster, CT; Pakes, GE; Pappa, KA; Ross, LL; Smith, KY; Weinberg, WG | 1 |
| Back, D; Dickinson, L; Erlwein, OW; Garvey, L; Latch, N; Mackie, NE; McClure, MO; Scullard, G; Walsh, J; Winston, A | 1 |
| Branco, T; Cavassini, M; Domingo, P; Fisher, M; Givens, N; Khuong-Josses, MA; Lim, ML; Moyle, GJ; Norden, AG; Pearce, HC; Podzamczer, D; Post, FA; Rieger, A; Stellbrink, HJ; Vavro, C | 1 |
| Floridia, M; Manconi, PE; Ortu, F; Weimer, LE | 1 |
| Absalon, J; Malan, N; Mancini, M; McGrath, D; Su, J; Wirtz, V; Yang, R | 1 |
| Behrens, G; Ho, NA; Schmidt, RE | 1 |
| Chang, LW; Harris, J; Humphreys, EH | 1 |
| Bernstein, B; Cohen, D; da Silva, B; Fredrick, L; González-García, J; Johnson, M; Naylor, C; Sloan, L | 1 |
| German, P; Hui, J; Kearney, BP; Warren, D; West, S | 1 |
| DeJesus, E; Kakuda, TN; Lalezari, JP; Osiyemi, OO; Ruane, PJ; Ryan, R; Witek, J | 1 |
| Benabdelmoumen, G; Bouvet, E; Christian, B; Muller, P; Peyrouse, E; Prazuck, T; Quertainmont, Y; Rabaud, C; Tosini, W | 1 |
| Alcaro, S; Alteri, C; Antinori, A; Artese, A; Balzarini, J; Ceccherini-Silberstein, F; Costa, G; Forbici, F; Narciso, P; Perno, CF; Santoro, MM; Schols, D; Svicher, V; Tommasi, C; Van Laethem, K; Zaccarelli, M | 1 |
| Arrivé, E; Avit, D; Blanche, S; Chaix, ML; Dabis, F; Ekouévi, DK; Gray, G; Kruy, LS; McIntyre, J; Nerrienet, E; Rouzioux, C; Say, L | 1 |
| Arribas, JR; Compston, J; Gerstoft, J; Hughes, S; Lambert, J; Lazzarin, A; Leather, D; Orkin, C; Pearce, H; Rizzardini, G; Sprenger, HG; Stellbrink, HJ; Sture, G; Van Wijngaerden, E; Zucchi, P | 1 |
| Avihingsanon, A; Bowden, S; Chang, JJ; Dore, GJ; Kerr, S; Lange, J; Lewin, SR; Matthews, GV; Napissanant, N; Piyawat, K; Ruxrungtham, K | 1 |
| Boucher, CA; van de Vijver, DA | 1 |
| Allegri, R; Amadasi, S; Carosi, G; Cristini, G; Gatti, F; Izzo, I; Mendeni, M; Motta, D; Paraninfo, G; Quiros-Roldan, E; Torti, C | 1 |
| Murphy, B; Romanelli, F | 1 |
| Rutherford, GW; Siegfried, N; Spaulding, A | 1 |
| Alston-Smith, B; Asmelash, A; Atwine, D; Chipato, T; Conradie, F; Currier, JS; Eshleman, S; Hakim, J; Hogg, E; Hosseinipour, MC; Hughes, MD; Kanyama, C; Lockman, S; McIntyre, J; Mellors, JW; Mngqibisa, R; Mohapi, L; Purcelle-Smith, E; Rahim, S; Rooney, J; Salata, RA; Sawe, F; Schooley, RT; Shaffer, D; Siika, A; Stringer, E; Walawander, A; Wools-Kaloustian, K; Zheng, Y | 1 |
| Arrivé, E; Avit, D; Benaboud, S; Blanche, S; Dabis, F; Ekouévi, DK; Gray, G; Hirt, D; McIntyre, J; Nerrienet, E; Rey, E; Sim, KL; Tréluyer, JM; Urien, S | 1 |
| Anton, P; Becker, S; Burns, D; DeGruttola, V; Fletcher, CV; McGowan, I; Veronese, F; Zwerski, S | 1 |
| Chêne, G; Gallien, S; Journot, V; Leclercq, P; Molina, JM; Morlat, P; Poizot-Martin, I; Reliquet, V; Reynes, J; Rozenbaum, W; Simon, F; Yéni, P | 1 |
| Anglaret, X; Attia, A; Chenal, H; Danel, C; Eholié, S; Gabillard, D; Messou, E; N'Dri-Yoman, T; Polneau, S; Seyler, C; Toni, T; Wakasugi, N | 1 |
| Bangsberg, DR; Deeks, SG; Monk, A; Ragland, K | 1 |
| Batard, ML; Martinot, M; Roth, B; Springinsfeld, G; Tortel, MC | 1 |
| Michael, NL | 1 |
| Amico, KR; Anderson, PL; Bekker, LG; Buchbinder, SP; Burns, DN; Bushman, LR; Casapía, M; Chariyalertsak, S; Defechereux, P; Fernández, T; Ganoza, C; Glidden, DV; Goicochea, P; Grant, RM; Guanira-Carranza, JV; Hance, RJ; Jaffe, HS; Kallás, EG; Lama, JR; Lee, J; Liu, AY; Martinez, AI; Mayer, KH; McConnell, JJ; McMahan, V; Montoya-Herrera, O; Mulligan, K; Postle, B; Ramirez-Cardich, ME; Rooney, JF; Schechter, M; Vargas, L; Veloso, VG; Wang, F; Zheng, JH | 1 |
| Benhamou, Y; Pais, R | 1 |
| Anderson, PL; Gardner, EM; Grant, RM; Kiser, JJ; Meditz, A; Rower, JE | 1 |
| Borroto-Esoda, K; Goodman, DD; Margot, NA; McColl, DJ; Miller, MD; Svarovskaia, ES; Zhong, L; Zhou, Y | 1 |
| Burleson, D; Gayton, JC; Laughlin, RT; Polenakovik, H | 1 |
| Mallet, V; Pol, S; Vallet-Pichard, A | 1 |
| Wainberg, MA | 1 |
| Mayer, KH; Myers, GM | 1 |
| Bentley, TG; Broder, MS; Chang, EY; Juday, T; Uy, J | 1 |
| Arribas, JR; Hill, A; Moecklinghoff, C; Pulido, F; Van Delft, Y | 1 |
| de Béthune, MP; De Meyer, S; Dierynck, I; Lathouwers, E; Lavreys, L; Picchio, G; Van de Casteele, T | 1 |
| León, E; Lozano de León-Naranjo, F; Pérez-Rivera, AÁ; Sáez, P | 1 |
| Beadsworth, MB; Pennell, A; Phillips, M; Ratcliffe, L; Vilar, FJ | 1 |
| Ajisawa, A; Fukutake, K; Kato, Y; Nakamura, T; Negishi, M; Odawara, T; Shirasaka, T; Tadokoro, T; Yamamoto, Y | 1 |
| Chuck, SL; Cohen, C; DeJesus, E; Elion, R; Kearney, BP; Liu, HC; Ramanathan, S; Rashbaum, B; Ruane, P; Shamblaw, D; Warren, DR; Yale, K | 1 |
| Avettand-fenoel, V; Blanche, S; Briand, N; Chaix, ML; Frange, P; Mahlaoui, N; Moshous, D; Rouzioux, C; Veber, F | 1 |
| French, P; Pittrof, R; Sauer, U | 1 |
| Underhill, K | 1 |
| Malgarini, RB; Pimpinella, G | 1 |
| Lafuente-Lafuente, C; Roques, P; Sellier, PO | 1 |
| Lee, DH; Vielemeyer, O | 1 |
| Cooper, V; Ewan, J; Fisher, M; Horne, R; Liu, HC; Moyle, GJ; Reilly, G | 1 |
| Barry, AC; Chu, H; Eron, JJ; Ferrari, G; Fiscus, SA; Gay, CL; Hicks, CB; Kerkau, M; Kuruc, JD; Margolis, DM; Mayo, AJ; McGee, KS; Mfalila, CK; Sebastian, J | 1 |
| Chan, DJ; Jeganathan, S; Maruszak, H; Smith, DE | 1 |
| Andrade-Villanueva, J; Cairns, V; Clotet, B; de Rossi, L; Domingo, P; Gellermann, HJ; Podzamczer, D; Reiss, P; Rockstroh, JK; Soriano, V; Taylor, S | 1 |
| Andrade-Villanueva, J; Antunes, F; Arastéh, K; de Rossi, L; Di Perri, G; Domingo, P; Gellermann, H; Lutz, T; Migrone, H; Opravil, M; Podzamczer, D; Soriano, V; Taylor, S | 1 |
| Stephenson, J | 1 |
| Wepner, U | 1 |
| Daar, ES; Ha, B; Jahed, NC; Kitch, D; McComsey, GA; Melbourne, K; Myers, L; Sax, PE; Tebas, P; Tierney, C | 1 |
| Barragán, P; Bonet, R; Curran, A; Gatell, JM; Knobel, H; Loncá, M; Martínez, E; Negredo, E; Ordoñez-Llanos, J; Podzamczer, D; Ribera, E; Saumoy, M | 1 |
| Chan, K; Cooper, C; Hogg, RS; Klein, MB; Loutfy, MR; Machouf, N; Montaner, JS; Raboud, J; Rourke, SB; Tan, DH; Tsoukas, C; Walmsley, S | 1 |
| Bonasso, M; Bonora, S; Calcagno, A; D'Avolio, A; Di Perri, G; Imperiale, D; Romito, A; Rostagno, R; Simiele, M; Tettoni, MC | 1 |
| Akimoto, T; Hamano, Y; Iwazu, Y; Kusano, E; Miki, T; Muto, S; Numata, A; Otani, N; Saito, O; Sugase, T; Takemoto, F; Toshima, M; Ueda, Y | 1 |
| Farajallah, A; McGrath, D; Sheppard, L; Uy, J; Wirtz, V; Yang, R | 1 |
| Debyser, Z; Desimmie, BA; Schrijvers, R | 1 |
| Karim, QA; Karim, SS; Kashuba, AD; Werner, L | 1 |
| Karim, QA; Karim, SS | 2 |
| Burlacu, R; de Lastours, V; Fonsart, J; Gourmel, B; Molina, JM | 1 |
| Bruzzone, B; Callegaro, AP; Di Biagio, A; Maggiolo, F; Nulvesu, L; Rosso, R; Taramasso, L; Viscoli, C | 1 |
| Gatanaga, H; Kikuchi, Y; Nagata, N; Nishijima, T; Oka, S; Teruya, K; Tsukada, K; Watanabe, K | 1 |
| Chuck, SL; Cohen, C; Elion, R; Gathe, J; Hawkins, T; Kearney, BP; Liu, HC; Mathias, AA; Shalit, P; Warren, DR | 1 |
| Allavena, C; Dejesus, E; Fernandez Garcia, E; Fisher, M; Hardy, WD; Jackson, AG; Jayaweera, DT; Katlama, C; Mauss, S; Moyle, GJ; Raffi, F; Reiss, P; Slama, L; van Eeden, A; Vrouenraets, SM; Wit, FW | 1 |
| Ammassari, A; Castagna, A; Delaugerre, C; Ghosn, J; Medrano, J; Molina, JM; Pavie, J; Porcher, R; Rusconi, S; Torti, C; Valin, N | 1 |
| Holodniy, M; Schirmer, P; Winters, M | 1 |
| Bardeguez, A; Cotter, A; Fiscus, SA; Flynn, PM; Heckman, B; Huang, S; Jean-Philippe, P; Kearney, B; Mirochnick, M; Mofenson, LM; Purswani, M; Robbins, B; Rodman, J; Rooney, JF; Shapiro, DE; Thorpe, E; Van Rompay, KK; Watts, DH | 1 |
| Hull, MW; Montaner, JS | 1 |
| Budhathoki, C; Collier, AC; Daar, ES; Farajallah, A; Feinberg, J; Fischl, MA; Godfrey, C; Ha, B; Jahed, NC; Katzenstein, D; Mollan, K; Murphy, RL; Myers, L; Rooney, JF; Sax, PE; Tashima, K; Tierney, C; Woodward, WC | 1 |
| Hitomi, S; Kiyasu, Y; Koganemaru, H | 1 |
| Dejesus, E; Dinubile, MJ; Lazzarin, A; Leavitt, R; Lennox, JL; Nguyen, BY; Rockstroh, JK; Rodgers, AJ; Saag, MS; Sklar, P; Teppler, H; Walker, ML; Wan, H; Xu, X; Zhao, J | 1 |
| Frederiksen, CA; Langdahl, BL; Laursen, AL; Melchjorsen, J; Nielsen, US; Rasmussen, TA; Tolstrup, M; Østergaard, L | 1 |
| Albini, L; Bellagamba, R; Calabresi, A; Cesana, BM; Fezza, R; Focà, E; Gotti, D; Guaraldi, G; Izzo, I; Lapadula, G; Maggi, P; Manili, L; Motta, D; Narciso, P; Quiros-Roldan, E; Sighinolfi, L; Torti, C | 1 |
| Baeten, JM; Barnes, L; Bukusi, E; Campbell, JD; Celum, C; Cohen, CR; Coombs, RW; Donnell, D; Farquhar, C; Fife, KH; Ingram, C; John-Stewart, G; Katabira, E; Kiarie, J; Kidoguchi, L; Krows, M; Lingappa, JR; Morrison, S; Mugo, NR; Mujugira, A; Ndase, P; Ondrejcek, L; Panteleeff, D; Revall, J; Ronald, A; Shah, H; Tappero, JW; Tumwesigye, E; Wangisi, J; Were, E | 1 |
| Clercq, ED | 1 |
| Furrer, H; Rauch, A; Wandeler, G | 1 |
| Keller, SB; Smith, DM | 1 |
| Aboulker, JP; Andreo, C; Capitant, C; Carrieri, MP; Cook, E; Fugon, L; Le Gall, JM; Lorente, N; Molina, JM; Spire, B | 1 |
| Branger, M; Collin, G; Fraqueiro, G; Gervais, A; Hamet, G; Lada, O; Marcellin, P; Martinot-Peignoux, M; Matheron, S; Moucari, R; Peytavin, G; Roquebert, B | 1 |
| Caro-Vega, Y; Crabtree-Ramírez, B; López-Martínez, A; O'Brien, NM; Sierra-Madero, J | 1 |
| Bertz, R; Child, M; Eley, T; Farajallah, A; Krystal, M; Liao, S; McGrath, D; Molina, JM; Persson, A; Sevinsky, H; Xu, X; Zhang, J; Zhu, L | 1 |
| Chipato, T; Cole, SR; Currier, JS; D'Amico, R; Eron, JJ; Hosseinipour, M; Hughes, MD; Lockman, S; McCarthy, JS; Meshnick, SR; Poole, C; Porter, KA; Salata, R; Sawe, FK; Shaffer, D; Siika, A; Skinner-Adams, TS; Stringer, E; Zheng, Y | 1 |
| Barr, E; Best, BM; Burchett, S; Capparelli, E; Hu, C; Jennings, A; Li, H; Luo, W; Mirochnick, M; Read, JS; Rossi, SS; Smith, E; Stek, AM | 1 |
| Angarano, G; Bellacosa, C; Graziano, G; Maggi, P; Montinaro, V; Pietanza, S; Strippoli, GF; Volpe, A | 1 |
| Cooper, DA; Duncombe, C; Emery, S; Gill, JM; Kerr, SJ; Li, PC; Puls, R; Taylor-Robinson, SD; Winston, A | 1 |
| Cane, PA; Crook, AM; Delpech, V; Dolling, D; Dunn, D; Fearnhill, E; Hill, T; Phillips, AN; Pillay, D; Shepherd, J | 1 |
| Cohen, MS; Jenkins, AJ; Kashuba, AD; Kraft, E; Patterson, KB; Prince, HA; Rooney, JF; Shaheen, NJ | 1 |
| Camp, R; Connick, E; Daar, ES; Degruttola, V; Del Rio, C; Fiscus, SA; Hare, CB; Hogan, CM; Kallungal, B; Little, S; Macatangay, B; Markowitz, M; Morton, T; Sun, X; Tashima, KT | 1 |
| Conway, B; Tossonian, H | 1 |
| Aboulker, JP; Bocquentin, M; Charreau, I; Izopet, J; Marchou, B; Molina, JM; Taburet, AM; Tangre, P; Trancart, S | 1 |
| Gelman, M; Grasso, C; Mayer, KH; Mimiaga, MJ | 1 |
| Baeten, JM; Bangsberg, DR; Celum, CL; Haberer, JE; Kintu, A; Psaros, C; Safren, S; Tumwesigye, E; Ware, NC; Wyatt, MA | 1 |
| Berrino, L; Scaglione, F | 1 |
| Celum, CL | 1 |
| Bangsberg, DR; Haberer, JE; Van Damme, L; van der Straten, A | 1 |
| Amoroso, A; Edozien, A; Etienne-Mesubi, M; Hossain, MB; Obiefune, M; Ojoo, S; Redfield, RR; Sheneberger, R; Stafford, K | 1 |
| Kanki, PJ; Shafer, RW; Tang, MW | 1 |
| Aubron-Olivier, C; Calvez, V; Charpentier, C; Descamps, D; Katlama, C; Landman, R; Marcelin, AG; Simon, A; Valantin, MA; Wirden, M; Yeni, P | 1 |
| Barragan, P; Crespo, M; Curran, A; Falco, V; Gatell, JM; Imaz, A; Lonca, M; Martinez, E; Martinez, M; Podzamczer, D; Ribera, E; Vidal-Sicart, S | 1 |
| Brinkman, K; Furrer, H; Fux, CA; Garcia, EF; Hoek, FJ; Krediet, RT; Reiss, P; van Straalen, JP; Vrouenraets, SM; Wit, FW | 1 |
| Birn, H; Erlandsen, EJ; Jensen, D; Langdahl, BL; Laursen, AL; Nielsen, US; Rasmussen, TA; Tolstrup, M; Østergaard, L | 1 |
| Aguilar-Bernier, M; Del Boz, J; Fernández-Morano, T; Fúnez-Liébana, R | 1 |
| Bookstaver, PB; Bryant, JE; Millisor, VE; Rokas, KE; Shamroe, CL; Sutton, SS; Weissman, SB | 1 |
| Anzala, O; Bangsberg, D; Barin, B; Chetty, P; Fast, P; Haberer, JE; Mark, D; Mugo, P; Mutua, G; Priddy, FH; Rooney, JF; Sanders, E | 1 |
| Naggie, S; Sulkowski, MS | 1 |
| Ang, BC; Teoh, SC | 1 |
| Edelman, EJ; Gordon, K; Justice, AC; Rodriguez-Barradas, MC | 1 |
| Buscher, A; Giordano, TP; Hartman, C; Kallen, MA | 1 |
| Haire, B; Jordens, CF; Kaldor, J | 1 |
| Amin, J; Carr, A; Ebeling, PR; Emery, S; Haskelberg, H; Hoy, JF | 1 |
| Bobardt, MD; Dezzutti, CS; Esch, T; Gallay, PA; Gunaseelan, S; Maskiewicz, R | 1 |
| Cheng, AK; DeJesus, E; Gathe, J; Henry, K; Kearney, BP; Molina, JM; Ramanathan, S; Rockstroh, JK; Szwarcberg, J; Wei, X; White, K; Yale, K | 1 |
| Cheng, AK; Cohen, C; DeJesus, E; Gallant, JE; Kearney, BP; Liu, HC; Mills, A; Quirk, E; Sax, PE; Szwarcberg, J; White, K; Wohl, D; Yale, K; Zhong, L; Zolopa, A | 1 |
| Baden, LR; Cohen, MS | 1 |
| Abdool Karim, SS; Gray, GE; Martinson, N | 1 |
| Abebe, D; Brooks, JT; Buliva, E; Chillag, KL; Chirwa, LI; Gvetadze, RJ; Hart, C; Henderson, FL; Hendrix, CW; Johnson, JA; Johnson, S; Kasonde, M; Kebaabetswe, PM; Malotte, CK; Mutanhaurwa, R; Pathak, SR; Paxton, LA; Rose, CE; Segolodi, TM; Smith, DK; Soud, FA; Sukalac, T; Thigpen, MC; Thomas, VT | 1 |
| Agot, K; Ahmed, K; Corneli, A; Crucitti, T; Deese, J; Fransen, K; Grant, R; Kapiga, S; Kashuba, A; Kiernan, H; Kirkendale, S; Lombaard, J; Mak'Oketch, P; Makanda, M; Makatu, SE; Malahleha, M; Mandala, J; Manongi, R; Mastro, TD; Monedi, MC; Nanda, K; Onyango, J; Owino, F; Reblin, I; Saylor, L; Taylor, D; Temu, L; Van Damme, L; Wong, C | 1 |
| Apaka, C; Baeten, JM; Bangsberg, D; Bukusi, EA; Bumpus, NN; Campbell, JD; Celum, C; Cohen, CR; Coombs, RW; Donnell, D; Emmanuel-Ogier, M; Farquhar, C; Fife, KH; Frenkel, L; Gabona, F; Haberer, JE; Haugen, H; Hendrix, C; John-Stewart, G; Kakia, A; Katabira, E; Kiarie, J; Kidoguchi, L; Krows, M; Lingappa, JR; Morrison, S; Mucunguzi, A; Mugo, NR; Mujugira, A; Nakku-Joloba, E; Ndase, P; Ngure, K; Odoyo, J; Ondrejcek, L; Panteleeff, D; Revall, J; Ronald, A; Stevens, WS; Tamooh, H; Tappero, JW; Thomas, KK; Tumwesigye, E; Twesigye, R; Wangisi, J; Were, E | 1 |
| Okoromah, CA; Okwundu, CI; Uthman, OA | 1 |
| Daly, F | 1 |
| Chianura, L; Errante, I; Moioli, MC; Orcese, C; Orso, M; Puoti, M; Rossotti, R; Schiantarelli, C; Schlacht, I; Travi, G; Vigo, B; Villa, MR; Volonterio, A | 1 |
| Krakower, D; Mayer, KH | 1 |
| Bellosillo, N; Berzins, B; Calvez, V; Diallo, F; Fofana, DB; Katile, D; Maiga, AI; Maiga, MY; Marcelin, AG; Murphy, R; Penugonda, S; Sylla, A; Taiwo, B; Tounkara, A; Traore, HA | 1 |
| Gibbs, C; Guyer, B; Haddad, M; McColl, DJ; Miller, MD; Su, C | 1 |
| Holmes, D | 2 |
| Aguilera, A; Alcamí, J; Álvarez, M; Anta, L; Betancor, G; Blanco, JL; Caballero, E; Cañizares, A; Clotet, B; Córdoba, J; Dalmau, D; de Mendoza, C; del Romero, J; Galindo, MJ; García, F; Garrido, C; Garriga, C; Gatel, JM; Gómez Sirvent, JL; Gutiérrez, C; Gutiérrez, F; Iribarren, JA; Jaén, A; Leal, M; Llibre, JM; López Aldeguer, J; Manuzza, G; Martínez, MA; Martinez-Picado, J; Menéndez-Arias, L; Miralles, C; Morano, L; Moreno, S; Nevot, M; Ocampo, A; Palomares, JC; Pedreira, J; Peraire, J; Pérez-Elías, MJ; Pérez-Olmeda, M; Pérez-Romero, P; Pineda, JA; Poveda, E; Puertas, MC; Ribera, E; Riera, M; Rodríguez, C; Rodríguez, P; Santos, J; Soriano, V; Viciana, I; Viciana, P; Vidal, C; Vidal, F | 1 |
| Pommer, P | 1 |
| Aaron, E; Cohan, D | 1 |
| Borghi, V; Capetti, A; Cicconi, P; Di Biagio, A; Di Giambenedetto, S; Francisci, D; Giacometti, A; Giannarelli, D; Maggiolo, F; Monno, L; Penco, G; Prinapori, R; Sterrantino, G; Zoncada, A | 1 |
| Grulich, AE; Poynten, IM; Zablotska, I | 1 |
| Lyseng-Williamson, KA; Scott, LJ | 1 |
| Anderson, PL; Bushman, LR; Castillo-Mancilla, JR; Fernandez, C; Gardner, EM; Kiser, JJ; Langness, J; Meditz, A; Predhomme, J; Rower, JE; Zheng, JH | 1 |
| Gnarini, M; Maserati, R; Uglietti, A; Zanaboni, D | 1 |
| Henry, K | 1 |
| Alvarez, A; Calatayud, S; De Pablo, C; Esplugues, JV; Martí-Cabrera, M; Orden, S | 1 |
| Bonovas, S; Hatzakis, A; Nikolopoulos, G; Tsiodras, S | 1 |
| Hendrix, CW | 1 |
| Anderson, PL; Bekker, LG; Buchbinder, S; Bushman, LR; Casapía, M; Chariyalertsak, S; Glidden, DV; Grant, RM; Guanira, JV; Kallás, EG; Lama, JR; Liu, A; Mayer, KH; McMahan, V; Montoya-Herrera, O; Schechter, M; Veloso, VG | 1 |
| Borderi, M; Calza, L; Colangeli, V; Di Bari, MA; Magistrelli, E; Manfredi, R; Salvadori, C; Trapani, F; Viale, P | 1 |
| Amin, J; Cooper, DA; Cordery, DV; Emery, S; Kelleher, AD; Martin, A | 1 |
| Barrail-Tran, A; Descamps, D; Duval, X; Goujard, C; Mentré, F; Nembot, G; Panhard, X; Savic, RM; Taburet, AM; Verstuyft, C; Vrijens, B | 1 |
| Grabmeier-Pfistershammer, K; Kosi, L; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A; Strassl, R | 1 |
| Fätkenheuer, G; Kümmerle, T | 1 |
| Adams, JL; Crucitti, T; De Baetselier, I; Fransen, K; Kashuba, AD; Menezes, P; Patterson, KB; Prince, HM; Sykes, C; Van Damme, L | 1 |
| Cabie, A; Charpentier, C; Chene, G; Colin de Verdiere, N; Descamps, D; Fagard, C; Grondin, C; Joly, V; Raffi, F; Tabuteau, S; Yazdanpanah, Y; Yeni, P | 1 |
| Burger, DM; Colbers, AP; Giaquinto, C; Gingelmaier, A; Hawkins, DA; Ivanovic, J; Kabeya, K; Moltó, J; Rockstroh, JK; Sadiq, ST; Taylor, GP; Weizsäcker, K; Wyen, C | 1 |
| Blevins, S; Dumond, JB; Eron, JJ; Floris-Moore, M; Hudgens, MG; Kashuba, AD; Massengale, K; Pittard, D; Ragan, D; Richardson, A; Walsh, K; Wang, R; Wohl, DA | 1 |
| Craig, C; Fätkenheuer, G; Heera, J; Leal, M; McFadyen, L; Mildvan, D; Mills, A; Podzamczer, D; Portsmouth, S; Rinehart, AR; Than, S; Valdez, H; Valluri, SR; Vourvahis, M | 1 |
| Collier, AC; Daar, ES; Fichtenbaum, CJ; Fink, H; Gerschenson, M; Kosmiski, L; Libutti, DE; McComsey, GA; O'Riordan, M; Santana, JL; Sax, PE | 1 |
| Aral, SO; Cates, W | 1 |
| Ammara, A; Back, D; Boffito, M; Gazzard, B; Jackson, A; Mohabeer, M; Moyle, G; Tjia, J; Watson, V | 1 |
| Cannizzaro, MV; Chimenti, S; Chiricozzi, A; Giunta, A; Nisticò, SP; Saraceno, R | 1 |
| Armishaw, J; Cameron, PU; Chuah, J; Cooper, DA; Crowe, SM; Fairley, C; Gouillou, M; Hearps, A; Koelsch, KK; Leeansyah, E; Lewin, SR; Liu, JP; Pierce, AB; Smit, de V; Solomon, A; Spelman, T; Tennakoon, S; Velayudham, P | 1 |
| Avihingsanon, A; Bowden, S; Dore, GJ; Finlayson, R; Hoy, JF; Lewin, SR; Littlejohn, M; Locarnini, S; Matthews, GV; Revill, PA; Ruxrungtham, K; Sasadeusz, J; Saulynas, M; Seaberg, EC; Thio, CL | 1 |
| Freedberg, KA; Nakamura, YM; Paltiel, AD; Pei, PP; Sax, PE; Schackman, BR; Walensky, RP; Weinstein, MC | 1 |
| Cooper, DA; Craig, C; Goodrich, J; Kaplan, R; Lazzarin, A; Mori, J; Pozniak, A; Pulik, P; Tawadrous, M; Valdez, H; Vernazza, P; Wang, C; Weil, E | 1 |
| Abram, M; Cheng, AK; DeJesus, E; Fordyce, MW; Gathe, J; Henry, K; Molina, JM; Plummer, A; Ramanathan, S; Rockstroh, JK; Szwarcberg, J; Wei, X | 1 |
| Calvez, V; Charpentier, C; Descamps, D; Flandre, P; Fofana, DB; Fourati, S; Lambert-Niclot, S; Marcelin, AG; Masquelier, B; Morand-Joubert, L; Soulié, C; Storto, A; Visseaux, B; Wirden, M | 1 |
| Benson, P; Bredeek, UF; Brinson, C; Campo, R; Dau, L; DeJesus, E; Flaherty, J; Fralich, T; Guyer, B; Henry, K; Khanlou, H; Logue, K; Piontkowsky, D; Wang, H; White, K | 1 |
| Bang, LM; Scott, LJ | 1 |
| Barry, DW; Harris, J; Hulett, L; Mommeja-Marin, H; Moxham, C; Quinn, JB; Rousseau, FS; Sanne, I; Wakeford, C; Wang, LH | 1 |
| Cahn, P | 1 |
| Bakshi, SS; Chittick, GE; Emmanuel, PJ; Flynn, PM; Rathore, MH; Wang, LH; Wiznia, AA | 1 |
| Cunningham, CK; McKinney, RE | 1 |
| Boyle, BA | 1 |
| Chene, G; Lascoux-Combes, C; Molina, JM; Perusat, S; Peytavin, G; Rozenbaum, W; Sereni, D | 1 |
| Ala, A; Dieterich, DT | 1 |
| Herman, RA; Modrzejewski, KA | 1 |
| Almond, MR; Liotta, DC; Mao, S; Painter, GR | 1 |
| Nelson, M; Schiavone, M | 1 |
| Barry, DW; Borroto-Esoda, K; Cahn, P; Hinkle, J; Molina, JM; Mondou, E; Pearce, D; Powderly, W; Quinn, JB; Raffi, F; Rousseau, F; Saag, MS; Shaw, AL; Wolff, M | 1 |
| Otto, MJ | 1 |
| Blum, MR; Kearney, BP; Rousseau, FS; Stevens, RC | 1 |
| Benson, CA; Haas, DW; Lamarca, A; McDonald, CK; Mondou, E; Quinn, JB; Rousseau, F; Rublein, J; Steinhart, CR; van der Horst, C | 1 |
| Begley, J; Harris, J; Rousseau, FS; St Claire, RL; Wakeford, C; Wang, LH | 1 |
| Kronborg, G | 1 |
| Chene, G; Collin, F; Dellamonica, P; Dupont, B; Fournier, S; Goujard, C; Journot, V; Molina, JM; Morand-Joubert, L; Morlat, P; Palmer, P; Poizot-Martin, I; Rancinan, C; Rozenbaum, W; Yéni, P | 1 |
| Feinberg, J | 1 |
| Benhamou, Y; Bonacini, M; Brook, G; Cargnel, A; Puoti, M; Rockstroh, J; Soriano, V; Thio, C | 1 |
| Hurwitz, SJ; Otto, MJ; Schinazi, RF | 1 |
| Frampton, JE; Perry, CM | 1 |
| Arastèh, K; Beard, A; Cartee, L; Drauz, D; Herzmann, C; Kreckel, P; Murphy, RL; Otto, MJ; Schinazi, RF; Schulbin, H | 1 |
| Cox, SL; Molina, JM | 1 |
| Arribas, JR; Campo, RE; Cheng, AK; Chuck, S; DeJesus, E; Enejosa, J; Gallant, JE; Gazzard, B; Lu, B; McColl, D; Pozniak, AL; Toole, JJ | 1 |
| Gazzard, BG | 1 |
| Bower, M; Gazzard, B; Nelson, M; Pollock, K; Stebbing, J | 1 |
| Hammerstrom, TS; Laessig, KA; Lewis, LL | 1 |
| Jenny-Avital, ER | 1 |
| Piacenti, FJ | 1 |
| Croom, KF; Frampton, JE | 1 |
| Grant, RM; Levy, V | 1 |
| Arribas López, JR; Muñoz de Benito, RM | 1 |
| Laurence, J | 1 |
| Arribas, JR; Campo, RE; Chen, SS; Cheng, AK; DeJesus, E; Enejosa, J; Gallant, JE; Gazzard, B; McColl, D; Pozniak, AL; Toole, JJ | 1 |
| Antinori, A; Borrelli, I; Liuzzi, G; Lorenzini, P; Marconi, P; Sette, P; Zaccarelli, M | 1 |
| Berg, T; Kuecherer, C; Neifer, S; Poggensee, G; Schlote, F; Somogyi, S | 1 |
| Gallant, JE | 1 |
| Aguilar, I; Hidalgo, A; Palacios, R; Santos, J | 1 |
| Best, B; Goicoechea, M | 1 |
| Amoroso, A; Chan-Tack, KM; Kopack, AM; Polk, C | 1 |
| Gripshover, B; Gupta, S; Hammond, SP; Hatano, H; Hu, Z; Kalayjian, RC; Kuritzkes, DR; Smith, D; Whitcomb, J; Wild, M | 1 |
| Acosta, EP; Jennings, HC; Parks, DA; Taylor, CW | 1 |
| Chêne, G; De Castro, N; Furco, A; Journot, V; May, T; Molina, JM; Morlat, P; Palmer, P; Raffi, F; Rancinan, C | 1 |
| Cascone, A; Colella, G; Di Martino, F; Filippini, A; Filippini, P; Lanza, A; Martini, S; Masiello, A; Pisapia, R | 1 |
| Abrams, E; Blum, MR; Britto, P; Chittick, GE; Cunningham, C; Dickover, R; Draper, L; Flynn, P; Hu, C; Hughes, M; Kraimer, J; McKinney, RE; Ortiz, AA; Rathore, M; Reynolds, L; Rodman, J; Scites, M; Serchuck, LK; Smith, ME; Spector, S; Tran, P; Weinberg, A; Yogev, R | 1 |
| Cohen, DE; Golub, SA; Mayer, KH; Rosenthal, L | 1 |
| Bridges, AS; Cohen, MS; Corbett, AH; Dumond, JB; Jung, BH; Kashuba, AD; Patterson, KB; Rezk, NL; Stewart, PW; Yeh, RF | 1 |
| Bae, AS; Borroto-Esoda, K; Harris, JL; Hinkle, JE; Quinn, JB; Rousseau, FS; Waters, JM | 1 |
| Killingley, B; Pozniak, A | 1 |
| Arribas, JR; Campo, RE; Chen, SS; Cheng, AK; Dejesus, E; Enejosa, J; Gallant, JE; Gazzard, B; Holmes, CB; McColl, D; Pozniak, AL; Toole, JJ | 1 |
| Aldrovandi, GM; Cantrell, RA; Chi, BH; Chintu, N; Kankasa, C; Kruse, G; Mbewe, F; Safrit, JT; Sinkala, M; Stringer, EM; Stringer, JS | 1 |
| Liras, A | 1 |
| Ananworanich, J; Chetchotisakd, P; Hirschel, B; Jupimai, T; Klinbuayam, W; Mahanontharit, A; Nüesch, R; Prasithsirikul, W; Ruxrungtham, K; Srasuebkul, P | 1 |
| Bill, R; Cohen, D; Fisher, A; Grasso, C; Mayer, KH; Mimiaga, MJ; Van Derwarker, R | 1 |
| Shacklett, BL | 1 |
| Denton, PW; Estes, JD; Garcia, JV; Haase, AT; Othieno, FA; Payne, D; Powell, DA; Sun, Z; Wege, AK; Wei, BL | 1 |
| Adda, N; Blum, MR; Cashat, M; Chittick, G; Harris, J; Hinkle, J; Ndiweni, D; Rousseau, F; Saez-Llorens, X; Violari, A; Wiznia, A; Yogev, R | 1 |
| Herrera, L; Moreno, S; Sánchez-de la Rosa, R | 1 |
| Larsen, CS; Lybaek, D | 1 |
| Calabresi, A; Carosi, G; Costarelli, S; Izzo, I; Lapadula, G; Quiros-Roldan, E; Torti, C | 1 |
| Darque, A; Rousseau, F; Sommadossi, JP; Valette, G; Wang, LH; Zhou, XJ | 1 |
| Sidley, P | 1 |
| Chêne, G; Decazes, JM; Ferchal, F; Journot, V; Molina, JM; Morlat, P; Raffi, F; Rancinan, C; Rozenbaum, W; Sereni, D | 1 |
| Richman, DD | 1 |
| Delehanty, J; Kahn, JO; Mildvan, D; Quinn, JB; Rousseau, FS; Shepp, D; Simpson, JN; Sommadossi, JP; Thompson, M; van der Horst, C; Wakeford, C; Wang, LH | 1 |
158 review(s) available for emtricitabine and HIV Infections
| Article | Year |
|---|---|
Is tenofovir disoproxil fumarate associated with weight loss?
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Randomized Controlled Trials as Topic; Tenofovir; Thailand; Weight Loss | 2021 |
Acquired HIV drug resistance mutations on first-line antiretroviral therapy in Southern Africa: Systematic review and Bayesian evidence synthesis.
Topics: Adult; Anti-Retroviral Agents; Bayes Theorem; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Tenofovir; Viral Load; Zidovudine | 2022 |
Kidney function in tenofovir disoproxil fumarate-based oral pre-exposure prophylaxis users: a systematic review and meta-analysis of published literature and a multi-country meta-analysis of individual participant data.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Kidney; Pre-Exposure Prophylaxis; Tenofovir | 2022 |
The best backbone for HIV prevention, treatment, and elimination: Emtricitabine+tenofovir.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Emtricitabine; HIV Infections; HIV-1; Humans; Male; Tenofovir | 2022 |
Increased viral load in a hospitalized patient on treatment with crushed bictegravir/emtricitabine/tenofovir alafenamide: A case report and review of the literature.
Topics: Adenine; Adult; Alanine; Amides; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Piperazines; Pyridones; Tenofovir; Viral Load | 2022 |
Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir; Treatment Outcome | 2022 |
The predictive value of macaque models of preexposure prophylaxis for HIV prevention.
Topics: Animals; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Macaca; Pre-Exposure Prophylaxis | 2022 |
The future of long-acting agents for preexposure prophylaxis.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2022 |
Safety of oral tenofovir disoproxil - emtricitabine for HIV preexposure prophylaxis in adults.
Topics: Adult; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Middle Aged; Pre-Exposure Prophylaxis; Tenofovir | 2022 |
How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Broadly Neutralizing Antibodies; Drug Resistance; Emtricitabine; HIV Infections; HIV-1; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2022 |
The Italian PrEPventHIV challenge: a scoping systematic review on HIV pre-exposure prophylaxis monitoring in Italy.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Tenofovir | 2022 |
Cabotegravir: The First Long-Acting Injectable for HIV Preexposure Prophylaxis.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Male; Tenofovir | 2023 |
Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis.
Topics: Adolescent; Adult; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Sexual and Gender Minorities | 2022 |
Achievement of virologic suppression with HIV antiretroviral therapy in a patient also taking multiple daily cation supplement doses: A case report and review of the literature.
Topics: Adenine; Anti-HIV Agents; Anti-Retroviral Agents; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Middle Aged; Pyridones | 2023 |
Comparison of the design and methodology of Phase 3 clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir-based dual therapy (DTG) in HIV: a systematic review of the literature.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans | 2023 |
Effectiveness and safety of tenofovir alafenamide in children and adolescents living with HIV: a systematic review.
Topics: Adenine; Adolescent; Anti-HIV Agents; Child; Emtricitabine; HIV Infections; HIV-1; Humans; Infant; Tenofovir | 2023 |
Efficacy and safety of switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed Asian adults living with HIV: A pooled analysis from three international phase III randomized trials.
Topics: Adenine; Adult; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Randomized Controlled Trials as Topic; RNA | 2023 |
Personalizing prevention: Advances in pharmacotherapy for HIV prevention.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; United States | 2023 |
Acute Immune Reconstitution Inflammatory Syndrome-HBV Flare in an HIV/HBV Coinfected Patient After Antiretroviral Therapy Initiation: Case Report and Literature Review.
Topics: Adult; Coinfection; Emtricitabine; Hepatitis B virus; HIV Infections; Humans; Immune Reconstitution Inflammatory Syndrome; Male; Transaminases; Young Adult | 2023 |
Real-world discontinuations due to neuropsychiatric symptoms in people living with HIV treated with second-generation integrase inhibitors: a systematic review.
Topics: Amides; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Integrase Inhibitors; Treatment Outcome | 2023 |
PrEP for women in Europe: a systematic literature review.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Pregnancy; Sexual and Gender Minorities; Tenofovir | 2023 |
Efficacy and safety of long-acting cabotegravir versus oral tenofovir disoproxil fumarate-emtricitabine as HIV pre-exposure prophylaxis: A systematic review and meta-analysis.
Topics: Anti-HIV Agents; Creatinine; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2023 |
Antivirals for prevention of hepatitis B virus mother-to-child transmission in human immunodeficiency virus positive pregnant women co-infected with hepatitis B virus.
Topics: Antiviral Agents; Coinfection; DNA, Viral; Emtricitabine; Female; Hepatitis B e Antigens; Hepatitis B virus; HIV; HIV Infections; HIV Seropositivity; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Pregnancy; Pregnant Women; Ritonavir; Tenofovir; Zidovudine | 2023 |
Increased human immunodeficiency virus viral load with cerebral infarction due to varicella zoster virus vasculopathy on treatment with bictegravir/emtricitabine/tenofovir alafenamide suspension: a case report and literature review.
Topics: Anti-HIV Agents; Cerebral Infarction; Drug Combinations; Emtricitabine; Herpesvirus 3, Human; Heterocyclic Compounds, 3-Ring; HIV; HIV Infections; Humans; Male; Middle Aged; Tenofovir; Viral Load | 2023 |
Post-exposure prophylaxis to prevent HIV: new drugs, new approaches, and more questions.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Post-Exposure Prophylaxis; Pre-Exposure Prophylaxis; Tenofovir | 2023 |
Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline.
Topics: Adenine; Administration, Cutaneous; Administration, Oral; Alanine; Contraceptive Devices, Female; Delayed-Action Preparations; Deoxyadenosines; Emtricitabine; Female; HIV Infections; Humans; Incidence; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir | 2019 |
Mosaic effectiveness: measuring the impact of novel PrEP methods.
Topics: Administration, Oral; Anti-HIV Agents; Clinical Trials as Topic; Combined Modality Therapy; Delayed-Action Preparations; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir; Treatment Outcome | 2019 |
PrEP 1.0 and Beyond: Optimizing a Biobehavioral Intervention.
Topics: Anti-HIV Agents; Behavioral Risk Factor Surveillance System; Cognitive Behavioral Therapy; Drug Therapy, Combination; Emtricitabine; Health Promotion; HIV Infections; Humans; Pre-Exposure Prophylaxis; Sexual Behavior; Social Stigma; Tenofovir | 2019 |
Human Immunodeficiency Virus-1 Viral Load Is Elevated in Individuals With Reverse-Transcriptase Mutation M184V/I During Virological Failure of First-Line Antiretroviral Therapy and Is Associated With Compensatory Mutation L74I.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Viral Load | 2020 |
Bictegravir, a novel integrase inhibitor for the treatment of HIV infection.
Topics: Adenine; Alanine; Amides; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Integrase Inhibitors; Humans; Piperazines; Pyridones; Tenofovir | 2019 |
Clinical pharmacology of the single tablet regimen bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF).
Topics: Adenine; Amides; Anti-HIV Agents; Clinical Trials as Topic; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Piperazines; Pyridones; Tablets; Tenofovir | 2019 |
The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV.
Topics: Adenine; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Comorbidity; Drug Combinations; Emtricitabine; Equivalence Trials as Topic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Piperazines; Pyridones; Risk Factors; Socioeconomic Factors; Tablets; Tenofovir | 2020 |
Update on HIV prevention and preexposure prophylaxis.
Topics: Adenine; Antiviral Agents; Emtricitabine; Female; HIV Infections; Humans; Male; Physician Assistants; Pre-Exposure Prophylaxis; Primary Health Care; Tenofovir; Treatment Outcome | 2020 |
Approaches to Objectively Measure Antiretroviral Medication Adherence and Drive Adherence Interventions.
Topics: Adenine; Adult; Anti-HIV Agents; Emtricitabine; Female; Hair; HIV Infections; Humans; Leukocytes, Mononuclear; Male; Medication Adherence; Monitoring, Ambulatory; Organophosphates; Pre-Exposure Prophylaxis; Tenofovir; Viral Load | 2020 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
Same-day prescribing of daily oral pre-exposure prophylaxis for HIV prevention.
Topics: Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Drug Prescriptions; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Practice Patterns, Physicians'; Pre-Exposure Prophylaxis; Safe Sex; Tenofovir; United States | 2021 |
A Bayesian averted infection framework for PrEP trials with low numbers of HIV infections: application to the results of the DISCOVER trial.
Topics: Adenine; Anti-HIV Agents; Bayes Theorem; Emtricitabine; Equivalence Trials as Topic; HIV Infections; Humans; Outcome Assessment, Health Care; Pre-Exposure Prophylaxis; Sample Size; Tenofovir | 2020 |
Primary HIV-1 infection in users of pre-exposure prophylaxis.
Topics: Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; HIV Seropositivity; HIV-1; Humans; Pre-Exposure Prophylaxis; Tenofovir; Viral Load | 2021 |
Evaluating the combination of emtricitabine/ tenofovir alafenamide fumarate to reduce the risk of sexually acquired HIV-1-infection in at-risk adults.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Emtricitabine; Female; Fumarates; HIV Infections; HIV-1; Humans; Male; Tenofovir | 2021 |
Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Prospective Studies; Randomized Controlled Trials as Topic; Tenofovir | 2021 |
Pre-Exposure Prophylaxis for HIV Infection and the Role of the Women's Health Care Provider in HIV Prevention.
Topics: Anti-HIV Agents; Emtricitabine; Female; Health Personnel; HIV Infections; Humans; Pre-Exposure Prophylaxis; United States | 2021 |
Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort.
Topics: Adult; Anti-HIV Agents; COVID-19; Cross-Sectional Studies; Emtricitabine; Female; HIV Infections; Humans; Male; Prevalence; Reverse Transcriptase Inhibitors; Seroepidemiologic Studies; Spain; Tenofovir | 2021 |
The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir dis
Topics: Alanine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Obesity; Oxazines; Piperazines; Pregnancy; Pregnancy Outcome; Pyridones; Tenofovir | 2021 |
Tenofovir alafenamide nephrotoxicity: a case report and literature review.
Topics: Adenine; Alanine; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Middle Aged; Tenofovir | 2021 |
The future of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection.
Topics: Administration, Intravaginal; Anti-HIV Agents; Clinical Trials as Topic; Contraceptive Devices, Female; Drug Administration Schedule; Drug Combinations; Drugs, Investigational; Emtricitabine; Female; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Male; Pre-Exposure Prophylaxis; Reverse Transcriptase Inhibitors; Tenofovir | 2017 |
Offering pre-exposure prophylaxis for HIV prevention to pregnant and postpartum women: a clinical approach.
Topics: Anti-HIV Agents; Counseling; Emtricitabine; Female; HIV Infections; Humans; Lactation; Male; Postpartum Period; Pre-Exposure Prophylaxis; Pregnancy; Tenofovir | 2017 |
A cost-savings analysis of a candidate universal antiretroviral regimen.
Topics: Adenine; Anti-HIV Agents; Drug Combinations; Drugs, Generic; Drugs, Investigational; Emtricitabine; HIV Infections; Humans; Tenofovir | 2017 |
Candidates for inclusion in a universal antiretroviral regimen: are lamivudine and emtricitabine interchangeable?
Topics: Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Treatment Outcome | 2017 |
A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection.
Topics: Anti-HIV Agents; Clinical Trials, Phase III as Topic; Cobicistat; Diarrhea; Disease Management; Drug Combinations; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; Headache; HIV Infections; HIV-1; Humans; Nausea; Quinolones; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome | 2018 |
Safety of oral tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis use in lactating HIV-uninfected women.
Topics: Administration, Oral; Animals; Anti-HIV Agents; Breast Feeding; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Infant; Infant, Newborn; Lactation; Pre-Exposure Prophylaxis; Tenofovir | 2017 |
Antiretroviral therapy for pregnant women living with HIV or hepatitis B: a systematic review and meta-analysis.
Topics: Adult; Anti-Retroviral Agents; Drug Combinations; Emtricitabine; Female; Hepatitis B; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Ritonavir; Tenofovir; Young Adult; Zidovudine | 2017 |
Raltegravir Once-Daily Tablet: A Review in HIV-1 Infection.
Topics: Adult; Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Raltegravir Potassium; Tablets; Tenofovir | 2017 |
Fixed dose darunavir boosted with cobicistat combined with emtricitabine and tenofovir alafenamide fumarate.
Topics: Anti-HIV Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Darunavir; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Randomized Controlled Trials as Topic; Tenofovir | 2018 |
HIV Preexposure Prophylaxis: A Review.
Topics: Anti-HIV Agents; Disease Transmission, Infectious; Drug Combinations; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Risk Factors; Tenofovir | 2018 |
Pre-exposure Prophylaxis for HIV Infection in the Older Patient: What can be Recommended?
Topics: Aged; Aged, 80 and over; Anti-HIV Agents; Drug Interactions; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Middle Aged; Pre-Exposure Prophylaxis; Tenofovir; Treatment Outcome | 2018 |
Bictegravir.
Topics: Adenine; Amides; Anti-HIV Agents; Clinical Trials, Phase III as Topic; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Tenofovir | 2018 |
The averted infections ratio: a novel measure of effectiveness of experimental HIV pre-exposure prophylaxis agents.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; Health Services Accessibility; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir; Treatment Outcome | 2018 |
Pharmacology of Antiretrovirals in the Female Genital Tract for HIV Prevention.
Topics: Anti-HIV Agents; Emtricitabine; Female; Genitalia, Female; Gonadal Steroid Hormones; HIV Infections; Humans; Microbiota; Pre-Exposure Prophylaxis; Tenofovir | 2018 |
Darunavir for the treatment of HIV infection.
Topics: Adenine; Clinical Trials as Topic; Cobicistat; Darunavir; Drug Therapy, Combination; Emtricitabine; Half-Life; HIV Infections; HIV Protease Inhibitors; Humans; Tenofovir; Treatment Outcome | 2018 |
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
Topics: Adenine; Alanine; Anti-HIV Agents; Bone Density; Cobicistat; Darunavir; Dose-Response Relationship, Drug; Drug Therapy, Combination; Emtricitabine; Genes, MDR; HIV Infections; HIV-1; Humans; Renal Reabsorption; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2018 |
Tolerability of Current Antiretroviral Single-Tablet Regimens
Topics: Adenine; Alanine; Anti-Retroviral Agents; Cobicistat; Darunavir; Drug Combinations; Emtricitabine; HIV Infections; Humans; Tablets; Tenofovir | 2018 |
[HIV - Innovation of diagnosis and treatment during the last decade].
Topics: Anti-HIV Agents; Emtricitabine; HIV; HIV Infections; HIV Integrase Inhibitors; Humans | 2018 |
Comparative effectiveness of anti-viral drugs with dual activity for treating hepatitis B and HIV co-infected patients: a network meta-analysis.
Topics: Adenine; Adult; Aged; Antiviral Agents; Coinfection; Emtricitabine; Female; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Network Meta-Analysis; Organophosphonates; Tenofovir; Treatment Outcome; Young Adult | 2018 |
Community and activists demand for tenofovir/emtricitabine or lamivudine/dolutegravir and routine viral load testing.
Topics: Anti-HIV Agents; Drug Monitoring; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Residence Characteristics; Tenofovir; Viral Load | 2019 |
Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Emtricitabine; HIV; HIV Infections; Humans; Protease Inhibitors; Randomized Controlled Trials as Topic; Tenofovir | 2018 |
Getting pre-exposure prophylaxis (PrEP) to the people: opportunities, challenges and emerging models of PrEP implementation.
Topics: Administration, Oral; Anti-HIV Agents; Emtricitabine; Health Equity; Health Services Accessibility; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2018 |
Going global: the adoption of the World Health Organization's enabling recommendation on oral pre-exposure prophylaxis for HIV.
Topics: Administration, Oral; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Practice Guidelines as Topic; Pre-Exposure Prophylaxis; Tenofovir; World Health Organization | 2018 |
An evaluation of elvitegravir plus cobicistat plus tenofovir alafenamide plus emtricitabine as a single-tablet regimen for the treatment of HIV in children and adolescents.
Topics: Adenine; Adolescent; Alanine; Anti-HIV Agents; Child; Cobicistat; Emtricitabine; HIV Infections; Humans; Quinolones; Tablets; Tenofovir; United States; United States Food and Drug Administration | 2019 |
Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications.
Topics: Adenine; Alanine; Amides; Animals; Anti-HIV Agents; Drug Combinations; Drug Interactions; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Piperazines; Pyridones; Tablets; Tenofovir | 2019 |
A Review of Telehealth Innovations for HIV Pre-Exposure Prophylaxis (PrEP).
Topics: Anti-HIV Agents; Continuity of Patient Care; Cost-Benefit Analysis; Emtricitabine; HIV Infections; Humans; Male; Mobile Applications; Pre-Exposure Prophylaxis; Primary Health Care; Telemedicine; Tenofovir | 2019 |
Drug Resistance During HIV Pre-Exposure Prophylaxis.
Topics: Animals; Anti-HIV Agents; Anti-Retroviral Agents; Drug Resistance, Viral; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2019 |
Antiretroviral agents in pre-exposure prophylaxis: emerging and advanced trends in HIV prevention.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Pre-Exposure Prophylaxis; Tenofovir | 2019 |
Implementation Strategies to Increase PrEP Uptake in the South.
Topics: Anti-HIV Agents; Emtricitabine; Epidemics; HIV Infections; Homosexuality, Male; Humans; Male; Mass Screening; Medication Adherence; Patient Protection and Affordable Care Act; Pre-Exposure Prophylaxis; Safe Sex; Sexual and Gender Minorities; Social Stigma; Telemedicine; Tenofovir; United States | 2019 |
Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Topics: Administration, Oral; Anti-Retroviral Agents; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Risk; Tenofovir | 2019 |
Current and Future PrEP Medications and Modalities: On-demand, Injectables, and Topicals.
Topics: Administration, Topical; Adult; Anti-HIV Agents; Anti-Infective Agents; Contraceptive Devices, Female; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Injections; Male; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Tenofovir | 2019 |
Pre-Exposure Prophylaxis for HIV Prevention in Women: Current Status and Future Directions.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Risk-Taking; Sexual and Gender Minorities; Tenofovir | 2019 |
Genital Human Immunodeficiency Virus-1 RNA and DNA Shedding in Virologically Suppressed Individuals Switching From Triple- to Dual- or Monotherapy: Pooled Results From 2 Randomized, Controlled Trials.
Topics: Anti-HIV Agents; DNA; Emtricitabine; Female; Genitalia; HIV Infections; HIV-1; Humans; Lamivudine; Male; Randomized Controlled Trials as Topic; RNA; Viral Load | 2020 |
Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Patient Acceptance of Health Care; Randomized Controlled Trials as Topic; Safe Sex; Sexual Behavior; Sexuality; Tenofovir | 2013 |
Preexposure prophylaxis for HIV prevention: where have we been and where are we going?
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; Humans; Medication Adherence; Organophosphonates; Risk Factors; Tenofovir | 2013 |
Pre-exposure prophylaxis for HIV infection: how antiretroviral pharmacology helps to monitor and improve adherence.
Topics: Adenine; Animals; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Drug Monitoring; Emtricitabine; HIV Infections; Humans; Medication Adherence; Phosphorous Acids; Reverse Transcriptase Inhibitors | 2013 |
[Pre-exposure prophylaxis for the prevention of sexual HIV transmission; new preventative strategy using tenofovir/emtricitabine].
Topics: Adenine; Anti-HIV Agents; Chemoprevention; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Netherlands; Organophosphonates; Patient Compliance; Risk-Taking; Sexual Behavior; Tenofovir | 2013 |
EFV/FTC/TDF-associated hepatotoxicity: a case report and review.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Liver; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2013 |
Single-tablet regimens in HIV: does it really make a difference?
Topics: Adenine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Nitriles; Organophosphonates; Pyrimidines; Quinolones; Reverse Transcriptase Inhibitors; Rilpivirine; Tablets; Tenofovir; Thiazoles | 2014 |
Comparative efficacy of Lamivudine and emtricitabine: a systematic review and meta-analysis of randomized trials.
Topics: Adult; Anti-HIV Agents; Databases, Bibliographic; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Therapeutic Equivalency; Treatment Outcome; Viral Load | 2013 |
[Mechanism of action and pharmacokinetics of rilpivirine].
Topics: Adenine; Adult; Aged; Animals; Anti-HIV Agents; Biological Availability; Child; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Deoxycytidine; Drug Administration Routes; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Food-Drug Interactions; Half-Life; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Intestinal Absorption; Molecular Structure; Nanoparticles; Nitriles; Organophosphonates; Proton Pump Inhibitors; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir | 2013 |
Systemic preexposure prophylaxis for HIV: translating clinical data to clinical practice.
Topics: Adenine; Anti-HIV Agents; Cost-Benefit Analysis; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Incidence; Medication Adherence; Organophosphonates; Risk Reduction Behavior; Safe Sex; Tenofovir | 2014 |
Effects of hormonal contraception on antiretroviral drug metabolism, pharmacokinetics and pharmacodynamics.
Topics: Adenine; Anti-HIV Agents; Contraception; Contraceptives, Oral, Hormonal; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Deoxycytidine; Drug Interactions; Emtricitabine; Family Planning Services; Female; HIV Infections; HIV-1; Humans; Organophosphonates; Pregnancy; Progestins; Tenofovir; Treatment Outcome | 2014 |
Tenofovir, emtricitabine, and darunavir/ritonavir pharmacokinetics in an HIV-infected patient after Roux-en-Y gastric bypass surgery.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Deoxycytidine; Emtricitabine; Gastric Bypass; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Ritonavir; Sulfonamides; Tenofovir | 2014 |
Which patients have greatest need for elvitegravir/cobicistat/ emtricitabine/tenofovirDF-based therapy?
Topics: Adenine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Patents as Topic; Phosphorous Acids; Quinolones; Thiazoles | 2014 |
Virological efficacy of abacavir: systematic review and meta-analysis.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome | 2014 |
Pre-exposure prophylaxis of HIV: A right way to go or a long way to go?
Topics: Anti-HIV Agents; Cost-Benefit Analysis; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Male; Patient Compliance; Pre-Exposure Prophylaxis; Randomized Controlled Trials as Topic; Risk-Taking; Sexual Behavior; Tenofovir; Treatment Outcome | 2016 |
48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Lopinavir; Nitriles; Organophosphonates; Oxazines; Piperazines; Pyridones; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Rilpivirine; Ritonavir; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2014 |
Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a review of its use in HIV infection.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Nitriles; Organophosphonates; Pyrimidines; Rilpivirine; Tablets; Tenofovir | 2014 |
Oral preexposure prophylaxis to prevent HIV infection: clinical and public health implications.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Incidence; Male; Medication Adherence; Public Health; Risk Factors; Risk Reduction Behavior; Safe Sex; Tenofovir; United States; Vulnerable Populations | 2014 |
Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges.
Topics: Anti-HIV Agents; Drug Combinations; Emtricitabine; HIV Infections; Humans; Practice Guidelines as Topic; Pre-Exposure Prophylaxis; Randomized Controlled Trials as Topic; Tenofovir | 2015 |
Choice of antiretroviral drugs for postexposure prophylaxis for adults and adolescents: a systematic review.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Emtricitabine; HIV; HIV Infections; Humans; Lopinavir; Post-Exposure Prophylaxis; Ritonavir; Tenofovir; World Health Organization | 2015 |
What people want from sex and preexposure prophylaxis.
Topics: Anti-HIV Agents; Chemoprevention; Disease Transmission, Infectious; Emtricitabine; Female; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Safe Sex; Tenofovir; United States | 2016 |
The European preexposure prophylaxis revolution.
Topics: Anti-HIV Agents; Chemoprevention; Disease Transmission, Infectious; Emtricitabine; Europe; Female; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir; Treatment Outcome | 2016 |
Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice.
Topics: Anti-HIV Agents; Chemoprevention; Clinical Trials as Topic; Delivery of Health Care; Disease Transmission, Infectious; Emtricitabine; HIV Infections; Humans; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir; Treatment Outcome | 2016 |
Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?
Topics: Anti-HIV Agents; Chemoprevention; Disease Transmission, Infectious; Drug Resistance, Viral; Emtricitabine; HIV Infections; Humans; Models, Theoretical; Pre-Exposure Prophylaxis; Tenofovir | 2016 |
Nondaily preexposure prophylaxis for HIV prevention.
Topics: Administration, Oral; Animals; Anti-HIV Agents; Chemoprevention; Clinical Trials as Topic; Disease Models, Animal; Disease Transmission, Infectious; Emtricitabine; Female; HIV Infections; Humans; Macaca; Male; Pre-Exposure Prophylaxis; Tenofovir | 2016 |
Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention.
Topics: Administration, Oral; Animals; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Risk; Tenofovir | 2016 |
Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for the treatment of HIV in adults.
Topics: Anti-HIV Agents; Bone Density; Clinical Trials as Topic; Cobicistat; Drug Combinations; Drug Resistance, Viral; Emtricitabine; HIV Infections; Humans; Quinolones; Tablets; Tenofovir | 2016 |
Successful Implementation of HIV Preexposure Prophylaxis: Lessons Learned From Three Clinical Settings.
Topics: Ambulatory Care Facilities; Anti-HIV Agents; Delivery of Health Care; Emtricitabine; Health Maintenance Organizations; HIV Infections; Humans; Pre-Exposure Prophylaxis; Primary Health Care; Risk Reduction Behavior; Tenofovir | 2016 |
Care of Patients With HIV Infection: Antiretroviral Drug Regimens.
Topics: Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Tenofovir | 2016 |
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
Topics: Adenine; Adolescent; Adult; Alanine; Anti-HIV Agents; Clinical Trials, Phase III as Topic; Cobicistat; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Quinolones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir | 2016 |
Pharmacologic Considerations for Preexposure Prophylaxis in Transgender Women.
Topics: Anti-HIV Agents; Delivery of Health Care, Integrated; Directive Counseling; Emtricitabine; Female; Health Status Disparities; HIV Infections; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir; Transgender Persons | 2016 |
Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Bone Diseases; Clinical Trials as Topic; Cyclopropanes; Drug Interactions; Emtricitabine; HIV Infections; Humans; Incidence; Kidney Diseases; Tenofovir; Treatment Outcome | 2016 |
Topics: Absorptiometry, Photon; Adult; Air Pollutants; Alkynes; Alleles; Animals; Anthracenes; Anthraquinones; Anti-HIV Agents; Benzoxazines; Black or African American; Bone Density; Bone Density Conservation Agents; C-Reactive Protein; Calcium, Dietary; Capsid Proteins; Cardiomyopathy, Dilated; Cardiovascular Diseases; CD4 Lymphocyte Count; Cholesterol; Collagen Type I; Cyclopropanes; Darunavir; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Emtricitabine; Epitopes; Female; Femur Neck; Gene Expression Profiling; Genetic Predisposition to Disease; Hepatitis, Viral, Animal; Hip Joint; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunization; Inflammation Mediators; Lipoproteins, LDL; Lupus Erythematosus, Systemic; Male; Mice; Mice, Inbred BALB C; Nitrates; Osteocalcin; Oxidation-Reduction; Parathyroid Hormone; Parvovirus B19, Human; Peptides; Phenotype; Pilot Projects; Polymorphism, Single Nucleotide; Raltegravir Potassium; Ritonavir; RNA, Viral; Sodium Chloride; Tenofovir; Transcriptome; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms; Vaccines; Vascular Endothelial Growth Factor A; Vitamin D; Young Adult | 2016 |
Where next with preexposure prophylaxis?
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Organophosphonates; Pre-Exposure Prophylaxis; Randomized Controlled Trials as Topic; Tenofovir | 2017 |
Pre-exposure prophylaxis (PrEP) for men who have sex with men in Europe: review of evidence for a much needed prevention tool.
Topics: Anti-HIV Agents; Emtricitabine; Europe; HIV Infections; Homosexuality, Male; Humans; Male; Patient Acceptance of Health Care; Pre-Exposure Prophylaxis; Sexual Behavior; Tenofovir | 2017 |
Emtricitabine + tenofovir alafenamide for the treatment of HIV.
Topics: Adenine; Anti-HIV Agents; Bone Density; Emtricitabine; HIV Infections; HIV-1; Humans; Kidney; Leukocytes, Mononuclear; Prodrugs; Tenofovir | 2017 |
Treatment of chronic hepatitis B infection: an update of Swedish recommendations.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Immunocompromised Host; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Transplantation; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Sweden; Tenofovir | 2008 |
[Hepatitis B in patients with HIV infection].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Comorbidity; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B; Hepatitis B Vaccines; Hepatitis B virus; HIV; HIV Infections; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Practice Guidelines as Topic; Pyrimidinones; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Virus Replication | 2008 |
[Clinical data II. Clinical experience of tenofovir DF in combination with protease inhibitors].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Cohort Studies; Deoxycytidine; Diabetic Nephropathies; Double-Blind Method; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Emtricitabine; HIV; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Kidney Diseases; Multicenter Studies as Topic; Organophosphonates; Randomized Controlled Trials as Topic; Retrospective Studies; Reverse Transcriptase Inhibitors; Salvage Therapy; Tenofovir; Treatment Outcome | 2008 |
The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Lopinavir; Multicenter Studies as Topic; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Randomized Controlled Trials as Topic; Ritonavir; Tenofovir; Treatment Outcome | 2009 |
Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
Topics: Adenine; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Intention to Treat Analysis; Lamivudine; Male; Organophosphonates; Randomized Controlled Trials as Topic; Regression Analysis; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2009 |
Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy.
Topics: Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Developing Countries; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Treatment Failure | 2010 |
The risk of HIV drug resistance following implementation of pre-exposure prophylaxis.
Topics: Adenine; Animals; Anti-HIV Agents; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV; HIV Infections; Humans; Organophosphonates; Risk Assessment; Tenofovir; Viremia | 2010 |
Systemic preexposure prophylaxis for human immunodeficiency virus infection.
Topics: Adenine; Animals; Anti-HIV Agents; Antiviral Agents; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Occupational Exposure; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Risk Factors; Risk-Taking; Tenofovir | 2010 |
Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2010 |
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.
Topics: Adenine; Chemoprevention; Deoxycytidine; Drug Interactions; Emtricitabine; Female; Food-Drug Interactions; HIV Infections; Humans; Male; Organophosphonates; Tenofovir | 2011 |
The impact of human immunodeficiency virus on viral hepatitis.
Topics: Adenine; Antiviral Agents; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B; Hepatitis C; Hepatitis Viruses; HIV Infections; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine | 2011 |
Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Chemoprevention; Clinical Trials as Topic; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Risk; Tenofovir; United States | 2011 |
A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphonates; Tenofovir; Treatment Failure; Viral Load; World Health Organization | 2012 |
Role of raltegravir in HIV-1 management.
Topics: Adenine; Animals; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Tenofovir | 2012 |
Where rilpivirine meets with tenofovir, the start of a new anti-HIV drug combination era.
Topics: Adenine; Animals; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; Emtricitabine, Rilpivirine, Tenofovir Drug Combination; HIV Infections; HIV-1; Humans; Nitriles; Organophosphonates; Oxazines; Pyrimidines; Rilpivirine; Tenofovir | 2012 |
Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Deoxycytidine; Dideoxynucleosides; Disease Progression; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Hepatitis C, Chronic; HIV Infections; Homosexuality, Male; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Diseases; Male; Oligopeptides; Organophosphonates; Polyethylene Glycols; Proline; Pyrrolidinones; Raltegravir Potassium; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Substance Abuse, Intravenous; Tenofovir; Treatment Outcome | 2012 |
Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals.
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Organophosphonates; Premedication; Randomized Controlled Trials as Topic; Risk; Risk-Taking; Tenofovir; Unsafe Sex | 2012 |
What primary care providers need to know about preexposure prophylaxis for HIV prevention: a narrative review.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Directive Counseling; Emtricitabine; Evidence-Based Medicine; Heterosexuality; HIV Infections; Homosexuality; Humans; Medication Adherence; Organophosphonates; Primary Health Care; Risk Assessment; Risk-Taking; Sexual Partners; Tenofovir | 2012 |
Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF.
Topics: Adenine; Anti-HIV Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cobicistat; Deoxycytidine; Drug Combinations; Drug Resistance, Multiple, Viral; Emtricitabine; HIV Infections; Humans; Organophosphonates; Quinolones; Tenofovir; Thiazoles | 2012 |
Considerations regarding antiretroviral chemoprophylaxis in MSM.
Topics: Adenine; Administration, Oral; Animals; Anti-HIV Agents; Chemoprevention; Clinical Trials as Topic; Deoxycytidine; Disease Models, Animal; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Leukocytes, Mononuclear; Male; Medication Adherence; Organophosphonates; Plasma; Tenofovir; Treatment Outcome | 2012 |
Emtricitabine/tenofovir in the treatment of HIV infection: current PK/PD evaluation.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Emtricitabine; HIV Infections; HIV-1; Humans; Organophosphonates; Practice Guidelines as Topic; Tenofovir | 2012 |
Antiretrovirals for HIV Exposure Prophylaxis.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Emtricitabine; HIV; HIV Infections; Humans; Lamivudine; Occupational Exposure; Organophosphonates; Stavudine; Tenofovir; Zidovudine | 2012 |
Oral antiretroviral chemoprophylaxis: current status.
Topics: Adenine; Administration, Oral; Animals; Anti-HIV Agents; Chemoprevention; Clinical Trials as Topic; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Organophosphonates; Tenofovir | 2012 |
The clinical pharmacology of antiretrovirals for HIV prevention.
Topics: Adenine; Administration, Oral; Administration, Topical; Anti-Retroviral Agents; Chemoprevention; Clinical Trials as Topic; Colon; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Organophosphonates; Tenofovir; Vagina | 2012 |
Complete resolution of erythrodermic psoriasis in an HIV and HCV patient unresponsive to antipsoriatic treatments after highly active antiretroviral therapy (Ritonavir, Atazanavir, Emtricitabine, Tenofovir).
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Hepatitis C, Chronic; HIV Infections; Humans; Immunocompromised Host; Male; Middle Aged; Oligopeptides; Organophosphonates; Psoriasis; Pyridines; Ritonavir; Tenofovir; Treatment Outcome | 2012 |
Emtricitabine: an antiretroviral agent for HIV infection.
Topics: Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Reverse Transcriptase Inhibitors | 2003 |
Emtricitabine: a new nucleoside analogue for once-daily antiretroviral therapy.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Drug Administration Schedule; Emtricitabine; HIV Infections; HIV-1; Humans; Randomized Controlled Trials as Topic; Treatment Outcome | 2004 |
Newer treatments for HIV in children.
Topics: Adenine; Anti-Bacterial Agents; Anti-HIV Agents; Child; Deoxycytidine; Didanosine; Drug Therapy, Combination; Emtricitabine; Enfuvirtide; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; Humans; Microbial Sensitivity Tests; Organophosphonates; Organophosphorus Compounds; Peptide Fragments; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir | 2004 |
The continuing evolution of HIV therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cyclopropanes; Delayed-Action Preparations; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Monitoring; Emtricitabine; Furans; HIV Infections; Humans; Lamivudine; Nevirapine; Oligopeptides; Organophosphates; Organophosphonates; Organophosphorus Compounds; Oxazines; Pyridines; Randomized Controlled Trials as Topic; Stavudine; Sulfonamides; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2003 |
Editorial comment: HIV and HBV coinfection--a coming-of-age in treatment strategies.
Topics: Adenine; Antiviral Agents; Comorbidity; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2004 |
Emtricitabine: a once-daily nucleoside reverse transcriptase inhibitor.
Topics: Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Drug Resistance, Multiple, Viral; Emtricitabine; HIV Infections; HIV-1; HIV-2; Humans; Reverse Transcriptase Inhibitors | 2004 |
Biochemical and mechanistic basis for the activity of nucleoside analogue inhibitors of HIV reverse transcriptase.
Topics: Adenine; Cytidine Triphosphate; Deoxycytidine; Deoxycytidine Monophosphate; Deoxyribonucleotides; Dioxolanes; DNA, Viral; Emtricitabine; HIV Infections; HIV Reverse Transcriptase; Humans; Kinetics; Molecular Structure; Nucleosides; Organophosphonates; Organophosphorus Compounds; Phosphorylation; Protein Binding; Protein Conformation; Purine Nucleosides; Reverse Transcriptase Inhibitors; Substrate Specificity; Tenofovir; Zalcitabine | 2004 |
Emtricitabine (FTC) for the treatment of HIV infection.
Topics: Animals; Anti-HIV Agents; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Viral; Emtricitabine; HIV Infections; Humans; Mice; Multicenter Studies as Topic; Randomized Controlled Trials as Topic | 2004 |
New nucleoside reverse transcriptase inhibitors for the treatment of HIV infections.
Topics: Animals; Anti-HIV Agents; Clinical Trials as Topic; Cytidine Triphosphate; Deoxycytidine; Dideoxynucleosides; Dioxolanes; Emtricitabine; HIV Infections; Humans; Purine Nucleosides; Reverse Transcriptase Inhibitors; Thionucleosides; Zalcitabine | 2004 |
Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel.
Topics: Adenine; Antiviral Agents; Comorbidity; Deoxycytidine; Disease Progression; Drug Monitoring; Emtricitabine; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Tenofovir | 2005 |
Emtricitabine: a review of its use in the management of HIV infection.
Topics: Adult; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Treatment Outcome | 2005 |
Emtricitabine: a novel nucleoside reverse transcriptase inhibitor.
Topics: Adult; Area Under Curve; Cell Line, Tumor; Child; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Hepatitis B; HIV Infections; HIV-1; Humans; Metabolic Clearance Rate; Reverse Transcriptase Inhibitors | 2005 |
Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus.
Topics: Anti-Retroviral Agents; Deoxycytidine; Emtricitabine; Hepatitis B, Chronic; HIV Infections; Humans | 2006 |
Use of tenofovir disoproxil fumarate and emtricitabine combination in HIV-infected patients.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Organophosphonates; Tenofovir | 2006 |
An update and review of antiretroviral therapy.
Topics: Adenine; Animals; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Deoxycytidine; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Drugs, Investigational; Emtricitabine; Enfuvirtide; Furans; HIV Envelope Protein gp41; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Oligopeptides; Organophosphates; Organophosphonates; Patient Compliance; Peptide Fragments; Pyridines; Pyrones; Reverse Transcriptase Inhibitors; Sulfonamides; Tenofovir | 2006 |
Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Deoxycytidine; Drug Combinations; Emtricitabine; Guanine; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Preventive Medicine; Tenofovir | 2006 |
Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone.
Topics: Adenine; Animals; Chemistry, Pharmaceutical; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Emtricitabine; HIV Infections; HIV Reverse Transcriptase; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2006 |
Didanosine, lamivudine-emtricitabine and efavirenz as initial therapy in naive patients.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Didanosine; Drug Resistance, Viral; Emtricitabine; HIV; HIV Infections; Humans; Lamivudine; Oxazines; Quality of Life; Reverse Transcriptase Inhibitors | 2006 |
Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all?
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Organophosphonates; Oxazines; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
The first once-daily single-tablet regimen for the treatment of HIV-infected patients.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tablets; Tenofovir; Therapeutic Equivalency | 2007 |
Antiretroviral activity of emtricitabine, a potent nucleoside reverse transcriptase inhibitor.
Topics: Anti-HIV Agents; Deoxycytidine; Drug Resistance, Microbial; Emtricitabine; HIV Infections; HIV-1; HIV-2; Humans; Mitochondria; Reverse Transcriptase Inhibitors | 2001 |
394 trial(s) available for emtricitabine and HIV Infections
| Article | Year |
|---|---|
Comparison between daily and on-demand PrEP (pre-exposure prophylaxis) regimen in covering condomless anal intercourse for men who have sex with men in Hong Kong: A randomized, controlled, open-label, crossover trial.
Topics: Anti-HIV Agents; Cross-Over Studies; Emtricitabine; HIV Infections; Homosexuality, Male; Hong Kong; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Sexual and Gender Minorities | 2021 |
Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate.
Topics: Alanine; Anti-HIV Agents; Diphosphates; Emtricitabine; HIV Infections; Humans; Leukocytes, Mononuclear; Tenofovir | 2021 |
Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials.
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Amides; Anti-HIV Agents; Child; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Middle Aged; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Young Adult | 2021 |
Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Treatment Outcome | 2022 |
An Open-Label Pharmacokinetic and Pharmacodynamic Assessment of Tenofovir Gel and Oral Emtricitabine/Tenofovir Disoproxil Fumarate.
Topics: Anti-HIV Agents; Cross-Over Studies; Emtricitabine; Female; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Reverse Transcriptase Inhibitors; Sexual and Gender Minorities; Tenofovir | 2022 |
Risk factors for HIV infection among men who have sex with men in the ANRS IPERGAY PrEP trial.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Illicit Drugs; Male; Pre-Exposure Prophylaxis; Risk Factors; Sexual and Gender Minorities; Sexual Behavior | 2022 |
Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and women: HPTN 069/ACTG A5305.
Topics: Adult; Anti-HIV Agents; Double-Blind Method; Emtricitabine; Female; HIV Infections; Humans; Male; Maraviroc; Tenofovir | 2022 |
Bone mineral density, kidney function and participant-reported outcome measures in women who switch from tenofovir disoproxil emtricitabine and a nonnucleoside reverse transcriptase inhibitor to abacavir, lamivudine and dolutegravir.
Topics: Adult; Anti-HIV Agents; Bone Density; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Kidney; Lamivudine; Middle Aged; Oxazines; Patient Reported Outcome Measures; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir | 2022 |
Genital Mucosal Drug Concentrations and anti-HIV Activity in Tenofovir-Based PrEP Products: Intravaginal Ring vs. Oral Administration.
Topics: Administration, Intravaginal; Administration, Oral; Anti-HIV Agents; Emtricitabine; Female; Genitalia; HIV Infections; Humans; Tenofovir | 2022 |
Overcoming barriers to HIV pre-exposure prophylaxis (PrEP) coverage in Australia among Medicare-ineligible people at risk of HIV: results from the MI-EPIC clinical trial.
Topics: Adult; Aged; Anti-HIV Agents; Australia; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; National Health Programs; Pre-Exposure Prophylaxis | 2022 |
Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.
Topics: Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Male; Middle Aged; Piperazines; Pyridones; Retrospective Studies; Tenofovir | 2022 |
Efficacy and safety of Efavirenz 400 mg-based regimens switching from 600 mg-based regimens in people living with HIV with virological suppression in China: a randomized, open-label, non-inferiority study.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Emtricitabine; HIV Infections; HIV-1; Humans; Quality of Life; Viral Load | 2022 |
Population pharmacokinetics of tenofovir, emtricitabine and intracellular metabolites in transgender women.
Topics: Anti-HIV Agents; Creatinine; Emtricitabine; Female; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir; Transgender Persons | 2022 |
Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084.
Topics: Anti-HIV Agents; Diketopiperazines; DNA-Directed RNA Polymerases; Emtricitabine; Female; HIV; HIV Infections; Humans; Nucleosides; Pre-Exposure Prophylaxis; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir | 2022 |
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.
Topics: Adult; Anti-HIV Agents; Child; Diketopiperazines; Emtricitabine; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Infant, Newborn; Pregnancy; Pyridones | 2022 |
Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people ≥65 years of age.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Tenofovir | 2023 |
Brief Report: Impact of Antiretroviral Regimen on Pregnancy and Infant Outcomes in Women With HIV/ HBV Coinfection.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Coinfection; Emtricitabine; Female; Hepatitis B e Antigens; HIV Infections; Humans; Infant, Newborn; Lamivudine; Pregnancy; Pregnancy Outcome; Tenofovir; Zidovudine | 2022 |
Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection: the OPTIPRIM2-ANRS 169 randomized, open-label, Phase 3 trial.
Topics: Adult; Anti-HIV Agents; Cobicistat; Darunavir; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Oxazines; Piperazines; Pyridones; RNA; Tenofovir; Viral Load | 2022 |
72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; Female; Follow-Up Studies; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Male; Oxazines; Piperazines; Postpartum Period; Pregnancy; Pyridones; Tenofovir; Viral Load | 2022 |
Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial.
Topics: Adult; Anti-HIV Agents; COVID-19; COVID-19 Drug Treatment; Dexamethasone; Emtricitabine; HIV Infections; Humans; Tenofovir | 2023 |
Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers.
Topics: Adenine; Anti-HIV Agents; COVID-19; COVID-19 Drug Treatment; Deoxycytidine; Double-Blind Method; Emtricitabine; Health Personnel; HIV Infections; Humans; Hydroxychloroquine; Organophosphonates; Pre-Exposure Prophylaxis; SARS-CoV-2; Tenofovir | 2023 |
Randomized Trial of Individualized Texting for Adherence Building (iTAB) Plus Motivational Interviewing for PrEP Adherence in Transgender Individuals: The iM-PrEPT Study.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Motivational Interviewing; Pre-Exposure Prophylaxis; Text Messaging; Transgender Persons | 2022 |
The ATEAM study: Advances in technology to enhance PrEP adherence monitoring (ATEAM) among young men who have sex with men.
Topics: Adolescent; Adult; Anti-HIV Agents; Cross-Over Studies; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Sexual and Gender Minorities; Technology; Tenofovir; Young Adult | 2022 |
Point-of-Care Tenofovir Urine Testing for the Prediction of Treatment Failure and Drug Resistance During Initial Treatment for Human Immunodeficiency Virus Type 1 (HIV-1) Infection.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Case-Control Studies; Emtricitabine; HIV Infections; HIV-1; Humans; Point-of-Care Systems; Retrospective Studies; South Africa; Tenofovir; Treatment Failure | 2023 |
EVG/COBI/FTC/TAF Bioequivalence Comparing Whole Tablets with Tablets Dissolved in Tap Water.
Topics: Adenine; Adult; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Male; Tablets; Tenofovir; Therapeutic Equivalency | 2023 |
Bioavailability of dissolved and crushed single tablets of bictegravir, emtricitabine, tenofovir alafenamide in healthy adults: the SOLUBIC randomized crossover study.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Biological Availability; Cross-Over Studies; Emtricitabine; HIV Infections; Humans; Tablets; Tenofovir | 2022 |
MPrEP+ study protocol: a prospective cohort study assessing the feasibility and acceptability of an HIV pre-exposure prophylaxis (PrEP) strategy for male clients of female sex workers in Kisumu, Kenya.
Topics: Anti-HIV Agents; Emtricitabine; Feasibility Studies; Female; HIV Infections; Humans; Kenya; Male; Pre-Exposure Prophylaxis; Prospective Studies; Sex Workers | 2022 |
INSTIs for the management of HIV-associated TB (INSIGHT study): a phase 2b study to evaluate the efficacy, safety and pharmacokinetics of a combination of bictegravir, emtricitabine and tenofovir alafenamide fumarate for the treatment of HIV-1 infection i
Topics: Adenine; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Fumarates; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Pyridones; Rifampin; Tuberculosis | 2022 |
Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG.
Topics: Adenine; Anti-HIV Agents; Benzoxazines; Emtricitabine; HIV Infections; Humans; Lamivudine; Tenofovir | 2023 |
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Oxazines; RNA; Tenofovir; Treatment Outcome; Viral Load | 2023 |
MyTPill: study protocol for a cross-over randomised controlled trial comparing novel strategies to monitor antiretroviral adherence among HIV+ prescription opioid users.
Topics: Analgesics, Opioid; Anti-HIV Agents; Anti-Retroviral Agents; Cross-Over Studies; Emtricitabine; HIV Infections; Humans; Medication Adherence; Randomized Controlled Trials as Topic; Viral Load | 2023 |
Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial.
Topics: Adult; Anti-Retroviral Agents; Benzoxazines; Emtricitabine; HIV Infections; Humans; Lamivudine; RNA; Tenofovir | 2023 |
Retention among transgender women treated with dolutegravir associated with tenofovir/lamivudine or emtricitabine in Argentina: TransViiV study.
Topics: Adult; Anti-Retroviral Agents; Argentina; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Prospective Studies; Pyridones; Tenofovir; Transgender Persons | 2023 |
An open-label evaluation of safety and tolerability of coformulated bictegravir/emtricitabine/tenofovir alafenamide for post-exposure prophylaxis following potential exposure to human immunodeficiency virus-1.
Topics: Adult; Anti-HIV Agents; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Post-Exposure Prophylaxis; Prospective Studies; Tablets; Treatment Outcome; Young Adult | 2022 |
Pregnancy and neonatal safety outcomes of timing of initiation of daily oral tenofovir disoproxil fumarate and emtricitabine pre-exposure prophylaxis for HIV prevention (CAP016): an open-label, randomised, non-inferiority trial.
Topics: Adenine; Anti-HIV Agents; Birth Weight; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Pre-Exposure Prophylaxis; Pregnancy; Premature Birth; South Africa; Stillbirth; Tenofovir; Treatment Outcome | 2023 |
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve (AMBER) and virologically suppressed (EMERALD) participants with neurological and/or psychiatric comorbidities: Week 96 subgroup analysis.
Topics: Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Emtricitabine; HIV Infections; Humans | 2023 |
Bictegravir/emtricitabine/tenofovir alafenamide plus doravirine in highly treatment-experienced men with multidrug-resistant HIV.
Topics: Aged; Anti-HIV Agents; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Pyridones; Reverse Transcriptase Inhibitors | 2023 |
Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial.
Topics: Adenine; Anti-HIV Agents; Benzoxazines; Child; Emtricitabine; Female; HIV Infections; Humans; Male; Pregnancy; RNA; Tenofovir; Viral Load | 2023 |
A randomized clinical trial of on-demand oral pre-exposure prophylaxis does not modulate lymphoid/myeloid HIV target cell density in the foreskin.
Topics: Anti-HIV Agents; Claudin-1; Emtricitabine; Foreskin; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis | 2023 |
First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; Child; Darunavir; Emtricitabine; Fumarates; HIV Infections; Humans; Lopinavir; Protease Inhibitors; Ritonavir; Tenofovir | 2023 |
Dose finding study for on-demand HIV pre-exposure prophylaxis for insertive sex in sub-Saharan Africa: results from the CHAPS open label randomised controlled trial.
Topics: Africa South of the Sahara; Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Leukocytes, Mononuclear; Male; Pre-Exposure Prophylaxis | 2023 |
Bioequivalence of a Pediatric Fixed-Dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Compared With Coadministration of the Separate Agents in Healthy Adults: An Open-Label, Randomized, Replicate Crossover Study.
Topics: Adult; Anti-HIV Agents; Cobicistat; Cross-Over Studies; Darunavir; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Tablets; Therapeutic Equivalency | 2023 |
Decay of HIV RNA in Seminal Plasma and Rectal Fluid in Treatment-Naive Adults Starting Antiretroviral Therapy With Dolutegravir Plus Lamivudine or Bictegravir/Emtricitabine/Tenofovir Alafenamide.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Pyridones; RNA, Viral; Semen | 2023 |
Tenofovir alafenamide plus dolutegravir as a switch strategy in HIV-infected patients: a pilot randomized controlled trial.
Topics: Adenine; Anti-HIV Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; HIV Infections; Humans; Pilot Projects; RNA; Tenofovir; Treatment Outcome | 2023 |
Decay kinetics of HIV-1-RNA in seminal plasma with dolutegravir/lamivudine versus dolutegravir plus emtricitabine/tenofovir alafenamide in treatment-naive people living with HIV.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Kinetics; Lamivudine; Male; Oxazines; Pyridones; RNA, Viral; Semen | 2023 |
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a random
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Female; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Seropositivity; HIV-1; Humans; Infant, Newborn; Injection Site Reaction; Male; Middle Aged; Rilpivirine; RNA; Tenofovir; Viral Load; Young Adult | 2023 |
Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Cobicistat; Darunavir; DNA; Emtricitabine; Female; HIV Infections; Humans; Male; Prospective Studies; Tandem Mass Spectrometry | 2023 |
Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; HIV-1; Hormones; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir; Thailand; Transgender Persons | 2023 |
Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial.
Topics: Adolescent; Anti-HIV Agents; Cross-Over Studies; Emtricitabine; Female; HIV Infections; Humans; Pre-Exposure Prophylaxis; Reverse Transcriptase Inhibitors; South Africa; Tenofovir | 2023 |
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary anal
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Pre-Exposure Prophylaxis; Retrospective Studies; Tenofovir; Transgender Persons | 2023 |
DELIVER: A Safety Study of a Dapivirine Vaginal Ring and Oral PrEP for the Prevention of HIV During Pregnancy.
Topics: Emtricitabine; Female; Gestational Age; HIV Infections; Humans; Malawi; Pregnancy; Tenofovir | 2024 |
Protocol for a multicenter, real-world study of HIV pre-exposure prophylaxis among men who have sex with men in China (CROPrEP).
Topics: Adult; Anti-HIV Agents; China; Cohort Studies; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Multicenter Studies as Topic; Pre-Exposure Prophylaxis; Safe Sex; Self Report; Sexual and Gender Minorities; Sexual Behavior; Surveys and Questionnaires; Tenofovir | 2019 |
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
Topics: Adenine; Adult; Alanine; Amides; Amino Acid Substitution; Anti-HIV Agents; Double-Blind Method; Drug Resistance, Multiple, Viral; Drug Substitution; Drug Therapy, Combination; Emtricitabine; Genotype; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; Retrospective Studies; RNA, Viral; Sustained Virologic Response; Tenofovir | 2019 |
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study.
Topics: Adenine; Adult; Aged; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Darunavir; Drug Combinations; Drug Substitution; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Protease Inhibitors; Sustained Virologic Response; Tablets; Tenofovir; Viral Load; Young Adult | 2019 |
Limited correlation between systemic biomarkers and neurocognitive performance before and during HIV treatment.
Topics: Adult; AIDS Dementia Complex; Anti-HIV Agents; Biomarkers; Darunavir; Double-Blind Method; Emtricitabine; Female; HIV Infections; Humans; Inflammation; Male; Maraviroc; Ritonavir; Tenofovir | 2020 |
Linked dual-class HIV resistance mutations are associated with treatment failure.
Topics: Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Viral; Emtricitabine; Female; Genome, Viral; HIV Infections; HIV-1; Humans; Mutation; Nevirapine; Tenofovir; Treatment Failure; Whole Genome Sequencing | 2019 |
HPTN 067/ADAPT: Correlates of Sex-Related Pre-exposure Prophylaxis Adherence, Thai Men Who Have Sex With Men, and Transgender Women, 2012-2013.
Topics: Adolescent; Adult; Emtricitabine; Feasibility Studies; Female; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir; Transgender Persons; Young Adult | 2019 |
Determinants of blood telomere length in antiretroviral treatment-naïve HIV-positive participants enrolled in the NEAT 001/ANRS 143 clinical trial.
Topics: Adult; Aged; Anti-Retroviral Agents; Cross-Sectional Studies; Darunavir; Emtricitabine; Female; HIV Infections; Humans; Logistic Models; Male; Middle Aged; Raltegravir Potassium; Ritonavir; RNA, Viral; Telomere; Tenofovir | 2019 |
Switching from efavirenz to rilpivirine improves sleep quality and self-perceived cognition but has no impact on neurocognitive performances.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cognition; Cyclopropanes; Drug Substitution; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Quality of Life; Rilpivirine; RNA, Viral; Sleep; Tenofovir; Viral Load | 2020 |
Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a m
Topics: Adenine; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Bone Density; Cobicistat; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Tablets; Tenofovir | 2019 |
Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-HIV Agents; CD4 Lymphocyte Count; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Middle Aged; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Young Adult | 2019 |
Early safety of tenofovir alafenamide in patients with a history of tubulopathy on tenofovir disoproxil fumarate: a randomized controlled clinical trial.
Topics: Adenine; Alanine; Creatinine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Kidney Tubules, Proximal; Linear Models; Male; Middle Aged; Retinol-Binding Proteins; Tenofovir; Treatment Outcome; United Kingdom | 2020 |
Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001
Topics: Adult; Anti-HIV Agents; Constitutive Androstane Receptor; Darunavir; Emtricitabine; Female; HIV Infections; Humans; Liver-Specific Organic Anion Transporter 1; Male; Multidrug Resistance-Associated Protein 2; Pharmacogenetics; Raltegravir Potassium; Ritonavir; Tenofovir; Viral Load | 2020 |
Association between HIV antiretroviral therapy and preterm birth based on antenatal ultrasound gestational age determination: a comparative analysis.
Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Gestational Age; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Logistic Models; Lopinavir; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Premature Birth; Risk; Ritonavir; Tenofovir; Ultrasonography, Prenatal; Young Adult; Zidovudine | 2019 |
Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Quinolones; Tablets; Tenofovir | 2020 |
Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Protease Inhibitors; Tablets; Tenofovir; Treatment Outcome; Viral Load | 2020 |
Antenatal Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate and Associations Between Tenofovir Diphosphate and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) Trial.
Topics: Adenine; Anti-HIV Agents; Case-Control Studies; Chromatography, Liquid; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Logistic Models; Lopinavir; Medication Adherence; Organophosphates; Polyphosphates; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Retrospective Studies; Ritonavir; Tenofovir | 2020 |
Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Viral Load; Young Adult | 2020 |
HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.
Topics: Adenine; Adult; Aged; Alanine; Benzimidazoles; Coinfection; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; Fluorenes; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Male; Middle Aged; RNA, Viral; Sofosbuvir; Tenofovir | 2020 |
Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy.
Topics: Adult; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Hormones; Humans; Pharmaceutical Preparations; Pre-Exposure Prophylaxis; Tenofovir; Transgender Persons | 2020 |
Rilpivirine plus cobicistat-boosted darunavir as a two-drug switch regimen in HIV-infected, virologically suppressed subjects on steady standard three-drug therapy: a randomized, controlled, non-inferiority trial (PROBE 2).
Topics: Adenine; Anti-HIV Agents; Cobicistat; Darunavir; Emtricitabine; HIV Infections; HIV-1; Humans; Pharmaceutical Preparations; Rilpivirine; Treatment Outcome; Viral Load | 2020 |
Five-year follow-up of patients enrolled in the NEAT 001/ANRS 143 randomized clinical trial: NEAT 001/ANRS 143 LONG TERM study.
Topics: Anti-HIV Agents; Darunavir; Emtricitabine; Follow-Up Studies; HIV Infections; HIV-1; Humans; Retrospective Studies; Ritonavir; Viral Load | 2020 |
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials
Topics: Adenine; Adult; Aged; Alanine; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; RNA, Viral; Tenofovir; Treatment Outcome; Young Adult | 2020 |
Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study.
Topics: Adenine; Adolescent; Adult; Alanine; Anti-HIV Agents; Cross-Over Studies; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Organophosphates; Polyphosphates; Pre-Exposure Prophylaxis; Prospective Studies; Tenofovir; Young Adult | 2020 |
Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate.
Topics: Adult; Anti-HIV Agents; Emtricitabine; Female; Health Behavior; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Plasma; Tenofovir; Young Adult | 2020 |
Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus.
Topics: Adult; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; Tenofovir | 2021 |
A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults
Topics: Adenine; Adult; Alanine; Amides; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Male; Mutation; Pilot Projects; Piperazines; Prospective Studies; Protease Inhibitors; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2020 |
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance.
Topics: Adenine; Amides; Anti-HIV Agents; Double-Blind Method; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Logistic Models; Multivariate Analysis; Oxazines; Piperazines; Pyridones; RNA, Viral; Tenofovir | 2020 |
Real-time monitoring and just-in-time intervention for adherence to pre-exposure prophylaxis among men who have sex with men in China: a multicentre RCT study protocol.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; China; Computer Systems; Early Medical Intervention; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Prospective Studies; Reminder Systems; Self Report; Tenofovir; Text Messaging; Young Adult | 2020 |
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Europe; Female; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; North America; Placebos; Pre-Exposure Prophylaxis; Prevalence; Safety; Sexual and Gender Minorities; Tenofovir; Treatment Outcome | 2020 |
Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones Study.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; Estradiol; Female; HIV Infections; Humans; Male; Organophosphates; Pre-Exposure Prophylaxis; Transgender Persons | 2021 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
Bone mineral density, kidney function, weight gain and insulin resistance in women who switch from TDF/FTC/NNRTI to ABC/3TC/DTG.
Topics: Adult; Anti-HIV Agents; Bone Density; Dideoxynucleosides; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Insulin Resistance; Kidney; Lamivudine; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Weight Gain | 2021 |
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, n
Topics: Adenine; Adolescent; Adult; Alanine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Body Composition; Body Weight; Cyclopropanes; Duration of Therapy; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2020 |
Effects of vitamin D and calcium supplementation on bone mineral density among Thai youth using daily HIV pre-exposure prophylaxis.
Topics: Absorptiometry, Photon; Adolescent; Anti-HIV Agents; Bone Density; Calcium; Dietary Supplements; Emtricitabine; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir; Thailand; Vitamin D; Young Adult | 2020 |
Unexpected interactions between dolutegravir and folate: randomized trial evidence from South Africa.
Topics: Adult; Anti-HIV Agents; Drug Interactions; Emtricitabine; Female; Folic Acid; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Oxazines; Piperazines; Pregnancy; Pyridones; South Africa | 2021 |
Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial.
Topics: Adult; Anti-HIV Agents; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Switzerland | 2020 |
Individualized Adherence Benchmarks for HIV Pre-Exposure Prophylaxis.
Topics: Anti-HIV Agents; Benchmarking; Emtricitabine; Female; HIV Infections; Humans; Medication Adherence; Pre-Exposure Prophylaxis | 2021 |
Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial.
Topics: Adolescent; Adult; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; South Africa; Tenofovir; Young Adult | 2020 |
Week 96 resistance analyses of the once-daily, single-tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV-1 from the phase 3 randomized AMBER and EMERALD trials.
Topics: Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Drug Resistance, Multiple, Viral; Emtricitabine; HIV Infections; HIV-1; Sequence Analysis, DNA; Tablets; Tenofovir; Viral Load | 2021 |
New Insights on Long-Term Hepatitis B Virus Responses in HIV-Hepatitis B virus Co-infected Patients: Implications for Antiretroviral Management in Hepatitis B virus-Endemic Settings.
Topics: Adult; Alanine Transaminase; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Cohort Studies; Coinfection; DNA, Viral; Drug Resistance, Viral; Emtricitabine; Female; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Retrospective Studies; Uganda; Zimbabwe | 2021 |
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Emtricitabine; Fumarates; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Tenofovir; Treatment Outcome; Triazoles | 2021 |
Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)
Topics: Adult; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Emtricitabine; HIV Infections; HIV-1; Humans; Middle Aged; Tablets; Tenofovir | 2020 |
Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Bone Density; Breast Feeding; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lopinavir; Postpartum Period; Ritonavir; Tenofovir; Young Adult | 2021 |
Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System; Cyclopropanes; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Pyridones; Tenofovir; Treatment Outcome; Triazoles | 2021 |
Successful integration of HIV pre-exposure prophylaxis into a community-based HIV prevention program for female sex workers in Kolkata, India.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; India; Medication Adherence; Pre-Exposure Prophylaxis; Sex Workers | 2021 |
Kidney injury biomarkers during exposure to tenofovir-based preexposure prophylaxis.
Topics: Adult; Anti-HIV Agents; Biomarkers; Emtricitabine; HIV Infections; Humans; Kidney; Pre-Exposure Prophylaxis; Tenofovir | 2021 |
Tenofovir disoproxil fumarate and emtricitabine maintenance strategy in virologically controlled adults with low HIV-1 DNA: 48 week results from a randomized, open-label, non-inferiority trial.
Topics: Adenine; Adult; Anti-HIV Agents; DNA; Emtricitabine; HIV Infections; HIV-1; Humans; Tenofovir; Treatment Outcome; Viral Load | 2021 |
A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants.
Topics: Adenine; Alanine; Anti-HIV Agents; Emtricitabine; Healthy Volunteers; HIV Infections; HIV-1; Humans; Male; Tenofovir | 2021 |
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; Female; Gestational Age; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Oxazines; Piperazines; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Pyridones; Tenofovir; Ultrasonography, Prenatal | 2021 |
Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen.
Topics: Anti-HIV Agents; Drug Combinations; Emtricitabine; HIV Infections; Humans; Integrases; Pharmaceutical Preparations; Viremia | 2021 |
Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants.
Topics: Alanine; Amides; Anti-HIV Agents; Drug Combinations; Drug Resistance; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; Retrospective Studies; Tenofovir | 2021 |
Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes.
Topics: Adult; Anti-HIV Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Emtricitabine; Female; HIV Infections; Humans; Male; Retrospective Studies; South Africa; Weight Gain | 2021 |
Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial.
Topics: Anti-HIV Agents; Bayes Theorem; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Tenofovir | 2021 |
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Adenine; Adult; Aged; Alanine; Anti-HIV Agents; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Pre-Exposure Prophylaxis; Tenofovir; Treatment Outcome; Young Adult | 2021 |
Estimated pill intake with on-demand PrEP with oral TDF/FTC using TFV-DP concentration in dried blood spots in the ANRS IPERGAY trial.
Topics: Adenine; Adult; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Organophosphates; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Tenofovir | 2021 |
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study.
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Amides; Anti-HIV Agents; Black or African American; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Seropositivity; HIV-1; Humans; Male; Middle Aged; Piperazines; Pyridones; RNA; Tenofovir; United States; Viral Load | 2021 |
Detection of new HIV infections in a multicentre HIV antiretroviral pre-exposure prophylaxis trial.
Topics: Anti-HIV Agents; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2017 |
Insulin-Like Growth Factor Is Associated with Changes in Body Composition with Antiretroviral Therapy Initiation.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Body Composition; Cyclopropanes; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Insulin-Like Growth Factor I; Lamivudine; Male; Prospective Studies; Tenofovir; Zidovudine | 2017 |
Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Bone Density; Bone Diseases; Emtricitabine; Female; Follow-Up Studies; HIV Infections; Homosexuality, Male; Humans; Male; Patient Compliance; Pre-Exposure Prophylaxis; Tenofovir | 2017 |
Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Rilpivirine; Tenofovir; Treatment Outcome; Viral Load | 2017 |
Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI.
Topics: Adult; Antiretroviral Therapy, Highly Active; Cobicistat; Drug Combinations; Drug Substitution; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Patient Reported Outcome Measures; Quinolones; Tablets; Tenofovir; Time Factors; Treatment Outcome | 2017 |
Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome | 2017 |
Efficacy of oral pre-exposure prophylaxis (PrEP) for HIV among women with abnormal vaginal microbiota: a post-hoc analysis of the randomised, placebo-controlled Partners PrEP Study.
Topics: Adult; Anti-HIV Agents; Dysbiosis; Emtricitabine; Female; Gardnerella vaginalis; HIV Infections; HIV Seropositivity; HIV-1; Humans; Kenya; Microbiota; Pre-Exposure Prophylaxis; Prospective Studies; Sexual Partners; Tenofovir; Uganda; Vagina; Vaginosis, Bacterial | 2017 |
High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women.
Topics: Administration, Oral; Administration, Rectal; Adolescent; Adult; Anti-HIV Agents; Cross-Over Studies; Emtricitabine; Female; Gels; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Tenofovir; Transgender Persons; Young Adult | 2017 |
Combination antiretroviral therapy improves cognitive performance and functional connectivity in treatment-naïve HIV-infected individuals.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Brain; Cognition; Diffusion Tensor Imaging; Emtricitabine; HIV Infections; Humans; Male; Tenofovir | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Internationality; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Prognosis; Pyridones; Risk Assessment; Survival Rate; Tenofovir; Treatment Outcome; Young Adult | 2017 |
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiori
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Double-Blind Method; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Oxazines; Piperazines; Prognosis; Pyridones; Risk Assessment; Survival Rate; Tenofovir; Treatment Outcome; Young Adult | 2017 |
Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128).
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HIV Infections; HIV-1; Humans; Microbial Sensitivity Tests; Mutation; Quinolones; Sequence Analysis, DNA; Tenofovir; Time Factors; Treatment Failure; Treatment Outcome; Viral Load | 2017 |
Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Body Mass Index; Body Weight; Cyclopropanes; Dideoxynucleosides; Drug Substitution; Drug Therapy, Combination; Elasticity Imaging Techniques; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Raltegravir Potassium; Tenofovir; Triglycerides; Waist-Hip Ratio | 2017 |
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Biological Availability; Coinfection; Double-Blind Method; Emtricitabine; Female; Hepatitis B; Hepatitis C; HIV Infections; HIV-1; Humans; Male; Quality of Life; Raltegravir Potassium; RNA, Viral; Tenofovir; Viral Load | 2017 |
Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Drug Administration Schedule; Emtricitabine; Feasibility Studies; Female; HIV Infections; Humans; Medication Adherence; Pre-Exposure Prophylaxis; South Africa; Tenofovir; Treatment Outcome; Young Adult | 2018 |
Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppr
Topics: Adult; Cobicistat; Darunavir; Drug Administration Schedule; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Tenofovir; Treatment Outcome; Viral Load | 2018 |
Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppressi
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Dideoxynucleosides; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Medication Therapy Management; Middle Aged; Ritonavir; RNA, Viral; Tenofovir; Viral Load | 2017 |
Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Cross-Over Studies; Directly Observed Therapy; Dried Blood Spot Testing; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphates; Patient Compliance; Pre-Exposure Prophylaxis; Prospective Studies; Sexual and Gender Minorities; Young Adult | 2018 |
Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis.
Topics: Adult; Anti-HIV Agents; Cobicistat; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Medication Adherence; Post-Exposure Prophylaxis; Prospective Studies; Quinolones; Reverse Transcriptase Inhibitors; Ritonavir; Tablets; Tenofovir | 2017 |
HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study.
Topics: Adult; Aged; Anti-HIV Agents; Cobicistat; Darunavir; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Integrase Inhibitors; Male; Middle Aged; Protease Inhibitors; Quinolones; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load | 2017 |
TDF and quantitative ultrasound bone quality in African patients on second line ART, ANRS 12169 2LADY sub-study.
Topics: Adult; Antiretroviral Therapy, Highly Active; Bone and Bones; Bone Demineralization, Pathologic; Bone Density; Burkina Faso; Cameroon; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Osteoporosis; Senegal; Tenofovir | 2017 |
Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Emtricitabine; Female; HIV Infections; HIV Seropositivity; Humans; Incidence; Male; Mass Screening; Middle Aged; Research Design; South Africa; Tenofovir; Treatment Outcome; Young Adult | 2018 |
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.
Topics: Adult; Aged; Anti-HIV Agents; Bone Density; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Treatment Outcome; Viral Load | 2018 |
Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.
Topics: Adenine; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Cobicistat; Drug Combinations; Drug Substitution; Emtricitabine; HIV Infections; HIV-1; Humans; Kidney; Quinolones; RNA, Viral; Tenofovir; Treatment Outcome | 2018 |
Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine.
Topics: Absorptiometry, Photon; Adiposity; Administration, Oral; Adult; Anti-HIV Agents; Body Mass Index; Body Weight; Double-Blind Method; Emtricitabine; Female; HIV Infections; Humans; Lipid Metabolism; Lipids; Male; Pre-Exposure Prophylaxis; Tenofovir; Transgender Persons; Young Adult | 2018 |
Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Administration Schedule; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir; Transgender Persons; Young Adult | 2018 |
Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
Topics: Administration, Oral; Adult; Brazil; Emtricitabine; Feasibility Studies; Female; HIV Infections; Homosexuality, Male; Humans; Incidence; Male; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Risk-Taking; Sexually Transmitted Diseases, Viral; Tenofovir; Transgender Persons; Young Adult | 2018 |
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial.
Topics: Adenine; Adult; Aged; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2018 |
Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Integrase Inhibitors; Protease Inhibitors; Quinolones; RNA, Viral; Tenofovir | 2018 |
First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2).
Topics: Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-2; Humans; Integrase Inhibitors; Male; Middle Aged; Raltegravir Potassium; RNA, Viral; Tenofovir; Viral Load | 2018 |
Virological and immunological responses to raltegravir and dolutegravir in the gut-associated lymphoid tissue of HIV-infected men and women.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Colon, Transverse; DNA, Viral; Emtricitabine; Female; Gene Expression; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Ileum; Immunity, Innate; Lymphoid Tissue; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Raltegravir Potassium; Receptors, Antigen, T-Cell, gamma-delta; Rectum; RNA, Viral; Tenofovir; Treatment Outcome | 2018 |
Pre-exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Kidney Tubular Dysfunction in HIV-Uninfected Individuals.
Topics: Adult; Albuminuria; Alpha-Globulins; Anti-HIV Agents; Biomarkers; Cross-Sectional Studies; Emtricitabine; Female; Glomerular Filtration Rate; HIV; HIV Infections; Humans; Kidney Diseases; Kidney Function Tests; Male; Pre-Exposure Prophylaxis; Proteinuria; Tenofovir; Transgender Persons; Urine; Young Adult | 2018 |
Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial.
Topics: Adenine; Adult; Anti-HIV Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Phosphorous Acids; Placebos; Raltegravir Potassium; RNA, Viral | 2018 |
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phas
Topics: Adult; Aged; Amides; Anti-HIV Agents; Dideoxynucleosides; Double-Blind Method; Drug Substitution; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Sustained Virologic Response; Tenofovir; Viral Load; Young Adult | 2018 |
Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, ph
Topics: Adenine; Adult; Aged; Alanine; Amides; Anti-Retroviral Agents; Drug Substitution; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Middle Aged; Piperazines; Protease Inhibitors; Pyridones; Sustained Virologic Response; Tenofovir; Viral Load; Young Adult | 2018 |
Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir,
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Amides; Anti-HIV Agents; Cohort Studies; Emtricitabine; Europe; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Piperazines; Pyridones; Tenofovir; United States; Young Adult | 2018 |
Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Black or African American; Bone and Bones; Bone Density; Cohort Studies; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Parathyroid Hormone; Pre-Exposure Prophylaxis; Tenofovir; Vitamin D; Vitamin D Deficiency; White People; Young Adult | 2018 |
Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
Topics: Administration, Intravaginal; Adult; Anti-HIV Agents; Contraceptive Devices, Female; Cross-Over Studies; Drug Compounding; Drug Delivery Systems; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Maraviroc; Patient Satisfaction; Pre-Exposure Prophylaxis; Tenofovir; Young Adult | 2018 |
Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cognition; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Interleukin-6; Lamivudine; Male; Memory, Short-Term; Middle Aged; Neuropsychological Tests; Prospective Studies; Ritonavir; Tenofovir | 2019 |
Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Half-Life; HIV Infections; HIV-1; Humans; Male; Middle Aged; RNA, Viral; Tenofovir; Treatment Outcome; Triterpenes | 2018 |
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferior
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; RNA, Viral; Tenofovir; Viral Load | 2019 |
Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40).
Topics: Adenine; Adult; Alanine; Anti-Retroviral Agents; Cobicistat; Emtricitabine; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Quinolones; RNA, Viral; Semen; Semen Analysis; Tenofovir | 2019 |
No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305.
Topics: Adolescent; Adult; Aged; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Quality of Life; Tenofovir; United States | 2018 |
Randomized clinical trial on efficacy of fixed-dose efavirenz/tenofovir/emtricitabine on alternate days versus continuous treatment.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2019 |
Factors Associated With Sex-Related Pre-exposure Prophylaxis Adherence Among Men Who Have Sex With Men in New York City in HPTN 067.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; New York City; Phosphorous Acids; Pre-Exposure Prophylaxis | 2019 |
Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-infer
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome | 2019 |
Pharmacokinetics of tenofovir monoester and association with intracellular tenofovir diphosphate following single-dose tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Anti-HIV Agents; Blood Chemical Analysis; Cross-Over Studies; Emtricitabine; Female; HIV Infections; Humans; Male; Organophosphates; Phosphorous Acids | 2019 |
Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus-1: An Integrated Safety Analysis.
Topics: Adult; Anti-HIV Agents; Emtricitabine; HIV Infections; HIV-1; Humans; Pyridones; Tenofovir; Triazoles | 2020 |
Once-daily Doravirine in Human Immunodeficiency Virus Type 1-Infected, Antiretroviral-naive Adults: An Integrated Efficacy Analysis.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Emtricitabine; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Treatment Outcome; Triazoles | 2020 |
Changes in Bone Mass After Discontinuation of Preexposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113.
Topics: Adolescent; Adult; Anti-HIV Agents; Bone Density; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Tenofovir; Young Adult | 2020 |
Baseline Characteristics Explain Differences in Effectiveness of Randomization to Daily Oral TDF/FTC PrEP Between Transgender Women and Cisgender Men Who Have Sex With Men in the iPrEx Trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Emtricitabine; Female; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Sex Factors; Tenofovir; Transgender Persons; Treatment Outcome | 2019 |
NZPrEP Demonstration Project: protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) to determine feasibility, acceptability, adverse and behavioural effects of PrEP provision to gay and bisexual men in publicly funded sexual
Topics: Emtricitabine; Feasibility Studies; HIV Infections; Homosexuality, Male; Humans; Logistic Models; Male; New Zealand; Pre-Exposure Prophylaxis; Safe Sex; Sexual and Gender Minorities; Sexual Behavior; Tenofovir | 2019 |
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/
Topics: Adenine; Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Drug Substitution; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Protease Inhibitors; Sustained Virologic Response; Tablets; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Urine Tenofovir Concentrations Correlate With Plasma and Relate to Tenofovir Disoproxil Fumarate Adherence: A Randomized, Directly Observed Pharmacokinetic Trial (TARGET Study).
Topics: Adult; Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Male; Pharmaceutical Preparations; Plasma; Pre-Exposure Prophylaxis; Tenofovir | 2020 |
Short- and Long-Term Pharmacologic Measures of HIV Pre-exposure Prophylaxis Use Among High-Risk Men Who Have Sex With Men in HPTN 067/ADAPT.
Topics: Adult; Emtricitabine; Hair; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir | 2019 |
Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Oxazines; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2013 |
Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Deoxycytidine; Drug Administration Schedule; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Medication Adherence; Middle Aged; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Ritonavir; Surveys and Questionnaires; Tenofovir; Viral Load | 2013 |
Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Thiazoles; Treatment Outcome; Viral Load | 2013 |
Abacavir/lamivudine versus tenofovir/emtricitabine with atazanavir/ritonavir for treatment-naive Japanese patients with HIV-1 infection: a randomized multicenter trial.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Asian People; Atazanavir Sulfate; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; Tenofovir; Treatment Outcome | 2013 |
Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Interactions; Emtricitabine; Female; Healthy Volunteers; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nitriles; Organophosphonates; Pyrazoles; Tenofovir; Young Adult; Zidovudine | 2013 |
Intentions to use preexposure prophylaxis among current phase 2B preventive HIV-1 vaccine efficacy trial participants.
Topics: Adenine; Adolescent; Adult; AIDS Vaccines; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Heterosexuality; HIV Infections; Homosexuality, Male; Humans; Intention; Male; Middle Aged; Organophosphonates; Research Design; Surveys and Questionnaires; Tenofovir; Young Adult | 2013 |
Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cote d'Ivoire; Deoxycytidine; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Female; Gastrointestinal Diseases; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Zidovudine | 2013 |
Variability of raltegravir plasma levels in the clinical setting.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Tenofovir | 2013 |
96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Bone and Bones; Bone Density; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney; Lamivudine; Male; Organophosphonates; Tenofovir; Time Factors; Treatment Outcome | 2013 |
Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Kidney; Kidney Function Tests; Lopinavir; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Sulfonamides; Tenofovir; Viral Load | 2013 |
Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Creatine Kinase; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Organophosphonates; Prospective Studies; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Tenofovir | 2014 |
Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa.
Topics: Adenine; Adult; Africa, Eastern; Anti-HIV Agents; Cohort Studies; Deoxycytidine; Emtricitabine; Family Characteristics; Female; HIV Infections; HIV Seropositivity; Humans; Male; Medication Adherence; Multivariate Analysis; Organophosphonates; Regression Analysis; Tenofovir | 2013 |
Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Organophosphonates; Patient Compliance; Tenofovir; Uganda | 2013 |
Participant experiences and facilitators and barriers to pill use among men who have sex with men in the iPrEx pre-exposure prophylaxis trial in San Francisco.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiviral Agents; Deoxycytidine; Double-Blind Method; Emtricitabine; Focus Groups; Health Knowledge, Attitudes, Practice; HIV Infections; HIV-1; Homosexuality, Male; Humans; Interviews as Topic; Male; Medication Adherence; Middle Aged; Organophosphonates; Qualitative Research; Risk Factors; San Francisco; Tenofovir; Young Adult | 2013 |
Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection.
Topics: Adenine; Adult; Anti-HIV Agents; Cross-Over Studies; Deoxycytidine; Drug Combinations; Emtricitabine; Fasting; Female; Food-Drug Interactions; HIV Infections; Humans; Male; Middle Aged; Nitriles; Organophosphonates; Pyrimidines; Rilpivirine; Tablets; Tenofovir; Young Adult | 2014 |
Dynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lymphocyte Activation; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Tenofovir; Young Adult | 2013 |
Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial.
Topics: Adenine; Adult; Anti-Retroviral Agents; Chemoprevention; Deoxycytidine; Emtricitabine; Female; Heterosexuality; HIV Infections; HIV-1; Humans; Incidence; Kenya; Male; Organophosphonates; Placebos; Tenofovir; Treatment Outcome; Uganda | 2013 |
Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine.
Topics: Adenine; Adult; Antiviral Agents; Creatinine; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Kidney Diseases; Lopinavir; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome | 2014 |
Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Chemoprevention; Creatinine; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Kidney; Kidney Function Tests; Male; Metabolic Clearance Rate; Middle Aged; Organophosphonates; Phosphorus; Placebos; Tenofovir; Young Adult | 2014 |
Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infection.
Topics: Absorptiometry, Photon; Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Body Composition; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lopinavir; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Tomography, X-Ray Computed; Young Adult | 2014 |
Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE).
Topics: Adenine; Adult; Africa South of the Sahara; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood Pressure; Body Mass Index; Cardiovascular Diseases; CD4-Positive T-Lymphocytes; Cholesterol, HDL; Cholesterol, LDL; Deoxycytidine; Emtricitabine; Endpoint Determination; Female; HIV Infections; HIV-1; Humans; Linear Models; Logistic Models; Lopinavir; Multivariate Analysis; Nevirapine; Organophosphonates; Prospective Studies; Risk Factors; Ritonavir; RNA, Viral; Tenofovir; Triglycerides | 2014 |
HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Condoms; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV Seropositivity; Homosexuality, Male; Humans; Male; Phosphorous Acids; Sexual Partners; Sexually Transmitted Diseases; South Africa; South America; Thailand; Transgender Persons; United States; Young Adult | 2014 |
Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana.
Topics: Absorptiometry, Photon; Adolescent; Adult; Anti-HIV Agents; Bone Density; Botswana; Communicable Disease Control; Emtricitabine; Female; Forearm; Hip; HIV Infections; Humans; Longitudinal Studies; Male; Pre-Exposure Prophylaxis; Spine; Tenofovir; Young Adult | 2014 |
Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiviral Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Organophosphonates; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; RNA, Viral; Tenofovir; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2014 |
HLA alleles association with changes in bone mineral density in HIV-1-infected adults changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
Topics: Adenine; Adult; Alleles; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; HLA-DQ Antigens; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir | 2014 |
Normal laboratory reference intervals among healthy adults screened for a HIV pre-exposure prophylaxis clinical trial in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Botswana; Deoxycytidine; Emtricitabine; Female; Hematologic Tests; HIV Infections; Humans; Male; Organophosphonates; Reference Values; Tenofovir; Young Adult | 2014 |
Hip structural parameters over 96 weeks in HIV-infected adults switching treatment to tenofovir-emtricitabine or abacavir-lamivudine.
Topics: Adenine; Anti-HIV Agents; Bone Density; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Substitution; Emtricitabine; Female; Hip Joint; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Radiography; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2014 |
Combination antiretroviral treatment for women previously treated only in pregnancy: week 24 results of AIDS clinical trials group protocol a5227.
Topics: Adenine; Adult; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Organophosphonates; Pregnancy; Prospective Studies; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2014 |
HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Cohort Studies; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Seropositivity; Humans; Male; Medication Adherence; Organophosphonates; Predictive Value of Tests; Proportional Hazards Models; Tenofovir; Young Adult | 2014 |
A 48-week study of fat molecular alterations in HIV naive patients starting tenofovir/emtricitabine with lopinavir/ritonavir or efavirenz.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Gene Expression Regulation; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Organophosphonates; Ritonavir; Subcutaneous Fat; Tenofovir; Transcriptome | 2014 |
Successful discontinuation of the placebo arm and provision of an effective HIV prevention product after a positive interim efficacy result: the partners PrEP study experience.
Topics: Adenine; Administration, Oral; Africa, Eastern; Anti-HIV Agents; Clinical Protocols; Deoxycytidine; Emtricitabine; Female; Heterosexuality; HIV Infections; HIV-1; Humans; Incidence; Information Dissemination; Male; Phosphorous Acids; Placebos; Sexual Partners; Treatment Outcome | 2014 |
Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Deoxycytidine; Drug Carriers; Emtricitabine; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome; Viral Load | 2014 |
Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results o
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Protease Inhibitors; Quinolones; Ritonavir; Tenofovir; Thiazoles; Viral Load | 2014 |
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week r
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Quinolones; Reverse Transcriptase Inhibitors; Tenofovir; Thiazoles; Viral Load | 2014 |
Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Incidence; Male; Middle Aged; Organophosphonates; Placebos; Pre-Exposure Prophylaxis; Prevalence; Syphilis; Tenofovir; Transgender Persons; Treatment Outcome; Young Adult | 2014 |
Predictors of suboptimal CD4 response among women achieving virologic suppression in a randomized antiretroviral treatment trial, Africa.
Topics: Adenine; Adult; Africa; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lopinavir; Nevirapine; Organophosphonates; Ritonavir; Tenofovir; Treatment Outcome | 2014 |
Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
Topics: Adenine; Administration, Oral; Adult; Anti-Retroviral Agents; Antiviral Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Herpes Genitalis; Herpesvirus 2, Human; Heterosexuality; HIV Infections; HIV Seronegativity; HIV-1; Humans; Incidence; Male; Medication Adherence; Organophosphonates; RNA, Viral; Tenofovir | 2014 |
First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2014 |
Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cholesterol, HDL; Cholesterol, LDL; Darunavir; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; Tenofovir; Treatment Outcome | 2014 |
Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine.
Topics: Adenine; Adult; Albuminuria; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Linear Models; Male; Organophosphonates; Proteinuria; Tenofovir | 2014 |
FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Logistic Models; Male; Medication Adherence; Multivariate Analysis; Organophosphonates; Risk Factors; Tenofovir; Young Adult | 2014 |
The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health.
Topics: Adenine; Adult; Bone Density; Darunavir; Deoxycytidine; Emtricitabine; HIV Infections; HIV-1; Humans; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Sulfonamides; Tenofovir | 2014 |
Factors Associated with Adherence and Concordance Between Measurement Strategies in an HIV Daily Oral Tenofovir/Emtricitibine as Pre-exposure Prophylaxis (Prep) Clinical Trial, Botswana, 2007-2010.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Botswana; Emtricitabine; Female; HIV Infections; Humans; Logistic Models; Male; Medication Adherence; Multivariate Analysis; Pre-Exposure Prophylaxis; Self Report; Surveys and Questionnaires; Tenofovir | 2015 |
Pre-exposure prophylaxis does not affect the fertility of HIV-1-uninfected men.
Topics: Adenine; Adult; Anti-Retroviral Agents; Chemoprevention; Deoxycytidine; Emtricitabine; Female; Fertility; HIV Infections; Humans; Male; Organophosphonates; Placebos; Pre-Exposure Prophylaxis; Pregnancy; Tenofovir | 2014 |
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.
Topics: Adenine; Adult; Atazanavir Sulfate; Darunavir; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; RNA, Viral; Sulfonamides; Tenofovir; Therapeutic Equivalency; Viral Load | 2014 |
Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Kenya; Male; Organophosphonates; Placebos; Pre-Exposure Prophylaxis; Tenofovir; Treatment Outcome; Uganda | 2014 |
Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cobicistat; Cyclopropanes; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Microbial Sensitivity Tests; Mutation; Quinolones; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2015 |
Pre-antiretroviral therapy serum selenium concentrations predict WHO stages 3, 4 or death but not virologic failure post-antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Body Mass Index; C-Reactive Protein; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Didanosine; Disease Progression; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Logistic Models; Male; Multivariate Analysis; Oligopeptides; Prospective Studies; Pyridines; Risk Factors; Selenium; World Health Organization; Zidovudine | 2014 |
Understanding Adherence to Daily and Intermittent Regimens of Oral HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men in Kenya.
Topics: Administration, Oral; Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Kenya; Male; Medication Adherence; Middle Aged; Outcome Assessment, Health Care; Pre-Exposure Prophylaxis; Socioeconomic Factors; Tenofovir | 2015 |
Sino-implant (II)® continuation and effect of concomitant tenofovir disoproxil fumarate-emtricitabine use on plasma levonorgestrel concentrations among women in Bondo, Kenya.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Contraceptive Agents, Female; Deoxycytidine; Drug Combinations; Drug Implants; Emtricitabine; Female; HIV Infections; Humans; Kenya; Levonorgestrel; Longitudinal Studies; Organophosphonates; Polypharmacy; Prospective Studies; Tenofovir; Young Adult | 2015 |
Switching from zidovudine/lamivudine to tenofovir/emtricitabine improves fat distribution as measured by fat mass ratio.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Fat Distribution; Drug Combinations; Drug Substitution; Emtricitabine; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Regression Analysis; Tenofovir; Zidovudine | 2015 |
Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; High-Throughput Nucleotide Sequencing; HIV Infections; HIV-1; Humans; Organophosphonates; Plasma; Pre-Exposure Prophylaxis; RNA, Viral; Tenofovir | 2015 |
Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Kidney Function Tests; Kidney Glomerulus; Male; Medication Adherence; Middle Aged; Organophosphonates; Tenofovir; Young Adult | 2015 |
Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-HIV Agents; Aspartate Aminotransferases; Black People; Chemical and Drug Induced Liver Injury; Creatinine; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Kidney Diseases; Organophosphonates; Phosphorus; Pre-Exposure Prophylaxis; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult | 2014 |
Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis.
Topics: Adenine; Anti-HIV Agents; Anti-Retroviral Agents; Deoxycytidine; Double-Blind Method; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV Seropositivity; HIV-1; Humans; Organophosphonates; Risk; Tenofovir | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the Sahara; Anti-Retroviral Agents; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Medication Adherence; Middle Aged; Organophosphonates; Pre-Exposure Prophylaxis; Surveys and Questionnaires; Tenofovir; Young Adult | 2015 |
A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individuals.
Topics: Adult; Alkynes; Benzoxazines; Cholesterol; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Hypercholesterolemia; Lamivudine; Male; Middle Aged; Tenofovir | 2015 |
Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial.
Topics: Adult; Anti-HIV Agents; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Patient Outcome Assessment; Patient Satisfaction; Rilpivirine; Tenofovir | 2015 |
Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV-coinfected patients from Côte d'Ivoire.
Topics: Adult; Alanine Transaminase; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aspartate Aminotransferases; Coinfection; Cote d'Ivoire; DNA, Viral; Drug Resistance, Viral; Emtricitabine; Female; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; HIV-2; Humans; Lamivudine; Male; Prospective Studies; Tenofovir; Viral Load | 2015 |
The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial.
Topics: Adult; Anti-HIV Agents; Cross-Over Studies; Double-Blind Method; Emtricitabine; Female; HIV Infections; Humans; Lipids; Male; Middle Aged; Placebos; Tenofovir | 2015 |
Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Intention to Treat Analysis; Longitudinal Studies; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2015 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; Headache; HIV Infections; Humans; Kidney; Male; Nausea; Organophosphonates; Quinolones; Respiration Disorders; Sleep Initiation and Maintenance Disorders; Tenofovir; Thiazoles; Treatment Outcome; Viral Load | 2015 |
Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Absorptiometry, Photon; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Bone Density; Chemoprevention; Cytoplasm; Double-Blind Method; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Placebos; Plasma; Tenofovir; Young Adult | 2015 |
Sexual Relationships Outside Primary Partnerships and Abstinence Are Associated With Lower Adherence and Adherence Gaps: Data From the Partners PrEP Ancillary Adherence Study.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Organophosphonates; Pre-Exposure Prophylaxis; Sexual Abstinence; Sexual Partners; Tenofovir; Uganda; Young Adult | 2015 |
Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bone Density; Darunavir; Drug Therapy, Combination; Emtricitabine; Female; HIV; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Male; Middle Aged; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load; Young Adult | 2015 |
Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus Continuation of Non-Nucleoside Reverse Tra
Topics: Adult; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Patient Outcome Assessment; Quality of Life; Quinolones; Tenofovir | 2015 |
[In Process Citation].
Topics: Age Factors; Aged; Comorbidity; Cross-Sectional Studies; Darunavir; Drug Interactions; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Middle Aged; Raltegravir Potassium; Tenofovir | 2015 |
Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a random
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Intention to Treat Analysis; Lamivudine; Lopinavir; Maintenance Chemotherapy; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Viral Load | 2015 |
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Substitution; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Viral Load; Zidovudine | 2015 |
Depression and Oral FTC/TDF Pre-exposure Prophylaxis (PrEP) Among Men and Transgender Women Who Have Sex With Men (MSM/TGW).
Topics: Adolescent; Adult; Anti-HIV Agents; Cross-Sectional Studies; Depression; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Longitudinal Studies; Male; Middle Aged; Pre-Exposure Prophylaxis; Sexual Behavior; Tenofovir; Transgender Persons | 2016 |
Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; RNA, Viral; Tenofovir; Thiazoles; Viral Load | 2015 |
Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Middle Aged; Organophosphates; Rilpivirine; Tenofovir; Young Adult | 2015 |
Emtricitabine seminal plasma and blood plasma population pharmacokinetics in HIV-infected men in the EVARIST ANRS-EP 49 study.
Topics: Adult; Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Male; Middle Aged; Plasma; Semen | 2015 |
Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease In
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Combinations; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; Female; HIV Infections; Humans; Logistic Models; Male; Patient Outcome Assessment; Patient Satisfaction; Protease Inhibitors; Ritonavir; Tenofovir | 2015 |
Efavirenz Capsule Sprinkle and Liquid Formulations With Didanosine and Emtricitabine in HIV-1-infected Infants and Children 3 Months to 6 Years of Age: Study AI266-922.
Topics: Alkynes; Benzoxazines; Child, Preschool; Cyclopropanes; Didanosine; Emtricitabine; Female; HIV Infections; Humans; Infant; Male; Prospective Studies | 2015 |
Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066).
Topics: Adult; Anti-HIV Agents; Benchmarking; Body Fluids; Drug Administration Schedule; Emtricitabine; Female; Healthy Volunteers; HIV Infections; Humans; Male; Patient Compliance; Pre-Exposure Prophylaxis; ROC Curve; Tablets; Tenofovir | 2016 |
Rapid Antiretroviral Therapy Initiation for Women in an HIV-1 Prevention Clinical Trial Experiencing Primary HIV-1 Infection during Pregnancy or Breastfeeding.
Topics: Adult; Africa, Eastern; Anti-HIV Agents; Breast Feeding; Early Medical Intervention; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Post-Exposure Prophylaxis; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Young Adult | 2015 |
Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Biomarkers; Bone Density; Bone Diseases, Metabolic; CD4 Lymphocyte Count; Comorbidity; Darunavir; Drug Therapy, Combination; Emtricitabine; Europe; Female; HIV Infections; Humans; Inflammation; Male; Middle Aged; Osteopetrosis; Raltegravir Potassium; Ritonavir; Tenofovir; Viral Load | 2015 |
HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
Topics: Adult; Anti-HIV Agents; Brazil; Clinical Trials, Phase III as Topic; Condoms; Delivery of Health Care, Integrated; Directive Counseling; Ecuador; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Peru; Pre-Exposure Prophylaxis; Sexual Partners; South Africa; Tenofovir; Thailand; Transgender Persons; United States | 2015 |
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.
Topics: Adult; Condoms; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Homosexuality, Male; Humans; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Risk Factors; Sexual Behavior; Sexually Transmitted Diseases; Tenofovir | 2015 |
Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.
Topics: Adult; Albuminuria; Bone Density; Cobicistat; Drug Substitution; Drug Therapy, Combination; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Male; Middle Aged; Proteinuria; Quinolones; Renal Insufficiency; Tenofovir | 2016 |
Regulatory T-Cell Activity But Not Conventional HIV-Specific T-Cell Responses Are Associated With Protection From HIV-1 Infection.
Topics: Adult; AIDS Vaccines; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Immunity, Cellular; Lymphocyte Activation; Male; Pre-Exposure Prophylaxis; Prospective Studies; T-Lymphocytes, Regulatory; Tenofovir | 2016 |
Associations between vitamin D metabolites, antiretroviral therapy and bone mineral density in people with HIV.
Topics: Adult; Anti-HIV Agents; Body Mass Index; Bone Density; Calcitriol; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Hip Joint; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Osteoporosis; Prospective Studies; Tenofovir; Vitamin D | 2016 |
Switching from a two-tablet regimen of tenofovir/emtricitabine and efavirenz to a one-tablet regimen may affect patients' perceptions and drug management.
Topics: Adult; Alkynes; Benzoxazines; Cohort Studies; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Emtricitabine; Female; Health Surveys; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Patient Satisfaction; Prospective Studies; Tablets; Tenofovir; Treatment Outcome | 2016 |
Brief Report: HIV-1 Evolution in Breakthrough Infections in a Human Trial of Oral Pre-exposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate.
Topics: Anti-HIV Agents; Botswana; CD4 Lymphocyte Count; Double-Blind Method; Emtricitabine; Evolution, Molecular; HIV Antibodies; HIV Infections; HIV-1; Humans; Pre-Exposure Prophylaxis; Tenofovir; Treatment Outcome; Viral Load | 2016 |
Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessation.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Emtricitabine; Family Characteristics; Female; High-Throughput Nucleotide Sequencing; HIV; HIV Infections; Humans; Male; Mutation, Missense; Placebos; Pre-Exposure Prophylaxis; RNA, Viral; Sequence Analysis, DNA; Tenofovir | 2016 |
Does Adherence Change When No One is Looking? Comparing Announced and Unannounced Tenofovir Levels in a PrEP Trial.
Topics: Adult; Anti-HIV Agents; Drug Monitoring; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Self Care; Sexual Partners; Tenofovir; Uganda | 2016 |
Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension.
Topics: Adult; Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir | 2016 |
Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results.
Topics: Adenine; Alanine; Albuminuria; Anti-HIV Agents; Bone Density; CD4 Lymphocyte Count; Cobicistat; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Proteinuria; Quinolones; RNA, Viral; Tenofovir | 2016 |
Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Cobicistat; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Tenofovir; Young Adult | 2016 |
A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine.
Topics: Adult; Anti-HIV Agents; Dose-Response Relationship, Drug; Emtricitabine; Female; Forecasting; HIV Infections; Humans; Male; New York; Pre-Exposure Prophylaxis; Tenofovir; Translational Research, Biomedical; Young Adult | 2016 |
Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial.
Topics: Adolescent; Adult; Contraceptive Agents, Female; Delayed-Action Preparations; Drug Interactions; Emtricitabine; Female; HIV Infections; Humans; Kenya; Medroxyprogesterone Acetate; Pre-Exposure Prophylaxis; Pregnancy; Pregnancy Tests; Tenofovir; Young Adult | 2016 |
Nucleoside-Sparing Regimens With Raltegravir and a Boosted Protease Inhibitor: An Unsettled Issue.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Raltegravir Potassium; Ritonavir; RNA, Viral; Surveys and Questionnaires; Tenofovir; Treatment Outcome | 2016 |
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, activ
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiviral Agents; Double-Blind Method; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Tenofovir | 2016 |
Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Coinfection; Drug Combinations; Drug Substitution; Emtricitabine; Female; Hepatitis B; HIV Infections; Humans; Male; Middle Aged; Quinolones; Tenofovir; Treatment Outcome | 2016 |
An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
Topics: Adult; Algorithms; Anti-HIV Agents; Cobicistat; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Oxazines; Patient Safety; Piperazines; Pyridones; Quinolones; Risk; Tenofovir | 2016 |
Differential CD4+ cell count increase and CD4+ : CD8+ ratio normalization with maraviroc compared with tenofovir.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-CD8 Ratio; Cyclohexanes; Darunavir; Double-Blind Method; Emtricitabine; Female; Flow Cytometry; HIV Infections; Humans; Male; Maraviroc; Placebos; Prospective Studies; Tenofovir; Treatment Outcome; Triazoles | 2016 |
Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Hospitals, Private; Humans; Male; Medication Adherence; Middle Aged; New South Wales; Pre-Exposure Prophylaxis; Public Health Practice; Research Design; Risk-Taking; Self Report; Tenofovir; Time Factors; Young Adult | 2016 |
Analysis of the Endogenous Deoxynucleoside Triphosphate Pool in HIV-Positive and -Negative Individuals Receiving Tenofovir-Emtricitabine.
Topics: Adult; Anti-HIV Agents; Case-Control Studies; Deoxyadenine Nucleotides; Deoxycytosine Nucleotides; Deoxyguanine Nucleotides; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Linear Models; Male; Tenofovir; Thymine Nucleotides | 2016 |
Population Pharmacokinetics of Tenofovir in HIV-1-Uninfected Members of Serodiscordant Couples and Effect of Dose Reporting Methods.
Topics: Adult; Anti-HIV Agents; Body Weight; Creatinine; Double-Blind Method; Electronic Health Records; Emtricitabine; Family Characteristics; Female; HIV Infections; HIV-1; Humans; Male; Medication Adherence; Models, Statistical; Monitoring, Physiologic; Pre-Exposure Prophylaxis; Sexual Partners; Tenofovir | 2016 |
Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Maintenance Chemotherapy; Male; Maraviroc; Middle Aged; Raltegravir Potassium; Tenofovir; Treatment Outcome; Triazoles; Viral Load; Young Adult | 2016 |
Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cobicistat; Double-Blind Method; Emtricitabine; Female; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; International Cooperation; Quinolones; Ritonavir; RNA, Viral; Tenofovir; Viral Load | 2016 |
Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Case-Control Studies; Dried Blood Spot Testing; Drug Administration Schedule; Emtricitabine; Female; Half-Life; HIV; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Prospective Studies; Tenofovir | 2016 |
Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Carotid Intima-Media Thickness; Darunavir; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Linear Models; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Oxidation-Reduction; Prospective Studies; Raltegravir Potassium; Ritonavir; RNA, Viral; Tenofovir | 2017 |
Treatment of HIV infection with a raltegravir-based regimen increases LDL levels, but improves HDL cholesterol efflux capacity.
Topics: Adult; Anti-HIV Agents; Biological Transport, Active; Cholesterol, HDL; Emtricitabine; Female; HIV Infections; Humans; Lipoproteins, LDL; Male; Middle Aged; Raltegravir Potassium; RNA, Viral; Tenofovir; Young Adult | 2017 |
Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.
Topics: Adenine; Adolescent; Alanine; Anti-HIV Agents; Area Under Curve; CD4 Lymphocyte Count; Child; Cobicistat; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lost to Follow-Up; Male; Quinolones; RNA, Viral; South Africa; Tablets; Tenofovir; Thailand; Uganda; United States; Viral Load | 2016 |
Topics: Absorptiometry, Photon; Adult; Air Pollutants; Alkynes; Alleles; Animals; Anthracenes; Anthraquinones; Anti-HIV Agents; Benzoxazines; Black or African American; Bone Density; Bone Density Conservation Agents; C-Reactive Protein; Calcium, Dietary; Capsid Proteins; Cardiomyopathy, Dilated; Cardiovascular Diseases; CD4 Lymphocyte Count; Cholesterol; Collagen Type I; Cyclopropanes; Darunavir; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Emtricitabine; Epitopes; Female; Femur Neck; Gene Expression Profiling; Genetic Predisposition to Disease; Hepatitis, Viral, Animal; Hip Joint; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunization; Inflammation Mediators; Lipoproteins, LDL; Lupus Erythematosus, Systemic; Male; Mice; Mice, Inbred BALB C; Nitrates; Osteocalcin; Oxidation-Reduction; Parathyroid Hormone; Parvovirus B19, Human; Peptides; Phenotype; Pilot Projects; Polymorphism, Single Nucleotide; Raltegravir Potassium; Ritonavir; RNA, Viral; Sodium Chloride; Tenofovir; Transcriptome; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms; Vaccines; Vascular Endothelial Growth Factor A; Vitamin D; Young Adult | 2016 |
Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-lin
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; CD4 Lymphocyte Count; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; International Cooperation; Lamivudine; Lopinavir; Male; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load | 2017 |
Efficacy and safety of tenofovir-containing antiretroviral therapy in women who acquired HIV while enrolled in tenofovir gel prophylaxis trials.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Emtricitabine; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Patient Safety; Pregnancy; Primary Prevention; RNA, Viral; South Africa; Tenofovir; Treatment Outcome; Vaginal Creams, Foams, and Jellies; Viral Load; Zidovudine | 2017 |
Markov Mixed Effects Modeling Using Electronic Adherence Monitoring Records Identifies Influential Covariates to HIV Preexposure Prophylaxis.
Topics: Adult; Anti-HIV Agents; Double-Blind Method; Drug Therapy, Combination; Electronic Health Records; Emtricitabine; Female; HIV Infections; Humans; Male; Markov Chains; Medication Adherence; Middle Aged; Models, Psychological; Sexual Behavior; Tenofovir; Young Adult | 2017 |
Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.
Topics: Adolescent; Anti-HIV Agents; Bone Density; Creatinine; Emtricitabine; Fibroblast Growth Factor-23; Glomerular Filtration Rate; HIV Infections; Homosexuality, Male; Humans; Kidney; Male; Parathyroid Hormone; Pre-Exposure Prophylaxis; Renal Insufficiency; Tenofovir; Young Adult | 2017 |
Concentrations of Pro-Inflammatory Cytokines Are Not Associated with Senescence Marker p16INK4a or Predictive of Intracellular Emtricitabine/Tenofovir Metabolite and Endogenous Nucleotide Exposures in Adults with HIV Infection.
Topics: Adult; Aged; Anti-HIV Agents; Biomarkers; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p16; Cytokines; Emtricitabine; Female; HIV Infections; Humans; Inflammation; Male; Middle Aged; Nucleotides; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Young Adult | 2016 |
Viral blips were infrequent in treatment-naive adults treated with rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF through 96 weeks.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Rilpivirine; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Viremia | 2017 |
Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cobicistat; Cohort Studies; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Maintenance Chemotherapy; Male; Middle Aged; Polymerase Chain Reaction; Quinolones; RNA, Viral; Tablets; Tenofovir; Viral Load; Viremia | 2017 |
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
Topics: Adenine; Adolescent; Adult; Alanine; Amides; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Oxazines; Piperazines; Pyridones; RNA, Viral; Tenofovir; Viral Load; Young Adult | 2017 |
Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-i
Topics: Adenine; Adult; Alanine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Middle Aged; Rilpivirine; Tenofovir | 2017 |
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Rilpivirine; Tenofovir | 2017 |
Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results.
Topics: Adenine; Alanine; Anti-HIV Agents; Bone Density; CD4 Lymphocyte Count; Cobicistat; Double-Blind Method; Emtricitabine; HIV Infections; Humans; Middle Aged; Quinolones; Tenofovir; Treatment Outcome; United States | 2017 |
Addition of single-dose tenofovir and emtricitabine to intrapartum nevirapine to reduce perinatal HIV transmission.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapine; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Tenofovir | 2008 |
Switch from zidovudine- to non-zidovudine-containing regimens is associated with modest haematological improvement and no obvious clinical benefit: a substudy of the ANRS 099 ALIZE trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Bacterial Infections; Benzoxazines; Blood Platelets; Cardiovascular Diseases; Cyclopropanes; Deoxycytidine; Didanosine; Emtricitabine; Female; Hemoglobins; HIV Infections; Humans; Leukocyte Count; Male; Middle Aged; Neutrophils; Pancytopenia; Platelet Count; Prevalence; Zidovudine | 2008 |
Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone.
Topics: Adenine; Adult; Anti-HIV Agents; Blood; Cohort Studies; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tenofovir; Treatment Outcome; Viral Load | 2008 |
Effectiveness and safety of generic fixed-dose combination of tenofovir/emtricitabine/efavirenz in HIV-1-infected patients in Western India.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Drugs, Generic; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Immunosuppression Therapy; India; Male; Middle Aged; Organophosphonates; Prevalence; Tenofovir; Treatment Outcome; Young Adult | 2008 |
[Two novel fixed formulations of nucleoside analogues (tenofovir-emtricitabine, and abacavir-lamivudine). Prospective, open study on clinical practice and therapeutic perspectives, in patients naïve and in subjects pre-treated with antiretrovirals].
Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |
Abacavir/3TC vs. tenofovir/FTC: interim results from ACTG 5202.
Topics: Adenine; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |
Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1.
Topics: Adenine; Adult; Anti-HIV Agents; Cambodia; Cote d'Ivoire; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; Genotype; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Nevirapine; Organophosphonates; Pregnancy; RNA, Viral; South Africa; Tenofovir; Viral Load | 2009 |
Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Patient Compliance; Tenofovir | 2009 |
A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Spain; Tenofovir; Treatment Failure; Treatment Outcome | 2009 |
Switch from a ZDV/3TC-based regimen to a completely once daily (QD) regimen of emtricitabine/tenofovir DF fixed dose combination plus a third QD agent (SONETT).
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Emtricitabine; Female; Hemoglobins; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Young Adult; Zidovudine | 2009 |
Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cardiovascular Diseases; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Double-Blind Method; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Pyrimidinones; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome | 2009 |
A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals.
Topics: Adenine; Adipose Tissue; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabine; Extremities; Female; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lipids; Male; Middle Aged; Organophosphonates; Tenofovir; Young Adult; Zidovudine | 2009 |
Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Aged; Anti-HIV Agents; Deoxycytidine; Dose-Response Relationship, Drug; Emtricitabine; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Organophosphonates; Pyrimidinones; Retrospective Studies; RNA, Viral; Stavudine; Tenofovir; Treatment Outcome; Young Adult | 2009 |
Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.
Topics: Adenine; Alkynes; Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Genome, Viral; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Mutation, Missense; Organophosphonates; Tenofovir; Treatment Failure; Zidovudine | 2009 |
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.
Topics: Adenine; Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Prognosis; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Safety; Tenofovir; Treatment Outcome; Viral Load | 2009 |
[Efficacy and safety of TAM-sparing antiretroviral regimens in naïve HIV-positive patients].
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Hyperinsulinism; Hyperlipidemias; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Prospective Studies; Tenofovir; Thymidine; Treatment Outcome; Young Adult | 2009 |
Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Female; HIV Infections; HLA-B Antigens; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load | 2009 |
Modified directly observed therapy to improve HIV treatment outcomes: little impact with potent, once-daily therapy in unselected antiretroviral-naïve patients.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Lopinavir; Medication Adherence; Organophosphonates; Pyrimidinones; Ritonavir; Self Administration; Stavudine; Tenofovir; Treatment Outcome | 2009 |
Intrapartum tenofovir and emtricitabine reduces low-concentration drug resistance selected by single-dose nevirapine for perinatal HIV prevention.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Infectious Disease Transmission, Vertical; Mutation; Nevirapine; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2009 |
Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.
Topics: Adenine; Adolescent; Adult; Analysis of Variance; Anti-HIV Agents; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; Fractures, Bone; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; RNA, Viral; Tenofovir; Therapeutic Equivalency; Time Factors; Treatment Failure; Viral Load; Young Adult | 2009 |
Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Cardiovascular Diseases; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2010 |
Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lipids; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2010 |
Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients.
Topics: Adenine; Adult; Anti-HIV Agents; Cholesterol, LDL; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Nucleosides; Organophosphonates; Tenofovir; Triglycerides | 2010 |
Viro-immunological dynamics in HIV-1-infected subjects receiving once-a-week emtricitabine to delay treatment change after failure: a pilot randomised trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation, Missense; Salvage Therapy; Treatment Failure; Viral Load | 2010 |
Long-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: a 72-week prospective multicenter study (TENOR-trial).
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Organophosphonates; Prospective Studies; Tenofovir; Treatment Outcome | 2009 |
Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
Topics: Adenine; Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Patient Compliance; Patient Preference; Puerto Rico; Quality of Life; Reverse Transcriptase Inhibitors; Severity of Illness Index; Tablets; Tenofovir; Treatment Outcome; United States; Young Adult | 2010 |
Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Atazanavir Sulfate; Carbamates; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Emtricitabine; Furans; Genetic Variation; HIV Infections; HIV-1; Humans; Middle Aged; Oligopeptides; Organophosphates; Organophosphonates; Pyridines; Ritonavir; RNA, Viral; Sequence Analysis, RNA; Sulfonamides; Tenofovir; Treatment Failure | 2010 |
The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Tenofovir; Treatment Outcome; Young Adult | 2010 |
Tenofovir/emtricitabine combination results in lower bone-mineral density.
Topics: Adenine; Anti-HIV Agents; Bone Density; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Organophosphonates; Tenofovir; Treatment Outcome | 2010 |
Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; beta 2-Microglobulin; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney; Lamivudine; Male; Middle Aged; Organophosphonates; Retinol-Binding Proteins; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2010 |
Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study.
Topics: Adenine; Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Gastrointestinal Diseases; HIV Infections; HIV-1; Humans; Irritable Bowel Syndrome; Lopinavir; Male; Medication Adherence; Middle Aged; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Pyrimidinones; Quality of Life; Ritonavir; Surveys and Questionnaires; Tenofovir; Young Adult | 2010 |
Short communication: Comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine + tenofovir DF in antiretroviral-naïve, HIV type 1-infected subjects: 96 week final results of the randomized t
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Lopinavir; Organophosphonates; Pyrimidinones; Ritonavir; Tenofovir | 2010 |
Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV.
Topics: Adenine; Administration, Oral; Adult; Anti-HIV Agents; Biological Availability; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; Humans; Male; Organophosphonates; Plasma; Quinolones; Tablets; Tenofovir | 2010 |
Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Nitriles; Organophosphonates; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Tenofovir; Treatment Outcome | 2010 |
Maternal and nenonatal tenofovir and emtricitabine to prevent vertical transmission of HIV-1: tolerance and resistance.
Topics: Adenine; Adult; Antiviral Agents; Cambodia; Cote d'Ivoire; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Genotype; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Organophosphonates; Pregnancy; RNA, Viral; South Africa; Tenofovir; Viral Load | 2010 |
Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study.
Topics: Absorptiometry, Photon; Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Bone and Bones; Bone Density; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Europe; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Young Adult | 2010 |
Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Deoxycytidine; DNA, Viral; Emtricitabine; Female; Hepatitis B, Chronic; HIV Infections; Humans; Male; Organophosphonates; Prospective Studies; Tenofovir; Thailand | 2010 |
Antiretroviral therapies in women after single-dose nevirapine exposure.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; CD4 Lymphocyte Count; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Kaplan-Meier Estimate; Linear Models; Lopinavir; Nevirapine; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Pyrimidinones; Ritonavir; Statistics, Nonparametric; Tenofovir; Treatment Failure; Young Adult | 2010 |
Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Infant, Newborn; Nevirapine; Organophosphonates; Pregnancy; Tenofovir; Treatment Outcome; Young Adult; Zidovudine | 2011 |
Four year follow-up of simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-infected patients (ALIZE ANRS 099 trial).
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Didanosine; Emtricitabine; Female; Follow-Up Studies; HIV Infections; Humans; Male; RNA, Viral; Treatment Outcome; Viral Load | 2011 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Follow-Up Studies; HIV; HIV Antibodies; HIV Infections; HIV Seropositivity; Homosexuality, Male; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Nausea; Organophosphonates; Patient Compliance; RNA, Viral; Tenofovir; Transsexualism; Young Adult | 2010 |
Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy.
Topics: Adenine; Adult; Alkynes; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Tenofovir; Treatment Failure; Viral Load | 2011 |
Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men.
Topics: Adenine; Antiviral Agents; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Tenofovir; Unsafe Sex | 2011 |
Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Genetic Association Studies; HIV Infections; HIV-1; Humans; Lopinavir; Male; Mutation; Organophosphonates; Polymorphism, Genetic; Pyrimidinones; Ritonavir; RNA, Viral; Sulfonamides; Tenofovir; Treatment Failure; Viral Load | 2011 |
Investigation of emtricitabine-associated skin pigmentation and safety in HIV-1-infected Japanese patients.
Topics: Adult; Aged; Analysis of Variance; Anti-HIV Agents; Deoxycytidine; Dermoscopy; Emtricitabine; Female; Hand; HIV Infections; Humans; Incidence; Japan; Lentigo; Male; Middle Aged; Pigmentation Disorders; Prospective Studies; Skin; Skin Pigmentation; Viral Load | 2011 |
Initial results reported on raltegravir once-daily dosing.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Integrase Inhibitors; Humans; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Tenofovir; Treatment Outcome | 2011 |
Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cobicistat; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Patient Compliance; Patient Selection; Quinolones; Tenofovir; Thiazoles; Treatment Outcome | 2011 |
Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz.
Topics: Adenine; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Drug Substitution; Drug Therapy, Combination; Emtricitabine; Female; Health Knowledge, Attitudes, Practice; HIV Infections; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Organophosphonates; Quality of Life; Tenofovir; Treatment Outcome; Young Adult; Zidovudine | 2011 |
Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study).
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Dyslipidemias; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lipids; Male; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Viral Load | 2011 |
Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Cardiovascular Diseases; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2011 |
Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG
Topics: Absorptiometry, Photon; Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Bone Density; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Fractures, Bone; HIV Infections; Humans; Intention to Treat Analysis; Lamivudine; Male; Middle Aged; Oligopeptides; Organophosphonates; Osteoporosis; Pyridines; Risk Factors; Ritonavir; Tenofovir; Viral Load | 2011 |
Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Cardiovascular Diseases; Cholesterol, LDL; Clinical Protocols; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Organophosphonates; Phospholipases A2; Reverse Transcriptase Inhibitors; Tenofovir | 2011 |
Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine.
Topics: Adenine; Adult; Aged; Antiviral Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Young Adult | 2011 |
Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; CD4 Lymphocyte Count; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; RNA, Viral; Tenofovir; Thiazoles; Treatment Outcome | 2011 |
Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients.
Topics: Adenine; Adult; Atazanavir Sulfate; Deoxycytidine; Drug Administration Schedule; Dyslipidemias; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Male; Oligopeptides; Organophosphonates; Pyridines; Saquinavir; Tenofovir; Treatment Outcome | 2011 |
Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Infant; Infectious Disease Transmission, Vertical; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Young Adult | 2011 |
Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Double-Blind Method; Emtricitabine; Female; HIV; HIV Infections; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Middle Aged; Organophosphonates; RNA, Viral; Tenofovir; Viral Load | 2011 |
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.
Topics: Absorptiometry, Photon; Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2011 |
Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Cardiovascular Diseases; Deoxycytidine; Dideoxynucleosides; E-Selectin; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Plasma; Tenofovir; Vascular Cell Adhesion Molecule-1 | 2011 |
A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Creatinine; Cyclopropanes; Cystatin C; Deoxycytidine; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; Tenofovir | 2012 |
Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Cohort Studies; Deoxycytidine; Emtricitabine; Female; Heterosexuality; HIV Infections; HIV Seronegativity; HIV Seropositivity; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Risk-Taking; Sexual Behavior; Tenofovir; Young Adult | 2011 |
Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine.
Topics: Adenine; Adipose Tissue; Adult; Biomarkers; Body Fat Distribution; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Extremities; HIV Infections; Humans; Lamivudine; Middle Aged; Organophosphonates; Predictive Value of Tests; Tenofovir | 2011 |
Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir | 2012 |
HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Incidence; Lopinavir; Malaria; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2012 |
Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cognition; Cognition Disorders; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Zidovudine | 2012 |
The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Organophosphonates; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2012 |
Presence of lamivudine or emtricitabine is associated with reduced emergence of nonnucleoside reverse transcriptase inhibitor mutations in an efavirenz-based intermittent antiretroviral treatment regimen.
Topics: Adult; Alkynes; Amino Acid Substitution; Anti-HIV Agents; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; Deoxycytidine; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Half-Life; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Mutation; Reverse Transcriptase Inhibitors; Viral Load | 2012 |
Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence.
Topics: Adenine; Adult; Anti-HIV Agents; Boston; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Patient Compliance; Post-Exposure Prophylaxis; Pyrrolidinones; Raltegravir Potassium; Tenofovir; Young Adult | 2012 |
What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples.
Topics: Adenine; Administration, Oral; Adult; Anti-HIV Agents; Attitude to Health; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV Seronegativity; HIV Seropositivity; Humans; Interpersonal Relations; Male; Medication Adherence; Middle Aged; Organophosphonates; Sexual Partners; Tenofovir; Uganda; Young Adult | 2012 |
Treatment outcomes of recommended first-line antiretroviral regimens in resource-limited clinics.
Topics: Adenine; Adult; Age Factors; Anti-HIV Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; Deoxycytidine; Developing Countries; Drug Costs; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2012 |
Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO trial.
Topics: Adenine; Adult; Anti-HIV Agents; Body Composition; Bone Density; Deoxycytidine; Dideoxynucleosides; DNA, Mitochondrial; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir | 2012 |
A comparison of measured and estimated glomerular filtration rate in successfully treated HIV-patients with preserved renal function.
Topics: Adenine; Adult; Anti-HIV Agents; Body Mass Index; Deoxycytidine; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Lamivudine; Linear Models; Male; Middle Aged; Netherlands; Organophosphonates; Pilot Projects; Research Design; Statistics, Nonparametric; Tenofovir; Treatment Outcome; Zidovudine | 2012 |
Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial.
Topics: Adenine; Adult; Alkaline Phosphatase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Bone and Bones; Bone Density; Creatinine; Cystatin C; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Kidney; Kidney Function Tests; Lamivudine; Male; Middle Aged; Organophosphonates; Osteocalcin; Tenofovir; Time Factors; Treatment Outcome | 2012 |
Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Homosexuality, Male; Humans; Kenya; Male; Middle Aged; Organophosphonates; Patient Compliance; Sex Workers; Tenofovir | 2012 |
Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
Topics: Absorptiometry, Photon; Adenine; Adult; Bone Density; Bone Remodeling; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2012 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Quinolones; Ritonavir; Tenofovir; Thiazoles | 2012 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cobicistat; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Quinolones; Tenofovir; Thiazoles | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Seropositivity; HIV-1; HIV-2; Humans; Kaplan-Meier Estimate; Male; Organophosphonates; Proportional Hazards Models; RNA, Viral; Sexual Behavior; Tenofovir; Viral Load; Young Adult | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Incidence; Kaplan-Meier Estimate; Medication Adherence; Organophosphonates; Risk-Taking; RNA, Viral; Sexual Behavior; Tenofovir; Treatment Failure; Viral Load; Young Adult | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; Heterosexuality; HIV Infections; HIV Seropositivity; HIV-1; Humans; Incidence; Male; Middle Aged; Organophosphonates; Pregnancy; RNA, Viral; Sexual Behavior; Tenofovir; Young Adult | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Tenofovir | 2012 |
Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.
Topics: Adenine; Adult; Aged; Alleles; Atazanavir Sulfate; Cytochrome P-450 CYP3A; Deoxycytidine; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Female; Genotype; HIV Infections; HIV Protease Inhibitors; Humans; Male; Medication Adherence; Middle Aged; Models, Biological; Nonlinear Dynamics; Oligopeptides; Organophosphonates; Pharmacogenetics; Pyridines; Ritonavir; Tenofovir; Young Adult | 2012 |
Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo).
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Immune Tolerance; Lopinavir; Male; Organophosphonates; Peptide Fragments; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2013 |
The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Europe; Female; Fetal Blood; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Third; Tenofovir; Viral Load; Young Adult | 2013 |
Raltegravir pharmacokinetics in treatment-naive patients is not influenced by race: results from the raltegravir early therapy in African-Americans living with HIV (REAL) study.
Topics: Adenine; Adult; Black or African American; Body Mass Index; CD4 Lymphocyte Count; Deoxycytidine; Drug Administration Schedule; Emtricitabine; Female; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; Humans; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Racial Groups; Raltegravir Potassium; Tenofovir; Viral Load; White People | 2013 |
Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; RNA, Viral; Tenofovir; Triazoles; Viral Load; Young Adult | 2013 |
Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.
Topics: Adenine; Adipose Tissue; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; DNA, Mitochondrial; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Mitochondria; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2013 |
Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB study.
Topics: Absorptiometry, Photon; Adenine; Adipose Tissue; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Treatment Outcome | 2013 |
Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Intention to Treat Analysis; Male; Middle Aged; Mutation; Nitriles; Organophosphonates; Pyrazoles; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Young Adult | 2013 |
A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Aspartate Aminotransferases; Atazanavir Sulfate; Bilirubin; Bone Density; Carbamates; Cobicistat; Confidence Intervals; Creatinine; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Quinolones; Ritonavir; RNA, Viral; Tenofovir; Thiazoles; Triglycerides | 2013 |
SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen.
Topics: Adenine; Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; Protease Inhibitors; Proteinuria; Risk; Tenofovir | 2013 |
Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Deoxycytidine; Dose-Response Relationship, Drug; Emtricitabine; HIV Infections; Humans; Lamivudine; Middle Aged; Prospective Studies | 2003 |
Pharmacokinetics and safety of single oral doses of emtricitabine in human immunodeficiency virus-infected children.
Topics: Adolescent; Aging; Anti-HIV Agents; Area Under Curve; Body Weight; Capsules; Child; Child, Preschool; Deoxycytidine; Dose-Response Relationship, Drug; Emtricitabine; Female; HIV Infections; Humans; Infant; Male; Pharmaceutical Solutions; Reverse Transcriptase Inhibitors | 2004 |
Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial).
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Oxazines; Prospective Studies; Treatment Outcome | 2004 |
Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Didanosine; Double-Blind Method; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Stavudine; Viral Load | 2004 |
New once-daily HIV combination better tolerated.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Oxazines; Tenofovir; Zidovudine | 2004 |
A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Deoxycytidine; Emtricitabine; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load | 2004 |
Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection.
Topics: Adult; Anti-HIV Agents; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged | 2004 |
Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Didanosine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome | 2005 |
Comparative pharmacokinetics of Racivir, (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine in rats, rabbits, dogs, monkeys and HIV-infected humans.
Topics: Animals; Antiviral Agents; Dogs; Emtricitabine; Female; HIV Infections; Humans; Macaca mulatta; Male; Pregnancy; Rabbits; Rats; Rats, Sprague-Dawley; Species Specificity; Zalcitabine | 2005 |
Safety, pharmacokinetics, and efficacy of (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine with efavirenz and stavudine in antiretroviral-naïve human immunodeficiency virus-infected patients.
Topics: Administration, Oral; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Middle Aged; Oxazines; Plasma; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Urine; Zalcitabine | 2005 |
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Oxazines; Prospective Studies; RNA, Viral; Tenofovir; Zidovudine | 2006 |
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Oxazines; RNA, Viral; Tenofovir; Time Factors; Viral Load; Zidovudine | 2006 |
Five-year follow up of once-daily therapy with emtricitabine, didanosine and efavirenz (Montana ANRS 091 trial).
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Antiviral Agents; Benzoxazines; CD4 Lymphocyte Count; Cholesterol; Cyclopropanes; Deoxycytidine; Didanosine; Drug Tolerance; Emtricitabine; Female; France; HIV Infections; HIV-1; Humans; Lipids; Lipoproteins; Male; RNA, Viral; Time Factors; Treatment Outcome | 2007 |
Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021.
Topics: Adolescent; Adult; Alkynes; Benzoxazines; Child; Child, Preschool; Clinical Protocols; Cyclopropanes; Deoxycytidine; Didanosine; Drug Administration Schedule; Emtricitabine; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Male; Time | 2007 |
Determinants of high-risk sexual behavior during post-exposure prophylaxis to prevent HIV infection.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Interviews as Topic; Lamivudine; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Factors; Risk-Taking; Sexual Partners; Surveys and Questionnaires; Tenofovir; Treatment Outcome | 2008 |
Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Didanosine; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Middle Aged; Regression Analysis; Stavudine; Treatment Failure | 2007 |
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.
Topics: Adenine; Adult; Alkynes; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2008 |
Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial.
Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Nevirapine; Organophosphonates; Pregnancy; Reverse Transcriptase Inhibitors; Tenofovir; Zambia | 2007 |
Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection.
Topics: Adenine; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Deoxycytidine; Drug Administration Schedule; Emtricitabine; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Male; Organophosphonates; Tenofovir; Thailand; Transaminases; Treatment Outcome; Viral Load | 2008 |
Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2008 |
Long-term safety and efficacy results of once-daily emtricitabine-based highly active antiretroviral therapy regimens in human immunodeficiency virus-infected pediatric subjects.
Topics: Administration, Oral; Adolescent; Age Factors; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Emtricitabine; Female; Follow-Up Studies; HIV Infections; Humans; Infant; Logistic Models; Long-Term Care; Male; Multivariate Analysis; Patient Compliance; Prospective Studies; Risk Assessment; Sex Factors; Treatment Outcome | 2008 |
Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2008 |
Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Didanosine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Male; Oxazines; Pilot Projects; RNA, Viral | 2000 |
765 other study(ies) available for emtricitabine and HIV Infections
| Article | Year |
|---|---|
Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
Topics: Amino Acid Sequence; Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Nucleosides; Phenotype; Reverse Transcriptase Inhibitors | 2009 |
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
Topics: Anti-HIV Agents; Cell Line, Tumor; Cell Survival; Cells, Cultured; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Molecular Structure; Reverse Transcriptase Inhibitors | 2009 |
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
Topics: Adenine; Anti-HIV Agents; Cell Survival; Cells, Cultured; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Macrophages; Nucleosides; Nucleotides; Organophosphonates; Tenofovir | 2010 |
Synergistic reduction of HIV-1 infectivity by 5-azacytidine and inhibitors of ribonucleotide reductase.
Topics: Anti-HIV Agents; Azacitidine; Dose-Response Relationship, Drug; Enzyme Inhibitors; HIV Infections; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Structure; Ribonucleotide Reductases; Structure-Activity Relationship | 2016 |
Synthesis and anti-HIV activities of unsymmetrical long chain dicarboxylate esters of dinucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Dicarboxylic Acids; Esters; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Nucleosides; Reverse Transcriptase Inhibitors | 2017 |
Cerebrospinal fluid exposure to bictegravir/emtricitabine/tenofovir in HIV-1-infected patients with CNS impairment.
Topics: Adenine; Aged; Alanine; Amides; Anti-HIV Agents; Chromatography, Liquid; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Middle Aged; Oxazines; Piperazines; Pyridones; Tandem Mass Spectrometry; Tenofovir | 2021 |
Bone and fat hormonal crosstalk with antiretroviral initiation.
Topics: Absorptiometry, Photon; Anti-HIV Agents; Bone Density; Cross-Sectional Studies; Emtricitabine; Femur Neck; HIV Infections; Humans | 2022 |
T cell derived HIV-1 is present in the CSF in the face of suppressive antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; T-Lymphocytes; Tenofovir | 2021 |
Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV.
Topics: Aged; Aged, 80 and over; Alanine; Drug Combinations; Drug Substitution; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Piperazines; Pyridones; Retrospective Studies; Tenofovir; Treatment Outcome | 2021 |
Renal profile of patients treated with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort.
Topics: Anti-HIV Agents; Cobicistat; Creatinine; Emtricitabine; Fumarates; HIV Infections; Humans; Lamivudine | 2023 |
Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life setting.
Topics: Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Rilpivirine; Viral Load | 2021 |
Switching from efavirenz to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide reduces central nervous system symptoms in people living with HIV.
Topics: Adenine; Adult; Alanine; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System; Cobicistat; Cyclopropanes; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Male; Prospective Studies; Quality of Life; Quinolones; Sleep Quality; Tenofovir | 2021 |
Combined cART including Tenofovir Disoproxil, Emtricitabine, and Dolutegravir has potent therapeutic effects in HIV-1 infected humanized mice.
Topics: Animals; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Mice; Oxazines; Piperazines; Pyridones; Tenofovir; Viral Load | 2021 |
First pharmacokinetic data of bictegravir in pregnant women living with HIV.
Topics: Amides; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Piperazines; Pregnancy; Pregnant Women; Pyridones | 2021 |
Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Drug Resistance; Emtricitabine; HIV Infections; Humans; South Africa; Tenofovir; Viral Load; Viremia | 2022 |
Crushed bictegravir/emtricitabine/tenofovir alafenamide in a human immunodeficiency virus-positive patient with pancreatic cancer.
Topics: Adenine; Aged; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV; HIV Infections; Humans; Male; Oxazines; Pancreatic Neoplasms; Piperazines; Pyridones; Tenofovir; Treatment Outcome | 2022 |
Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Isoniazid; Latent Tuberculosis; Piperazines; Pyridones; Rifampin; Tenofovir | 2021 |
Cohort profile: the Netherlands Cohort Study on Acute HIV infection (NOVA), a prospective cohort study of people with acute or early HIV infection who immediately initiate HIV treatment.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Emtricitabine; HIV Infections; Humans; Male; Netherlands; Prospective Studies; Treatment Outcome; Viral Load | 2021 |
Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Pyridones | 2021 |
Pre-Exposure Prophylaxis Perspectives, Sociodemographic Characteristics, and HIV Risk Profiles of Cisgender Women Seeking and Initiating PrEP in a US Demonstration Project.
Topics: Adolescent; Adult; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Medication Adherence; Pre-Exposure Prophylaxis; United States | 2021 |
Retrospective evaluation of an observational cohort by the Central and Eastern Europe Network Group shows a high frequency of potential drug-drug interactions among HIV-positive patients receiving treatment for coronavirus disease 2019 (COVID-19).
Topics: Adenine; Adult; Anti-HIV Agents; COVID-19 Drug Treatment; Drug Interactions; Emtricitabine; Female; HIV Infections; HIV Seropositivity; Humans; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; SARS-CoV-2; Tenofovir | 2022 |
Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir.
Topics: Alanine; Amides; Anti-HIV Agents; Dideoxynucleosides; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir; Weight Gain | 2022 |
Osteonecrosis of the humeral head in a human immunodeficiency virus-infected patient under tenofovir disoproxil fumarate-emtricitabine-lopinavir/ritonavir for 10 years: a case report.
Topics: Emtricitabine; Female; HIV; HIV Infections; Humans; Humeral Head; Lopinavir; Middle Aged; Osteonecrosis; Ritonavir; Tenofovir | 2021 |
Durability of single tablet regimen for patients with HIV infection in Southern Taiwan: data from a real-world setting.
Topics: Adult; Anti-HIV Agents; Drug Combinations; Emtricitabine; HIV Infections; Humans; Retrospective Studies; Tablets; Taiwan | 2022 |
Safety and Tolerability of Once Daily Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Exposure.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Fatigue; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Piperazines; Post-Exposure Prophylaxis; Pyridones; Tenofovir | 2022 |
Pharmacokinetics and tissue distribution of tenofovir, emtricitabine and dolutegravir in mice.
Topics: Animals; Anti-HIV Agents; Chromatography, Liquid; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Mice; Oxazines; Piperazines; Pyridones; Tandem Mass Spectrometry; Tenofovir; Tissue Distribution | 2022 |
Synthesis of (±)-Emtricitabine and (±)-Lamivudine by Chlorotrimethylsilane-Sodium Iodide-Promoted Vorbrüggen Glycosylation.
Topics: Anti-HIV Agents; Deoxycytidine; Emtricitabine; Glycosylation; HIV Infections; HIV-1; Humans; Lamivudine; Sodium Iodide; Trimethylsilyl Compounds; Water | 2022 |
Point-of-care semi-quantitative test for adherence to tenofovir alafenamide or tenofovir disoproxil fumarate.
Topics: Adult; Alanine; Anti-HIV Agents; Emtricitabine; HIV Infections; HIV-1; Humans; Point-of-Care Systems; Tenofovir | 2022 |
HIV Pre-Exposure Prophylaxis (PrEP) in a Brazilian Clinical Setting: Adherence, Adverse Events, Sexual Behavior, and Sexually Transmitted Infections.
Topics: Anti-HIV Agents; Brazil; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Prospective Studies; Sexual Behavior; Sexually Transmitted Diseases | 2022 |
Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre.
Topics: Adult; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Piperazines; Pyridones; Retrospective Studies; Tenofovir | 2022 |
Brief Report: Patients' Experiences and Opinions After Desimplification of Their Single-Tablet Regimens for the Treatment of HIV Infection: A Survey in a Multicentre Cohort.
Topics: Anti-HIV Agents; Drug Combinations; Emtricitabine; HIV Infections; Humans; Lamivudine; Quality of Life; Surveys and Questionnaires; Tablets; Tenofovir | 2022 |
Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis.
Topics: Anti-HIV Agents; Child; Cost-Benefit Analysis; Drugs, Generic; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Tenofovir; United States | 2022 |
Current Antiretroviral Treatment Among People With Human Immunodeficiency Virus in the United States: Findings from the Centers for AIDS Research Network of Integrated Clinic Systems Cohort.
Topics: Acquired Immunodeficiency Syndrome; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV; HIV Infections; Humans; Tenofovir; United States | 2022 |
Genital Immune Cell Activation and Tenofovir Gel Efficacy: A Case-Control Study.
Topics: Anti-HIV Agents; Case-Control Studies; Deoxyadenosines; Emtricitabine; Female; Genitalia; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2022 |
Hepatitis B surface antigen and hepatitis B RNA changes in HIV/hepatitis B virus co-infected participants receiving hepatitis B virus-active antiretroviral therapy.
Topics: Adult; Coinfection; Emtricitabine; Female; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Retrospective Studies; RNA | 2022 |
Incidence of low-level viremia and its impact on virologic failure among people living with HIV-1 who switched to elvitegravir-based antiretroviral therapy.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; HIV-1; Humans; Incidence; Quinolones; Raltegravir Potassium; Retrospective Studies; Viremia | 2022 |
Long-Term Effectiveness of Rilpivirine-Based Single-Tablet Regimens in a Seven-Year, Two-Center Observational Cohort of People Living with HIV.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Retrospective Studies; Rilpivirine; Tablets; Tenofovir | 2022 |
A four-year observation of HIV and sexually transmitted infections among men who have sex with men before and during pre-exposure prophylaxis in Tokyo.
Topics: Adult; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Sexually Transmitted Diseases; Tokyo | 2022 |
Effectiveness and safety of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet combination among HIV-infected patients in Turkey: results from a real world setting.
Topics: Adult; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Quinolones; Retrospective Studies; Tablets; Tenofovir; Turkey | 2021 |
A flexural exanthem following postexposure prophylaxis.
Topics: Emtricitabine; Exanthema; HIV Infections; Humans; Tenofovir | 2022 |
Use of Generic Antiretroviral Drugs and Single-Tablet Regimen De-Simplification for the Treatment of HIV Infection in Spain.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Drug Combinations; Drugs, Generic; Emtricitabine; HIV Infections; Humans; Lamivudine; Rilpivirine; Spain; Tablets | 2022 |
Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence
Topics: Anti-HIV Agents; Emtricitabine; Forgiveness; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Integrases; Lamivudine; Pyridones | 2022 |
HIV-1-infection in a man who has sex with men despite self-reported excellent adherence to pre-exposure prophylaxis, the Netherlands, August 2021: be alert to emtricitabine/tenofovir-resistant strain transmission.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Medication Adherence; Netherlands; Pre-Exposure Prophylaxis; Self Report; Sexual and Gender Minorities; Tenofovir | 2022 |
Changing from Tenofovir/Emtricitabine to Cabotegravir for Pre Exposure Prophylaxis for HIV in Men who have Sex with Men: A Cost Utility Analysis from an Endemic Country.
Topics: Anti-HIV Agents; Cost-Benefit Analysis; Diketopiperazines; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Pyridones; Sexual and Gender Minorities; Tenofovir | 2022 |
High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I.
Topics: Adenine; Adult; Alanine; Amides; Anti-HIV Agents; Clinical Trials as Topic; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; RNA; Tenofovir | 2022 |
Characterizing HIV-Preventive, Plasma Tenofovir Concentrations-A Pooled Participant-level Data Analysis From Human Immunodeficiency Virus Preexposure Prophylaxis Clinical Trials.
Topics: Anti-HIV Agents; Clinical Trials, Phase III as Topic; Data Analysis; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir | 2022 |
Brief Report: Previous Preexposure Prophylaxis Use Among Men Who Have Sex With Men Newly Diagnosed With HIV Infection in King County, WA.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Sexual and Gender Minorities | 2022 |
Bictegravir-based antiretroviral therapy in HIV-1 group O patients: data from real-life bictegravir/emtricitabine/tenofovir alafenamide switches.
Topics: Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; Tenofovir | 2022 |
Doravirine/tenofovir disoproxyl fumarate/lamivudine-induced alopecia: A case report.
Topics: Alopecia; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Fumarates; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Pyridones; Tenofovir; Triazoles; Viral Load | 2022 |
Advancing HIV prevention using tenofovir-based pre-exposure prophylaxis.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir | 2022 |
Simplification from tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted protease inhibitor to ritonavir-boosted atazanavir plus lamivudine in virologically suppressed HIV-infected adults with osteopenia: a pilot study.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bone Diseases, Metabolic; Drug Substitution; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Pilot Projects; Ritonavir; Tenofovir | 2022 |
Linear and branched polymer prodrugs of the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine as structural materials for long-acting implants.
Topics: Anti-HIV Agents; DNA-Directed RNA Polymerases; Emtricitabine; HIV Infections; Humans; Nucleosides; Polymers; Prodrugs; Reverse Transcriptase Inhibitors; Water | 2022 |
Fanconi syndrome in a patient receiving pre-exposure prophylaxis for HIV infection: case report.
Topics: Anti-HIV Agents; Emtricitabine; Fanconi Syndrome; HIV Infections; Humans; Male; Middle Aged; Pre-Exposure Prophylaxis; Proteinuria; Renal Insufficiency; Tenofovir | 2022 |
[Real-world efficacy of switching to bictegravir/ emtricitabine/tenofovir alafenamide in pretreated patients with triple therapy containing rilpivirine].
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; Retrospective Studies; Rilpivirine; Tenofovir | 2022 |
Doravirine Concentrations and Human Immunodeficiency Virus Type 1 RNA in the Genital Fluids of Virologically Suppressed Adults Switching to Doravirine Plus Emtricitabine/Tenofovir Alafenamide.
Topics: Adult; Anti-HIV Agents; Emtricitabine; Genitalia; HIV Infections; HIV-1; Humans; RNA | 2022 |
Tenofovir disoproxil and renal mitochondrial toxicity: more studies in Africans are needed.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Tenofovir | 2022 |
Short-term Neuropsychiatric and Body Weight Changes in Patients Switching From EVG/Cobi/FTC/TAF to BIC/FTC/TAF (PreEC/RIS69).
Topics: Anti-HIV Agents; Body Weight; Emtricitabine; Female; HIV Infections; Humans; Male; Tenofovir | 2022 |
Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study.
Topics: Anti-HIV Agents; COVID-19; COVID-19 Testing; Emtricitabine; HIV Infections; Humans; Lamivudine; Propensity Score; Prospective Studies; SARS-CoV-2; Tenofovir | 2022 |
Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305).
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Maraviroc; Medication Adherence; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Sexual Behavior; Tenofovir | 2022 |
HIV drug resistance in persons initiating or reinitiating first-line antiretroviral therapy in Paraguay: Results of a National Patient Survey.
Topics: Adolescent; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Cross-Sectional Studies; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV-1; Humans; Paraguay; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2022 |
A Layer Plus Approach to Implementation Research and Collaboration for Long-Acting Injectable Preexposure Prophylaxis for HIV Prevention.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir | 2022 |
Pill related oesophagitis due to tenofovir disproxil fumarate/emtricitabine (Truvada) HIV pre-exposure prophylaxis.
Topics: Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Esophagitis; Fumarates; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2022 |
A Rare Case of Didanosine-Induced Mid-Peripheral Chorioretinal Atrophy Identified Incidentally 11 Years after the Drug Cessation.
Topics: Adult; Atrophy; Choroid Diseases; Didanosine; Emtricitabine; Female; HIV Infections; Humans; Hydroxychloroquine; Retinal Degeneration; Tenofovir; Tomography, Optical Coherence | 2022 |
Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study.
Topics: Adolescent; Adult; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Prospective Studies; Sexual and Gender Minorities; Tenofovir | 2022 |
Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice.
Topics: Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2022 |
Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based regimens.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Retrospective Studies; Tenofovir; Viral Load; Viremia | 2022 |
Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Piperazines; Pyridones; Tenofovir | 2022 |
The Nucleoside/Nucleotide Analogs Tenofovir and Emtricitabine Are Inactive against SARS-CoV-2.
Topics: Anti-HIV Agents; COVID-19 Drug Treatment; Emtricitabine; HIV Infections; HIV-1; Humans; Nucleosides; Nucleotides; Pandemics; RNA-Dependent RNA Polymerase; RNA, Viral; SARS-CoV-2; Tenofovir | 2022 |
A 28-Year-Old Man With Diffuse Bilateral Pulmonary Nodules.
Topics: Adult; Anti-HIV Agents; Child; Cobicistat; Drug Combinations; Emtricitabine; HIV Infections; Humans; Male; Quinolones; Tenofovir | 2022 |
Impact of feminizing hormone therapy on tenofovir and emtricitabine plasma pharmacokinetics: a nested drug-drug interaction study in a cohort of Brazilian transgender women using HIV pre-exposure prophylaxis.
Topics: Anti-HIV Agents; Brazil; Cohort Studies; Drug Interactions; Emtricitabine; Estradiol; Female; HIV Infections; Humans; Pre-Exposure Prophylaxis; Spironolactone; Tenofovir; Transgender Persons | 2022 |
Impact of preexisting nucleos(t)ide reverse transcriptase inhibitor resistance on the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in treatment experience patients.
Topics: Adenine; Anti-HIV Agents; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Reverse Transcriptase Inhibitors; RNA; Tenofovir | 2022 |
Tenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV.
Topics: Anti-HIV Agents; Cohort Studies; COVID-19; COVID-19 Testing; Emtricitabine; HIV Infections; Humans; Lamivudine; Male; SARS-CoV-2; Tenofovir | 2022 |
Real-world medication persistence among HIV-1 patients initiating integrase inhibitor-based antiretroviral therapy in Japan.
Topics: Adult; Anti-HIV Agents; Emtricitabine; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Japan; Medication Adherence; Tablets | 2022 |
Safety and efficacy of a biodegradable implant releasing tenofovir alafenamide for vaginal protection in a macaque model.
Topics: Absorbable Implants; Alanine; Animals; Anti-HIV Agents; Emtricitabine; Female; HIV; HIV Infections; Macaca; Necrosis; Simian Immunodeficiency Virus; Tenofovir | 2022 |
Overdose of the HIV Medicine Genvoya® in Two Auto-Intoxications.
Topics: Anti-HIV Agents; Drug Combinations; Drug Overdose; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; HIV; HIV Infections; Humans | 2023 |
Excessive Weight Gain: Current Antiretroviral Agents in Virologically Suppressed People with HIV.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Cobicistat; Darunavir; Emtricitabine; HIV Infections; HIV-1; Humans; Tenofovir; Weight Gain | 2022 |
Pharmacokinetics of Emtricitabine/Tenofovir Disoproxil Fumarate Among Transgender Adolescents and Young Adults Without HIV Receiving Gender Affirming Hormones.
Topics: Adolescent; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Hormones; Humans; Leukocytes, Mononuclear; Male; Pre-Exposure Prophylaxis; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Transgender Persons; Young Adult | 2022 |
Mobilization of systemic CCL4 following HIV pre-exposure prophylaxis in young men in Africa.
Topics: Anti-HIV Agents; Chemokine CCL3; Chemokine CCL4; Emtricitabine; HIV Infections; HIV Seropositivity; HIV-1; Humans; Male; Pre-Exposure Prophylaxis; Proteomics; South Africa | 2022 |
Concentrations of Efavirenz, Tenofovir, and Emtricitabine in Obesity: A Cross-Sectional Study.
Topics: Adenine; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Emtricitabine; HIV Infections; Humans; Obesity, Abdominal; Tenofovir | 2022 |
Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Tenofovir Alafenamide/Emtricitabine/Bictegravir.
Topics: Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Pyridones | 2022 |
A public health approach to monitoring HIV with resistance to HIV pre-exposure prophylaxis.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV-1; Humans; Pre-Exposure Prophylaxis; Public Health; Viremia | 2022 |
Low prevalence of hepatitis B virus infection in HIV-uninfected pregnant women in Cape Town, South Africa: implications for oral pre-exposure prophylaxis roll out.
Topics: Adult; Cohort Studies; Cross-Sectional Studies; Emtricitabine; Female; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; Humans; Infant; Pre-Exposure Prophylaxis; Pregnancy; Pregnant Women; Prevalence; South Africa; Tenofovir | 2022 |
Serum Interleukin-6 and Weight Loss in Antiretroviral-naïve and Antiretroviral-treated Patients with HIV/AIDS: Relationships and Predictors.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; Emtricitabine; HIV Infections; Humans; Interleukin-6; Lamivudine; Middle Aged; Nevirapine; Tenofovir; Weight Loss; Zidovudine | 2022 |
Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China.
Topics: Adenine; Alanine; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cholesterol, LDL; Cobicistat; Cyclopropanes; Emtricitabine; HIV Infections; HIV-1; Humans; Hypercholesterolemia; Hypertriglyceridemia; Lamivudine; Lipoproteins, HDL; Quinolones; Retrospective Studies; Tenofovir | 2022 |
Continued attendance in a PrEP program despite low adherence and non-protective drug levels among adolescent girls and young women in Kenya: Results from a prospective cohort study.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Child; Contraceptive Agents; Diphosphates; Emtricitabine; Female; HIV Infections; Humans; Infant; Kenya; Male; Medication Adherence; Organophosphates; Pre-Exposure Prophylaxis; Prospective Studies; Tenofovir; Young Adult | 2022 |
Use and safety of appearance and performance enhancing supplements in gay, bisexual, and other men who have sex with men receiving daily tenofovir disoproxil fumarate/emtricitabine as HIV pre-exposure prophylaxis.
Topics: Anti-HIV Agents; Cross-Sectional Studies; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Tenofovir | 2023 |
A mAb for the detection of the antiretroviral drug emtricitabine.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2022 |
Inflammation and intracellular exposure of dolutegravir, darunavir, tenofovir and emtricitabine in people living with HIV.
Topics: Anti-HIV Agents; Darunavir; Emtricitabine; HIV Infections; Humans; Inflammation; Interleukin-6; Lipopolysaccharide Receptors; Lipopolysaccharides; Tenofovir | 2023 |
Comparison between the impact of tenofovir alafenamide and that of abacavir on rapid kidney function decline: A retrospective observational study.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Emtricitabine; HIV Infections; Humans; Kidney; Lamivudine; Retrospective Studies | 2023 |
The Elegance of the Acyclic Nucleoside Phosphonates (ANPs), Honorary Tribute to Antonín Holý, Who Passed Away on 16 July 2012, at the 10th Anniversary of His Death.
Topics: Anniversaries and Special Events; Anti-HIV Agents; Antiviral Agents; Cidofovir; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Nucleosides; Organophosphonates; Prodrugs; Tenofovir | 2022 |
Safety and efficacy of pharmacotherapy containing INSTIs and chemotherapy drugs in people living with HIV and concomitant colorectal cancer.
Topics: Amides; Anti-HIV Agents; Colorectal Neoplasms; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Integrase Inhibitors; Lamivudine; Piperazines; Pyridones; Raltegravir Potassium; Tenofovir | 2022 |
Economic evaluation of doravirine/tenofovir disoproxil fumarate/lamivudine for HIV-1-infected adults in Russia: a cost-minimization and budget impact analysis.
Topics: Adult; Anti-HIV Agents; Cost-Benefit Analysis; Drug Combinations; Drugs, Essential; Emtricitabine; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; RNA, Viral; Tenofovir; Viral Load | 2022 |
Estimating the budget impact of adopting tenofovir/emtricitabine for pre-exposure prophylaxis of HIV in the public health sector in Namibia (2021 - 2023).
Topics: Anti-HIV Agents; Cost-Benefit Analysis; Emtricitabine; HIV; HIV Infections; Homosexuality, Male; Humans; Male; Namibia; Pre-Exposure Prophylaxis; Public Health; Public Sector; Tenofovir | 2022 |
Vaginal microbial shifts are unaffected by oral pre-exposure prophylaxis in South African women.
Topics: Anti-Bacterial Agents; Cross-Sectional Studies; Emtricitabine; Female; HIV Infections; Humans; Pre-Exposure Prophylaxis; South Africa; Tenofovir; Vagina; Vaginosis, Bacterial | 2022 |
Impact on renal function of daily and on-demand HIV pre-exposure prophylaxis in the ANRS-PREVENIR study.
Topics: Adult; Anti-HIV Agents; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Kidney; Male; Pre-Exposure Prophylaxis; Retrospective Studies; Sexual and Gender Minorities | 2022 |
Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014.
Topics: Adolescent; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Child; Emtricitabine; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Pyridones; RNA, Viral; Tablets; Tenofovir | 2023 |
A retrospective analysis of bone loss in tenofovir-emtricitabine therapy for HIV PrEP.
Topics: Anti-HIV Agents; Bone Diseases, Metabolic; Emtricitabine; HIV Infections; Humans; Osteoporosis; Retrospective Studies; Tenofovir | 2022 |
Antiretroviral therapy resistance mutations among HIV infected people in Kazakhstan.
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV-1; Humans; Kazakhstan; Mutation; Nevirapine; Viral Load; Zidovudine | 2022 |
[The analysis of the availability of fixed-dose combinations in antiretroviral therapy for HIV infection in the Russian Federation].
Topics: Adenine; Anti-HIV Agents; Drug Combinations; Drugs, Essential; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Rilpivirine; Tenofovir | 2021 |
Interaction of Depot Medroxyprogesterone Acetate and Tenofovir Disoproxil Fumarate/Emtricitabine on Peripheral Blood Mononuclear Cells and Cervical Tissue Susceptibility to HIV Infection and Pharmacokinetics.
Topics: Emtricitabine; Female; HIV Infections; Humans; Leukocytes, Mononuclear; Medroxyprogesterone Acetate; Tenofovir | 2023 |
Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis.
Topics: Adenine; Adolescent; Anti-HIV Agents; Cost-Benefit Analysis; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Sex Workers; Sexual and Gender Minorities; South Africa; Tenofovir | 2022 |
Determinants of therapy failure among adults on first-line antiretroviral therapy in Asmara, Eritrea: a multicenter retrospective matched case-control study.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Case-Control Studies; Emtricitabine; Eritrea; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Stavudine; Viral Load | 2022 |
Utilization of bictegravir/emtricitabine/tenofovir alafenamide in patients with end-stage renal disease on hemodialysis.
Topics: Adenine; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Kidney Failure, Chronic; Pyridones; Quality of Life; Renal Dialysis | 2023 |
Crushed vs dissolved bictegravir/emtricitabine/tenofovir alafenamide.
Topics: Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Pyridones; Tenofovir | 2023 |
Tenofovir disoproxil fumarate/emtricitabine and severity of coronavirus disease 2019 in people with HIV infection.
Topics: Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; COVID-19; Drug Combinations; Emtricitabine; HIV Infections; Humans; Lamivudine; Middle Aged; SARS-CoV-2; Tenofovir | 2022 |
Doravirine/lamivudine/tenofovir disoproxil fumarate-induced hypertriglyceridemia in a newly diagnosed AIDS patient.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Emtricitabine; Fumarates; HIV Infections; Humans; Hypertriglyceridemia; Lamivudine; Tenofovir | 2022 |
Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Mutation; Retrospective Studies; Tenofovir; Viral Load | 2023 |
Case of organising pneumonia in HIV infection.
Topics: Cryptogenic Organizing Pneumonia; Emtricitabine; HIV Infections; Humans; Male; Pneumonia; Tenofovir | 2022 |
Bictegravir/emtricitabine/tenofovir alafenamide in a virologically suppressed adult with HIV and end-stage renal disease on chronic peritoneal dialysis: A case report.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Combinations; Emtricitabine; HIV Infections; Humans; Kidney Failure, Chronic; Peritoneal Dialysis | 2023 |
Supporting the Art: Medication Adherence Patterns in Persons Prescribed Ingestible Sensor-enabled Oral Pre-Exposure Prophylaxis to Prevent Human Immunodeficiency Virus Infection.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Methamphetamine; Middle Aged; Pre-Exposure Prophylaxis; Young Adult | 2023 |
Pharmacology of boosted and unboosted integrase strand transfer inhibitors for two-dose event-driven HIV prevention regimens among men.
Topics: Adolescent; Adult; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Homosexuality, Male; Humans; Integrases; Male; Middle Aged; Pyridones; Sexual and Gender Minorities; Young Adult | 2023 |
Model-informed intermittent tenofovir disoproxil fumarate and emtricitabine dosing for HIV pre-exposure prophylaxis in subjects with renal impairment: a case report.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Renal Insufficiency; Tenofovir | 2023 |
[Research advances in HIV pre-exposure prophylaxis drug].
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir; United States | 2022 |
Advantages of switching to elvitegravir/cobicistat/emtricitabine/tenofovir therapy in virologically-suppressed people living with human immunodeficiency virus/acquired immune deficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; HIV; HIV Infections; Humans; Tenofovir | 2022 |
Safety and efficacy of switching to elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate in treatment-experienced people with HIV: a multicenter cohort study.
Topics: Adult; Anti-HIV Agents; Cobicistat; Cohort Studies; Emtricitabine; Female; HIV Infections; Humans; Integrase Inhibitors; Male; RNA; Tenofovir | 2023 |
Updating the Adherence-Response for Oral Emtricitabine/Tenofovir Disoproxil Fumarate for Human Immunodeficiency Virus Pre-Exposure Prophylaxis Among Cisgender Women.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Reverse Transcriptase Inhibitors; Tenofovir | 2023 |
Same-day initiation of bictegravir/emtricitabine/tenofovir alafenamide: Week 48 results of the FAST study-IMEA 055.
Topics: Adenine; Alanine; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Prospective Studies; Pyridones | 2023 |
A possible case of bictegravir-associated severe unconjugated hyperbilirubinemia.
Topics: Adolescent; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Hyperbilirubinemia; Male | 2023 |
Recycling Tenofovir in Second-line Antiretroviral Treatment With Dolutegravir: Outcomes and Viral Load Trajectories to 72 weeks.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Prospective Studies; Pyridones; Tenofovir; Viral Load; Viremia | 2023 |
Virologic status and pattern of drug resistance mutation among ART-experienced HIV-infected patients in Butuo County, China.
Topics: Anti-HIV Agents; Cross-Sectional Studies; Emtricitabine; HIV Infections; Humans; Lamivudine; Lopinavir; Mutation; Nevirapine; Reverse Transcriptase Inhibitors | 2023 |
Real world use of dolutegravir two drug regimens.
Topics: Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Homosexuality, Male; Humans; Lamivudine; Male; Middle Aged; Pyridones; Sexual and Gender Minorities; Tablets; Viremia | 2023 |
Impact of the Early COVID-19 Pandemic on the Number of HIV Preexposure Prophylaxis Uses and the Proportion of Preexposure Prophylaxis Users Receiving Sexually Transmitted Infection Testing Services.
Topics: COVID-19; Emtricitabine; Gonorrhea; HIV Infections; Homosexuality, Male; Humans; Male; Pandemics; Pre-Exposure Prophylaxis; Retrospective Studies; Sexually Transmitted Diseases; Tenofovir | 2023 |
Immune response to ART initiation in advanced HIV infection.
Topics: Adult; Anti-HIV Agents; Darunavir; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Immunity; Tenofovir | 2023 |
Patient-reported outcomes among virally suppressed people living with HIV after switching to Co-formulated bictegravir, emtricitabine and tenofovir alafenamide.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Patient Reported Outcome Measures; Quality of Life; Tenofovir; Treatment Outcome | 2023 |
Renal impairment associated with tenofovir disoproxil fumarate for antiretroviral therapy and HIV pre-exposure prophylaxis: An observational cohort study.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Cohort Studies; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Renal Insufficiency; Tenofovir | 2023 |
Question of Whether Tenofovir Disoproxil Fumarate/Emtricitabine Provides Protection Against Clinical Severity of Coronavirus Disease 2019.
Topics: Anti-HIV Agents; COVID-19; Emtricitabine; HIV; HIV Infections; Humans; Tenofovir; United States | 2023 |
Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting.
Topics: Anti-HIV Agents; Cobicistat; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Integrase Inhibitors; Pyridones; Raltegravir Potassium | 2023 |
Acute antagonism in three-drug combinations for vaginal HIV prevention in humanized mice.
Topics: Animals; Anti-HIV Agents; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Male; Mice; Tenofovir | 2023 |
Weight gain in HIV-infected patients.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Pyridones; Tenofovir; Weight Gain | 2023 |
Understanding Retention in the HIV Pre-Exposure Prophylaxis Cascade Among Cisgender Women.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir; United States | 2023 |
Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Retrospective Studies; Tenofovir; Transgender Persons | 2023 |
Weight gain following the single substitution of tenofovir disoproxil fumarate by tenofovir alafenamide in HIV-infected people from the French Dat'AIDS cohort: A propensity score-matched analysis.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Propensity Score; Retrospective Studies; Tenofovir; Weight Gain | 2023 |
Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.
Topics: Adenine; Adult; Anti-HIV Agents; Belgium; Cohort Studies; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Middle Aged; Retrospective Studies; Treatment Outcome | 2023 |
Weight Gain After 12 Months of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV Patients.
Topics: Adenine; Anti-HIV Agents; Cholesterol; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Weight Gain | 2023 |
Tenofovir alafenamide and weight: What do we still need to know to inform clinical decisions?
Topics: Adenine; Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Tenofovir | 2023 |
Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice.
Topics: Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Pyridones | 2023 |
Federal Funding For Discovery And Development Of Costly HIV Drugs Was Far More Than Previously Estimated.
Topics: Anti-HIV Agents; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Pharmaceutical Preparations; Tenofovir | 2023 |
Point-of-care urine tenofovir testing: making a good thing better.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Point-of-Care Systems; Point-of-Care Testing; Tenofovir | 2023 |
HIV-1 RNA and DNA Genotyping Drug Resistance Detection in Patients with Low-Level Viremia in Liangshan, China.
Topics: Adult; Anti-HIV Agents; Drug Resistance; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; RNA; Viremia | 2023 |
Understanding the Uptake and Outcomes of Non-occupational Postexposure Prophylaxis Use Through an Online Medical Platform in China: Web-Based Cross-sectional Study.
Topics: Adult; Anti-HIV Agents; Cross-Sectional Studies; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Retrospective Studies; Sexual and Gender Minorities; Surveys and Questionnaires; Tenofovir | 2023 |
Determinants of adherence to daily PrEP measured as intracellular tenofovir diphosphate concentrations over 24 months of follow-up among men who have sex with men.
Topics: Anti-HIV Agents; Emtricitabine; Follow-Up Studies; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Sexual Behavior | 2023 |
Utilization of Chemometric-Aided UV Spectrophotometric Methods for Concurrent Assessment of Emtricitabine, Tenofovir Disoproxil Fumarate, Elvitegravir, and Cobicistat in Tablet Formulation.
Topics: Adenine; Anti-HIV Agents; Chemometrics; Cobicistat; Drug Combinations; Emtricitabine; HIV Infections; Humans; Tablets; Tenofovir | 2023 |
Impact of pre-exposure prophylaxis uptake among gay, bisexual, and other men who have sex with men in urban centers in Brazil: a modeling study.
Topics: Brazil; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Sexual and Gender Minorities | 2023 |
Weight gain in Namibians with HIV switching from efavirenz to dolutegravir.
Topics: Anti-HIV Agents; Benzoxazines; Emtricitabine; Female; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Male; Retrospective Studies; Tenofovir; Weight Gain | 2023 |
Treatment-emergent reverse transcriptase resistance during antiretroviral therapy with bictegravir, tenofovir alafenamide, and emtricitabine: A case series.
Topics: Adenine; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Tenofovir | 2023 |
[Sleep disorders related to HIV treatment.]
Topics: Adenine; Cross-Sectional Studies; Emtricitabine; HIV Infections; Humans; Pyridones; Sleep Wake Disorders; Spain; Tenofovir | 2023 |
High rates of kidney impairment among older people (≥ 60 years) living with HIV on first-line antiretroviral therapy at screening for a clinical trial in Kenya.
Topics: Adenine; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Female; HIV Infections; Humans; Kenya; Kidney; Male; Middle Aged; Tenofovir | 2023 |
Counterfactual estimation of efficacy against placebo for novel PrEP agents using external trial data: example of injectable cabotegravir and oral PrEP in women.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Organophosphonates; Pre-Exposure Prophylaxis | 2023 |
Quantification of nine antiretroviral drugs in cerebrospinal fluid: An approach to overcome sample collection tube adsorption.
Topics: Adsorption; Ammonium Hydroxide; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Chromatography, Liquid; Emtricitabine; HIV Infections; Humans; Lamivudine; Methanol; Ritonavir; Tandem Mass Spectrometry; Tenofovir; Water | 2023 |
Population-level impact of expanding PrEP coverage by offering long-acting injectable PrEP to MSM in three high-resource settings: a model comparison analysis.
Topics: Black People; Canada; Emtricitabine; Georgia; HIV Infections; Homosexuality, Male; Humans; Male; Netherlands; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Tenofovir; White | 2023 |
Analysis of online user discussions on Reddit associated with the transition of use between HIV PrEP therapy.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anti-HIV Agents; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Homosexuality, Male; Humans; Male; Retrospective Studies; Sexual and Gender Minorities | 2023 |
Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study.
Topics: Adenine; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lamivudine; Retrospective Studies; Treatment Outcome | 2023 |
Transcriptomics age acceleration in prolonged treated HIV infection.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; HIV Infections; HIV-1; Humans; Tenofovir; Transcriptome | 2023 |
Is injectable PrEP superior to oral therapy for HIV protection?
Topics: Administration, Oral; Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2023 |
Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir.
Topics: Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lipoproteins, HDL; Male; Middle Aged; Pyridones | 2023 |
Reply: Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men.
Topics: Anti-HIV Agents; Emtricitabine; Hepatitis B virus; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Tenofovir | 2023 |
Heart transplantation and human immunodeficiency virus-navigating drug-drug interactions: a case report.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; HIV Seropositivity; HIV-1; Humans; Male; Middle Aged; Tenofovir | 2023 |
Preexposure Prophylaxis for the Prevention of HIV: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Topics: Adult; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Sexual and Gender Minorities; Systematic Reviews as Topic; Tenofovir | 2023 |
Clinical efficacy, safety, and subjective experience based on ePRO in HIV-infected individuals administered Bictegravir/Emtricitabine/Tenofovir Alafenamide in southwest China.
Topics: China; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Electronics; Emtricitabine; HIV Infections; Humans; Prospective Studies; Quality of Life; Treatment Outcome | 2023 |
Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV.
Topics: Adult; Anti-HIV Agents; Cobicistat; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Fumarates; HIV Infections; Humans; Lamivudine; Tenofovir | 2023 |
Oestradiol concentrations in trans women with HIV suppressed on unboosted integrase inhibitor regimens versus trans women without HIV taking oral oestradiol: a pilot study.
Topics: Adolescent; Adult; Cross-Sectional Studies; Emtricitabine; Female; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Pilot Projects | 2023 |
Emergent HIV drug resistance in non-inferiority trials.
Topics: Emtricitabine; HIV Infections; Humans; Tenofovir; Treatment Outcome | 2023 |
Letter to the Editor: Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men.
Topics: Anti-HIV Agents; Emtricitabine; Hepatitis B virus; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Tenofovir | 2023 |
Optimizing Antiretroviral Therapy with Bictegravir/Emtricitabine/Tenofovir Alafenamide in virologically suppressed PLWH.
Topics: Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Pregnancy; Quality of Life | 2023 |
Effectiveness, durability and safety of dolutegravir and lamivudine versus bictegravir, emtricitabine and tenofovir alafenamide in a real-world cohort of HIV-infected adults.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lamivudine; Pyridones | 2023 |
Viral dissemination and immune activation modulate antiretroviral drug levels in lymph nodes of SIV-infected rhesus macaques.
Topics: Animals; Anti-Retroviral Agents; COVID-19; Emtricitabine; HIV Infections; Leukocytes, Mononuclear; Lymph Nodes; Macaca mulatta; SARS-CoV-2; Tenofovir | 2023 |
Efficacy estimates of oral pre-exposure prophylaxis for HIV prevention in cisgender women with partial adherence.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir | 2023 |
Impact of Treatment Adherence on Efficacy of Dolutegravir + Lamivudine and Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Week 144 Analysis of the GEMINI-1 and GEMINI-2 Clinical Studies.
Topics: Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Pyridones; Tenofovir; Treatment Adherence and Compliance | 2023 |
Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lamivudine; Pyridones; Tenofovir | 2023 |
Outcomes of bictegravir/emtricitabine/tenofovir alafenamide versus efavirenz-based regimens in central China: a real-world assessment.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Tenofovir | 2023 |
Uptake of Oral HIV Pre-Exposure Prophylaxis (PrEP) and Associated Factors among Female Sex Workers in Tanga, Tanzania.
Topics: Anti-HIV Agents; Child; Cross-Sectional Studies; Emtricitabine; Female; HIV Infections; Humans; Pre-Exposure Prophylaxis; Sex Workers; Tanzania; Tenofovir | 2023 |
Efficacy and safety profiles of dolutegravir plus lamivudine vs . bictegravir/emtricitabine/tenofovir alafenamide in therapy-naïve adults with HIV-1.
Topics: Adult; Anti-HIV Agents; China; Emtricitabine; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Retrospective Studies | 2023 |
Geographic Variation in Qualified Health Plan Coverage and Prior Authorization Requirements for HIV Preexposure Prophylaxis.
Topics: Anti-HIV Agents; Cross-Sectional Studies; Emtricitabine; HIV Infections; Humans; Patient Protection and Affordable Care Act; Prior Authorization; Tenofovir; United States | 2023 |
Same-Day Initiation of Oral Pre-Exposure Prophylaxis is High Among Adolescent Men Who Have Sex With Men and Transgender Women in Brazil.
Topics: Adolescent; Anti-HIV Agents; Brazil; Cohort Studies; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Prospective Studies; Sexual and Gender Minorities; Tenofovir; Transgender Persons; Young Adult | 2023 |
Cost-effectiveness analysis of antiretroviral drugs for treatment-naive HIV infection in China.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cost-Effectiveness Analysis; Dideoxynucleosides; Emtricitabine; HIV Infections; Humans; Lamivudine | 2023 |
Model-based predictions of protective HIV pre-exposure prophylaxis adherence levels in cisgender women.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir | 2023 |
Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01.
Topics: Adult; Anti-HIV Agents; Antibodies, Monoclonal; Emtricitabine; HIV Infections; HIV-1; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir | 2023 |
Effect of implementation strategies on pre-exposure prophylaxis persistence among female sex workers in South Africa: an interrupted time series study.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Interrupted Time Series Analysis; Pre-Exposure Prophylaxis; Sex Workers; South Africa | 2023 |
HIV preexposure prophylaxis treatment patterns in a national health plan population.
Topics: Aged; Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Male; Medicare; Medication Adherence; Middle Aged; Retrospective Studies; United States | 2023 |
Tenofovir DF/emtricitabine/rilpivirine as HIV post-exposure prophylaxis: results from a multicentre prospective study-authors' response.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Prospective Studies; Rilpivirine; Tenofovir | 2019 |
Efavirenz-Induced Vanishing Bile Duct Syndrome: A Case Report.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Bile Ducts; Cholestasis; Cyclopropanes; Emtricitabine; HIV Infections; Humans; Male; Middle Aged | 2021 |
Switching to Tenofovir Alafenamide in Elvitegravir-Based Regimens: Pharmacokinetics and Antiviral Activity in Cerebrospinal Fluid.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Quinolones; Tenofovir | 2020 |
Switching antiretrovirals in older patients.
Topics: Adenine; Aged; Alanine; Bone Density; Cobicistat; Emtricitabine; HIV Infections; HIV-1; Humans; Middle Aged; Quinolones; Tablets; Tenofovir | 2019 |
Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia.
Topics: Adenine; Adult; Anti-HIV Agents; Cholesterol; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Hypercholesterolemia; Lipid Metabolism; Lipidomics; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Retrospective Studies; Rilpivirine; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Antiretroviral Penetration across Three Preclinical Animal Models and Humans in Eight Putative HIV Viral Reservoirs.
Topics: Animals; Anti-HIV Agents; Anti-Retroviral Agents; Atazanavir Sulfate; Emtricitabine; Female; HIV Infections; Humans; In Vitro Techniques; Maraviroc; Mice; Raltegravir Potassium; Tenofovir | 2019 |
Fevers and Night Sweats in a 35-year-old Man With Recent Travel to Southeast Asia.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Asia, Southeastern; Cobicistat; Emtricitabine; HIV Infections; Humans; Laos; Male; Quinolones; Sweating; Tenofovir; Thailand; Travel; United States | 2019 |
HIV drug resistance in a cohort of HIV-infected MSM in the United States.
Topics: Adult; Cohort Studies; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV Integrase Inhibitors; HIV-1; Homosexuality, Male; Humans; Male; Phylogeny; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Tenofovir; United States; Viral Load | 2020 |
HIV 101: fundamentals of antiretroviral therapy.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Integrase Inhibitors; Lamivudine; Life Cycle Stages; Male; Middle Aged; Mutation; Oxazines; Piperazines; Pyridones; RNA, Viral; Tenofovir; Viral Load | 2019 |
Where Were the Women? Gender Parity in Clinical Trials.
Topics: Adenine; Alanine; Anti-HIV Agents; Clinical Trials as Topic; Drug Approval; Drug Combinations; Emtricitabine; Equivalence Trials as Topic; Female; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Sex Factors; Tenofovir; United States; United States Food and Drug Administration | 2019 |
New PrEP formulation approved…but only for some.
Topics: Adenine; Anti-HIV Agents; Drug Approval; Emtricitabine; Female; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Research Design; Sexism; Tenofovir; Transgender Persons; United States; United States Food and Drug Administration | 2019 |
Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men.
Topics: Adult; Anti-HIV Agents; Drug Interactions; Emtricitabine; Estrogens; Female; HIV Infections; Humans; Male; Middle Aged; Pre-Exposure Prophylaxis; Tenofovir; Transgender Persons; Young Adult | 2019 |
Brief Report: Incidence of HIV in a Nationwide Cohort Receiving Pre-exposure Prophylaxis for HIV Prevention.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; HIV; HIV Infections; Humans; Incidence; Male; Medication Adherence; Middle Aged; Mutation; Phosphorous Acids; Pre-Exposure Prophylaxis; Retrospective Studies; United States; United States Department of Veterans Affairs; Young Adult | 2019 |
Translational Approach to Predicting the Efficacy of Maraviroc-Based Regimens as HIV Preexposure Prophylaxis.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Cohort Studies; Computer Simulation; Demography; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Maraviroc; Pre-Exposure Prophylaxis; Reproductive Tract Infections; Tenofovir; Treatment Outcome | 2020 |
Kaposi's Sarcoma Occurring in HIV Infection Controlled on HAART.
Topics: Ankle; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Emtricitabine; Foot; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lymphedema; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Sarcoma, Kaposi; Skin Neoplasms; Sustained Virologic Response; Tenofovir; Viral Load | 2020 |
Narrowing down the causes of failure of tenofovir (only) for preexposure prophylaxis.
Topics: Emtricitabine; Genetic Variation; HIV Infections; HIV-1; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2019 |
Successful use of once-daily high-dose darunavir and dolutegravir in multidrug-resistant HIV.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Directly Observed Therapy; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Ritonavir; Tenofovir; Treatment Outcome | 2020 |
On-demand PrEP efficacy: forgiveness or timely dosing.
Topics: Emtricitabine; Forgiveness; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Tenofovir | 2020 |
HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine and changes in kidney function and tubular health.
Topics: Adult; Aged; Anti-HIV Agents; Biomarkers; Creatinine; Cystatin C; Emtricitabine; Female; HIV Infections; Humans; Kidney; Kidney Function Tests; Kidney Glomerulus; Longitudinal Studies; Male; Middle Aged; Pre-Exposure Prophylaxis; Tenofovir | 2020 |
A case of M184V mutant human immunodeficiency virus in a patient using daily pre-exposure prophylaxis.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Reverse Transcriptase Inhibitors; Tenofovir; Virus Replication | 2020 |
Potential Impact and Cost-Effectiveness of Condomless-Sex-Concentrated PrEP in KwaZulu-Natal Accounting for Drug Resistance.
Topics: Adolescent; Adult; Anti-HIV Agents; Cost-Benefit Analysis; Drug Resistance; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Models, Theoretical; Pre-Exposure Prophylaxis; Sex Workers; South Africa; Unsafe Sex; Young Adult | 2021 |
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study.
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Diamond; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Tenofovir; Viral Load; Young Adult | 2020 |
Switch from tenofovir disoproxil fumarate to raltegravir is not associated with weight gain over 96 weeks.
Topics: Adult; Anti-HIV Agents; Body Mass Index; Emtricitabine; HIV Infections; HIV-1; Humans; Male; Middle Aged; Raltegravir Potassium; Tenofovir; Weight Gain | 2020 |
Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Tenofovir; Treatment Failure; United Kingdom | 2020 |
Drug-drug Interactions Among Thai Transgender Women Living with Human Immunodeficiency Undergoing Feminizing Hormone Therapy and Antiretroviral Therapy: The iFACT Study.
Topics: Anti-HIV Agents; Drug Interactions; Emtricitabine; Female; HIV Infections; Humans; Pharmaceutical Preparations; Thailand; Transgender Persons | 2021 |
On-Demand Oral Pre-exposure Prophylaxis with Tenofovir/Emtricitabine: What Every Clinician Needs to Know.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2020 |
Descovy Approved for HIV Prexposure Prophylaxis.
Topics: Adenine; Anti-HIV Agents; Drug Approval; Emtricitabine; HIV Infections; Humans; Tenofovir; United States; United States Food and Drug Administration | 2020 |
Failure to bictegravir and development of resistance mutations in an antiretroviral-experienced patient.
Topics: Adenine; Adult; Alanine; Amides; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Mutation; Piperazines; Pyridones; Tenofovir; Toxoplasmosis, Cerebral; Treatment Failure | 2020 |
HIV-1 superinfection in a patient with known HIV-2 - A case report.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Darunavir; Emtricitabine; Female; HIV Infections; HIV Seropositivity; HIV-1; HIV-2; Humans; Male; Middle Aged; Superinfection; Tenofovir; Treatment Outcome | 2020 |
Sustained virologic suppression with abacavir, emtricitabine, and crushed dolutegravir and tenofovir alafenamide in a patient with HIV and eosinophilic esophagitis.
Topics: Adult; Alanine; Anti-HIV Agents; Deglutition Disorders; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Eosinophilic Esophagitis; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Viral Load | 2020 |
Development of gynecomastia following initiation of bictegravir/emtricitabine/tenofovir alafenamide.
Topics: Adenine; Adult; Alanine; Amides; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Combinations; Emtricitabine; Gynecomastia; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Piperazines; Pyridones; Tenofovir; Treatment Outcome | 2020 |
Uptake, engagement, and adherence to pre-exposure prophylaxis offered after population HIV testing in rural Kenya and Uganda: 72-week interim analysis of observational data from the SEARCH study.
Topics: Adolescent; Adult; Anti-HIV Agents; Emtricitabine; Female; HIV; HIV Infections; Humans; Kenya; Male; Mass Screening; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Rural Population; Sex Workers; Tenofovir; Uganda; Young Adult | 2020 |
Frequency and Predictors of Tenofovir-diphosphate Detection Among Young Kenyan Women in a Real-world Pre-exposure Prophylaxis Implementation Program.
Topics: Anti-HIV Agents; Diphosphates; Emtricitabine; Female; HIV Infections; Humans; Kenya; Medication Adherence; Pre-Exposure Prophylaxis; Pregnancy; Tenofovir | 2020 |
Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Cost-Benefit Analysis; Drugs, Generic; Emtricitabine; Fractures, Bone; HIV Infections; Homosexuality, Male; Humans; Kidney Failure, Chronic; Male; Middle Aged; Pre-Exposure Prophylaxis; Quality-Adjusted Life Years; Tenofovir; United States; Young Adult | 2020 |
Rilpivirine in HIV-1-positive women initiating pregnancy: to switch or not to switch?
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Pregnancy; Rilpivirine; Viral Load | 2020 |
Emtricitabine.
Topics: Anti-HIV Agents; Emtricitabine; Hepatitis B; HIV Infections; Humans; Reverse Transcriptase Inhibitors | 2020 |
Brief Report: High Accuracy of a Real-Time Urine Antibody-Based Tenofovir Point-of-Care Test Compared With Laboratory-Based ELISA in Diverse Populations.
Topics: Adult; Anti-HIV Agents; Antibodies; Drug Combinations; Drug Monitoring; Emtricitabine; Enzyme-Linked Immunosorbent Assay; Female; HIV Infections; Humans; Kenya; Laboratories; Male; Patient Compliance; Point-of-Care Testing; Sensitivity and Specificity; Tenofovir; Uganda | 2020 |
Plasma nucleotide reverse transcriptase inhibitor concentration and their associations with liver and renal parameters in people living with HIV.
Topics: Anti-HIV Agents; Cohort Studies; Cross-Sectional Studies; Drug Combinations; Emtricitabine; HIV Infections; Humans; Kidney; Lamivudine; Liver; Nucleotides; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2020 |
Failure of pre-exposure prophylaxis with daily tenofovir/emtricitabine and the scenario of delayed HIV seroconversion.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV Infections; HIV Seropositivity; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Seroconversion; Tenofovir; Treatment Failure; Young Adult | 2020 |
Mother-to-Child HIV Transmission With In Utero Dolutegravir vs. Efavirenz in Botswana.
Topics: Adult; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Botswana; Cyclopropanes; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP3A Inducers; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Mothers; Oxazines; Piperazines; Pregnancy; Pyridones; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir; Young Adult | 2020 |
Crushed bictegravir/emtricitabine/tenofovir alafenamide in a human immunodeficiency virus-positive patient with esophageal cancer.
Topics: Adenine; Alanine; Anti-HIV Agents; Drug Combinations; Emtricitabine; Esophageal Neoplasms; Gastrostomy; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Piperazines; Pyridones; Tablets; Tenofovir | 2020 |
Short-term neuropsychiatric tolerability of bictegravir combined with emtricitabine/tenofovir alafenamide in clinical practice.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Amides; Anti-HIV Agents; Depression; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Piperazines; Pyridones; Retrospective Studies; Tenofovir; Time Factors; Young Adult | 2020 |
The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Emtricitabine; Female; Fumarates; HIV Infections; HIV-1; Humans; Male; Middle Aged; Retrospective Studies; Rilpivirine; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Weight Gain | 2020 |
PrEP for HIV Prevention: Evidence, Global Scale-up, and Emerging Options.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir; United States | 2020 |
Evaluating statewide HIV preexposure prophylaxis implementation using All-Payer Claims Data.
Topics: Adult; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Insurance Claim Review; Male; Pre-Exposure Prophylaxis; Rhode Island; Tenofovir | 2020 |
Usefulness of therapeutic drug monitoring of rilpivirine and its relationship with virologic response and resistance in a cohort of naive and pretreated HIV-infected patients.
Topics: Adult; Aged; Anti-HIV Agents; Cohort Studies; Drug Monitoring; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Retrospective Studies; Rilpivirine; Tenofovir; Viral Load; Young Adult | 2020 |
Satisfaction and knowledge among patients with HIV after switching from tenofovir to tenofovir alafenamide in regimens containing emtricitabine and rilpivirine
Topics: Adenine; Adult; Alanine; Antiviral Agents; Drug Combinations; Drug Substitution; Emtricitabine; Female; Health Knowledge, Attitudes, Practice; HIV Infections; Humans; Male; Middle Aged; Patient Satisfaction; Prospective Studies; Rilpivirine; Tenofovir | 2020 |
Previously unreported emergence of A265V substitution in the integrase gene in association with bictegravir virological failure.
Topics: Adenine; Aged; Alanine; Amides; Cell Line; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HEK293 Cells; HeLa Cells; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Male; Mutation; Piperazines; Pyridones; Tenofovir; Treatment Failure | 2020 |
Regional Disparities in Qualified Health Plans' Prior Authorization Requirements for HIV Pre-exposure Prophylaxis in the United States.
Topics: Anti-HIV Agents; Cross-Sectional Studies; Emtricitabine; Health Services Accessibility; HIV Infections; Humans; Patient Protection and Affordable Care Act; Pre-Exposure Prophylaxis; Prior Authorization; Tenofovir; United States | 2020 |
Changes in functional connectivity in people with HIV switching antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asymptomatic Diseases; Benzoxazines; Cognitive Dysfunction; Connectome; Cyclopropanes; Drug Substitution; Emtricitabine; Executive Function; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Magnetic Resonance Imaging; Male; Memory, Short-Term; Middle Aged; Neuropsychological Tests; Oxazines; Piperazines; Prospective Studies; Pyridones; Raltegravir Potassium; Rilpivirine; Tenofovir | 2020 |
Coronavirus disease 2019 and Pneumocystis jirovecii pneumonia: a diagnostic dilemma in HIV.
Topics: Anti-Bacterial Agents; Anti-HIV Agents; Asthma; Betacoronavirus; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Testing; Diagnosis, Differential; DNA, Bacterial; Emtricitabine; Glucocorticoids; HIV Infections; Humans; Lung; Male; Middle Aged; Multiplex Polymerase Chain Reaction; Oxygen Inhalation Therapy; Pandemics; Pneumocystis carinii; Pneumonia, Pneumocystis; Pneumonia, Viral; Prednisolone; Raltegravir Potassium; Real-Time Polymerase Chain Reaction; RNA, Viral; SARS-CoV-2; Tenofovir; Tomography, X-Ray Computed; Trimethoprim, Sulfamethoxazole Drug Combination; Viral Load | 2020 |
Weighing considerations with newer antiretrovirals.
Topics: Adenine; Alanine; Amides; Double-Blind Method; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Oxazines; Piperazines; Pyridones; Tenofovir | 2020 |
Post-exposure prophylaxis completion and condom use in the context of potential sexual exposure to HIV.
Topics: Adult; Condoms; Emtricitabine; Female; France; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Multivariate Analysis; Post-Exposure Prophylaxis; Retrospective Studies; Sexual Partners; Tenofovir; Unsafe Sex | 2020 |
Pharmacokinetic and Pharmacodynamic Impacts of Depot Medroxyprogesterone Acetate Use on HIV Pre-exposure Prophylaxis in Women.
Topics: Adolescent; Adult; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Leukocytes, Mononuclear; Medroxyprogesterone Acetate; Middle Aged; Pilot Projects; Pre-Exposure Prophylaxis; Tenofovir; Young Adult | 2020 |
Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy : A Cohort Study.
Topics: Adenine; Adult; Aged; Antiretroviral Therapy, Highly Active; Betacoronavirus; Coronavirus Infections; COVID-19; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; Hospitalization; Humans; Incidence; Intensive Care Units; Lamivudine; Male; Middle Aged; Pandemics; Pneumonia, Viral; Reverse Transcriptase Polymerase Chain Reaction; SARS-CoV-2; Severity of Illness Index; Spain; Tenofovir | 2020 |
Cases of coronavirus disease-2019 in HIV-infected transgender women.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Oxazines; Pandemics; Piperazines; Pneumonia, Viral; Pyridones; Ritonavir; SARS-CoV-2; Tenofovir; Transgender Persons | 2020 |
Severe rhabdomyolysis and acute asymptomatic pancreatitis following the concomitant use of Biktarvy in the setting of hyperosmolar diabetic crisis.
Topics: Adenine; Alanine; Anti-HIV Agents; Cholangiopancreatography, Magnetic Resonance; Diabetes Mellitus; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Insulin; Male; Middle Aged; Pancreatitis; Piperazines; Pyridones; Rhabdomyolysis; Tenofovir | 2020 |
Intracellular Tenofovir and Emtricitabine Concentrations in Younger and Older Women with HIV Receiving Tenofovir Disoproxil Fumarate/Emtricitabine.
Topics: Adult; Aged; Anti-HIV Agents; CD8-Positive T-Lymphocytes; Emtricitabine; Female; HIV Infections; Humans; Leukocytes, Mononuclear; Middle Aged; Tenofovir | 2020 |
HIV antiretroviral therapy and prevention use in US blood donors: a new blood safety concern.
Topics: Adolescent; Adult; Anti-HIV Agents; Blood Donors; Blood Safety; Chromatography, Liquid; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Post-Exposure Prophylaxis; Pre-Exposure Prophylaxis; Risk; Single-Blind Method; Tandem Mass Spectrometry; Tenofovir; Truth Disclosure; United States; Viremia; Young Adult | 2020 |
Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral sup
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Combinations; Drug Monitoring; Drug Substitution; Emtricitabine; HIV Infections; Humans; Lamivudine; Male; Prospective Studies; Taiwan; Tenofovir; Treatment Outcome; Viral Load | 2021 |
Use of Drug-level Testing and Single-genome Sequencing to Unravel a Case of Human Immunodeficiency Virus Seroconversion on Pre-exposure Prophylaxis.
Topics: Anti-HIV Agents; Emtricitabine; HIV; HIV Infections; Humans; Medication Adherence; Pharmaceutical Preparations; Pre-Exposure Prophylaxis; Seroconversion; Tenofovir | 2021 |
Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study.
Topics: Adult; Anti-HIV Agents; Cobicistat; Darunavir; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Spain; Tenofovir; Treatment Outcome; Viral Load | 2020 |
Bictegravir/emtricitabine/tenofovir alafenamide-induced acute pancreatitis: a case report.
Topics: Acute Disease; Adenine; Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lipase; Male; Pancreas; Pancreatitis; Piperazines; Pyridones; Tenofovir; Ultrasonography | 2020 |
PrEParing for Preexposure Prophylaxis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Pre-Exposure Prophylaxis; Tenofovir; United States | 2020 |
Single oral dose for HIV pre or post-exposure prophylaxis: user desirability and biological efficacy in macaques.
Topics: Adenine; Administration, Oral; Animals; Cross-Sectional Studies; Drug Combinations; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Macaca; Male; Patient Compliance; Pre-Exposure Prophylaxis; Quinolones; Rectum; Surveys and Questionnaires; Tenofovir | 2020 |
DISCOVER: much accomplished, but not yet for all.
Topics: Adenine; Alanine; Double-Blind Method; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2020 |
Marketing of Tenofovir Disoproxil Fumarate (TDF) Lawsuits and Social Media Misinformation Campaigns' Impact on PrEP Uptake Among Gender and Sexual Minority Individuals.
Topics: Anti-HIV Agents; Cohort Studies; Communication; Emtricitabine; Female; HIV Infections; Humans; Male; Marketing; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Social Media; Tenofovir | 2021 |
Impact of archived M184V/I mutation on the effectiveness of switch to co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide among virally suppressed people living with HIV.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cobicistat; Emtricitabine; HIV Infections; HIV-1; Humans; Mutation; Quinolones; Retrospective Studies; Tenofovir | 2020 |
Highly synergistic drug combination prevents vaginal HIV infection in humanized mice.
Topics: Administration, Intravaginal; Animals; Antiviral Agents; Drug Combinations; Drug Synergism; Emtricitabine; Female; HIV Infections; Humans; Mice; Tenofovir; Vagina | 2020 |
Changes in bone microarchitecture with abacavir--lamivudine versus tenofovir disoproxil fumarate--emtricitabine in adults living with HIV.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Emtricitabine; Fractures, Bone; HIV Infections; Humans; Incidence; Lamivudine; Osteoporotic Fractures; Tenofovir | 2020 |
Acceptability of pre-exposure prophylaxis for HIV prevention: facilitators, barriers and impact on sexual risk behaviors among men who have sex with men in Benin.
Topics: Adolescent; Adult; Anti-HIV Agents; Benin; Cities; Condoms; Cross-Sectional Studies; Emtricitabine; Health Services Accessibility; HIV Infections; Homosexuality, Male; Humans; Logistic Models; Male; Middle Aged; Odds Ratio; Patient Acceptance of Health Care; Pre-Exposure Prophylaxis; Risk-Taking; Safe Sex; Sexual and Gender Minorities; Sexual Behavior; Tenofovir; Young Adult | 2020 |
Successful Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment in a HIV Patient With Swallowing Difficulties.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Deglutition; Drug Combinations; Emtricitabine; Female; Fruit and Vegetable Juices; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Middle Aged; Piperazines; Pyridones; Solubility; Tenofovir | 2021 |
Population Pharmacokinetic and Pharmacodynamic Analysis To Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1.
Topics: Anti-HIV Agents; Emtricitabine; Fumarates; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Tenofovir; Triazoles | 2020 |
Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis.
Topics: Adenine; Alanine; Cost-Benefit Analysis; Emtricitabine; Family; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2020 |
Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis.
Topics: Adenine; Alanine; Cost-Benefit Analysis; Emtricitabine; Family; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2020 |
Dynamics of the Decay of Human Immunodeficiency Virus (HIV) RNA and Distribution of Bictegravir in the Genital Tract and Rectum in Antiretroviral-naive Adults Living With HIV-1 Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (Spanish HIV/AIDS
Topics: Adult; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Female; Genitalia; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Piperazines; Prospective Studies; Pyridones; Rectum; RNA; Tenofovir | 2021 |
Small-area spatial-temporal changes in pre-exposure prophylaxis (PrEP) use in the general population and among men who have sex with men in the United States between 2012 and 2018.
Topics: Adult; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Prevalence; Small-Area Analysis; Spatio-Temporal Analysis; Tenofovir; United States | 2020 |
Pharmacokinetics of tenofovir disoproxyl fumarate/emtricitabine in a client on pre-exposure prophylaxis after a total gastrectomy.
Topics: Adolescent; Adult; Anti-HIV Agents; Emtricitabine; Fumarates; Gastrectomy; HIV Infections; Humans; Middle Aged; Pre-Exposure Prophylaxis; Tenofovir; Young Adult | 2020 |
Treatment with Commonly Used Antiretroviral Drugs Induces a Type I/III Interferon Signature in the Gut in the Absence of HIV Infection.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Emtricitabine; Female; Gastrointestinal Microbiome; Gene Expression; HIV; HIV Infections; Humans; Interferon Type I; Male; Middle Aged; Pharmaceutical Preparations; Pre-Exposure Prophylaxis; Tenofovir; Transcriptome | 2020 |
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Leukocytes, Mononuclear; Mitochondria; Pre-Exposure Prophylaxis; Transcriptome | 2020 |
Where are we with pre-exposure prophylaxis use in Central and Eastern Europe? Data from the Euroguidelines in Central and Eastern Europe (ECEE) Network Group.
Topics: Anti-HIV Agents; Emtricitabine; Europe; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2021 |
Virtual HIV pre-exposure prophylaxis outpatient service in the era of COVID-19.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anti-HIV Agents; COVID-19; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Ireland; Male; Middle Aged; Pandemics; Pre-Exposure Prophylaxis; SARS-CoV-2; Tenofovir | 2021 |
Once-daily raltegravir with tenofovir disoproxil/emtricitabine as HIV post-exposure prophylaxis following sexual exposure.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Post-Exposure Prophylaxis; Pre-Exposure Prophylaxis; Raltegravir Potassium; Tenofovir | 2021 |
Post-Catalytic Complexes with Emtricitabine or Stavudine and HIV-1 Reverse Transcriptase Reveal New Mechanistic Insights for Nucleotide Incorporation and Drug Resistance.
Topics: Anti-HIV Agents; Catalysis; Crystallography, X-Ray; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Nucleotides; Reverse Transcriptase Inhibitors; Stavudine | 2020 |
Knowledge and barriers of PrEP delivery among diverse groups of potential PrEP users in Central Uganda.
Topics: Administration, Oral; Adult; Emtricitabine; Female; Health Knowledge, Attitudes, Practice; Health Services Accessibility; HIV Infections; Humans; Male; Patient Compliance; Pre-Exposure Prophylaxis; Surveys and Questionnaires; Tenofovir; Uganda | 2020 |
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide discontinuation and return to normal weight.
Topics: Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Quinolones; Tenofovir; Weight Gain | 2021 |
Two-dose emtricitabine/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection.
Topics: Adenine; Alanine; Amides; Animals; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Homosexuality, Male; Humans; Leukocytes, Mononuclear; Macaca; Male; Piperazines; Pre-Exposure Prophylaxis; Pyridones; Sexual and Gender Minorities; Tenofovir | 2021 |
PrEP Demonstration Project Showed Superior Adherence with Tenofovir Alafenamide/Emtricitabine Compared to Tenofovir Disoproxil Fumarate/Emtricitabine in a Sample of Partnered Sexual Minority Men.
Topics: Adenine; Alanine; Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Tenofovir; United States | 2021 |
Oral PrEP in adolescents in sub-Saharan Africa.
Topics: Adolescent; Africa South of the Sahara; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Safety; Tenofovir | 2020 |
Pharmacokinetics of tenofovir alafenamide with and without cobicistat in pregnant and postpartum women living with HIV.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cobicistat; Emtricitabine; Female; HIV Infections; Humans; Postpartum Period; Pregnancy; Prospective Studies; Tenofovir | 2021 |
Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment in HIV/HBV-Coinfected Patients.
Topics: Adult; Alanine; Anti-HIV Agents; Cobicistat; Cohort Studies; Drug Combinations; Drug Substitution; Emtricitabine; Female; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Quinolones; Taiwan; Tenofovir | 2021 |
Preoperative rapid suppression of viral load by elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide regimen in human immunodeficiency virus-positive fracture patients significantly reduces postoperative complications.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; HIV; HIV Infections; Humans; Postoperative Complications; Quinolones; Tenofovir; Viral Load | 2020 |
Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation.
Topics: Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation; Quinolones; Tenofovir; Young Adult | 2021 |
Comparison of Trends in Rates of Sexually Transmitted Infections Before vs After Initiation of HIV Preexposure Prophylaxis Among Men Who Have Sex With Men.
Topics: Adult; Anti-HIV Agents; Australia; Cohort Studies; Emtricitabine; Health Risk Behaviors; HIV Infections; Humans; Incidence; Male; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Sexual Behavior; Sexually Transmitted Diseases; Tenofovir | 2020 |
Universal health care needed to end HIV epidemic in the USA.
Topics: Anti-HIV Agents; Emtricitabine; Epidemics; Female; Health Services Needs and Demand; Healthcare Disparities; HIV Infections; Humans; Male; Tenofovir; United States; Universal Health Care | 2021 |
Evaluation of the Microbiome in Men Taking Pre-exposure Prophylaxis for HIV Prevention.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Male; Microbiota; Pre-Exposure Prophylaxis; RNA, Ribosomal, 16S | 2021 |
Short Communication: Evaluation of Antiretroviral Drug Concentrations in Minimally Invasive Specimens for Potential Development of Point-of-Care Drug Assays.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Male; Pharmaceutical Preparations; Point-of-Care Systems; Tenofovir | 2021 |
Effectiveness and safety of antiretroviral treatment in pre- and postmenopausal women living with HIV in a multicentre cohort.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Postmenopause; Viral Load | 2020 |
Differences in tenofovir trough concentrations between branded and generic formulations in people taking PrEP.
Topics: Drugs, Generic; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2021 |
Acute HIV at the Time of Initiation of Pre-exposure or Post-exposure Prophylaxis: Impact on Drug Resistance and Clinical Outcomes.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Middle Aged; Point-of-Care Testing; Post-Exposure Prophylaxis; Pre-Exposure Prophylaxis; Retrospective Studies; San Francisco; Tenofovir; Treatment Outcome; Undiagnosed Diseases | 2021 |
Urine Tenofovir Levels Measured Using a Novel Immunoassay Predict Human Immunodeficiency Virus Protection.
Topics: Anti-HIV Agents; Emtricitabine; HIV; HIV Infections; Humans; Immunoassay; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir | 2021 |
Preference for daily versus on-demand pre-exposure prophylaxis for HIV and correlates among men who have sex with men: the China Real-world Oral PrEP Demonstration study.
Topics: Administration, Oral; Adult; Anti-HIV Agents; China; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Infant, Newborn; Male; Patient Preference; Pre-Exposure Prophylaxis; Tenofovir | 2021 |
Failure of pre-exposure prophylaxis with on-demand tenofovir disoproxil fumarate/emtricitabine resulting in emergence of antiretroviral resistance.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Emtricitabine; HIV; HIV Infections; Humans; Male; Mutation; Pre-Exposure Prophylaxis; Tenofovir | 2021 |
Highlights of HIVR4P // Virtual.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Pyridones; Sexual Behavior; Tenofovir | 2021 |
Tenofovir-based PrEP for COVID-19: an untapped opportunity?
Topics: Anti-HIV Agents; COVID-19; Emtricitabine; HIV Infections; Humans; Medication Adherence; Pre-Exposure Prophylaxis; SARS-CoV-2; Tenofovir | 2021 |
Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure.
Topics: Adolescent; Anti-HIV Agents; Child; DNA; Drug Resistance, Viral; Emtricitabine; HIV Infections; Humans; Lamivudine; Prevalence; Proviruses; Viral Load | 2021 |
Tenofovir and emtricitabine concentrations in hair are comparable between individuals on tenofovir disoproxil fumarate versus tenofovir alafenamide-based ART.
Topics: Adenine; Anti-HIV Agents; Chromatography, High Pressure Liquid; Cobicistat; Dose-Response Relationship, Drug; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Hair; Hair Analysis; HIV Infections; Humans; Ritonavir; Tandem Mass Spectrometry; Tenofovir; Tissue Distribution | 2021 |
Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxis.
Topics: Anti-HIV Agents; Colorectal Neoplasms; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Leukocytes, Mononuclear; Male; Pre-Exposure Prophylaxis; Sexual and Gender Minorities | 2021 |
Results from a Pre-exposure Prophylaxis Demonstration Project for At-risk Cisgender Women in the United States.
Topics: Adolescent; Adult; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Tenofovir; United States | 2021 |
Electrospun fibers for vaginal administration of tenofovir disoproxil fumarate and emtricitabine in the context of topical pre-exposure prophylaxis.
Topics: Administration, Intravaginal; Animals; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Mice; Pre-Exposure Prophylaxis; Tenofovir | 2021 |
A retrospective evaluation of highly active antiretroviral therapy simplification in patients with end-stage renal disease receiving hemodialysis.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Emtricitabine; HIV Infections; HIV-1; Humans; Kidney Failure, Chronic; Renal Dialysis; Retrospective Studies; Viral Load | 2021 |
Adherence to event-driven HIV PrEP among men who have sex with men in Amsterdam, the Netherlands: analysis based on online diary data, 3-monthly questionnaires and intracellular TFV-DP.
Topics: Anti-HIV Agents; Diphosphates; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Netherlands; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Sexual Behavior; Surveys and Questionnaires; Transgender Persons | 2021 |
Rapid initiation of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in acute and early HIV-1 infection: a DIAMOND subgroup analysis.
Topics: Adolescent; Adult; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Tenofovir; Viral Load | 2021 |
Antiretroviral drug exposure in urethral and glans surface sampling of the penis.
Topics: Anti-HIV Agents; Cobicistat; Emtricitabine; HIV Infections; HIV-1; Humans; Male; Pharmaceutical Preparations; Urethra | 2021 |
[Effectiveness, safety, and economic impact of the bictegravir/emtricitabine/tenofovir alafenamide regimen in real clinical practice cohort of HIV-1 infected adult patients].
Topics: Adolescent; Adult; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; Retrospective Studies; Tenofovir | 2021 |
HIV pre-exposure prophylaxis for men who have sex with men in west Africa: a multicountry demonstration study.
Topics: Adult; Africa, Western; Anti-HIV Agents; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Pilot Projects; Pre-Exposure Prophylaxis; Prospective Studies; Sexual Behavior; Tenofovir; Young Adult | 2021 |
Dosing lamivudine or emtricitabine in renal impairment: new data confirm it's time for updated guidance!
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Kidney; Lamivudine | 2021 |
Failure to seroconvert after two doses of BNT162b2 SARS-CoV-2 vaccine in a patient with uncontrolled HIV.
Topics: Adenine; Adult; Alanine; Amides; Antiretroviral Therapy, Highly Active; BNT162 Vaccine; CD4 Lymphocyte Count; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; COVID-19; COVID-19 Vaccines; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Neutralization Tests; Piperazines; Pyridones; RNA, Viral; SARS-CoV-2; Tenofovir; Treatment Failure | 2021 |
Physiologically Relevant Concentrations of Dolutegravir, Emtricitabine, and Efavirenz Induce Distinct Metabolic Alterations in HeLa Epithelial and BV2 Microglial Cells.
Topics: Adenosine Triphosphate; Alkynes; Anti-HIV Agents; Benzoxazines; Cell Line, Tumor; Cyclopropanes; Emtricitabine; Epithelial Cells; HeLa Cells; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Membrane Potential, Mitochondrial; Microglia; Mitochondria; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Virus Latency; Xanthenes | 2021 |
Undisclosed Antiretroviral Therapy Use at Primary Health Care Clinics in Rural KwaZulu Natal South Africa: A DO-ART Trial Sub-study.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Primary Health Care; Rural Population; South Africa | 2021 |
Efficacy and tolerability of combined antiretroviral treatment with bictegravir/emtricitabine/tenofovir alafenamide initiated at the time of primary HIV infection.
Topics: Alanine; Amides; Anti-HIV Agents; Anti-Retroviral Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Piperazines; Pyridones; Tenofovir | 2021 |
Emtricitabine triphosphate in dried blood spots predicts future viremia in persons with HIV and identifies mismatch with self-reported adherence.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Medication Adherence; Polyphosphates; Prospective Studies; Self Report; Tenofovir; Viremia | 2021 |
Evaluation of kidney function tests in HIV-positive patients receiving combined antiretroviral therapy.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; HIV Infections; HIV-1; Humans; Kidney Function Tests; Tenofovir | 2021 |
Bictegravir/emtricitabine/tenofovir alafenamide combination in the management of kidney transplant patients with HIV receiving immunosuppressants.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Immunosuppressive Agents; Kidney Transplantation; Piperazines; Protease Inhibitors; Pyridones; Tacrolimus; Tenofovir | 2022 |
Transmitted drug resistance to Tenofovir/Emtricitabine among persons with newly diagnosed HIV infection in Shenyang city, Northeast China from 2016 to 2018.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Child; Child, Preschool; China; Drug Resistance, Viral; Emtricitabine; Epidemics; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Middle Aged; Phylogeny; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult | 2021 |
Renal impairment in a large-scale HIV preexposure prophylaxis implementation cohort.
Topics: Adult; Anti-HIV Agents; Australia; Emtricitabine; HIV Infections; Humans; Kidney Diseases; Male; Pre-Exposure Prophylaxis | 2021 |
Adherence to Daily Oral TDF/FTC for PrEP in Community Health Center Populations: The Sustainable Health Center Implementation PrEP Pilot (SHIPP) Study.
Topics: Anti-HIV Agents; Community Health Centers; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Transgender Persons | 2022 |
Mathematical Modelling of the Molecular Mechanisms of Interaction of Tenofovir with Emtricitabine against HIV.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Theoretical; Pre-Exposure Prophylaxis; Reverse Transcription; Tenofovir | 2021 |
A cross-species comparison of antiretroviral penetration into lymph nodes using novel physiologically based pharmacokinetic models.
Topics: Animals; Anti-Retroviral Agents; Emtricitabine; HIV Infections; Lymph Nodes; Models, Biological; Tenofovir | 2021 |
Why Are Patients Switching from Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) to Tenofovir Alafenamide/Emtricitabine (Descovy) for Pre-Exposure Prophylaxis?
Topics: Adenine; Alanine; Anti-HIV Agents; Cohort Studies; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir | 2021 |
Impact of dosing strategies on plasma concentrations of tenofovir: Implications in HIV pre-exposure prophylaxis in China.
Topics: Anti-HIV Agents; China; Emtricitabine; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir | 2021 |
Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients.
Topics: Anti-HIV Agents; DNA; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV-1; Humans; Kinetics; Lamivudine; Mutation; RNA | 2022 |
Pharmacokinetics of bictegravir, emtricitabine and tenofovir alafenamide in a gastrectomized patient with HIV.
Topics: Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Piperazines; Pyridones; Tenofovir | 2021 |
Predominance of Hepatitis B Virus Genotype A Among Treated HIV Infected Patients Experiencing High Hepatitis B Virus Drug Resistance in Nairobi, Kenya.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Cross-Sectional Studies; DNA, Viral; Drug Resistance, Viral; Emtricitabine; Female; Genes, pol; Genotype; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Kenya; Lamivudine; Male; Middle Aged; Tenofovir; Viral Load; Young Adult | 2017 |
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection-authors' response.
Topics: Adenine; Anti-HIV Agents; Cobicistat; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Organophosphonates; Quinolones; Tenofovir | 2017 |
US Black Women and Human Immunodeficiency Virus Prevention: Time for New Approaches to Clinical Trials.
Topics: Adult; Anti-HIV Agents; Black or African American; Clinical Trials, Phase III as Topic; Emtricitabine; Female; HIV Infections; Humans; Incidence; Medication Adherence; Pre-Exposure Prophylaxis; Racism; Research Design; Sample Size; Tenofovir; United States | 2017 |
Severe hypokalemia due to a possible drug-drug interaction between vinblastine and antiretrovirals in a HIV-infected patient with Hodgkin's lymphoma.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Doxorubicin; Drug Interactions; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; Hodgkin Disease; Humans; Hypokalemia; Middle Aged; Ritonavir; Tenofovir; Treatment Outcome; Vinblastine | 2017 |
High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project.
Topics: Adolescent; Adult; Anti-HIV Agents; Brazil; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Longitudinal Studies; Male; Medication Adherence; Pre-Exposure Prophylaxis; Prospective Studies; Sexual Behavior; Tenofovir; Transgender Persons; Young Adult | 2017 |
Bone Density, Microarchitecture, and Tissue Quality After Long-Term Treatment With Tenofovir/Emtricitabine or Abacavir/Lamivudine.
Topics: Absorptiometry, Photon; Anti-HIV Agents; Bone Density; Bone Remodeling; Cross-Sectional Studies; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Spain; Tenofovir | 2017 |
Factors associated with loss to follow-up after occupational HIV exposure in Cape Town, South Africa: a retrospective cohort study.
Topics: Adult; Anti-HIV Agents; Emtricitabine; Female; Health Personnel; HIV Infections; Humans; Infectious Disease Transmission, Patient-to-Professional; Lamivudine; Lost to Follow-Up; Male; Occupational Exposure; Post-Exposure Prophylaxis; Retrospective Studies; South Africa; Stavudine; Tenofovir; Young Adult; Zidovudine | 2017 |
Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis.
Topics: Adult; Antiviral Agents; Chromatography, Liquid; Drug Administration Schedule; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Pilot Projects; Pre-Exposure Prophylaxis; Tandem Mass Spectrometry; Tenofovir; Young Adult | 2017 |
Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Resistance, Viral; Emtricitabine; Europe; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation, Missense; Reverse Transcriptase Inhibitors; Tenofovir; Thymidine; United States | 2017 |
HIV prevention: response to pre-exposure prophylaxis failure with tenofovir disoproxil.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2017 |
Preexposure prophylaxis failure with tenofovir disoproxil.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2017 |
Stability behavior of antiretroviral drugs and their combinations. 7: Comparative degradation pathways of lamivudine and emtricitabine and explanation to their differential degradation behavior by density functional theory.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; HIV Infections; Lamivudine; Tenofovir | 2017 |
Decreased Absorption of Dolutegravir and Tenofovir Disoproxil Fumarate, But Not Emtricitabine, in an HIV-Infected Patient Following Oral and Jejunostomy-Tube Administration.
Topics: Administration, Oral; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; Enteral Nutrition; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Jejunostomy; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir | 2017 |
A Mathematical Model to Predict HIV Virological Failure and Elucidate the Role of Lymph Node Drug Penetration.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Lymph Nodes; Medication Adherence; Models, Biological; Mutation; Ritonavir; Tenofovir; Viral Load | 2017 |
Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Clinical Decision-Making; Computational Biology; Cross-Sectional Studies; Cyclopropanes; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Monitoring, Physiologic; Nevirapine; pol Gene Products, Human Immunodeficiency Virus; Stavudine; Tanzania; Tenofovir; Treatment Failure; Viral Load | 2017 |
High decay of blood HIV reservoir when tenofovir/emtricitabine/elvitegravir/cobicistat is initiated during the acute primary HIV infection.
Topics: Adult; Anti-HIV Agents; Blood; Cobicistat; Emtricitabine; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Secondary Prevention; Tenofovir; Treatment Outcome; Viral Load | 2017 |
Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project.
Topics: Adult; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quinolones; Safety; Tenofovir | 2017 |
InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Chemoprevention; Chromatography, Liquid; Disease Transmission, Infectious; Emtricitabine; Female; HIV Infections; Humans; London; Male; Middle Aged; Plasma; Pre-Exposure Prophylaxis; Tenofovir; Treatment Outcome; Young Adult | 2018 |
Urine tenofovir and emtricitabine concentrations provide biomarker for exposure to HIV preexposure prophylaxis.
Topics: Antiviral Agents; Biomarkers; Cross-Sectional Studies; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir; Urinalysis | 2017 |
Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks.
Topics: Adult; Anti-HIV Agents; Cholesterol, HDL; Drug Combinations; Drug Substitution; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Rilpivirine; RNA, Viral; Sustained Virologic Response; Tablets; Tenofovir; Triglycerides; Viral Load | 2017 |
Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
Topics: Adolescent; Adult; Anti-HIV Agents; Canada; Cohort Studies; Condoms; Emtricitabine; Follow-Up Studies; France; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Randomized Controlled Trials as Topic; Sexual Behavior; Tenofovir; Young Adult | 2017 |
Misleading
Topics: Adenocarcinoma; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Emtricitabine; Fluorodeoxyglucose F18; Gastrectomy; HIV Infections; Humans; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Stomach Neoplasms; Tenofovir; Treatment Outcome | 2018 |
Feasibility, Acceptability, and Adherence with Short-Term HIV Preexposure Prophylaxis in Female Sexual Partners of Migrant Miners in Mozambique.
Topics: Adult; Anti-HIV Agents; Condoms; Directive Counseling; Educational Status; Emtricitabine; Feasibility Studies; Female; Health Knowledge, Attitudes, Practice; HIV Infections; Humans; Medication Adherence; Middle Aged; Mining; Mozambique; Patient Acceptance of Health Care; Pre-Exposure Prophylaxis; Sexual Partners; Tenofovir; Transients and Migrants; Workforce | 2017 |
Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice.
Topics: Animals; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Mice; Pre-Exposure Prophylaxis; Rectum; Tenofovir; Vagina | 2017 |
Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; HIV Infections; HIV Seropositivity; HIV-1; Homosexuality, Male; Humans; Lymphogranuloma Venereum; Male; Medication Adherence; Middle Aged; Organophosphates; Pre-Exposure Prophylaxis; RNA, Viral; Tenofovir; Transgender Persons; Urinary Tract Infections | 2017 |
Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients.
Topics: Adult; Atazanavir Sulfate; CD4 Lymphocyte Count; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant, Newborn; Leukocytes, Mononuclear; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimesters; Prospective Studies; Ritonavir; RNA, Viral; Tenofovir; Viral Load | 2017 |
M184I/V substitutions and E138K/M184I/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA.
Topics: Amino Acid Substitution; Anti-HIV Agents; Clinical Trials as Topic; Deoxyadenosines; Drug Resistance, Viral; Emtricitabine; HEK293 Cells; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutagenesis, Site-Directed; Mutation; Reverse Transcriptase Inhibitors; Rilpivirine; Virus Replication | 2017 |
Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Creatinine; Disease Transmission, Infectious; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; Homosexuality, Male; Humans; Kidney Function Tests; Male; Metabolic Clearance Rate; Middle Aged; Pre-Exposure Prophylaxis; Prospective Studies; Proteins; Renal Insufficiency; Tenofovir; Transgender Persons; United States; Urinalysis; Young Adult | 2018 |
Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States.
Topics: Adolescent; Anti-HIV Agents; Blood Chemical Analysis; Disease Transmission, Infectious; Emtricitabine; Hair; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir; United States; Young Adult | 2018 |
The Female Genital Tract Microbiome Is Associated With Vaginal Antiretroviral Drug Concentrations in Human Immunodeficiency Virus-Infected Women on Antiretroviral Therapy.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Cohort Studies; Deoxycytidine; Emtricitabine; Female; Fumarates; Genitalia, Female; HIV Infections; Humans; Microbiota; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Young Adult | 2017 |
Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation.
Topics: Adolescent; Adult; Anti-HIV Agents; Cost-Benefit Analysis; Disease Transmission, Infectious; Emtricitabine; England; HIV Infections; Homosexuality, Male; Humans; Male; Middle Aged; Pre-Exposure Prophylaxis; Tenofovir; Young Adult | 2018 |
Brief Participant-Centered Convergence Interviews Integrate Self-Reports, Product Returns, and Pharmacokinetic Results to Improve Adherence Measurement in MTN-017.
Topics: Adult; Anti-HIV Agents; Counseling; Data Accuracy; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Self Report; Tenofovir | 2018 |
Utility of Different Adherence Measures for PrEP: Patterns and Incremental Value.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Emtricitabine; Female; Hair; HIV Infections; Humans; Kenya; Male; Medication Adherence; Pre-Exposure Prophylaxis; Self Report; Tenofovir; Uganda | 2018 |
Validation of an LC-MS/MS assay to simultaneously monitor the intracellular active metabolites of tenofovir, emtricitabine, and lamivudine in dried blood spots.
Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; Dried Blood Spot Testing; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Leukocytes, Mononuclear; Liquid-Liquid Extraction; Medication Adherence; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Tenofovir | 2018 |
Preference of Oral Tenofovir Disoproxil Fumarate/Emtricitabine Versus Rectal Tenofovir Reduced-Glycerin 1% Gel Regimens for HIV Prevention Among Cisgender Men and Transgender Women Who Engage in Receptive Anal Intercourse with Men.
Topics: Administration, Oral; Administration, Rectal; Adolescent; Adult; Anti-HIV Agents; Antiviral Agents; Emtricitabine; Female; Gels; HIV Infections; Humans; Lubricants; Male; Patient Acceptance of Health Care; Pre-Exposure Prophylaxis; Sexual Behavior; Sexual Partners; Tenofovir; Transgender Persons; Young Adult | 2017 |
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients.
Topics: Adult; Drug Therapy, Combination; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; HIV Integrase Inhibitors; Humans; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Rilpivirine; Tenofovir; Treatment Outcome | 2017 |
Short Communication: Tenofovir Disoproxil Fumarate/Emtricitabine Fits for All as Appropriate HIV-1 Pre-Exposure Prophylaxis?
Topics: Adult; Anti-HIV Agents; Drug Combinations; Emtricitabine; Female; HIV Core Protein p24; HIV Infections; Humans; Male; Patient Acceptance of Health Care; Pre-Exposure Prophylaxis; Safe Sex; Sexual Partners; Tenofovir; Young Adult | 2018 |
Medication Adherence in a Nationwide Cohort of Veterans Initiating Pre-exposure Prophylaxis (PrEP) to Prevent HIV Infection.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-HIV Agents; Emtricitabine; Ethnicity; Female; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Sex Factors; Tenofovir; Veterans | 2018 |
Hypersensitivity to antiretroviral drugs.
Topics: Anti-HIV Agents; Drug Hypersensitivity; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Skin Tests; Tenofovir | 2018 |
Brief Report: Abacavir/Lamivudine and Tenofovir/Emtricitabine in Pregnant Women With HIV: Laboratory and Clinical Outcomes in an Observational National Study.
Topics: Adult; AIDS-Associated Nephropathy; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cesarean Section; Cholesterol; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Hemoglobins; HIV Infections; HIV-1; Humans; Hypertension; Lamivudine; Lipoproteins, LDL; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Pregnancy Trimester, Third; RNA, Viral; Tenofovir | 2018 |
Family planning providers' role in offering PrEP to women.
Topics: Anti-HIV Agents; Emtricitabine; Family Planning Services; Female; Health Education; HIV Infections; Humans; Pre-Exposure Prophylaxis; Sex Education; Sexual Behavior; Tenofovir; United States | 2018 |
Composite films for vaginal delivery of tenofovir disoproxil fumarate and emtricitabine.
Topics: Administration, Intravaginal; Anti-HIV Agents; Cell Line; Cell Line, Tumor; Drug Discovery; Drug Liberation; Emtricitabine; Female; HeLa Cells; HIV Infections; Humans; Male; Nanoparticles; Tenofovir; Vagina | 2019 |
Preterm delivery and small-for-gestation outcomes in HIV-infected pregnant women on antiretroviral therapy in rural South Africa: Results from a cohort study, 2010-2015.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Infant, Newborn; Infant, Premature; Infant, Small for Gestational Age; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Premature Birth; Retrospective Studies; Rural Population; South Africa; Tenofovir; Young Adult | 2018 |
Awareness and Acceptance of HIV Pre-exposure Prophylaxis among Medical Personnel and Men Who Have Sex with Men in Korea.
Topics: Adult; Anti-HIV Agents; Cross-Sectional Studies; Emtricitabine; Health Knowledge, Attitudes, Practice; Health Personnel; HIV Infections; Homosexuality, Male; Humans; Male; Middle Aged; Patient Acceptance of Health Care; Pre-Exposure Prophylaxis; Republic of Korea; Sexual and Gender Minorities; Sexual Behavior; Sexual Partners; Surveys and Questionnaires; Tenofovir | 2018 |
The cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men and transgender women at high risk of HIV infection in Brazil.
Topics: Adult; Anti-HIV Agents; Cost-Benefit Analysis; Emtricitabine; Female; Health Care Costs; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir; Transgender Persons | 2018 |
Men who have sex with men more often chose daily than event-driven use of pre-exposure prophylaxis: baseline analysis of a demonstration study in Amsterdam.
Topics: Adult; Anti-HIV Agents; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Prospective Studies; Risk Factors; Tenofovir; Transgender Persons | 2018 |
Stable Caloric Intake and Continued Virologic Suppression for HIV-Positive Antiretroviral Treatment-Experienced Women After Switching to a Single-Tablet Regimen of Emtricitabine, Rilpivirine, and Tenofovir Disoproxil Fumarate.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Emtricitabine; Energy Intake; Female; HIV Infections; Humans; Maintenance Chemotherapy; Middle Aged; Reverse Transcriptase Inhibitors; Rilpivirine; Sustained Virologic Response; Tablets; Tenofovir; Treatment Outcome; Viral Load | 2018 |
3D printed, controlled release, tritherapeutic tablet matrix for advanced anti-HIV-1 drug delivery.
Topics: Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delayed-Action Preparations; Drug Liberation; Emtricitabine; HIV Infections; HIV-1; Humans; Printing, Three-Dimensional; Swine; Tablets; Tenofovir | 2019 |
Seroconversion on preexposure prophylaxis: a case report with segmental hair analysis for timed adherence determination.
Topics: Adult; Anti-HIV Agents; Chromatography, Liquid; Disease Transmission, Infectious; Drug Resistance, Multiple, Viral; Emtricitabine; Genotype; Hair; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Mass Spectrometry; Medication Adherence; Pre-Exposure Prophylaxis; Seroconversion; Tenofovir | 2018 |
Effect of Gestational Age at Tenofovir-Emtricitabine-Efavirenz Initiation on Adverse Birth Outcomes in Botswana.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Botswana; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; Fetal Death; Gestational Age; HIV Infections; Humans; Infant, Low Birth Weight; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Premature Birth; Stillbirth; Tenofovir | 2018 |
Maximizing the Benefits of HIV Preexposure Prophylaxis.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir | 2018 |
Birth Outcomes for Pregnant Women with HIV Using Tenofovir-Emtricitabine.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Disease Transmission, Infectious; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Infant, Low Birth Weight; Infant, Newborn; Lamivudine; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Premature Birth; Risk; Ritonavir; Tenofovir; Zidovudine | 2018 |
Acceptability of Antiretroviral Pre-exposure Prophylaxis from a Cohort of Sexually Experienced Young Transgender Women in Two U.S. Cities.
Topics: Adolescent; Adult; Anti-HIV Agents; Boston; Chicago; Cities; Cohort Studies; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Patient Acceptance of Health Care; Pre-Exposure Prophylaxis; Sexual Behavior; Sexual Partners; Tenofovir; Transgender Persons; Young Adult | 2018 |
Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study).
Topics: Adult; Atazanavir Sulfate; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Retrospective Studies; Tenofovir; Treatment Failure; Viral Load | 2018 |
CROI 2018: Advances in Antiretroviral Therapy.
Topics: Adenine; Amides; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Congresses as Topic; Deoxyadenosines; Drug Therapy, Combination; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; Tenofovir; Viral Load | 2018 |
Enhanced HIV viral load suppression with crushed combination tablets containing tenofovir alafenamide and emtricitabine.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Male; Middle Aged; Tablets; Tenofovir; Treatment Outcome; Viral Load | 2018 |
Efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide in the treatment of HIV-1.
Topics: Adenine; Alanine; Anti-HIV Agents; Clinical Trials as Topic; Cobicistat; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Kidney Diseases; Tablets; Tenofovir | 2018 |
Patterns and Correlates of Participant Retention in a Multi-City Pre-Exposure Prophylaxis Demonstration Project.
Topics: Adult; Anti-HIV Agents; District of Columbia; Drug Therapy, Combination; Emtricitabine; Female; Florida; HIV Infections; Homosexuality, Male; Humans; Male; Middle Aged; Pre-Exposure Prophylaxis; San Francisco; Tenofovir | 2018 |
The use of HIV post-exposure prophylaxis in forensic medicine following incidents of sexual violence in Hamburg, Germany: a retrospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Child; Child, Preschool; Emtricitabine; Female; Germany; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Post-Exposure Prophylaxis; Raltegravir Potassium; Retrospective Studies; Sex Offenses; Tenofovir; Young Adult | 2018 |
Lipid changes and tolerability in a cohort of adult HIV-infected patients who switched to rilpivirine/emtricitabine/tenofovir due to intolerance to previous combination ART: the PRO-STR study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Substitution; Dyslipidemias; Emtricitabine; Female; HIV Infections; Humans; Lipids; Male; Prospective Studies; Rilpivirine; Tenofovir; Viral Load | 2018 |
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study.
Topics: Adult; Anti-HIV Agents; CD4-CD8 Ratio; CD8-Positive T-Lymphocytes; Cohort Studies; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Tenofovir | 2018 |
Pseudoresistance of hepatitis B virus to tenofovir with emtricitabine.
Topics: Anti-HIV Agents; Coinfection; Drug Resistance, Viral; Emtricitabine; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Tenofovir | 2018 |
What did we learn from the bictegravir switch studies?
Topics: Adenine; Adult; Alanine; Amides; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Piperazines; Protease Inhibitors; Pyridones; Tenofovir | 2018 |
Day-On, Day-Off emtricitabine, tenofovir disoproxil fumarate and efavirenz single tablet regimen (DODO) as maintenance therapy in HIV-infected patients.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Emtricitabine; Female; HIV Infections; Humans; Maintenance Chemotherapy; Male; Middle Aged; Reverse Transcriptase Inhibitors; Tablets; Tenofovir | 2018 |
Acquisition of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Infection in a Patient Taking Preexposure Prophylaxis.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Multiple, Viral; Emtricitabine; HIV Infections; HIV Seropositivity; HIV-1; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; RNA, Viral; Tenofovir; Thailand | 2018 |
Access to sexual health services after the rapid roll out of the launch of pre-exposure prophylaxis for HIV in Melbourne, Australia: a retrospective cross-sectional analysis.
Topics: Adolescent; Adult; Anti-HIV Agents; Cross-Sectional Studies; Drug Therapy, Combination; Emtricitabine; Female; Health Services Accessibility; Health Services Needs and Demand; HIV Infections; Humans; Male; Middle Aged; Pre-Exposure Prophylaxis; Retrospective Studies; Sexually Transmitted Diseases, Viral; Tenofovir; Victoria | 2018 |
Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1.
Topics: Adult; Analysis of Variance; Anti-HIV Agents; Darunavir; DNA; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; Raltegravir Potassium; Randomized Controlled Trials as Topic; Ritonavir; Telomere; Tenofovir | 2018 |
HIV health care providers are ready to introduce pre-exposure prophylaxis in Central and Eastern Europe and neighbouring countries: data from the Euroguidelines in Central and Eastern Europe (ECEE) Network Group.
Topics: Adult; Emtricitabine; Europe; Female; Health Personnel; HIV Infections; Humans; Male; Middle Aged; Practice Guidelines as Topic; Pre-Exposure Prophylaxis; Safe Sex; Standard of Care; Surveys and Questionnaires; Tenofovir; Young Adult | 2018 |
Exploring an alternative explanation for the second phase of viral decay: Infection of short-lived cells in a drug-limited compartment during HAART.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4-Positive T-Lymphocytes; Cyclopropanes; Emtricitabine; HIV Infections; HIV-1; Host-Pathogen Interactions; Humans; Models, Statistical; Monocytes; RNA, Viral; Tenofovir; Viral Load; Virus Replication | 2018 |
Boosted darunavir, emtricitabine and tenofovir pharmacokinetics in sthe early and late postgastric bypass surgery periods.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Bariatric Surgery; Chromatography, Liquid; Darunavir; Emtricitabine; Female; Gastric Bypass; HIV Infections; Humans; Obesity; Plasma; Tandem Mass Spectrometry; Tenofovir | 2018 |
Clinical Outcomes Associated With Once-Daily Ritonavir-Boosted Darunavir Plus Tenofovir/Emtricitabine in HIV-Infected Patients Harboring at Minimum a M184V/I Resistance Mutation.
Topics: Adult; Aged; Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation; Retrospective Studies; Ritonavir; Treatment Outcome; Young Adult | 2019 |
Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis.
Topics: Adenine; Administration, Cutaneous; Animals; Antiviral Agents; Drug Delivery Systems; Emtricitabine; Equipment Design; HIV Infections; Humans; Infusion Pumps, Implantable; Lab-On-A-Chip Devices; Macaca mulatta; Organophosphates; Pre-Exposure Prophylaxis | 2018 |
Biktarvy--another INSTI-based combination for HIV.
Topics: Amides; Anti-HIV Agents; Drug Approval; Drug Combinations; Drug Interactions; Drug Resistance, Viral; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Piperazines; Pyridones; Randomized Controlled Trials as Topic; Tenofovir; United States; United States Food and Drug Administration | 2018 |
Overdose of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in an HIV-1-infected subject with attempted suicide.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Drug Overdose; Emtricitabine; HIV Infections; Humans; Male; Middle Aged; Quinolones; Renal Insufficiency; Suicide, Attempted; Tenofovir | 2019 |
A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Emtricitabine; Female; HIV; HIV Infections; Humans; Middle Aged; Pre-Exposure Prophylaxis; Tenofovir; Young Adult | 2018 |
Implementing HIV pre-exposure prophylaxis (PrEP): let's not get caught with our pants down.
Topics: Amphetamine-Related Disorders; Anti-HIV Agents; Cost-Benefit Analysis; Drug Combinations; Emtricitabine; Female; Healthcare Disparities; HIV Infections; Humans; Male; Morals; Patient Selection; Pre-Exposure Prophylaxis; Risk Factors; Sexual and Gender Minorities; Sexual Partners; Tenofovir; Transgender Persons; Treatment Outcome; Unsafe Sex; Vulnerable Populations | 2018 |
Substituting Generic Lamivudine for Emtricitabine in Virologically Suppressed HIV-Infected Patients.
Topics: Adult; Anti-HIV Agents; Drugs, Generic; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Patient Compliance; Retrospective Studies; Viral Load | 2018 |
Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis: experience from a hospital-based clinic in France.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Chemoprevention; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Female; HIV Infections; Hospitals; Humans; Incidence; Male; Outpatients; Paris; Pre-Exposure Prophylaxis; Prospective Studies; Sexual Behavior; Tenofovir | 2018 |
Similar tenofovir hair concentrations in men and women after directly observed dosing of tenofovir disoproxil fumarate/emtricitabine: implications for preexposure prophylaxis adherence monitoring.
Topics: Adult; Anti-HIV Agents; Chemoprevention; Chromatography, Liquid; Disease Transmission, Infectious; Emtricitabine; Female; Hair; Healthy Volunteers; HIV Infections; Humans; Male; Middle Aged; Pre-Exposure Prophylaxis; Sex Factors; Tandem Mass Spectrometry; Tenofovir; Young Adult | 2018 |
Cost-effectiveness of preexposure prophylaxis for HIV prevention for conception in the United States.
Topics: Adult; Anti-HIV Agents; Chemoprevention; Cost-Benefit Analysis; Disease Transmission, Infectious; Emtricitabine; Female; HIV Infections; Humans; Infant, Newborn; Male; Pre-Exposure Prophylaxis; Tenofovir; United States | 2018 |
Short Communication: Association of Vitamin D Insufficiency and Protective Tenofovir Diphosphate Concentrations with Bone Toxicity in Adolescent Boys and Young Men Using Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Pre-Exposure Prophylaxis.
Topics: Adolescent; Anti-HIV Agents; Bone and Bones; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Logistic Models; Male; Pre-Exposure Prophylaxis; Prospective Studies; Tenofovir; Vitamin D; Vitamin D Deficiency; Young Adult | 2019 |
HIV Pre-Exposure Prophylaxis Medication for Adolescents and Young Adults: A Position Paper of the Society for Adolescent Health and Medicine.
Topics: Adolescent; Adolescent Health; Adult; Anti-HIV Agents; Emtricitabine; Female; Health Services Accessibility; HIV Infections; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Tenofovir; Young Adult | 2018 |
Differential extracellular, but similar intracellular, disposition of two tenofovir formulations in the male genital tract.
Topics: Adenine; Anti-Retroviral Agents; Blood Cells; Emtricitabine; Genitalia, Male; HIV Infections; Humans; Leukocytes, Mononuclear; Male; Reproductive Tract Infections; Semen; Tenofovir | 2019 |
Implementation of a community pharmacy-based pre-exposure prophylaxis service: a novel model for pre-exposure prophylaxis care.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-HIV Agents; Community Pharmacy Services; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Pre-Exposure Prophylaxis; Sexually Transmitted Diseases, Viral; Tenofovir; Washington | 2018 |
A two-drug regimen for antiretroviral therapy.
Topics: Adult; Double-Blind Method; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir | 2019 |
Sleep and neuropsychological performance in HIV+ subjects on efavirenz-based therapy and response to switch in therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cobicistat; Cyclopropanes; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Sleep Wake Disorders; Tenofovir | 2018 |
Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observ
Topics: Adult; Cobicistat; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Quinolones; Retrospective Studies; RNA, Viral; Tenofovir; Viral Load | 2019 |
Abnormal elevation of international normalized ratio in a patient during the coadministration of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and warfarin: a case report.
Topics: Adenine; Alanine; Cobicistat; Emtricitabine; HIV Infections; Humans; International Normalized Ratio; Quinolones; Tenofovir; Warfarin | 2019 |
ART Denial: Results of a Home-Based Study to Validate Self-reported Antiretroviral Use in Rural South Africa.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Cohort Studies; Emtricitabine; Female; HIV Antibodies; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Rural Population; Self Report; Sensitivity and Specificity; Social Stigma; South Africa; Surveys and Questionnaires; Viral Load | 2019 |
Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission.
Topics: Adenine; Animals; Anti-HIV Agents; Cell Line; Delayed-Action Preparations; Drug Liberation; Emtricitabine; Endosomes; Female; HIV Infections; HIV-1; Mice; Nanoparticles; Pre-Exposure Prophylaxis; RNA, Viral; Tenofovir; Vagina; Viral Load | 2019 |
Simplification of combination antiretroviral therapy (cART) and the brain-a real-life experience.
Topics: Adult; Aging; Antiretroviral Therapy, Highly Active; Brain; Cognition; Cognitive Dysfunction; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Neuropsychological Tests; Quality of Life; Retrospective Studies; Reverse Transcriptase Inhibitors; Severity of Illness Index; Tenofovir | 2019 |
Emtricitabine triphosphate in dried blood spots is a predictor of viral suppression in HIV infection and reflects short-term adherence to antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Dried Blood Spot Testing; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Predictive Value of Tests; Prospective Studies; Self Report; Viral Load | 2019 |
Tenofovir DF/emtricitabine/rilpivirine as HIV post-exposure prophylaxis: results from a multicentre prospective study.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Medication Adherence; Middle Aged; Post-Exposure Prophylaxis; Prospective Studies; Rilpivirine; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Short Communication: Bioequivalence of Tenofovir Component of Tenofovir/Rilpivirine/Emtricitabine in Digital Pills.
Topics: Adult; Anti-HIV Agents; Capsules; Drug Delivery Systems; Emtricitabine; Emtricitabine, Rilpivirine, Tenofovir Drug Combination; Female; Healthy Volunteers; HIV Infections; Humans; Male; Medication Adherence; Radio Waves; Rilpivirine; Tenofovir; Therapeutic Equivalency; United States; United States Food and Drug Administration | 2019 |
Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics.
Topics: Adolescent; Adult; Anti-HIV Agents; Emtricitabine; Female; Genotype; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Leukocytes, Mononuclear; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Polymorphism, Single Nucleotide; Pregnancy; Tenofovir; Young Adult | 2019 |
Pre-exposure prophylaxis initiation and adherence among Black men who have sex with men (MSM) in three US cities: results from the HPTN 073 study.
Topics: Adolescent; Adult; Anti-HIV Agents; Black or African American; Cities; Emtricitabine; Female; Health Surveys; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Sexual Partners; Tenofovir; United States; Young Adult | 2019 |
Persistence on HIV preexposure prophylaxis medication over a 2-year period among a national sample of 7148 PrEP users, United States, 2015 to 2017.
Topics: Adult; Anti-HIV Agents; Emtricitabine; Female; Health Surveys; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Tenofovir; United States; Young Adult | 2019 |
Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Antiviral Agents; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir | 2019 |
Severe rhabdomyolysis-induced acute kidney injury following concomitant use of Genvoya® (EVG/COBI/FTC/TAF) and simvastatin; a case report.
Topics: Acute Kidney Injury; Anti-HIV Agents; Cobicistat; Drug Combinations; Drug Interactions; Dyslipidemias; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; Hepatitis A; Hepatitis C; HIV Infections; Humans; Hypolipidemic Agents; Liver Function Tests; Male; Middle Aged; Quinolones; Renal Dialysis; Rhabdomyolysis; Simvastatin; Tenofovir; Treatment Outcome | 2019 |
Long-term virological suppression on first-line efavirenz + tenofovir + emtricitabine/lamivudine for HIV-1.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Emtricitabine; Europe; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Sustained Virologic Response; Tenofovir; Treatment Failure; Viral Load; Young Adult | 2019 |
A Comparison of Plasma Efavirenz and Tenofovir, Dried Blood Spot Tenofovir-Diphosphate, and Self-Reported Adherence to Predict Virologic Suppression Among South African Women.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Emtricitabine; Female; HIV Infections; Humans; Logistic Models; Organophosphates; Plasma; Self Report; South Africa; Tenofovir | 2019 |
Barriers to HIV pre-exposure prophylaxis among African, Caribbean and Black men in Toronto, Canada.
Topics: Adolescent; Adult; Age Factors; Anti-HIV Agents; Black or African American; Canada; Emtricitabine; Health Knowledge, Attitudes, Practice; Hispanic or Latino; HIV Infections; Homosexuality, Male; Humans; Logistic Models; Male; Middle Aged; Pre-Exposure Prophylaxis; Risk; Surveys and Questionnaires; Tenofovir; Young Adult | 2019 |
Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies.
Topics: Anti-Retroviral Agents; Computer Simulation; Drug Delivery Systems; Drug Therapy, Combination; Emtricitabine; Emulsions; HIV Infections; Humans; Nanoparticles; Prodrugs; Solubility; Water | 2019 |
Emtricitabine-associated red cell aplasia.
Topics: Adult; Anemia, Aplastic; Anti-HIV Agents; Biopsy; Bone Marrow; Emtricitabine; Female; HIV Infections; Humans | 2019 |
Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection.
Topics: Adolescent; Adult; Anti-HIV Agents; Australia; Bisexuality; Drug Therapy, Combination; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Incidence; Male; Middle Aged; Population Surveillance; Pre-Exposure Prophylaxis; Proportional Hazards Models; Sexually Transmitted Diseases; Tenofovir; Unsafe Sex; Young Adult | 2019 |
Adherence to PrEP Among Young Men Who Have Sex With Men Participating in a Sexual Health Services Demonstration Project in Alameda County, California.
Topics: Adenine; Adolescent; Adult; Black or African American; California; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Organophosphates; Pre-Exposure Prophylaxis; Sexual Behavior; Sexual Health; Young Adult | 2019 |
Unsupervised PrEP in routine practice: a new challenge?
Topics: Adult; Anti-HIV Agents; Emtricitabine; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir; Viral Load | 2019 |
Predictors of Disengagement in Care for Individuals Receiving Pre-exposure Prophylaxis (PrEP).
Topics: Adult; Anti-HIV Agents; Black or African American; Drug Combinations; Emtricitabine; Ethnicity; Female; Hispanic or Latino; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Retrospective Studies; Risk Factors; Sexual Behavior; Surveys and Questionnaires; Tenofovir | 2019 |
Population Modeling Highlights Drug Disposition Differences Between Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in the Blood and Semen.
Topics: Adenine; Adult; Alanine; Anti-Retroviral Agents; Cell Count; Emtricitabine; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Male; Metabolic Clearance Rate; Plasma; Semen; Tenofovir; Tissue Distribution | 2019 |
Emtricitabine and lamivudine concentrations in saliva: a simple suitable test for treatment adherence.
Topics: Anti-HIV Agents; Chemistry Techniques, Analytical; Cohort Studies; Emtricitabine; HIV Infections; Humans; Lamivudine; Plasma; Saliva; Specimen Handling; Treatment Adherence and Compliance | 2019 |
Bictegravir and dolutegravir: head to head at 96 weeks.
Topics: Adenine; Alanine; Amides; Dideoxynucleosides; Double-Blind Method; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir | 2019 |
Quantification of tenofovir disoproxil fumarate and emtricitabine in generic pre-exposure prophylaxis tablets obtained from the internet.
Topics: Adult; Anti-HIV Agents; Drugs, Generic; Emtricitabine; Female; HIV Infections; Humans; Internet; Male; Pre-Exposure Prophylaxis; Tablets; Tenofovir | 2019 |
Brief Report: Short-Term Adherence Marker to PrEP Predicts Future Nonretention in a Large PrEP Demo Project: Implications for Point-of-Care Adherence Testing.
Topics: Adenine; Adult; Anti-HIV Agents; Dried Blood Spot Testing; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Organophosphates; Point-of-Care Testing; Pre-Exposure Prophylaxis; Proportional Hazards Models; Prospective Studies; Tenofovir | 2019 |
Widening the Net for Pre-Exposure Prophylaxis for HIV
Topics: Adenine; Attitude to Health; Emtricitabine; Female; HIV Infections; Humans; Male; Phosphorous Acids; Pre-Exposure Prophylaxis; Surveys and Questionnaires; Tablets | 2019 |
Depot Medroxyprogesterone Acetate and the Vaginal Microbiome as Modifiers of Tenofovir Diphosphate and Lamivudine Triphosphate Concentrations in the Female Genital Tract of Ugandan Women: Implications for Tenofovir Disoproxil Fumarate/Lamivudine in Preexp
Topics: Adenine; Anti-HIV Agents; Cytidine Triphosphate; Dideoxynucleotides; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Medroxyprogesterone Acetate; Microbiota; Organophosphates; Pre-Exposure Prophylaxis; Tenofovir; Uganda | 2020 |
Low Disclosure of PrEP Nonadherence and HIV-Risk Behaviors Associated With Poor HIV PrEP Adherence in the HPTN 067/ADAPT Study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Condoms; Directly Observed Therapy; Disclosure; Drug Therapy, Combination; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Risk-Taking; Sexual and Gender Minorities; Social Networking; South Africa; Surveys and Questionnaires; Tenofovir; Thailand; United States; Young Adult | 2019 |
Preexposure Prophylaxis for the Prevention of HIV Infection: US Preventive Services Task Force Recommendation Statement.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Advisory Committees; Anti-Retroviral Agents; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Risk Assessment; Risk Factors; Tenofovir; United States | 2019 |
Short Communication: Cascade of Antiretroviral Therapy Adherence in Virologically Suppressed Persons Living with HIV.
Topics: Adult; Anti-Retroviral Agents; Cross-Sectional Studies; Dried Blood Spot Testing; Emtricitabine; HIV Infections; Humans; Medication Adherence; Prospective Studies; Sustained Virologic Response; Tenofovir | 2020 |
First year of pre-exposure prophylaxis implementation in France with daily or on-demand tenofovir disoproxil fumarate/emtricitabine.
Topics: Adult; Anti-HIV Agents; Comorbidity; Emtricitabine; Female; France; Health Plan Implementation; HIV Infections; Homosexuality, Male; Humans; Male; Middle Aged; Odds Ratio; Outcome Assessment, Health Care; Pre-Exposure Prophylaxis; Tenofovir; Unsafe Sex | 2019 |
Cluster headache-like symptoms during treatment with tenofovir disoproxil fumarate and emtricitabine.
Topics: Anti-HIV Agents; Cluster Headache; Emtricitabine; Female; HIV Infections; Humans; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult | 2019 |
Comment on: Tenofovir DF/emtricitabine/rilpivirine as HIV post-exposure prophylaxis: results from a multicentre prospective study.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Prospective Studies; Rilpivirine; Tenofovir | 2019 |
Sustained HIV virologic suppression with crushed combination tablets containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Therapy, Combination; Emtricitabine; Enteral Nutrition; Gastrostomy; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Sustained Virologic Response; Tablets; Tenofovir | 2019 |
Early antiretroviral therapy and daily pre-exposure prophylaxis for HIV prevention among female sex workers in Cotonou, Benin: a prospective observational demonstration study.
Topics: Adult; Anti-HIV Agents; Benin; Emtricitabine; Female; HIV Infections; Humans; Pre-Exposure Prophylaxis; Prospective Studies; Safe Sex; Sex Workers; Sexual Behavior; Tenofovir | 2018 |
Incidence of cutaneous adverse events after exposure to tenofovir-emtricitabine in HIV-uninfected vs HIV-infected patients: pharmacovigilance within a large Midwestern U.S. patient population from the Research on Adverse Drug events And Reports program.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Incidence; Male; Middle Aged; Midwestern United States; Pharmacovigilance; Skin Diseases; Tenofovir; Young Adult | 2019 |
Adherence to Antiretroviral Therapy and Pre-exposure Prophylaxis: TARGETing the Ideal Measure.
Topics: Emtricitabine; HIV Infections; Humans; Plasma; Tenofovir | 2020 |
Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Biomarkers; Cobicistat; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Middle Aged; Quinolones; Sexual and Gender Minorities; Tenofovir; Time Factors; Young Adult | 2019 |
A case of esophageal cancer with human immunodeficiency virus infection that progressed rapidly after neoadjuvant chemoradiotherapy.
Topics: Aged; Alkynes; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoxazines; Chemoradiotherapy; Cisplatin; Cyclopropanes; Deglutition Disorders; Disease Progression; Drug Interactions; Emtricitabine; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fatal Outcome; Female; Fluorouracil; Gastrostomy; HIV Infections; Humans; Neoadjuvant Therapy; Neoplasm Staging; Renal Insufficiency; RNA, Viral; Tenofovir; Viral Load | 2020 |
Efficacy of Oral Tenofovir Alafenamide/Emtricitabine Combination or Single-Agent Tenofovir Alafenamide Against Vaginal Simian Human Immunodeficiency Virus Infection in Macaques.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Chemoprevention; Disease Models, Animal; Disease Transmission, Infectious; Emtricitabine; Female; HIV; HIV Infections; Macaca; Pre-Exposure Prophylaxis; Simian Immunodeficiency Virus; Tenofovir; Treatment Outcome; Vagina | 2019 |
Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.
Topics: Adenine; Aged; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Black or African American; Cyclopropanes; Data Interpretation, Statistical; Deoxycytidine; Emtricitabine; Female; Frail Elderly; HIV; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; Tenofovir; White People | 2013 |
[Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV].
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asthenia; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Eruptions; Drug Hypersensitivity; Drug Substitution; Emtricitabine; Female; Fever; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Syndrome; Tenofovir | 2013 |
Tenofovir-based combination therapy for HIV/HBV co-infection: factors associated with a partial HBV virological response in patients with undetectable HIV viraemia.
Topics: Adenine; Adult; Anti-HIV Agents; Case-Control Studies; Coinfection; Deoxycytidine; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Phosphorous Acids; Viremia | 2013 |
Cost-effectiveness of pre-exposure prophylaxis (PrEP) in preventing HIV-1 infections in rural Zambia: a modeling study.
Topics: Adenine; Anti-HIV Agents; Cost-Benefit Analysis; Deoxycytidine; Emtricitabine; HIV Infections; HIV-1; Humans; Models, Biological; Organophosphonates; Prevalence; Primary Prevention; Rural Population; Sensitivity and Specificity; Sexual Behavior; Tenofovir; Zambia | 2013 |
Boosting HIV treatment options: good news, new challenges.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Thiazoles | 2013 |
Access to treatment for HBV infection and its consistency with 2008 European guidelines in a multicentre cross-sectional study of HIV/HBV co-infected patients in Italy.
Topics: Adenine; Adult; Anti-Retroviral Agents; Coinfection; Cross-Sectional Studies; Deoxycytidine; Emtricitabine; Europe; Female; Guideline Adherence; Health Services Accessibility; Hepatitis B; HIV Infections; Humans; Infectious Disease Medicine; Italy; Lamivudine; Male; Multivariate Analysis; Organophosphonates; Practice Guidelines as Topic; Regression Analysis; Tenofovir; Treatment Outcome | 2013 |
Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Thymidine; Treatment Failure; Viral Load; Zidovudine | 2013 |
Could FDA approval of pre-exposure prophylaxis make a difference? A qualitative study of PrEP acceptability and FDA perceptions among men who have sex with men.
Topics: Adenine; Adult; Anti-Retroviral Agents; Chemoprevention; Deoxycytidine; Emtricitabine; Focus Groups; Health Knowledge, Attitudes, Practice; HIV Infections; Homosexuality, Male; Humans; Interviews as Topic; Male; Organophosphonates; Patient Acceptance of Health Care; Perception; Qualitative Research; Rhode Island; Sex Workers; Tenofovir; United States; United States Food and Drug Administration | 2014 |
Oral antiretroviral drugs as public health tools for HIV prevention: global implications for adherence, drug resistance, and the success of HIV treatment programs.
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Counseling; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Organophosphonates; Patient Compliance; Public Health; Tenofovir | 2013 |
Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Europe; HIV Infections; HIV Protease Inhibitors; HIV Seropositivity; HIV-1; Humans; Lamivudine; Lopinavir; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir; Time Factors; United States | 2013 |
Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricitabine for treatment-naïve patients with a baseline viral load of more than 100 000 copies/ml.
Topics: Adenine; Anti-HIV Agents; Darunavir; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Organophosphonates; Ritonavir; Sulfonamides; Tenofovir; Viral Load | 2013 |
Ethical considerations in determining standard of prevention packages for HIV prevention trials: examining PrEP.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Community-Based Participatory Research; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Ethics, Research; Health Services Needs and Demand; HIV Infections; Humans; Organophosphonates; Practice Guidelines as Topic; Primary Prevention; Research Design; Tenofovir; Treatment Failure; United States; United States Food and Drug Administration | 2013 |
Knowledge of and opinions on HIV preexposure prophylaxis among front-line service providers at Canadian AIDS service organizations.
Topics: Adenine; Adult; Anti-HIV Agents; Canada; Chemoprevention; Deoxycytidine; Emtricitabine; Female; Health Knowledge, Attitudes, Practice; Health Personnel; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Surveys and Questionnaires; Tenofovir | 2013 |
Peripheral T-cell apoptosis is not differentially affected by antiretroviral regimens in HIV-infected patients.
Topics: Adenine; Anti-HIV Agents; Apoptosis; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cross-Sectional Studies; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Organophosphonates; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2013 |
Emtricitabine compared with lamivudine may preserve future therapeutic options in HIV-1-infected children.
Topics: Anti-HIV Agents; Child; Child, Preschool; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV-1; Humans; Infant; Lamivudine | 2013 |
Update to Interim Guidance for Preexposure Prophylaxis (PrEP) for the Prevention of HIV Infection: PrEP for injecting drug users.
Topics: Adenine; Anti-HIV Agents; Centers for Disease Control and Prevention, U.S.; Deoxycytidine; Emtricitabine; Female; Heterosexuality; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Risk Assessment; Substance Abuse, Intravenous; Tenofovir; United States | 2013 |
Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventions.
Topics: Adenine; Anti-HIV Agents; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; Humans; Medication Adherence; Organophosphonates; Randomized Controlled Trials as Topic; Research Design; Sample Size; Tenofovir; Treatment Outcome; United States | 2013 |
Ethics and pre-exposure prophylaxis for HIV infection.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Organophosphonates; Public Health; Risk-Taking; Tenofovir; United States | 2013 |
Neutrophil gelatinase-associated lipocalin, a marker of tubular dysfunction, is not increased in long-term virologically controlled patients receiving a tenofovir/emtricitabine + nevirapine regimen.
Topics: Acute-Phase Proteins; Adenine; Adult; Anti-HIV Agents; Cross-Sectional Studies; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Lipocalin-2; Lipocalins; Male; Middle Aged; Nevirapine; Organophosphonates; Proto-Oncogene Proteins; Tenofovir | 2013 |
[Pre-exposure prophylaxis for HIV transmission? No, unless].
Topics: Adenine; Anti-HIV Agents; Chemoprevention; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Organophosphonates; Tenofovir | 2013 |
Effect of antiretroviral therapy on HIV reservoirs in elite controllers.
Topics: Adenine; Anti-HIV Agents; Asymptomatic Diseases; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Deoxycytidine; DNA, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Immunity, Innate; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Tenofovir; Viremia; Virus Replication | 2013 |
Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models.
Topics: Adenine; Adolescent; Adult; Africa South of the Sahara; Aged; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Models, Theoretical; Organophosphonates; Pre-Exposure Prophylaxis; Tenofovir; Young Adult | 2013 |
[Ophthalmological alterations at the initial diagnosis of HIV infection].
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Cyclohexanes; Deoxycytidine; Drug Therapy, Combination; Early Diagnosis; Emtricitabine; Eye Infections, Viral; HIV Infections; Humans; Lopinavir; Male; Maraviroc; Organophosphonates; Retinal Diseases; Syndrome; Tenofovir; Treatment Outcome; Triazoles; Zidovudine | 2014 |
Safety and efficacy of tenofovir/emtricitabine or abacavir/lamivudine in combination with efavirenz in treatment naïve HIV patients: a 5 year retrospective observational cohort study. (the TOKEN Study).
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cardiovascular Diseases; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Kidney Diseases; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Viral Load | 2013 |
[ First integrase inhibitor based single tablet regimen].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; Cobicistat; Deoxycytidine; Drug Approval; Drug Combinations; Emtricitabine; HIV Infections; HIV Integrase Inhibitors; Humans; Organophosphonates; Quinolones; Tenofovir; Thiazoles; Treatment Outcome | 2013 |
Non-occupational HIV post-exposure prophylaxis at a Sydney metropolitan sexual health clinic.
Topics: Adenine; Adult; Anti-HIV Agents; Australia; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Middle Aged; Organophosphonates; Post-Exposure Prophylaxis; Practice Guidelines as Topic; Practice Patterns, Physicians'; Risk-Taking; Stavudine; Tenofovir | 2013 |
Preexposure prophylaxis reduces HIV risk in injection-drug users.
Topics: Adenine; Adult; Anti-HIV Agents; Centers for Disease Control and Prevention, U.S.; Comorbidity; Deoxycytidine; Drug Administration Schedule; Drug Users; Emtricitabine; Female; Follow-Up Studies; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Male; Organophosphonates; Practice Guidelines as Topic; Pregnancy; Risk Reduction Behavior; Substance Abuse, Intravenous; Tenofovir; United States | 2013 |
The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Failure | 2014 |
Delayed emergence of HIV-1 variants resistant to 4'-ethynyl-2-fluoro-2'-deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001.
Topics: Adenine; Amino Acid Sequence; Anti-HIV Agents; Deoxyadenosines; Deoxycytidine; Drug Resistance, Multiple, Viral; Emtricitabine; HIV Infections; HIV-1; Human Immunodeficiency Virus Proteins; Humans; Lamivudine; Molecular Sequence Data; Molecular Structure; Organophosphonates; Tenofovir; Thymidine | 2014 |
Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV-1; Humans; Nitriles; Organophosphonates; Pyrimidines; Rilpivirine; Sequence Analysis, DNA; Tenofovir; Treatment Failure | 2014 |
CD4(+) cell count, viral load, and drug resistance patterns among heterosexual breakthrough HIV infections in a study of oral preexposure prophylaxis.
Topics: Adenine; Anti-HIV Agents; Botswana; CD4 Lymphocyte Count; Chemoprevention; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Heterosexuality; HIV; HIV Infections; Humans; Organophosphonates; Plasma; Post-Exposure Prophylaxis; Tenofovir; Viral Load | 2014 |
No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Middle Aged; Organophosphonates; Pregnancy; Sexual Behavior; Tenofovir; Transgender Persons; Young Adult | 2013 |
Population pharmacokinetics of emtricitabine in HIV-1-infected adult patients.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Young Adult | 2014 |
Early experiences implementing pre-exposure prophylaxis (PrEP) for HIV prevention in San Francisco.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Disease Management; Emtricitabine; Female; HIV Infections; Humans; Male; Organophosphonates; San Francisco; Tenofovir | 2014 |
HIV-1 genital shedding is suppressed in the setting of high genital antiretroviral drug concentrations throughout the menstrual cycle.
Topics: Adenine; Adult; Anti-Retroviral Agents; Deoxycytidine; DNA, Viral; Emtricitabine; Female; Genitalia, Female; HIV Infections; HIV-1; Humans; Menstrual Cycle; Middle Aged; Organophosphonates; Plasma; Ritonavir; RNA, Viral; Tenofovir; Viral Load; Virus Shedding | 2014 |
Single-tablet, once-daily treatment regimens for HIV.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cobicistat; Cyclopropanes; Cytochrome P-450 CYP3A Inhibitors; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; HIV Integrase Inhibitors; HIV Reverse Transcriptase; Humans; Nitriles; Organophosphonates; Pyrimidines; Quinolones; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Thiazoles | 2014 |
Virologic and serologic outcomes of mono versus dual HBV therapy and characterization of HIV/HBV coinfection in a US cohort.
Topics: Adenine; Adult; Antibodies, Viral; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Deoxycytidine; DNA, Viral; Emtricitabine; Female; Follow-Up Studies; Hepatitis B; Hepatitis B e Antigens; HIV Infections; Humans; Lamivudine; Logistic Models; Male; Middle Aged; Organophosphonates; Randomized Controlled Trials as Topic; Retrospective Studies; Tenofovir; United States | 2014 |
Successful switch to rilpivirine/tenofovir/emtricitabine in HIV-1-infected patients with an isolated K103N mutation acquired during prior nonnucleoside reverse transcriptase inhibitor therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Drug Substitution; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Mutation; Nitriles; Organophosphonates; Pilot Projects; Prospective Studies; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Viral Load; Young Adult | 2014 |
HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Mutation; Organophosphonates; RNA, Viral; Tenofovir; Transgender Persons; Viral Load | 2014 |
Sustained virological response after taking crushed elvitegravir-cobicistat-emtricitabine-tenofovir tablets.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Organophosphonates; Powders; Quinolones; Tablets; Tenofovir; Thiazoles; Viral Load | 2014 |
ACOG Committee Opinion no 595: Committee on Gynecologic Practice: Preexposure prophylaxis for the prevention of human immunodeficiency virus.
Topics: Adenine; Anti-Retroviral Agents; Deoxycytidine; Emtricitabine; Female; Gynecology; HIV Infections; Humans; Medication Adherence; Organophosphonates; Risk Factors; Tenofovir | 2014 |
An interesting case of 'diabetic foot ulcer' in an HIV-positive patient.
Topics: Adenine; Aged; Antiretroviral Therapy, Highly Active; Biopsy; Deoxycytidine; Diabetes Mellitus, Type 2; Diabetic Foot; Emtricitabine; Herpesvirus 8, Human; HIV Infections; HIV Seropositivity; Humans; Male; Organophosphonates; Sarcoma, Kaposi; Skin Neoplasms; Tenofovir; Treatment Outcome; Ulcer | 2015 |
Perceptions of emtricitabine-tenofovir in HIV PrEP.
Topics: Adenine; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Organophosphonates; Sex Education; Sexual Partners; Tenofovir; United States | 2014 |
Biomarkers of CD4+ T-cell activation as risk factors for tuberculosis-associated immune reconstitution inflammatory syndrome.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Biomarkers; CD4-Positive T-Lymphocytes; Cyclopropanes; Deoxycytidine; Emtricitabine; Enzyme-Linked Immunosorbent Assay; Female; HIV Infections; Humans; Immune Reconstitution Inflammatory Syndrome; Lymphocyte Activation; Male; Middle Aged; Mycobacterium tuberculosis; Organophosphonates; Risk Factors; Tenofovir; Tuberculosis | 2014 |
Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Drug Combinations; Drug Substitution; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Nitriles; Organophosphonates; Prospective Studies; Pyrimidines; Rilpivirine; Tenofovir; Treatment Outcome; Viral Load | 2014 |
Switching STRATEGIES in HIV treatment.
Topics: Adenine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Organophosphonates; Protease Inhibitors; Quinolones; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Thiazoles | 2014 |
Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model.
Topics: Adenine; Administration, Intravaginal; Animals; Anti-HIV Agents; Delayed-Action Preparations; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Macaca; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Vagina; Vaginal Creams, Foams, and Jellies | 2014 |
Pre-exposure prophylaxis accessibility research and evaluation (PrEPARE Study).
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; California; Deoxycytidine; Emtricitabine; Health Expenditures; Health Knowledge, Attitudes, Practice; Health Services Accessibility; Health Surveys; HIV Infections; Homosexuality, Male; Humans; Male; Middle Aged; Organophosphonates; Patient Acceptance of Health Care; Pre-Exposure Prophylaxis; Tenofovir; Unsafe Sex | 2014 |
Effect of antiretroviral HIV therapy on hepatitis B virus replication and pathogenicity.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Coinfection; Deoxycytidine; Emtricitabine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV Reverse Transcriptase; HIV Seropositivity; HIV-1; Humans; Inflammation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; tat Gene Products, Human Immunodeficiency Virus; Tenofovir; Virus Replication; vpr Gene Products, Human Immunodeficiency Virus | 2014 |
It's Time: The Case for PrEP as an Active Comparator in HIV Biomedical Prevention Trials.
Topics: Anti-HIV Agents; Biomedical Research; Comparative Effectiveness Research; Condoms; Emtricitabine; Female; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Research Design; Risk; Sexual Behavior; Tenofovir | 2015 |
Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Europe; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Plasma; Tablets; Tenofovir; Treatment Outcome; Viral Load | 2015 |
Initiation of rilpivirine, tenofovir and emtricitabine (RPV/TDF/FTC) regimen in 363 patients with virological vigilance assessment in 'real life'.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Genotype; HIV; HIV Infections; Humans; Microbial Sensitivity Tests; Nitriles; Organophosphonates; Pyrimidines; Rilpivirine; Tenofovir | 2014 |
Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV-1-infected patients: a cohort study.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Cohort Studies; Deoxycytidine; Drug Combinations; Drug Substitution; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Organophosphonates; Pyrimidines; Retrospective Studies; Rilpivirine; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2015 |
Drug interactions between voriconazole, darunavir/ritonavir and tenofovir/emtricitabine in an HIV-infected patient treated for Aspergillus candidus lung abscess.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antifungal Agents; Aspergillosis; Aspergillus; Darunavir; Drug Interactions; Emtricitabine; HIV Infections; HIV Protease Inhibitors; Humans; Lung Abscess; Male; Ritonavir; Tenofovir; Treatment Outcome; Voriconazole | 2015 |
Optimizing HIV therapy. A consensus project on differences between cytidine analogues and regime compactness.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Consensus; Cytidine; Delphi Technique; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Practice Patterns, Physicians' | 2014 |
Depot-medroxyprogesterone acetate does not reduce the prophylactic efficacy of emtricitabine and tenofovir disoproxil fumarate in macaques.
Topics: Adenine; Animals; Anti-HIV Agents; Contraceptive Agents, Female; Delayed-Action Preparations; Deoxycytidine; Disease Models, Animal; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Macaca nemestrina; Medroxyprogesterone Acetate; Phosphorous Acids; Pre-Exposure Prophylaxis; Treatment Outcome | 2014 |
Infection with the frequently transmitted HIV-1 M41L variant has no influence on selection of tenofovir resistance.
Topics: Adenine; Adult; Amino Acid Substitution; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Evolution, Molecular; Female; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Organophosphonates; Phenotype; Phylogeny; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2015 |
Lopinavir/r no longer recommended as a first-line regimen: a comparative effectiveness analysis.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Deoxycytidine; Emtricitabine; Female; France; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Treatment Failure; Viral Load | 2014 |
When is good good enough for HIV-1 prophylaxis?
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Organophosphonates; Pre-Exposure Prophylaxis; Tenofovir | 2014 |
Evaluation of the efficacy and safety of switching to tenofovir, emtricitabine, and rilpivirine in treatment-experienced patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Nitriles; Organophosphonates; Pyrimidines; Rilpivirine; Tenofovir; Young Adult | 2015 |
Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Clinical Trials, Phase III as Topic; Coinfection; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Oxazines; Piperazines; Pyridones; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Regression Analysis; Retrospective Studies; Ritonavir; Tenofovir; Treatment Outcome; Viral Load | 2015 |
Perception of HIV risk and adherence to a daily, investigational pill for HIV prevention in FEM-PrEP.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Blood Chemical Analysis; Chemoprevention; Deoxycytidine; Disease Transmission, Infectious; Emtricitabine; Female; Health Knowledge, Attitudes, Practice; HIV Infections; Humans; Medication Adherence; Organophosphonates; Risk-Taking; Tenofovir; Young Adult | 2014 |
Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men.
Topics: Adolescent; Adult; Anti-HIV Agents; Blood Chemical Analysis; Disease Transmission, Infectious; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Pre-Exposure Prophylaxis; Prospective Studies; Rectum; Tenofovir; Time Factors; Young Adult | 2015 |
Primary HIV infection presenting as limbic encephalitis and rhabdomyolysis.
Topics: Acute Kidney Injury; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Diagnosis, Differential; Diffusion Magnetic Resonance Imaging; Emtricitabine; HIV Infections; Humans; Limbic Encephalitis; Magnetic Resonance Imaging; Male; Rhabdomyolysis; Tenofovir | 2015 |
Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV-infected patients with mild-to-moderate renal impairment.
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Cohort Studies; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Quinolones; Renal Insufficiency; Tenofovir; Thiazoles; Treatment Outcome | 2015 |
High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Chemoprevention; Cohort Studies; Deoxycytidine; Disease Transmission, Infectious; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Longitudinal Studies; Male; Organophosphonates; Patient Acceptance of Health Care; Pre-Exposure Prophylaxis; Prospective Studies; Tenofovir; United States; Young Adult | 2015 |
Pregnancy and contraceptive use among women participating in the FEM-PrEP trial.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraceptive Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Incidence; Medication Adherence; Organophosphonates; Plasma; Pregnancy; Pregnancy Rate; Pregnancy, Unplanned; Tenofovir; Young Adult | 2015 |
Improved detection of resistance at failure to a tenofovir, emtricitabine and efavirenz regimen by ultradeep sequencing.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Emtricitabine; Genotyping Techniques; High-Throughput Nucleotide Sequencing; HIV; HIV Infections; Humans; Microbial Sensitivity Tests; Plasma; Tenofovir; Treatment Failure | 2015 |
Preventing HIV in women--still trying to find their VOICE.
Topics: Adenine; Anti-Retroviral Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Organophosphonates; Pre-Exposure Prophylaxis; Tenofovir | 2015 |
Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults.
Topics: Adolescent; Adult; Anti-HIV Agents; Diet; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Longitudinal Studies; Male; Middle Aged; Plasma; Rilpivirine; Tenofovir; Uganda; Young Adult | 2015 |
Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; Cognition Disorders; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Drug Substitution; Emtricitabine; Enzyme-Linked Immunosorbent Assay; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Pilot Projects; Prospective Studies; Tenofovir; Tumor Necrosis Factor-alpha; Viral Load | 2015 |
PrEP: A case study.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Male; Risk Reduction Behavior; Safe Sex; Tenofovir | 2015 |
The science of being a study participant: FEM-PrEP participants' explanations for overreporting adherence to the study pills and for the whereabouts of unused pills.
Topics: Adenine; Adult; Clinical Trials as Topic; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Interviews as Topic; Kenya; Medication Adherence; Organophosphonates; South Africa; Tenofovir; Treatment Outcome | 2015 |
Antiretroviral chemoprophylaxis: new successes and questions.
Topics: Adenine; Anti-HIV Agents; Anti-Retroviral Agents; Chemoprevention; Deoxycytidine; Drug Combinations; Emtricitabine; Gels; HIV Infections; Humans; Organophosphonates; Tenofovir | 2015 |
Painless penile papule.
Topics: Adenine; Adult; Anti-Bacterial Agents; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biopsy; CD4 Lymphocyte Count; Coinfection; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Male; Nevirapine; Organophosphonates; Penicillin G Benzathine; Penis; Syphilis, Cutaneous; Tenofovir; Treatment Outcome | 2015 |
Pharmacokinetics of dolutegravir in a premature neonate after HIV treatment intensification during pregnancy.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cytochrome P-450 CYP3A; Emtricitabine; Female; Glucuronosyltransferase; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infant, Newborn; Male; Oxazines; Piperazines; Pregnancy; Pyridones; Ritonavir; Tenofovir | 2015 |
Tenofovir alafenamide for HIV infection: is less more?
Topics: Adenine; Alanine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Organophosphonates; Quinolones; Tenofovir; Thiazoles | 2015 |
Editorial Commentary: Unmasking the Bare Bones of HIV Preexposure Prophylaxis.
Topics: Anti-HIV Agents; Bone Density; Chemoprevention; Emtricitabine; Female; HIV Infections; Humans; Male; Tenofovir | 2015 |
Pre-exposure prophylaxis works--it's time to deliver.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Health Services Accessibility; HIV Infections; Humans; Organophosphonates; Pre-Exposure Prophylaxis; Tenofovir | 2015 |
A post-partum single-dose TDF/FTC tail does not prevent the selection of NNRTI resistance in women receiving pre-partum ZDV and intrapartum single-dose nevirapine to prevent mother-to- child HIV-1 transmission.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Mothers; Mutation; Nevirapine; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA; South Africa; Tenofovir; Viral Load; Zidovudine | 2015 |
HIV-serodiscordant couples desiring a child: 'treatment as prevention,' preexposure prophylaxis, or medically assisted procreation?
Topics: Adenine; Anti-HIV Agents; Cost-Benefit Analysis; Deoxycytidine; Emtricitabine; Female; Fertile Period; France; Health Care Costs; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Insemination, Artificial; Male; Models, Economic; Organophosphonates; Pre-Exposure Prophylaxis; Pregnancy; Reproductive Techniques, Assisted; Semen; Tenofovir | 2015 |
Acceptability of drug detection monitoring among participants in an open-label pre-exposure prophylaxis study.
Topics: Adult; Anti-HIV Agents; Boston; Chicago; Emtricitabine; Female; HIV Infections; Humans; Interviews as Topic; Male; Medication Adherence; Middle Aged; Patient Acceptance of Health Care; Pre-Exposure Prophylaxis; San Francisco; Tenofovir | 2015 |
Pharmacological Measures of Treatment Adherence and Risk of HIV Infection in the VOICE Study.
Topics: Administration, Intravaginal; Administration, Oral; Administration, Topical; Anti-HIV Agents; Emtricitabine; Gels; HIV Infections; Humans; Medication Adherence; Pre-Exposure Prophylaxis; Regression Analysis; Risk Factors; Tenofovir | 2016 |
Use of Pharmacokinetic Data in Novel Analyses to Determine the Effect of Topical Microbicides as Preexposure Prophylaxis Against HIV Infection.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Medication Adherence; Tenofovir | 2016 |
The promises and challenges of pre-exposure prophylaxis as part of the emerging paradigm of combination HIV prevention.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2015 |
Use of PCR Signal and Therapeutic Drug Monitoring in a Switch Cohort Study to Tenofovir/Emtricitabine/Rilpivirine: A W96 Follow-Up.
Topics: Adult; Anti-HIV Agents; Drug Combinations; Drug Substitution; Drug Therapy, Combination; Emtricitabine; Emtricitabine, Rilpivirine, Tenofovir Drug Combination; Female; Follow-Up Studies; HIV Infections; Humans; Male; Middle Aged; Rilpivirine; Tenofovir; Viral Load | 2015 |
Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; Rilpivirine; Tenofovir | 2015 |
Effects of raltegravir combined with tenofovir/emtricitabine on body shape, bone density, and lipids in African-Americans initiating HIV therapy.
Topics: Adult; Anti-HIV Agents; Black or African American; Bone Density; Cohort Studies; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lipid Metabolism; Longitudinal Studies; Male; North Carolina; Raltegravir Potassium; Tenofovir | 2015 |
Hepatitis B surface antigen quantification as a predictor of seroclearance during treatment in HIV-hepatitis B virus coinfected patients from Sub-Saharan Africa.
Topics: Africa; Antiviral Agents; Biomarkers; Cohort Studies; Coinfection; Drug Therapy, Combination; Emtricitabine; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; HIV Infections; Humans; Lamivudine; Predictive Value of Tests; Prospective Studies; Randomized Controlled Trials as Topic; Sensitivity and Specificity; Tenofovir; Time Factors | 2016 |
Loss of Virologic Control and Severe Pneumocystis pneumonia in an HIV-Infected Patient Receiving Chemotherapy for Non-Small Cell Lung Cancer.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Carcinoma, Non-Small-Cell Lung; Cisplatin; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lung Neoplasms; Middle Aged; Oxazines; Pemetrexed; Piperazines; Pneumocystis carinii; Pneumonia, Pneumocystis; Pyridones; Tenofovir; Tomography, X-Ray Computed; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination; Viral Load | 2016 |
Pre-exposure prophylaxis is effective at preventing HIV in high risk gay men, study shows.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; England; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome; Unsafe Sex | 2015 |
Reassuring Birth Outcomes With Tenofovir/Emtricitabine/Efavirenz Used for Prevention of Mother-to-Child Transmission of HIV in Botswana.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Botswana; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Pregnancy; Tenofovir | 2016 |
The metabolic and cardiovascular consequences of obesity in persons with HIV on long-term antiretroviral therapy.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cardiovascular Diseases; Cohort Studies; Cyclopropanes; Emtricitabine; Female; HIV Infections; Humans; Male; Metabolic Diseases; Middle Aged; Obesity; Risk Assessment; Tenofovir | 2016 |
Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Biomarkers; Cyclopropanes; Dideoxynucleosides; Drug Combinations; E-Selectin; Emtricitabine; Female; HIV Infections; Humans; Inflammation; Intercellular Adhesion Molecule-1; Interleukin-6; Lamivudine; Male; Middle Aged; P-Selectin; Tenofovir; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2016 |
Effect of abacavir on sustained virologic response to HCV treatment in HIV/HCV co-infected patients, Cohere in Eurocoord.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Coinfection; Dideoxynucleosides; Drug Combinations; Emtricitabine; Europe; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Ribavirin; Tenofovir; Zidovudine | 2015 |
Adherence to Post-Exposure Prophylaxis (PEP) and Incidence of HIV Seroconversion in a Major North American Cohort.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV Seropositivity; Humans; Incidence; Lamivudine; Lopinavir; Male; Medication Adherence; Middle Aged; Post-Exposure Prophylaxis; Quebec; Ritonavir; Tenofovir; Young Adult; Zidovudine | 2015 |
PrEP on demand cuts HIV transmission in high risk men, study finds.
Topics: Emtricitabine; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir | 2015 |
Welcome to the preexposure prophylaxis revolution.
Topics: Anti-HIV Agents; Chemoprevention; Delivery of Health Care; Disease Transmission, Infectious; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir; Treatment Outcome | 2016 |
Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; Female; France; HIV Infections; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome; Tuberculosis; Viral Load | 2016 |
Antiretroviral therapy management and rationalisation of available resources.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Emtricitabine; Female; HIV Infections; Humans; Italy; Male; Middle Aged; Ritonavir; Surveys and Questionnaires; Tenofovir; Treatment Outcome | 2015 |
Tenofovir/emtricitabine metabolites and endogenous nucleotide exposures are associated with p16(INK4a) expression in subjects on combination therapy.
Topics: Adult; Aged; Aging; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclin-Dependent Kinase Inhibitor p16; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; Female; Gene Expression; HIV Infections; Humans; Male; Middle Aged; Nucleotides; Ritonavir; Tenofovir; Young Adult | 2016 |
Lamivudine Monotherapy-Based cART Is Efficacious for HBV Treatment in HIV/HBV Coinfection When Baseline HBV DNA <20,000 IU/mL.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; China; Cohort Studies; Coinfection; DNA, Viral; Drug Therapy, Combination; Emtricitabine; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Tenofovir | 2016 |
Top-down and bottom-up modeling in system pharmacology to understand clinical efficacy: An example with NRTIs of HIV-1.
Topics: Anti-HIV Agents; Dose-Response Relationship, Drug; Emtricitabine; HIV Infections; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2016 |
Presence of Minority Resistant Variants After Failure of a Tenofovir, Emtricitabine, and Rilpivirine Regimen.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Emtricitabine; Genotyping Techniques; High-Throughput Nucleotide Sequencing; HIV Infections; HIV-1; Humans; Rilpivirine; RNA-Directed DNA Polymerase; Tenofovir; Viral Load | 2016 |
Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots.
Topics: Adenine; Biological Assay; Dried Blood Spot Testing; Emtricitabine; Erythrocytes; Hematocrit; HIV Infections; Humans; Medication Adherence; Methanol; Organophosphates; Polyphosphates; Reproducibility of Results; Solutions; Temperature; Water | 2016 |
Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study.
Topics: Africa South of the Sahara; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Emtricitabine; Global Health; HIV Infections; HIV-1; Humans; Lamivudine; Pre-Exposure Prophylaxis; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2016 |
Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-naïve HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Netherlands; Treatment Failure; Viral Load; Young Adult | 2016 |
Genvoya--a new 4-drug combination for HIV.
Topics: Cobicistat; Drug Combinations; Drug Interactions; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Quinolones; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome | 2016 |
Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial.
Topics: Adolescent; Anti-HIV Agents; Canada; Condoms; Deoxycytidine; Double-Blind Method; Emtricitabine; Follow-Up Studies; France; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Middle Aged; Organophosphonates; Outcome Assessment, Health Care; Pre-Exposure Prophylaxis; Risk-Taking; Safe Sex; Sexual Behavior; Sexual Partners; Surveys and Questionnaires; Tenofovir | 2016 |
Severe reaction to emtricitabine and lamiduvine: evidence of cross-reactivity.
Topics: Anti-HIV Agents; Cross Reactions; Drug Eruptions; Drug Hypersensitivity; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Middle Aged; Patch Tests; Stevens-Johnson Syndrome | 2016 |
Elvitegravir/Cobicistat/Tenofovir/Emtricitabine Penetration in the Cerebrospinal Fluid of Three HIV-Positive Patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Quinolones; Tenofovir | 2016 |
TDF-FTC before and after sex reduced HIV infection but increased GI, renal events in men who have sex with men.
Topics: Emtricitabine; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir | 2016 |
Preexposure Prophylaxis with Tenofovir/Emtricitabine Prevents HIV Infection In Men who Have Unprotected Anal Intercourse.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; HIV; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir | 2016 |
Self-reported Recent PrEP Dosing and Drug Detection in an Open Label PrEP Study.
Topics: Adult; Anti-HIV Agents; Chromatography, Liquid; Condoms; Dried Blood Spot Testing; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Self Report; Tandem Mass Spectrometry; Tenofovir | 2016 |
Symptomatic Bradycardia and Heart Failure Triggered by Ivabradine in a Patient Receiving Antiretroviral Therapy.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Benzazepines; Bradycardia; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Emtricitabine; Female; Heart Failure; HIV Infections; Humans; Ivabradine; Middle Aged; Ritonavir; Tenofovir | 2016 |
Is sub-Saharan Africa ready for pre-exposure prophylaxis?
Topics: Administration, Oral; Africa South of the Sahara; Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2016 |
Comparative risk of failure of ABC/3TC or TDF/FTC based first-line regimens in patients with a high viral load.
Topics: Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; France; HIV Infections; Humans; Lamivudine; Male; Propensity Score; Prospective Studies; Risk Assessment; Tenofovir; Treatment Failure; Viral Load | 2016 |
UK PrEP decision re-ignites HIV activism.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; England; Health Policy; HIV Infections; Homosexuality, Male; Humans; Male; National Health Programs; Pre-Exposure Prophylaxis; Public Health; Tenofovir; United Kingdom | 2016 |
Renal Function and Tenofovir Disoproxil Fumarate for Preexposure Prophylaxis: How Safe Is Safe Enough?
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Pre-Exposure Prophylaxis; Tenofovir | 2016 |
NHS England should reconsider PrEP decision.
Topics: Emtricitabine; England; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; State Medicine; Tenofovir | 2016 |
[Brief notes. Approval recommendation for fixed combination Descovy(R) in treatment of HIV].
Topics: Adenine; Adolescent; Adult; Alanine; Anti-HIV Agents; Child; Dose-Response Relationship, Drug; Drug Approval; Drug Combinations; Emtricitabine; HIV Infections; Humans; Tenofovir; Young Adult | 2016 |
Dually Active HIV/HBV Antiretrovirals as Protection Against Incident Hepatitis B Infections: Potential for Prophylaxis.
Topics: Adult; Antiviral Agents; Chemoprevention; Emtricitabine; Female; Follow-Up Studies; Hepatitis B; HIV Infections; Humans; Lamivudine; Male; Prospective Studies; Tenofovir | 2016 |
Hepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic Study.
Topics: Adult; Anti-Retroviral Agents; Antiviral Agents; Bilirubin; Case-Control Studies; Coinfection; Drug Therapy, Combination; Emtricitabine; Female; Fibrosis; Hepacivirus; Hepatitis C; HIV Infections; Hospitalization; Humans; Liver; Male; Middle Aged; Retrospective Studies; Rilpivirine; Spain; Tablets; Tenofovir; Transaminases | 2016 |
Risks and benefits HIV preexposure prophylaxis with tenofovir/emtricitabine in an older male with comorbidities.
Topics: Aged; Anti-HIV Agents; Chemoprevention; Comorbidity; Emtricitabine; HIV Infections; Humans; Kidney Diseases; Male; Pre-Exposure Prophylaxis; Risk Assessment; Tenofovir | 2016 |
Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination.
Topics: Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; Emtricitabine; Genotype; Genotyping Techniques; HIV Infections; Humans; Microbial Sensitivity Tests; Mutation; Proviruses; Rilpivirine; RNA, Viral; Tenofovir | 2016 |
Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Comorbidity; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load | 2016 |
Plasma and Intracellular Concentrations in HIV-Infected Patients Requiring Hemodialysis Dosed With Tenofovir Disoproxil Fumarate and Emtricitabine.
Topics: Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Emtricitabine; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Prospective Studies; Renal Dialysis; Rilpivirine; RNA, Viral; Tenofovir; Young Adult | 2016 |
Off-label use of rilpivirine in combination with emtricitabine and tenofovir in HIV-1-infected pediatric patients: A multicenter study.
Topics: Adolescent; Anti-HIV Agents; Child; Drug Therapy, Combination; Emtricitabine; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Male; Off-Label Use; Retrospective Studies; RNA, Viral; Tenofovir; Treatment Outcome | 2016 |
HIV-1 Drug Resistance by Ultra-Deep Sequencing Following Short Course Zidovudine, Single-Dose Nevirapine, and Single-Dose Tenofovir with Emtricitabine for Prevention of Mother-to-Child Transmission.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Mutation; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Viral Load; Zidovudine | 2016 |
Effects of Antiretroviral Therapy on Immune Function and Arterial Inflammation in Treatment-Naive Patients With Human Immunodeficiency Virus Infection.
Topics: Adult; Anti-HIV Agents; Arteritis; CD4 Lymphocyte Count; Emtricitabine; HIV Infections; Humans; Inflammation; Middle Aged; Viral Load; Young Adult | 2016 |
Virological suppression after use of crushed tenofovir-emtricitabine and dolutegravir tablets in a patient with HIV infection.
Topics: Adult; Antiretroviral Therapy, Highly Active; Dosage Forms; Drug Therapy, Combination; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Male; Oxazines; Piperazines; Pyridones; Sustained Virologic Response; Tablets; Tenofovir; Viral Load | 2016 |
Emtricitabine/tenofovir alafenamide (Descovy) for HIV.
Topics: Adenine; Anti-HIV Agents; Drug Administration Schedule; Emtricitabine; HIV Infections; HIV-1; Humans; Tenofovir; Treatment Outcome | 2016 |
Simultaneous quantification of tenofovir, emtricitabine, rilpivirine, elvitegravir and dolutegravir in mouse biological matrices by LC-MS/MS and its application to a pharmacokinetic study.
Topics: Animals; Anti-Retroviral Agents; Chromatography, Liquid; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Mice; Oxazines; Piperazines; Pyridones; Quinolones; Rilpivirine; Solid Phase Extraction; Tandem Mass Spectrometry; Tenofovir | 2016 |
The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate+emtricitabine-containing HAART both in vivo and in vitro.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Emtricitabine; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Middle Aged; Polymorphism, Genetic; Tenofovir | 2016 |
Impact of circulating resistance-associated mutations on HIV pre-exposure prophylaxis (PrEP) efficacy: Modeling from antiretroviral resistance cohort analysis (ARCA) national database.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Middle Aged; Mutation; Pre-Exposure Prophylaxis; Risk; Tenofovir | 2016 |
Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; HIV Infections; Humans; Kidney; Lamivudine; Male; Middle Aged; Retrospective Studies; Ritonavir; Tenofovir; Viral Load | 2016 |
Anti-retroviral Therapy Based HIV Prevention Among a Sample of Men Who Have Sex with Men in Cape Town, South Africa: Use of Post-exposure Prophylaxis and Knowledge on Pre-exposure Prophylaxis.
Topics: Adult; Aged; Anti-HIV Agents; Condoms; Drug Combinations; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Middle Aged; Post-Exposure Prophylaxis; Pre-Exposure Prophylaxis; Risk-Taking; Safe Sex; Sexual and Gender Minorities; Sexual Behavior; South Africa; Surveys and Questionnaires; Tenofovir; Unsafe Sex; Young Adult | 2016 |
Interchangeability between first-line generic antiretroviral products prequalified by WHO using adjusted indirect comparisons.
Topics: Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Biological Availability; Cyclopropanes; Drug Combinations; Drugs, Generic; Emtricitabine; HIV Infections; Humans; Lamivudine; Models, Statistical; Tenofovir; Therapeutic Equivalency; World Health Organization | 2017 |
[Pre-exposure prophylaxis for HIV: clinical practice and challenge].
Topics: Adult; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir | 2016 |
PURLs: On-demand pill protocol protects against HIV.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir | 2016 |
Fixed-dose combination emtricitabine/tenofovir/efavirenz initiated during acute HIV infection; 96-week efficacy and durability.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD8-Positive T-Lymphocytes; Cyclopropanes; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Prospective Studies; RNA, Viral; Sustained Virologic Response; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2016 |
Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study.
Topics: Anti-HIV Agents; Cost-Benefit Analysis; Emtricitabine; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Models, Theoretical; Netherlands; Pre-Exposure Prophylaxis; Tenofovir | 2016 |
Pre-exposure Prophylaxis Use by Breastfeeding HIV-Uninfected Women: A Prospective Short-Term Study of Antiretroviral Excretion in Breast Milk and Infant Absorption.
Topics: Administration, Oral; Anti-HIV Agents; Breast Feeding; Emtricitabine; Female; HIV Infections; Humans; Lactation; Milk, Human; Pre-Exposure Prophylaxis; Prospective Studies; Tenofovir | 2016 |
Reactions and Receptivity to Framing HIV Prevention Message Concepts About Pre-Exposure Prophylaxis for Black and Latino Men Who Have Sex with Men in Three Urban US Cities.
Topics: Adenine; Adult; Anti-HIV Agents; Black or African American; Black People; Chicago; Cities; Condoms; Deoxycytidine; Emtricitabine; Female; Focus Groups; Health Knowledge, Attitudes, Practice; Hispanic or Latino; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Patient Acceptance of Health Care; Pre-Exposure Prophylaxis; Qualitative Research; Safe Sex; Tenofovir; United States; Urban Population | 2016 |
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cobicistat; Emtricitabine; HIV; HIV Infections; Humans; Male; Middle Aged; Quinolones; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2017 |
An Enhanced Emtricitabine-Loaded Long-Acting Nanoformulation for Prevention or Treatment of HIV Infection.
Topics: Anti-HIV Agents; Cell Line; Emtricitabine; Endosomes; Half-Life; HeLa Cells; HIV Infections; HIV-1; Humans; Hydrogen-Ion Concentration; Leukocytes, Mononuclear; Microbial Sensitivity Tests; Nanoparticles | 2017 |
Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.
Topics: Adult; Anti-HIV Agents; Computer Simulation; Deoxyadenine Nucleotides; Deoxycytosine Nucleotides; Diphosphates; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Models, Biological; Polyphosphates; Prospective Studies; Tenofovir; Young Adult | 2016 |
Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen.
Topics: Adult; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Rilpivirine; RNA, Viral; Tablets; Tenofovir; Viral Load | 2017 |
Better late than never: PrEP in England.
Topics: Anti-HIV Agents; Capital Financing; Disease Transmission, Infectious; Emtricitabine; England; Health Policy; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2017 |
Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.
Topics: Adenine; Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Drug Resistance, Viral; Emtricitabine; Genotype; HIV Infections; HIV-1; Humans; Microbial Sensitivity Tests; Mutation; Organophosphates; Phenotype; Tenofovir | 2017 |
Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.
Topics: Anti-HIV Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cobicistat; Drug Combinations; Drug Interactions; Emtricitabine; HIV Infections; Humans; Quinolones; Tenofovir | 2017 |
How to "PrEP" for HIV Prevention in Women.
Topics: Adult; Anti-HIV Agents; Contraceptive Agents, Female; Emtricitabine; Female; HIV Infections; HIV Seronegativity; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2017 |
Real-world persistence with antiretroviral therapy for HIV in the United Kingdom: A multicentre retrospective cohort study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Retrospective Studies; Rilpivirine; Tenofovir; United Kingdom; Viral Load | 2017 |
Predicting HIV Pre-exposure Prophylaxis Efficacy for Women using a Preclinical Pharmacokinetic-Pharmacodynamic In Vivo Model.
Topics: Animals; Anti-Retroviral Agents; Dose-Response Relationship, Drug; Emtricitabine; Female; Half-Life; HIV Infections; HIV-1; Humans; Mice; Mice, Inbred BALB C; Mice, Transgenic; Pre-Exposure Prophylaxis; Proportional Hazards Models; RNA, Viral; Tenofovir | 2017 |
Impact of Antiretroviral Therapy on Liver Fibrosis Among Human Immunodeficiency Virus-Infected Adults With and Without HBV Coinfection in Zambia.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Coinfection; Cyclopropanes; Elasticity Imaging Techniques; Emtricitabine; Female; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; Humans; Liver; Liver Cirrhosis; Logistic Models; Male; Prospective Studies; Viral Load; Zambia | 2017 |
Comment on: Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection.
Topics: Adenine; Anti-HIV Agents; Cobicistat; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Organophosphonates; Quinolones; Tenofovir | 2017 |
Acute Kidney Injury After Efavirenz/Tenofovir Disoproxil Fumarate/Emtricitabine (Atripla) Overdose.
Topics: Acute Kidney Injury; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Male; Middle Aged; Tenofovir | 2017 |
Dolutegravir with tenofovir disoproxil fumarate-emtricitabine as HIV postexposure prophylaxis in gay and bisexual men.
Topics: Anti-HIV Agents; Australia; Chemoprevention; Disease Transmission, Infectious; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Medication Adherence; Oxazines; Piperazines; Post-Exposure Prophylaxis; Pyridones; Sexual and Gender Minorities; Tenofovir; Treatment Failure | 2017 |
Stability of antiretroviral regimens in patients with viral suppression.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; London; Male; Prospective Studies; Protease Inhibitors; Reverse Transcriptase Inhibitors; RNA, Viral | 2008 |
Human immunodeficiency virus-induced uveitis: intraocular and plasma human immunodeficiency virus-1 RNA loads.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Aqueous Humor; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Eye Infections, Viral; HIV Antibodies; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Polymerase Chain Reaction; RNA, Viral; Tenofovir; Uveitis, Anterior; Viral Load | 2008 |
A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients.
Topics: Adenine; Anti-HIV Agents; Calibration; Chromatography, Liquid; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Organophosphonates; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction; Spectrometry, Mass, Electrospray Ionization; Tenofovir | 2008 |
Severe psoriasis due to cessation of antiretroviral therapy in a patient with human immunodeficiency virus.
Topics: Alkynes; Anti-HIV Agents; Anti-Inflammatory Agents; Anti-Retroviral Agents; Antiviral Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Male; Middle Aged; Mometasone Furoate; Pregnadienediols; Psoriasis; Risk Factors; Treatment Refusal | 2008 |
Drug-susceptible HIV-1 infection despite intermittent fixed-dose combination tenofovir/emtricitabine as prophylaxis is associated with low-level viremia, delayed seroconversion, and an attenuated clinical course.
Topics: Adenine; Adult; Amino Acid Sequence; Anti-HIV Agents; CD4 Lymphocyte Count; Chemoprevention; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV Seropositivity; HIV-1; HLA Antigens; Humans; Intestinal Mucosa; Male; Microbial Sensitivity Tests; Molecular Sequence Data; Organophosphonates; Phylogeny; Receptors, CCR5; Sequence Alignment; Tenofovir; Time Factors; Viral Load; Viremia | 2008 |
Combination antiretroviral therapy with tenofovir, emtricitabine or lamivudine, and nevirapine.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphonates; Tenofovir | 2008 |
[First line therapy. Tenofovir DF/emtricitabine--the potent backbone].
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Organophosphonates; Tenofovir; Viral Load | 2008 |
96-week CASTLE data show similar efficacy results.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Lopinavir; Multicenter Studies as Topic; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome; Viral Load | 2008 |
Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates.
Topics: Adenine; Anti-HIV Agents; Area Under Curve; Clinical Trials as Topic; Deoxycytidine; Emtricitabine; Female; Half-Life; HIV Infections; HIV-1; Humans; Infant, Newborn; Maternal-Fetal Exchange; Organophosphonates; Population Groups; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Tenofovir | 2009 |
HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness.
Topics: Adenine; Adult; Anti-HIV Agents; Chemoprevention; Computer Simulation; Cost-Benefit Analysis; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality; Humans; Male; Organophosphonates; Risk Assessment; Tenofovir; United States | 2009 |
Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort.
Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Hepatitis B; Hepatitis B Antigens; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Treatment Outcome; Virus Replication | 2009 |
FDA notifications. Generic emtricitabine is approved by the FDA.
Topics: Deoxycytidine; Drug Approval; Drugs, Generic; Emtricitabine; HIV Infections; Humans; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration | 2009 |
Generic Truvada approved.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Approval; Drug Combinations; Drugs, Generic; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; United States; United States Food and Drug Administration | 2009 |
Emtricitabine/tenofovir disoproxil fumarate: in combination with a protease inhibitor in HIV-1 infection.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Organophosphonates; Tenofovir | 2009 |
Rhabdomyolysis in an HIV-infected patient on anti-retroviral therapy precipitated by high-dose pravastatin.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Dyslipidemias; Emtricitabine; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Oligopeptides; Organophosphonates; Pravastatin; Pyridines; Rhabdomyolysis; Ritonavir; Tenofovir | 2009 |
Efavirenz + emtricitabine + tenofovir: new combination. HIV infection: do not modify ongoing therapy just to use one less tablet. Better adherence than with separate dosing has not been demonstrated, while reduced efficacy is plausible.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Approval; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; Europe; HIV Infections; Humans; Organophosphonates; Oxazines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2009 |
Hepatitis B in HIV patients: what is the current treatment and what are the challenges?
Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Nucleosides; Organophosphonates; Polyethylene Glycols; Pyrimidinones; Recombinant Proteins; Telbivudine; Tenofovir; Thymidine; Transaminases | 2009 |
Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Area Under Curve; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Plasma; Ritonavir; RNA, Viral; Saquinavir; Tenofovir; Treatment Outcome; Viral Load | 2009 |
Lower limb high arterial flow induced by tenofovir and emtricitabine treatment.
Topics: Adenine; Adult; Blood Flow Velocity; Deoxycytidine; Edema; Emtricitabine; HIV Infections; Humans; Leg; Male; Organophosphonates; Tenofovir | 2009 |
The art of managing human immunodeficiency virus infection: a balancing act.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Tenofovir; Treatment Outcome | 2009 |
A new drug combination therapy for treatment-naive patients with HIV-1 infection, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Tenofovir | 2009 |
FDA notifications. Generic efavirenz/emtricitabine/fenofovir has tentative approval.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Approval; Drug Combinations; Drugs, Generic; Emtricitabine; HIV Infections; Humans; Organophosphonates; Tenofovir; United States; United States Food and Drug Administration | 2009 |
Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Oligopeptides; Organophosphonates; Proportional Hazards Models; Prospective Studies; Pyridines; Pyrimidinones; Risk Factors; Switzerland; Tenofovir; Zidovudine | 2010 |
DAART for human immunodeficiency virus-infected patients: Studying subjects not at risk for nonadherence and use of untested interventions.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Aged; Anti-HIV Agents; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Organophosphonates; Patient Compliance; Pyrimidinones; Randomized Controlled Trials as Topic; RNA, Viral; Stavudine; Tenofovir; Treatment Outcome; Young Adult | 2010 |
Expanded postexposure prophylaxis for simultaneous multiple source HIV exposure in a health-care worker.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Deoxycytidine; Emtricitabine; Enfuvirtide; Female; Fingers; HIV Envelope Protein gp41; HIV Infections; Humans; Infectious Disease Transmission, Patient-to-Professional; Middle Aged; Needlestick Injuries; Occupational Diseases; Organophosphonates; Peptide Fragments; Post-Exposure Prophylaxis; Ritonavir; Sulfonamides; Tenofovir | 2010 |
Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice.
Topics: Adenine; Animals; Anti-HIV Agents; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Flow Cytometry; HIV Infections; HIV-1; Mice; Organophosphonates; Rectum; Tenofovir | 2010 |
Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine.
Topics: Adenine; Adult; Analysis of Variance; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Organophosphonates; Retrospective Studies; RNA, Viral; Tenofovir; Treatment Failure; Viral Load | 2010 |
Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Nevirapine; Organophosphonates; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2010 |
A controlled trial of initial antiviral regimens for HIV-1 infection.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Genotype; HIV Infections; HIV-1; Homosexuality, Male; Humans; Lamivudine; Male; Organophosphonates; Tenofovir; Treatment Failure | 2010 |
Efficacy of tenofovir-emtricitabine versus abacavir-lamivudine.
Topics: Adenine; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Tenofovir; Treatment Outcome | 2010 |
Findings in humanized-mouse model suggest benefit of further studies in HIV pre-exposure prophylaxis.
Topics: Adenine; Animals; Anti-HIV Agents; Bone Marrow Transplantation; Clinical Trials as Topic; Deoxycytidine; Disease Models, Animal; Drug Combinations; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV; HIV Antibodies; HIV Infections; Humans; Infection Control; Liver Transplantation; Mice; Occupational Exposure; Organophosphonates; Organophosphorus Compounds; Tenofovir; Thymus Gland; Transplantation Chimera | 2010 |
Raltegravir, tenofovir, and emtricitabine in an HIV-infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver toxicity.
Topics: Adenine; Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Chemical and Drug Induced Liver Injury; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Hepatitis C, Chronic; HIV Infections; Humans; Liver; Lymphocyte Count; Organophosphonates; Protease Inhibitors; Pyrrolidinones; Raltegravir Potassium; Tenofovir; Treatment Outcome; Viral Load | 2010 |
[Protease inhibitor or non-nucleoside reverse transcriptase inhibitor. ACTG study 5202 in focus].
Topics: Adenine; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Lamivudine; Multicenter Studies as Topic; Oligopeptides; Organophosphonates; Pyridines; Randomized Controlled Trials as Topic; Tenofovir | 2010 |
[HIV-therapy-associated immune reconstitution syndrome presenting as immunogenic hyperthyroidism].
Topics: Adenine; Alkynes; Anti-HIV Agents; Autoantibodies; Benzoxazines; Cyclopropanes; Deoxycytidine; Diagnosis, Differential; Drug Therapy, Combination; Emtricitabine; Graves Disease; HIV Infections; HIV-1; Humans; Immune Reconstitution Inflammatory Syndrome; Long-Term Care; Male; Middle Aged; Organophosphonates; Tenofovir; Thyroid Gland; Thyroiditis, Autoimmune | 2010 |
More research needed to find new HIV-suppressive functions of cytotoxic T cells.
Topics: Adenine; Animals; Combined Modality Therapy; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Lymphocyte Depletion; Macaca mulatta; Organophosphonates; Simian Acquired Immunodeficiency Syndrome; T-Lymphocyte Subsets; T-Lymphocytes, Cytotoxic; Tenofovir; Viral Load; Viremia | 2010 |
Tolerability of HIV postexposure prophylaxis with tenofovir/emtricitabine and lopinavir/ritonavir tablet formulation.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; CD4 Lymphocyte Count; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Organophosphonates; Post-Exposure Prophylaxis; Practice Guidelines as Topic; Pyrimidinones; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Young Adult | 2010 |
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens.
Topics: Adaptation, Biological; Adenine; Adult; Amino Acid Substitution; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation, Missense; Organophosphonates; pol Gene Products, Human Immunodeficiency Virus; RNA, Viral; Tenofovir | 2010 |
The impact of gender and anchor drugs on TDF renal toxicity.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Lamivudine; Male; Organophosphonates; Sex Factors; Tenofovir | 2010 |
Implications of HIV PrEP trials results.
Topics: Adenine; Anti-HIV Agents; Chemoprevention; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome; United States | 2011 |
Occult HBV infection in untreated HIV-infected adults in Côte d'Ivoire.
Topics: Adenine; Adult; Aged; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cote d'Ivoire; Cross-Sectional Studies; Deoxycytidine; DNA, Viral; Emtricitabine; Female; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prevalence; Tenofovir; World Health Organization; Young Adult | 2010 |
A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Ill-Housed Persons; Male; Middle Aged; Organophosphonates; Patient Compliance; Tenofovir; Viral Load | 2010 |
[Immune reconstitution inflammatory syndrome associated with eosinophilic pustular folliculitis in an HIV-infected patient].
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Diagnosis, Differential; Emtricitabine; Eosinophilia; Folliculitis; HIV Infections; Humans; Immune Reconstitution Inflammatory Syndrome; Organophosphonates; Rosacea; Skin Diseases, Infectious; Tenofovir | 2011 |
Oral preexposure prophylaxis for HIV--another arrow in the quiver?
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Patient Compliance; Tenofovir | 2010 |
[Long-term therapy for chronic hepatitis B in HIV co-infected patients].
Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Recombinant Proteins; Telbivudine; Tenofovir; Thymidine | 2010 |
Avascular necrosis of the talus in a HIV-infected patient.
Topics: Adenine; Carbamates; Deoxycytidine; Emtricitabine; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Immunocompromised Host; Male; Middle Aged; Organophosphates; Organophosphonates; Orthotic Devices; Osteonecrosis; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Talus; Tenofovir | 2010 |
The ART of preventing HIV.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Circumcision, Male; Deoxycytidine; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Random Allocation; Risk Assessment; Tenofovir | 2011 |
AIDS: Drugs that prevent HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Administration, Intravaginal; Administration, Oral; Animals; Anti-HIV Agents; Condoms; Controlled Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Organophosphonates; Placebos; Reverse Transcriptase Inhibitors; Safe Sex; Tenofovir; Vaginal Creams, Foams, and Jellies | 2011 |
Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Cost-Benefit Analysis; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Markov Chains; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Reverse Transcriptase Inhibitors; Risk Assessment; Ritonavir; Tenofovir; United States | 2011 |
Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy.
Topics: Adenine; Adult; Anti-HIV Agents; Clinical Trials as Topic; Darunavir; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Molecular Typing; Mutation; Organophosphonates; Ritonavir; RNA, Viral; Sulfonamides; Tenofovir; Treatment Outcome; Virus Replication | 2011 |
[HIV infected women with intense bone and muscular pain and general weakness].
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Fanconi Syndrome; Female; Hepatitis, Viral, Human; HIV Infections; Humans; Hypophosphatemia; Middle Aged; Muscle Weakness; Musculoskeletal Diseases; Organophosphonates; Osteomalacia; Pain; Radionuclide Imaging; Radiopharmaceuticals; Substance Abuse, Intravenous; Technetium Tc 99m Medronate; Tenofovir | 2011 |
Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Deoxycytidine; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Treatment Outcome | 2011 |
Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV Protease; HIV-1; Humans; Infant; Lamivudine; Lopinavir; Male; Mutation; Paris; Pyrimidinones; Ritonavir; Treatment Failure | 2011 |
Preexposure chemoprophylaxis for HIV prevention.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Risk-Taking; Sexual Behavior; Tenofovir | 2011 |
Preexposure chemoprophylaxis for HIV prevention.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Risk-Taking; Sexual Behavior; Tenofovir | 2011 |
Preexposure chemoprophylaxis for HIV prevention.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Tenofovir | 2011 |
Preexposure chemoprophylaxis for HIV prevention.
Topics: Adenine; Age Factors; Anti-HIV Agents; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Kaplan-Meier Estimate; Male; Organophosphonates; Tenofovir; Young Adult | 2011 |
Preexposure chemoprophylaxis for HIV prevention.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Costs; Drug Therapy, Combination; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Risk; Tenofovir | 2011 |
Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.
Topics: Acute Disease; Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2011 |
Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects.
Topics: Adenine; Adult; Anti-HIV Agents; Australia; Deoxycytidine; Drug Administration Schedule; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lost to Follow-Up; Male; Medical Audit; Middle Aged; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2011 |
Study halted: no benefit seen from antiretroviral pill in preventing HIV in women.
Topics: Adenine; Adult; Africa; Anti-Retroviral Agents; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Organophosphonates; Patient Compliance; Pregnancy; Pregnancy Rate; Randomized Controlled Trials as Topic; Tenofovir; Treatment Failure | 2011 |
[Efavirenz in fixed combination with tenofovir and emtricitabine. Long-term effectiveness verified in new studies].
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Medication Adherence; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load | 2011 |
Early end for FEM-PrEP HIV prevention trial.
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; Humans; Kenya; Organophosphonates; Organophosphorus Compounds; Patient Compliance; Randomized Controlled Trials as Topic; South Africa; Tanzania; Tenofovir | 2011 |
Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Canada; Cohort Studies; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Substitution; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Failure; Virus Replication | 2011 |
Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage.
Topics: Adenine; Adult; Blood-Brain Barrier; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Pilot Projects; Tenofovir | 2011 |
Membranous nephropathy in an HIV-positive patient complicated with hepatitis B virus infection.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Emtricitabine; Glomerulonephritis, Membranous; Hepatitis B; HIV Infections; Humans; Male; Nephrotic Syndrome; Organophosphonates; Prednisolone; Tenofovir | 2011 |
Rilpivirine: a step forward in tailored HIV treatment.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials, Phase III as Topic; Cyclopropanes; Delavirdine; Deoxycytidine; Drug Design; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Multicenter Studies as Topic; Mutation; Nevirapine; Nitriles; Organophosphonates; Pyrimidines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Viral Load | 2011 |
Antiretrovirals for HIV prevention: translating promise into praxis.
Topics: Adenine; Administration, Cutaneous; Administration, Oral; Algorithms; Anti-HIV Agents; Anti-Retroviral Agents; Congresses as Topic; Deoxycytidine; Emtricitabine; Female; Gels; Global Health; HIV Infections; Humans; Organophosphonates; Primary Prevention; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Sexual Behavior; Tenofovir; Treatment Outcome; Women's Health | 2011 |
Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Africa South of the Sahara; Anti-HIV Agents; Anti-Retroviral Agents; Coitus; Deoxycytidine; Early Termination of Clinical Trials; Emtricitabine; Female; Gels; HIV Infections; Humans; Incidence; Organophosphonates; Primary Prevention; Randomized Controlled Trials as Topic; Rectum; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Vagina; Women's Health | 2011 |
Antiretroviral prophylaxis: a defining moment in HIV control.
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Anti-Retroviral Agents; Botswana; Clinical Trials as Topic; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Kenya; Male; Organophosphonates; Tenofovir; Uganda | 2011 |
Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Saliva; Sexual Behavior; Tenofovir | 2011 |
Patient-reported outcomes and low-level residual HIV-RNA in adolescents perinatally infected with HIV-1 after switching to one-pill fixed-dose regimen.
Topics: Adenine; Adolescent; Alkynes; Anti-HIV Agents; Antiviral Agents; Benzoxazines; Child; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Patient Satisfaction; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2012 |
Antiretroviral therapy alone resulted in successful resolution of large idiopathic esophageal ulcers in a patient with acute retroviral syndrome.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Esophageal Diseases; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Organophosphonates; Pyrimidinones; Ritonavir; RNA, Viral; Syndrome; Tenofovir; Ulcer | 2011 |
Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cohort Studies; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Viral Load | 2011 |
HIV-HBV vaccine escape mutant infection with loss of HBV surface antibody and persistent HBV viremia on tenofovir/emtricitabine without antiviral resistance.
Topics: Adenine; Antiviral Agents; Coinfection; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Hepatitis B; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation; Organophosphonates; Tenofovir; Viral Load; Viremia | 2011 |
Optimizing initial therapy for HIV infection.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Tenofovir | 2011 |
Fanconi syndrome-like tubular acidosis associated with a tenofovir-containing antiretroviral regimen in a human immunodeficiency virus-1-infected Asian woman.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Fanconi Syndrome; Female; HIV Infections; HIV-1; Humans; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2012 |
Pre-exposure chemoprophylaxis of HIV infection: quo vadis?
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Administration, Topical; Anti-HIV Agents; Clinical Trials as Topic; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Molecular Structure; Organophosphonates; Patient Compliance; Tenofovir | 2012 |
Sustained virological response to a raltegravir-containing salvage therapy in an HIV-2-infected patient.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-2; Humans; Lopinavir; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Salvage Therapy; Tenofovir; Treatment Outcome; Viral Load | 2011 |
The price of tenofovir-emtricitabine undermines the cost-effectiveness and advancement of pre-exposure prophylaxis.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Models, Economic; Organophosphonates; Tenofovir | 2011 |
Acceptability of an "on-demand" pre-exposure HIV prophylaxis trial among men who have sex with men living in France.
Topics: Adenine; Adult; Anti-HIV Agents; Chemoprevention; Deoxycytidine; Drug Combinations; Educational Status; Emtricitabine; France; HIV Infections; HIV Serosorting; Homosexuality, Male; Humans; Male; Organophosphonates; Patient Acceptance of Health Care; Patient Selection; Post-Exposure Prophylaxis; Research Subjects; Risk Reduction Behavior; Self Administration; Tenofovir; Unsafe Sex | 2012 |
Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G.
Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; Deoxycytidine; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Genotype; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome | 2012 |
Different baseline characteristics and different outcomes of HIV-infected patients receiving HAART through clinical trials compared with routine care in Mexico.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Clinical Trials as Topic; Deoxycytidine; Emtricitabine; Epidemiologic Methods; Female; HIV Infections; Humans; Kaplan-Meier Estimate; Lopinavir; Male; Mexico; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir | 2012 |
Effect of pregnancy on emtricitabine pharmacokinetics.
Topics: Adult; Antiviral Agents; Area Under Curve; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Inhibitory Concentration 50; Metabolic Clearance Rate; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Third; Prospective Studies; Viral Load; Young Adult | 2012 |
Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir.
Topics: Adenine; Anti-HIV Agents; Biomarkers; Cohort Studies; Cytochromes c; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Glomerular Filtration Rate; Glutathione Transferase; HIV Infections; Humans; Kidney Diseases; Kidney Tubules, Proximal; Lamivudine; Male; Middle Aged; Mitochondria; Organophosphonates; Tenofovir; Time Factors | 2012 |
Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Cohort Studies; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Homosexuality, Male; Humans; Logistic Models; Male; Organophosphonates; Prevalence; Tenofovir; United Kingdom; Viral Load | 2012 |
Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Area Under Curve; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Organophosphonates; Tenofovir | 2011 |
FDA notifications. Complera approved.
Topics: Adenine; Deoxycytidine; Drug Approval; Drug Combinations; Drug Labeling; Emtricitabine; HIV Infections; Humans; Nitriles; Organophosphonates; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; United States; United States Food and Drug Administration | 2011 |
Recent HIV-1 infection: to treat or not to treat, that is the question.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Organophosphonates; Ritonavir; Tenofovir; Viral Load | 2012 |
Cytosine deoxyribonucleoside anti-HIV analogues: a small chemical substitution allows relevant activities.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Deoxycytidine; Emtricitabine; HIV Infections; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Treatment Outcome; Zalcitabine | 2012 |
HIV preexposure prophylaxis: new data and potential use.
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Deoxycytidine; Emtricitabine; Evidence-Based Medicine; Female; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Organophosphonates; Tenofovir | 2011 |
Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention.
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Patient Compliance; Risk Factors; Tenofovir; Treatment Outcome; Vaginal Creams, Foams, and Jellies | 2012 |
Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; France; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation, Missense; Organophosphonates; Retrospective Studies; RNA, Viral; Selection, Genetic; Tenofovir; Treatment Failure; Viral Load | 2012 |
Cutaneous CD8+ T-cell infiltrates associated with human immunodeficiency virus.
Topics: Adenine; Alopecia; Anti-HIV Agents; Antigens, Differentiation, T-Lymphocyte; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD8-Positive T-Lymphocytes; Deoxycytidine; Diagnosis, Differential; Emtricitabine; HIV Infections; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Oligopeptides; Organophosphonates; Prednisone; Pseudolymphoma; Pyridines; Ritonavir; Skin; Tenofovir | 2012 |
Case report of cytomegalovirus retinitis in an HIV-positive patient with a CD4-count nadir of 254 cells per μl.
Topics: Adenine; Administration, Oral; Adult; Alkynes; Anti-HIV Agents; Aqueous Humor; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; Cytomegalovirus; Cytomegalovirus Retinitis; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Male; Organophosphonates; Polymerase Chain Reaction; Tenofovir; Visual Acuity | 2012 |
Antiretroviral prophylaxis for HIV prevention reaches a key milestone.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; Humans; Organophosphonates; Tenofovir | 2012 |
Patient-reported symptoms on the antiretroviral regimen efavirenz/emtricitabine/tenofovir.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cross-Sectional Studies; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Health Status; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Quality of Life; Severity of Illness Index; Tenofovir; Treatment Outcome; Veterans | 2012 |
Impact of antiretroviral dosing frequency and pill burden on adherence among newly diagnosed, antiretroviral-naive HIV patients.
Topics: Adenine; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir | 2012 |
How good is "good enough"? The case for varying standards of evidence according to need for new interventions in HIV prevention.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Ethical Analysis; Ethical Theory; Ethics, Research; Evidence-Based Medicine; Female; Gels; Guidelines as Topic; Health Services Accessibility; Health Services Needs and Demand; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Organophosphorus Compounds; Primary Prevention; Randomized Controlled Trials as Topic; Research Subjects; Sex Work; Tenofovir; Therapeutic Equipoise; United States; United States Food and Drug Administration | 2012 |
Sustained local delivery of structurally diverse HIV-1 microbicides released from sublimation enthalpy controlled matrices.
Topics: Adenine; Animals; Anti-HIV Agents; Cells, Cultured; Contraceptive Devices, Female; Delayed-Action Preparations; Deoxycytidine; Drug Delivery Systems; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Macrophages; Monocytes; Organophosphonates; Sheep; Structure-Activity Relationship; Sublimation, Chemical; T-Lymphocytes; Tenofovir | 2012 |
Preexposure prophylaxis for HIV--where do we go from here?
Topics: Adenine; Anti-Retroviral Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Pregnancy; Tenofovir | 2012 |
Clinical decisions. Preexposure prophylaxis for HIV prevention.
Topics: Adenine; Adolescent; Anti-Retroviral Agents; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Safe Sex; Tenofovir | 2012 |
The introduction of new antiretroviral-based HIV prevention methods into health systems: an update.
Topics: Adenine; Africa South of the Sahara; Anti-Retroviral Agents; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; Humans; Organophosphonates; Tenofovir; Vaginal Creams, Foams, and Jellies | 2012 |
Prevention. Using PrEP cost-effective in high-risk MSM groups.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Drug Costs; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Risk Factors; Tenofovir | 2012 |
Lamivudine or emtricitabine (XTC)/protease inhibitor dual therapy as a harm-reduction strategy in patients with tenofovir-related renal toxicity: a case-control study.
Topics: Adenine; Adult; Aged; Case-Control Studies; CD4 Lymphocyte Count; Chi-Square Distribution; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Kidney Diseases; Kidney Function Tests; Lamivudine; Male; Middle Aged; Organophosphonates; Protease Inhibitors; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2012 |
Connection domain mutations during antiretroviral treatment failure in Mali: frequencies and impact on reverse transcriptase inhibitor activity.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Binding Sites; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mali; Mutation; Nevirapine; Phenotype; Treatment Failure | 2012 |
Trends in HIV-1 reverse transcriptase resistance-associated mutations and antiretroviral prescription data from 2003-2010.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Prescriptions; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Prevalence; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Zidovudine | 2012 |
FDA paves the way for pre-exposure HIV prophylaxis.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Deoxycytidine; Drug Combinations; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Primary Prevention; Tenofovir; United States; United States Food and Drug Administration | 2012 |
Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults.
Topics: Adenine; Administration, Oral; Adult; Anti-Retroviral Agents; Centers for Disease Control and Prevention, U.S.; Contraindications; Deoxycytidine; Drug Labeling; Emtricitabine; Female; Heterosexuality; HIV Infections; Homosexuality; Humans; Male; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Randomized Controlled Trials as Topic; Risk; Sexual Behavior; Tenofovir; United States | 2012 |
Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Sequence Data; Mutation, Missense; Organophosphonates; Selection, Genetic; Sequence Analysis, DNA; Tenofovir; Treatment Failure | 2012 |
[A single tablet against HIV: new combination preparation improves therapy].
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Clinical Trials, Phase III as Topic; Cobicistat; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Glomerular Filtration Rate; HIV Infections; Humans; Oligopeptides; Organophosphonates; Pyridines; Quinolones; Randomized Controlled Trials as Topic; Ritonavir; Tenofovir; Thiazoles; Viral Load | 2012 |
Preexposure prophylaxis for the prevention of HIV transmission to women.
Topics: Adenine; Anti-HIV Agents; Chemoprevention; Cost-Benefit Analysis; Deoxycytidine; Directive Counseling; Emtricitabine; Family Characteristics; Female; HIV Infections; Humans; Male; Medication Adherence; Organophosphonates; Primary Health Care; Primary Prevention; Reproductive Behavior; Risk-Taking; Tenofovir; United States; United States Food and Drug Administration | 2013 |
Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.
Topics: Adenine; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cohort Studies; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Italy; Longitudinal Studies; Lopinavir; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Retrospective Studies; Ritonavir; Tenofovir; Time Factors | 2013 |
Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a guide to its use in HIV-1 infection.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Nitriles; Organophosphonates; Patient Compliance; Pyrimidines; Rilpivirine; RNA, Viral; Tenofovir; Time Factors; Treatment Outcome | 2012 |
FDA treads carefully with PrEP.
Topics: Adenine; Anti-HIV Agents; Chemoprevention; Deoxycytidine; Drug Approval; Drug Combinations; Drug Resistance, Viral; Emtricitabine; HIV Infections; Humans; Medication Adherence; Organophosphonates; Tenofovir; United States; United States Food and Drug Administration | 2012 |
Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.
Topics: Adenine; Adult; Anti-HIV Agents; Blood Chemical Analysis; Chromatography, Liquid; Deoxycytidine; Desiccation; Emtricitabine; Erythrocytes; Female; Half-Life; HIV Infections; Humans; Leukocytes, Mononuclear; Male; Medication Adherence; Middle Aged; Organophosphonates; Plasma; Specimen Handling; Tandem Mass Spectrometry; Tenofovir; Young Adult | 2013 |
Antiretroviral medications as prevention: will the new paradigm reverse the HIV epidemic?
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Epidemics; Female; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Randomized Controlled Trials as Topic; Risk Factors; Tenofovir | 2012 |
Differential effects of tenofovir/emtricitabine and abacavir/lamivudine on human leukocyte recruitment.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Cell Adhesion; Cell Adhesion Molecules; Cell Communication; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Endothelial Cells; HIV Infections; Humans; Lamivudine; Leukocytes; Organophosphonates; Tenofovir | 2012 |
Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir.
Topics: Adenine; Adult; Alkynes; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabine; Female; Glomerular Filtration Rate; Glycosuria; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Diseases; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Proteinuria; Pyridines; Retrospective Studies; Ritonavir; Tenofovir | 2013 |
The influence of HLA supertype on thymidine analogue associated with low peripheral fat in HIV.
Topics: Adenine; Anti-HIV Agents; Australia; Biomarkers; Blood Glucose; Body Fat Distribution; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HIV Infections; HIV-Associated Lipodystrophy Syndrome; HLA Antigens; HLA-A1 Antigen; HLA-B8 Antigen; HLA-DQ Antigens; Humans; Lamivudine; Linkage Disequilibrium; Male; Middle Aged; Multicenter Studies as Topic; Organophosphonates; Predictive Value of Tests; Randomized Controlled Trials as Topic; Tenofovir; Thymidine | 2012 |
Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Coinfection; Deoxycytidine; Emtricitabine; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load; Virus Replication | 2012 |
[Preexposure prophylaxis for HIV infection--current data and recommendations].
Topics: Adenine; Africa; Anti-HIV Agents; Controlled Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Viral; Early Termination of Clinical Trials; Emtricitabine; Female; HIV Infections; Humans; Male; Organophosphonates; Risk Factors; Tenofovir | 2012 |
Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: a new measure of antiretroviral adherence?
Topics: Adenine; Adult; Anti-HIV Agents; Blood Cells; Deoxycytidine; Diphosphates; Emtricitabine; Female; HIV Infections; Humans; Leukocytes, Mononuclear; Male; Medication Adherence; Middle Aged; Organophosphonates; Polyphosphates; Tenofovir | 2013 |
FDA approves new 4-drug once-a-day HIV treatment.
Topics: Adenine; Carbamates; Cobicistat; Deoxycytidine; Drug Administration Schedule; Drug Approval; Drug Combinations; Emtricitabine; HIV Infections; Humans; Organophosphonates; Quinolones; Tenofovir; Thiazoles; United States; United States Food and Drug Administration | 2012 |
A 4-drug combination (Stribild) for HIV.
Topics: Adenine; Anti-HIV Agents; Carbamates; Clinical Trials as Topic; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Approval; Drug Combinations; Drug Interactions; Drug Resistance, Multiple, Viral; Emtricitabine; HIV; HIV Infections; Humans; Organophosphonates; Quinolones; Randomized Controlled Trials as Topic; Tenofovir; Thiazoles; United States; United States Food and Drug Administration | 2012 |
Coverage, context and targeted prevention: optimising our impact.
Topics: Adenine; Anti-HIV Agents; Circumcision, Male; Deoxycytidine; Emtricitabine; Female; Health Priorities; HIV Infections; Humans; Male; Organophosphonates; Sexual Behavior; Tenofovir; United States; Vaginal Creams, Foams, and Jellies | 2013 |
Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; Female; Half-Life; HIV Infections; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Organophosphonates; Tandem Mass Spectrometry; Tenofovir; Young Adult | 2013 |
Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging.
Topics: Adenine; Adult; Aging; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; Cells, Cultured; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Enzyme Activation; Female; HIV; HIV Infections; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Middle Aged; Organophosphonates; Polymerase Chain Reaction; Regression Analysis; Reverse Transcriptase Inhibitors; Risk Factors; Telomerase; Telomere; Telomere Shortening; Tenofovir; Time Factors; Young Adult; Zidovudine | 2013 |
Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus.
Topics: Adenine; Adult; Aged; Antiretroviral Therapy, Highly Active; Antiviral Agents; Australia; Coinfection; Deoxycytidine; DNA, Viral; Emtricitabine; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Organophosphonates; Tenofovir; Thailand; Treatment Failure; United States | 2013 |
Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cost-Benefit Analysis; Cyclopropanes; Deoxycytidine; Drug Combinations; Drugs, Generic; Emtricitabine; Female; HIV Infections; Humans; Male; Models, Theoretical; Organophosphonates; Quality-Adjusted Life Years; Reverse Transcriptase Inhibitors; Tenofovir; United States | 2013 |
Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Genotype; HIV Infections; HIV-1; Humans; Mutation; Nitriles; Organophosphonates; Prevalence; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir | 2013 |
Anti-HIV drug updates--three drugs on the near horizon.
Topics: Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Deoxycytidine; Drug Approval; Drug Design; Emtricitabine; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; Humans; Oligopeptides; Peptide Fragments; Pyridines; United States; United States Food and Drug Administration; Viral Load | 2003 |
Emtriva gets approval.
Topics: Deoxycytidine; Drug Approval; Emtricitabine; HIV Infections; Humans; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration | 2003 |
Atazanavir (Reyataz) and emtricitabine (Emtriva) for HIV infection.
Topics: Anti-Retroviral Agents; Atazanavir Sulfate; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance; Emtricitabine; HIV Infections; HIV-1; Humans; Jaundice; Oligopeptides; Pyridines; Randomized Controlled Trials as Topic | 2003 |
FDA notifications. NRTI Emtriva receives FDA approval.
Topics: Adult; CD4 Lymphocyte Count; Clinical Trials as Topic; Deoxycytidine; Drug Approval; Emtricitabine; HIV Infections; Humans; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration; Viral Load | 2003 |
[Improved long-term success. New nucleoside for once daily combinations].
Topics: Anti-HIV Agents; Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV-1; Humans; Long-Term Care; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2004 |
[Approval of a new nucleoside. Component of complete once daily regimen].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Deoxycytidine; Drug Approval; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Reverse Transcriptase Inhibitors; Viral Load | 2004 |
Intracellular pharmacology of emtricitabine and tenofovir.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Half-Life; HIV Infections; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
[Emtriva (emtricitabine, FTC)].
Topics: Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Humans | 2004 |
Meeting notes from ICAAC. Tenofovir + emtricitabine vs. AZT + 3TC.
Topics: Adenine; CD4 Lymphocyte Count; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load; Zidovudine | 2005 |
[Simply convincing. New fixed combination for HIV therapy].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Patient Compliance; Practice Guidelines as Topic; Survival Rate; Tenofovir | 2005 |
Case study: an active, 24-year-old woman positive for HIV.
Topics: Adenine; Adult; Anti-Retroviral Agents; Deoxycytidine; Disease Progression; Emtricitabine; Female; HIV Infections; Humans; Organophosphonates; Ritonavir; Tenofovir | 2006 |
Emtricitabine intolerance in treatment-experienced patients switched from lamivudine: a method of assessing toxicity.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Lamivudine; Randomized Controlled Trials as Topic; Viral Load | 2006 |
FDA makes final approvals.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Approval; Drug Combinations; Emtricitabine; HIV Infections; Humans; Organophosphonates; Tenofovir; United States; United States Food and Drug Administration | 2006 |
Tenofovir DF and emtricitabine vs. zidovudine and lamivudine.
Topics: Adenine; Anti-Retroviral Agents; Bias; Data Interpretation, Statistical; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Research Design; Tenofovir; Zidovudine | 2006 |
Tenofovir DF and emtricitabine vs. zidovudine and lamivudine.
Topics: Adenine; Bone Density; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; HIV; HIV Infections; Humans; Lamivudine; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2006 |
Efavirenz/emtricitabine/tenofovir disoproxil fumarate: triple combination tablet.
Topics: Adenine; Alkynes; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; Humans; Organophosphonates; Oxazines; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2006 |
A once-daily combination tablet (Atripla) for HIV.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Drug Interactions; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; HIV Infections; Humans; Organophosphonates; Oxazines; Tenofovir | 2006 |
Once-daily dosing and the treatment of HIV disease.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Emtricitabine; HIV Infections; Humans; Organophosphonates; Oxazines; Tenofovir | 2006 |
Safety and efficacy of regimens containing emtricitabine in HIV-infected patients taking highly active antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Drug Evaluation; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; Viral Load | 2006 |
Persistence of a sexually transmitted highly resistant HIV-1: pol quasispecies evolution over 33 months in the absence of treatment.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Genes, pol; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Reverse Transcriptase Inhibitors; Viral Load | 2006 |
The M184V mutation: what it does, how to prevent it, and what to do with it when it's there.
Topics: Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Virus Physiological Phenomena | 2006 |
Induction therapy with enfuvirtide-based highly active antiretroviral therapy in a patient with acute HIV-1 infection.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Emtricitabine; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Lopinavir; Male; Organophosphonates; Peptide Fragments; Pyrimidinones; Ritonavir; Tenofovir; Viral Load; Viremia | 2007 |
Virologic characterization of HIV type 1 with a codon 70 deletion in reverse transcriptase.
Topics: Adenine; Antiviral Agents; Cell Line, Transformed; Codon; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Emtricitabine; HeLa Cells; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Organophosphonates; Point Mutation; Reassortant Viruses; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Pharmacokinetics of once-daily tenofovir, emtricitabine, ritonavir and fosamprenavir in HIV-infected subjects.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Carbamates; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphates; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Sulfonamides; Tenofovir; Treatment Outcome | 2007 |
HPV oral infection. Case report of an HIV-positive Nigerian sex worker.
Topics: Adenine; Adult; Alphapapillomavirus; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; HIV Infections; Humans; Italy; Lamivudine; Lopinavir; Mouth Mucosa; Nigeria; Organophosphonates; Papillomavirus Infections; Pyrimidinones; Ritonavir; Sex Work; Stomatitis; Tenofovir; Treatment Refusal; Zidovudine | 2007 |
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.
Topics: Adenine; Administration, Oral; Adult; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Genitalia, Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2007 |
Disorder in clotting pattern after antiretroviral treatment with emtricitabine in an HIV-positive haemophiliac patient.
Topics: Antiviral Agents; Blood Coagulation Disorders; Coagulants; Deoxycytidine; Emtricitabine; Factor VIII; Hemophilia A; HIV Infections; Humans; Male; Middle Aged | 2007 |
Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Boston; Clinical Trials, Phase IV as Topic; Community Health Centers; Deoxycytidine; Disease Transmission, Infectious; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome | 2008 |
Can the new humanized mouse model give HIV research a boost.
Topics: Adenine; Administration, Intravaginal; Animals; Deoxycytidine; Disease Models, Animal; Disease Susceptibility; Drug Evaluation, Preclinical; Emtricitabine; Female; Hematopoietic Stem Cell Transplantation; HIV Infections; HIV-1; Humans; Liver Transplantation; Macaca mulatta; Mice; Mice, Inbred NOD; Mice, Inbred Strains; Mice, SCID; Organophosphonates; Radiation Chimera; Species Specificity; Tenofovir; Thymus Gland; Transplantation, Heterologous | 2008 |
Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice.
Topics: Adenine; Administration, Intravaginal; Animals; Anti-HIV Agents; Deoxycytidine; Disease Models, Animal; Drug Evaluation, Preclinical; Emtricitabine; Female; Fetal Tissue Transplantation; Genitalia, Female; Hematopoietic Stem Cell Transplantation; HIV Infections; HIV-1; Humans; Immunity, Mucosal; Liver Transplantation; Mice; Mice, Inbred Strains; Mice, SCID; Organophosphonates; Radiation Chimera; Species Specificity; Tenofovir; Thymus Gland; Transplantation, Heterologous | 2008 |
Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cost-Benefit Analysis; Cyclopropanes; Decision Trees; Deoxycytidine; Drug Costs; Emtricitabine; Health Care Costs; Health Resources; HIV Infections; HIV-1; Humans; Lamivudine; Models, Economic; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Treatment Outcome; Zidovudine | 2008 |
Syncope as a probable side effect to combination antiretroviral therapy initiated during primary HIV-1 infection.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Male; Nevirapine; Organophosphonates; Syncope; Tenofovir | 2008 |
European Commission approves Atripla.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Approval; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; European Union; HIV Infections; Humans; Organophosphonates; Oxazines; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |
Quantitation of intracellular triphosphate of emtricitabine in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients.
Topics: Administration, Oral; Anion Exchange Resins; Antiviral Agents; Chromatography, High Pressure Liquid; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Leukocytes, Mononuclear; Phosphates; Reference Standards | 1999 |
South Africa to tighten control on drug trials after five death.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Death, Sudden; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; Humans; Nevirapine; South Africa | 2000 |
Once-a-day HAART regimen containing Coviracil.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Drug Administration Schedule; Emtricitabine; HIV Infections; Humans | 2000 |
Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil).
Topics: Adult; Anti-HIV Agents; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Research Design; Reverse Transcriptase Inhibitors; Viral Load | 2001 |